

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2007 (21.06.2007)

PCT

(10) International Publication Number
WO 2007/068946 A2

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(74) Agents: SZCZUKA, Jan et al.; Marks & Clerk, 19 Royal Exchange Square, Glasgow G1 3AE (GB).

(21) International Application Number:
PCT/GB2006/004707

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:
15 December 2006 (15.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0525492.5 15 December 2005 (15.12.2005) GB

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE [GB/GB]; Nethergate, Perth Road, Dundee DD1 4HN (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MCLEAN, William, Henry, Irwin [GB/GB]; Human Genetics Unit, Division of Pathology & Neuroscience, Ninewells Medical School, University of Dundee, Dundee DD1 9SY (GB). SMITH, Frances, Jane, Dorothy [GB/GB]; Human Genetics Unit, Division of Pathology & Neuroscience, Ninewells Medical School, University of Dundee, Dundee DD1 9SY (GB).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FILAGGRIN

(57) Abstract: The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).



WO 2007/068946 A2

FILAGGRIN

Field of the Invention

The present invention relates to the identification of loss-of-function mutations in the filaggrin gene and their use in diagnosing ichthyosis vulgaris and/or susceptibility to other diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies (including food allergy).

Background to the Invention

Ichthyosis vulgaris (IV; OMIM# 146700) is the most common inherited disorder of keratinisation and one of the most frequent single gene disorders in humans. The most widely cited incidence figure is 1 in 250 based on a survey of 6051 healthy English schoolchildren¹.

The phenotypic characteristics of IV include palmar hyperlinearity, keratosis pilaris and a fine scale most markedly seen over the lower abdomen, arms and legs². Filaggrin (filament aggregating protein) is important in the formation of the stratum corneum³⁻⁵. Keratohyalin granules in the granular layer of interfollicular epidermis are predominantly composed of the 400 kDa protein profilaggrin. Following a short, unique N-terminal domain, most of the profilaggrin molecule consists of 10-12 repeats of the 324 amino acid filaggrin sequence⁶. Upon terminal differentiation of granular cells, profilaggrin is proteolytically cleaved into ~37 kDa filaggrin peptides and the N-terminal domain containing an S100-like calcium binding domain. Filaggrin rapidly aggregates the keratin cytoskeleton, causing collapse of the granular cells into flattened anuclear squames. This condensed cytoskeleton is cross-linked by transglutaminases during formation of the cornified cell envelope (CCE). The CCE is the outermost barrier layer of the skin which not only prevents water loss but also

impedes the entry of allergens and infectious agents⁷. Filaggrin is therefore a key protein in facilitating epidermal differentiation and maintaining barrier function.

Immunoblotting studies have shown that filaggrin protein was absent or markedly reduced in IV patients' skin and/or keratinocytes⁸⁻¹⁰. In addition, decreased filaggrin mRNA has been demonstrated in some individuals with IV¹¹. A recessive mouse mutant, flaky tail (*ft*), bears the histological and ultrastructural hallmarks of human IV¹² and strong genetic linkage has been obtained to the murine filaggrin locus (*FLG*)^{13,14}. Although biochemical analysis has shown defective profilaggrin processing in *ft/ft* homozygotes¹², any genomic mutation in the *FLG* gene has not hitherto been identified.

It is amongst the objects of the present invention to provide a method of diagnosing ichthyosis vulgaris and atopic diseases or predisposition thereto.

Summary of the Invention

The present invention is based on the identification for the first time of mutations in the human filaggrin (*FLG*) gene which lead to a loss or partial loss of protein function.

Thus, in a first aspect, the present invention provides a genetic test for ichthyosis vulgaris (IV) comprising the steps of:

- a) providing a nucleic acid sample from a subject to be tested; and
- b) detecting whether or not a mutation, which would lead to a loss of function or partial loss of function of the filaggrin (*FLG*) protein encoded by the filaggrin (*FLG*) gene, is present in the *FLG* gene of said nucleic acid.

It will be appreciated that the test may be used to diagnose IV and/or to test if a subject is predisposed to developing IV. Additionally, due to an association of IV, in severe or mild forms, with other diseases, the test may be used to also detect whether or not a subject is likely to be predisposed or suffering from atopic dermatitis (eczema), asthma, psoriasis or allergies, such as of a contact type allergy and food allergies (for example, peanut allergy). With regards to skin conditions, low levels of filaggrin expression may lead to development of mild and/or sub-clinical disease. In this manner, the present invention may also relate to the identification and/or treatment of said mild and/or sub-clinical forms of disease. Indeed, many skin conditions go undiagnosed and as such treatments may be considered more as a cosmetic treatment.

Thus, in a further aspect, the present invention provides a genetic test for atopic dermatitis (eczema), asthma, psoriasis and/or allergies comprising the steps of:

- a) providing a nucleic acid sample from a subject to be tested; and
- b) detecting whether or not a mutation, which would lead to a loss of function or partial loss of function of the FLG protein encoded by the *FLG* gene, is present in the *FLG* gene of said nucleic acid.

The sample to be tested may be any suitable sample from which nucleic acid may be obtained. Typically the nucleic acid is a sample of genomic DNA or mRNA. Conveniently the sample may be a sample of saliva, buccal scraping or blood sample. The sample may also be a tissue sample, such as a skin biopsy.

The subject may be any subject requiring to be tested and may suitably be a newborn or even a foetus. The subject may however be at any stage of life, and therefore includes neonates, children and adults. As mentioned above, said tests may be carried out on a subject in order to ascertain whether or not he/she is predisposed to

developing a disease. Thus, a test may be carried out, for example, in order to test a subject's suitability for a particular job, where he/she may come into contact with agents which are known to lead in some cases to the development of eczema and/or allergy. Alternatively, said test may be carried out in order to categorise a subject and predict an "at risk" status for, for example, atopic disease. In this manner subjects may be tested so as to categorise or stratify subjects for therapeutic intervention, when appropriate, based on any results obtained, so as to prevent and/or treat atopic disease.

Moreover, ascertaining a subject's *FLG* status and therefore degree of expression or lack of expression of the FLG protein may find use in determining suitable treatment for a subject suffering or predisposed to suffering from IV and/or any of the other aforementioned diseases. For example, depending on the degree of severity, or expected degree of severity, the skilled artisan can decide on an appropriate therapeutic and/or cosmetic regime and as such tailored treatments can be based on a subjects *FLG* status.

The present invention, in one embodiment, is based on the identification of previously unidentified mutations in the *FLG* gene, which lead to a loss of function of the profilaggrin and consequently filaggrin proteins. The present invention however extends to any mutation in the *FLG* gene which leads to a loss or partial loss of function of the profilaggrin and/or filaggrin proteins.

The mutation may be an addition, deletion, substitution or inversion. Typically, the mutation effects 1 – 10 nucleotides, such as a one-base substitution, or a 2 – 10 e.g. 4-base deletion. The mutation may also be due to a translocation. By partial or total loss of profilaggrin or filaggrin protein function, is understood to mean that the mutation or mutations result in incorrect processing and/or expression of the *FLG* gene such that one or more of the filaggrin peptides normally expressed, is not

functionally expressed. Typically 10 – 12 copies of the filaggrin peptide are expressed from a non-mutated *FLG* gene⁶. It is understood therefore that the mutant *FLG* genes of the present invention will result in the functional expression of less than 10-12 filaggrin peptides, typically less than 7, 5, 3 or 1 from one or both copies of the *FLG* gene, which are present in a genome.

Depending on the location and/or type of a mutation or mutations, any reduction in functional filaggrin expression can be mild, e.g. a 1 – 5 reduction in functional filaggrin peptides; significant e.g. a 7 – 13 reduction in functional filaggrin peptides; or severe, e.g. a 15 – 20 reduction in functional filaggrin peptides.

The mutation or mutations may be found in any of the exons 1, 2 and/or 3 of the *FLG* gene and may typically be found in exon 3. If the mutation or mutations is/are located in exon 3, the most detrimental mutations, with regards to functional filaggrin expression, will be found within the 5' (N-terminal) portion of the 3rd exon, such as within the first 2000 bases, e.g. mutation(s) is/are found within the unique, partial repeat, or first filaggrin repeat portion of exon 3 (see Figure 2a).

A significant number of mutations have been identified by the present inventors, which lead to a loss of function and in some cases, a total loss of function of one of the *FLG* copies. One such mutation is a 1-base substitution at position 1501 of the *FLG* gene herein (as shown in Figure 5 and SEQ ID NO.: 188). 1501C>T (numbering from initiating ATG), which results in the substitution of a cytidine by a thymidine and a corresponding amino acid change at position 501 of an arginine to a stop codon. As this mutation occurs in the first filaggrin repeat (see Figure 2) and results in the generation of a stop codon, no functional copies of the filaggrin peptide are produced.

A second mutation identified is a 4-base deletion starting at position 2282 (see Figure 5 and SEQ ID NO.: 186). The mutation has been named 2282del4 and this causes a resulting frame-shift which leads to an alternative stop codon 107 bases downstream. Again, this mutation occurs in the first filaggrin repeat and as such no functional copy of a filaggrin peptide is expressed, although a truncated mutant form of the peptide may be expressed, which possesses a unique C-terminal portion (see Figure 4 and SEQ ID NO.: 187).

A third mutation is a deletion of a G in the third filaggrin repeat. The deletion is at position 3702 and is shown in Figure 5. This mutation causes a frameshift in repeat 3, such that only 2 functional copies of filaggrin from repeats 1 and 2 are made.

Further mutations which have been identified include R2477X (repeat 7), S3247X (repeat 9), R1474X (repeat 4), Q1745X (repeat 4), Q3683X (repeat 10), 11029delCA (repeat 10), E2422X (repeat 6), 5369delG (repeat 5), 7367delCA (repeat 7), 11033del4 (repeat 10), 6867delAG (repeat 6), 3321delA (repeat 2) and S2554X (repeat 7). The most prevalent and/or recurrent mutations in the European population are R510X, 2282del4, 3702delG, R2447X and S3247X.

The nomenclature used above is to be understood as follows:

S3247X, for example means that there is a mutation found at codon position 3247 which results in a codon change from a codon which encodes a serine, to a stop codon. 5360delG is a deletion of a G at DNA base-pair position 5360 (numbering where the initiating ATG = 1), leading to a frameshift.

Detection of a mutation in the *FLG* gene may be carried out by a variety of techniques including quantitative or semi-quantitative PCR, including real-time PCR, nucleic acid sequencing, hybridisation studies and/or restriction fragment length

polymorphism (RFLP) analysis techniques, well known to the skilled addressee (see, for example, Sambrook & Russel, 2000).

Depending on where the mutation or mutations are located, it may be appropriate to amplify one or more exons or portions thereof. If the mutation(s) is/are located in exon 3, all or only a portion of exon 3 may be amplified using appropriate primers. If the mutation(s) is/are located in the first repeat, it may only be necessary to amplify the first repeat, or portion thereof comprising the mutation(s). By appropriate use of primers and optional labels, it can be possible to amplify a product and ascertain whether or not the product comprises a mutation. For example, primers may be designed which incorporate at (or very close to) the 3' terminal, a base capable of binding to the native or mutant base/sequence, such that only the native or mutant sequence will be amplified and detected. A selection of primers suitable for use in amplifying the entire exon 3, or certain specific regions of the repeated sequences of exon 3 are identified herein as SEQ ID NO.s: 1 – 182.]

SEQ ID NO.s 1 – 8 represent primers suitable for long range PCR and sequencing of the filaggrin repeats.

SEQ ID NO.s 9 – 12 represent primers suitable for generating short PCR fragments for detection of the R501X mutation.

SEQ ID NO.s 13 – 15 represent primers suitable for generating short PCR fragments for detection of mutation 2828del4.

SEQ ID NO.s 15 – 18 represent primers suitable for generating short PCR fragments for detection of mutation 3702delG.

SEQ ID NO.s 19 – 40 represent primers which are specific for repeat 0.

SEQ ID NO.s 41 – 67 represent primers which are specific for repeat 1.

SEQ ID NO.s 68 – 93 represent primers which are specific for repeat 2.

SEQ ID NO.s 94 – 136 represent primers which are specific for repeat 3.
SEQ ID NO.s 137 – 201 represent primers which are specific for repeat 4.
SEQ ID NO.s 202 – 264 represent primers which are specific for repeat 5.
SEQ ID NO.s 265 – 329 represent primers which are specific for repeat 6.
SEQ ID NO.s 330 – 377 represent primers which are specific for repeat 7.
SEQ ID NO.s 378 – 414 represent primers which are specific for repeat 8.
SEQ ID NO.s 415 – 461 represent primers which are specific for repeat 9.
SEQ ID NO.s 462 – 493 represent primers which are specific for repeat 10.
SEQ ID NO.s 494 – 497 represent primers which are specific for repeat 8.1.
SEQ ID NO.s 498 – 501 represent primers which are specific for repeat 8.2.
SEQ ID NO.s 502 – 518 represent primers which are specific for repeat 10.1.
SEQ ID NO.s 519 – 539 represent primers which are specific for repeat 10.2.
SEQ ID NO.s 540 – 544 represent primers which are specific for repeat 11.
SEQ ID NO. 545 represents a primer which is specific for the filaggrin tail.

In all cases, F at the end of a primer sequence shows that the primer is a forward primer and an R shows it is a reverse primer.

It will be appreciated that shorter or longer versions of the identified primer sequences may be used, for example, the primers may be from 12 – 50 bases in length. However, 3'-terminal base is critical for correct primer extension and so the 3'-end of any primer should be identical to the sequences as identified herein.

Labels, such as fluorescent, chemiluminescent, bioluminescent or radio-labels may be incorporated into the PCR primers so as to allow detection of the native or mutant sequence. The skilled man will appreciate that two separately labelled primers may be used in a PCR reaction, designed to facilitate amplification of a product

comprising either the native or mutant sequence and the sequence, native or mutant, detected based on the particular label being present in the product. Other labelling techniques such as the TaqMan[®] system of Applied Biosystems Inc., CA, USA, may be employed.

Of course, a fragment of DNA, which includes the portion of DNA which may include the mutation, may simply be amplified and sequenced, in order to determine whether or not the *FLG* gene comprises a mutation. Alternatively, such a fragment may be amplified and a hybridisation study carried out using an appropriate oligonucleotide and very stringent hybridisation conditions and washing conditions employed (see for example Sambrook et al, 2000¹⁵) so that only exactly matching oligonucleotides bind to the amplified fragment in the region or regions comprising the mutation(s).

It may also be appropriate to first amplify a fragment of DNA comprising the sequence which may or may not comprise a mutation(s) and thereafter detecting whether or not the fragment includes the native or mutant sequence by carrying out a further PCR reaction using primers internal to the amplified fragment, in order to detect or otherwise, a mutation(s). Such a technique is commonly known as nested PCR.

Moreover, any particular mutation may generate a new restriction site which may be detected by RFLP analysis. A fragment which would encompass a mutation which, if present, can first be amplified using appropriate primers and the fragment thereafter subjected to RFLP analysis providing the mutation or native sequence has a restriction site which is not present in the corresponding native or mutant sequence. In accordance with the present invention, the exemplary mutations identified herein result in the generation of new restriction sites which can easily be detected by first

amplifying a fragment comprising the mutation and thereafter restricting the fragment obtained using the appropriate restriction enzyme – only a fragment comprising the mutant sequence will be restricted (see Examples Section for further description).

The present invention also extends to kits which comprise one or more of the aforementioned oligonucleotides/primers. The kits may also comprise other reagents to facilitate, for example, sequencing, conducting PCR and/or RFLP analysis. Such kits may also comprise instructions for their use to detect one or more mutations in a filaggrin gene and optionally how to interpret whether or not a mutation may lead to development or predisposition to developing IV and/or any of the other aforementioned diseases/conditions.

The oligonucleotides/primers of the present invention may also be used in multiplex PCR techniques, known to the skilled addressee, see for example. Kuperstein G, Jack E and Narod SA; Genet Test. 10(1):1-7 (2006)., so as to identify mutations in the filaggrin sequence.

In addition to mutations which lead to a loss of function or partial loss of function of profilaggrin/filaggrin protein, the present inventors have now identified the specific repeat sequences which can lead to exon 3 of the filaggrin gene consisting of 11 or 12 full filaggrin repeats, as opposed to the “normal” 10 repeats. The inventors have identified that repeats 8 and/or 10 can be essentially duplicated in certain individuals, in order to generate 11 or 12 filaggrin repeats. Desirably therefore, the present invention also extends to identifying the number of filaggrin repeats in a subject as well as detecting one or more mutations. Heterozygous mutant subjects who possess one mutant allele which results in no or little filaggrin expression, but have a second wild-type allele encoding 11 or 12, filaggrin repeats, may express sufficient filaggrin to not develop disease, or only a mild form of disease.

For example, a carrier of a 12-repeat allele, will express 20% more filaggrin than a 10-repeat carrier and this difference in expression may be significant in terms of disease development.

It has been observed that the aforementioned 4-base deletion (2282del4) results in the expression of a unique peptide which comprises an N-terminal region corresponding to the N-terminal portion of the filaggrin peptide and a unique C-terminal region which has been expressed due to the frame-shift mutation. With respect to this unique peptide which is produced from the mutant sequence comprising the 4-base deletion, it is possible to detect the unique peptide using an appropriate binding agent, such as a specific antibody. It is appreciated that any such binding agent/antibody should be specific for the unique peptide and not therefore be capable of binding the native filaggrin peptide.

The skilled man will readily know how to obtain a suitable antibody, such as a monoclonal antibody, by, for example, producing the unique peptide recombinantly or using synthetic chemistry, coded for by the mutant sequence and raising antibodies thereto. Antibodies so produced can thereafter be screened to ascertain their specificity, such that only those antibodies which are specific for the unique peptide may be selected.

Such specifically reactive antibodies to the unique peptide can be optionally labelled and used in an immunoassay to detect for the presence of the unique peptide in a sample. Alternatively, the specifically reactive antibody can be used in an assay, such as an ELISA, to detect any of said unique peptide in a sample being tested.

Thus, in a further aspect there is provided a method of detecting a mutant peptide expressed from a mutant of the *FLG* gene, comprising the steps of:

- a) providing a sample from a subject to be tested; and

b) detecting whether or not a mutant peptide expressed from a mutant *FLG* gene is present in the sample, by using a binding agent which is specifically reactive to said mutant peptide.

In this aspect, the sample may preferably be a skin tissue sample. Typically, the binding agent is an antibody, monoclonal antibody or fragment thereof, such as a Fab fragment. Detection may be carried out by detecting a label, such as a fluorescent, chemiluminescent, bio-luminescent or radio-label coupled to the binding agent/antibody/fragment. Alternatively, the binding agent, antibody or antibody fragment may be unlabelled and detected by way of an antibody specific for said binding agent, antibody or antibody fragment, such as in an ELISA assay.

It will be understood that the nucleic acid and mutant peptide tests described herein may be conducted individually or together.

Identification of mutants in the *FLG* gene leading to loss or partial loss of function of the FLG protein opens up the possibility of treating prophylactically or therapeutically IV and/or any of the other aforementioned diseases by gene therapy. As such a correct non-mutant copy or copies of the *FLG* gene may be used to complement for a mutant version of the *FLG* gene present in a subject.

Thus, in a further aspect there is provided use of an *FLG* gene sequence or fragment thereof, capable of encoding one or more copies of the *FLG* protein, in the manufacture of a medicament. It is understood that the medicament may be used for the prophylactic or therapeutic treatment of IV and/or diseases including atopic dermatitis (eczema), asthma, psoriasis and allergies.

The present invention therefore also provides an *FLG* gene sequence or fragment thereof, which gene sequence or fragment thereof, is capable of expressing one or more copies of the filaggrin protein, for use in therapy or prophylaxis.

It will be appreciated that the present invention also extends to methods of treating prophylactically or therapeutically any of the aforementioned diseases/conditions by administering to a patient suffering or predisposed to developing any of said aforementioned diseases a DNA construct comprising an *FLG* gene sequence or fragment thereof, which gene sequence or fragment thereof is capable of expressing one or more copies of the *FLG* protein, whereby expression of said one or more copies of the *FLG* protein treats or ameliorates said disease(s)/condition(s).

Typically, the *FLG* sequence or fragment thereof will be administered to a subject in the form of a recombinant molecule comprising said *FLG* sequence or fragment under appropriate transcriptional/translational controls to allow expression of said filaggrin protein when administered to a subject. It will be appreciated that the *FLG* sequence or fragment may be under control of a suitable promoter, such as a constitutive and/or controllable promoter. Convenient promoters include the native filaggrin promoter, or an appropriate late differentiation-specific keratin promoter.

The present invention also therefore provides a recombinant molecule comprising an *FLG* sequence or fragment thereof for use in therapy. The recombinant molecule may be in the form of a plasmid, phagemid or viral vector. Furthermore, recombinantly expressed, or chemically synthesised filaggrin or profilaggrin protein, or functionally important fragments thereof, may be produced and applied to the skin via a suitable ointment or other pharmaceutical vehicle, as a treatment or prophylactic measure for ichthyosis vulgaris and/or atopic diseases. Such a treatment may also be of cosmetic value as it may increase the barrier function and/or moisture-retention properties of the skin. Since filaggrin is prominently expressed in hair from early in development¹⁶, such a treatment may also improve cosmetic qualities of the hair, such

as moisture retention, in individuals with either normal or reduced filaggrin expression.

Many different viral and non-viral vectors and methods of their delivery, for use in gene therapy, are known, such as adenovirus vectors, adeno-associated virus vectors, retrovirus vectors, lentiviral vectors, herpes virus vectors, liposomes, DNA vaccination and the like¹⁷.

The present invention also provides a method of treating, preventing and/or ameliorating IV and/or any of the aforementioned diseases, comprising the steps of:

- a) determining if expression of one or more copies of the FLG polypeptide would occur even if a subject's FLG gene comprises one or more mutations; and
- b) providing a subject carries *FLG* alleles capable of expressing at least one or more copies of the FLG polypeptide, treating the subject using UV light in order to seek to increase *FLG* expression.

The intention is to increase expression of FLG polypeptides in the skin. This may most easily be achieved in heterozygote subjects, i.e. those subjects who have one mutant copy of the *FLG* gene and one native copy.

The expression of the *FLG* gene is known to be induced by UV light¹⁸. Thus, UV treatment of the skin of an individual carrying a heterozygous copy of a filaggrin loss-of-function mutation could increase the expression of the normal allele and thereby produce a beneficial effect.

The present invention also relates to a transgenic non-human animal which possesses one or more mutations in one or both copies of the *FLG* gene which would lead to a loss or partial loss of function of the *FLG* protein encoded by the *FLG* gene. Desirably, the *FLG* gene of the non-human animal may be replaced with a mutant

human form of the gene, in order to "humanise" the non-human animal with respect to the *FLG* gene.

The transgenic animals of the present invention can be used for the development of various treatments for IV and/or the other diseases mentioned herein including the identification of various therapeutically active agents including but not limited to other proteins, peptides, peptidomimetic drugs, small molecule drugs, chemicals and nucleic acid-based agents.

The term non-human animals is used herein to include all vertebrate animals, except humans. It also includes an individual animal in all stages of development, including embryonic and foetal stages. A transgenic animal is any animal containing one or more cells bearing genetic information altered or received, directly or indirectly, by deliberate genetic manipulation at a subcellular level, such as by targeted recombination or microinjection or infection with recombinant virus. The term transgenic animal is not intended to encompass classical cross-breeding or *in vitro* fertilization, but rather is meant to encompass animals in which one or more cells are altered by, or receive, a recombinant DNA molecule.

To create a transgenic non-human animal expressing a mutant form of the *FLG* gene, mutant *FLG* nucleic acid sequences are inserted into a germ line of the animal using standard techniques of oocyte microinjection or transfection or microinjection into stem cells. Preferably, it is desired to replace the endogenous gene and homologous recombination using embryonic stem cells or foetal fibroblasts can be applied.

Mice are often used for transgenic animal models because they are easy to house, relatively inexpensive, and easy to breed. However, other non-human transgenic mammals can also be made in accordance with the present invention such

as but not limited to monkeys, sheep, rabbits, dogs and rats. Transgenic animals are those which carry a transgene, that is, a cloned gene introduced and stably incorporated which is passed on to successive generations.

For oocyte injection, for example in mice, one or more copies of the nucleic acid sequences encoding *FLG* can be inserted into the pronucleus of a just-fertilised mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The live born mice can then be screened for integrants using analysis of, for example, tail DNA for the presence of the mutant *FLG* sequences.

Methods of making transgenic mammals are known and described, e.g. in Wall, et al. (1992) J. Cell Biochem. 49(2): 113-20¹⁹; McCreath, et al. (2000) Nature 405: 1066-1069²⁰; Lai, et al. (2002) Science 295: 1089-92²¹; Hogan, et al. (1986) In: Manipulating the mouse embryo. A Laboratory Manual. Cold Spring Harbour Laboratory Press, Cold Spring Harbor, N.Y.²²; in WO 91/08216 or U.S. Pat. No. 4,736,866. The mice disclosed herein can be crossed with a hairless or nude mouse background so that skin abnormalities are visible to facilitate monitoring of disease progression and/or potential therapies.

An *in vivo* assay for identifying an agent which is useful for treating or preventing IV and/or any of the other aforementioned diseases associated with mutant *FLG* expression comprising the steps of administering a test agent to a *FLG* mutant transgenic animal; and measuring or determining whether the agent decreases or inhibits at least one sign or symptom of IV and/or any of the other aforementioned diseases which is indicative that the test agent is capable of treating or preventing IV and/or any of the other aforementioned diseases. The results of the screening assay can be compared with a control, e.g., an animal which has not been administered a test agent or an animal which has received an agent known to reduce a sign or

symptom of said diseases. The route of administration of the test agent may vary. Examples of administration routes include, but are not limited, to oral, nasal, rectal, transmucosal, intestinal, parenteral, intravenous, intraperitoneal and topical.

Examples Section

The present invention will now be further described by way of example and with reference to the Figures which show:

Figure 1 shows Pedigrees of IV families studied.

Pedigrees of IV families studied here where a family history was available. Families 1-3 are of Irish origin, Families 4-6 are Scottish and Family 7 is of US origin. In addition, 8 isolated IV cases were studied where a family history was not available (not shown). Of the latter, one case was Irish, 4 were Scottish and 3 were of US origin. All patients studied were White Caucasians. Black-filled symbols refer to the marked IV presentation; cross-hatched symbols refer to the very mild IV presentation; open symbols refer to no detectable IV phenotype. The genotypes for the two mutations R501X and 2282del4 are shown. Note that wt/wt refers only to the regions screened and does not preclude other sequence changes in the central regions of exon 3. Only two people with no detectable IV phenotype were found to have a filaggrin mutation: individual II-5 in Family 5, who carries R501X; and individual II-1 in Family 7, who is an obligate carrier of R501X. On this basis, we estimate the penetrance in heterozygotes as ~90%, although this is probably an overestimate due to ascertainment bias. Many individuals in these families, who carry one or other filaggrin mutation, either heterozygously or homozygously, have, in addition to ichthyosis vulgaris, atopic dermatitis (eczema) and/or asthma and/or allergies (see

also Figure 4). Thus, filaggrin mutations predispose individuals to these other conditions.

Figure 2 shows FLG mutation detection and confirmation.

- (a) Schematic diagram of the filaggrin gene (*FLG*), annotated to show the corresponding protein structure. Exon 1 consists of a short 5'UTR sequence. Exon 2 and the 5' end of exon 3 encode the profilaggrin N-terminal domain. The remainder of exon 3 consists of 10-12 repeats of approximately 1 kb, each encoding a filaggrin peptide separated by linker sequences, followed by a short unique coding sequence and the 3'UTR. Upon terminal differentiation of the epidermis, each profilaggrin molecule is proteolytically cleaved to release 10 – 12 copies of filaggrin, which aggregate the keratin cytoskeleton and cause physical collapse of the granular cells to form squamous cells. The positions of PCR fragments used here and of the two null-mutations, R501X and 2282del4 in repeat 1 of exon 3, are shown.
- (b) Long-range PCR product from genomic DNA covering exon 3 and therefore all the filaggrin repeats.
- (c) Normal sequence from filaggrin repeat 1 in exon 3, corresponding to codons 499-503.
- (d) The same region of the *FLG* as seen in (c), showing heterozygous transition mutation 1502C>T resulting in nonsense mutation R501X.
- (e) The same region of *FLG* as in (c) showing a homozygous mutation resulting in a nonsense codon, R501X.
- (f) Confirmation of mutation R501X by *Nla* III restriction digest and 2282del4 by *Dra* III restriction digest from some members of Family 3.
- (g) Normal sequence from filaggrin repeat 1 in exon 3, corresponding to codons 713-717.

- (h) The same region of *FLG* as in (f), showing overlapping peaks due to a heterozygous deletion mutation, 2282del4.
- (i) The same region of the *FLG* as in (f), derived from a mutant clone confirming mutation 2282del4. This mutation leads to a premature stop codon 107 bp downstream and terminates translation within filaggrin repeat 1.

Figure 3 shows morphological features of filaggrin-null ichthyosis vulgaris.

- (a) Skin biopsy from a normal (non-ichthyotic) control. Haematoxylin and eosin staining of formaldehyde-fixed paraffin-embedded tissue shows prominent keratohyalin granules in the granular cell layers of the superficial epidermis (arrows).
- (b) Skin biopsy from the proband in Family 4, who is homozygous for nonsense mutation R501X in the *FLG* gene. In contrast with the normal control seen in (a), there is a complete absence of keratohyalin granules in the upper layers of the epidermis. The degenerating nuclei seen in the uppermost living layers (arrows), indicate that this is the area where one would normally see keratohyalin granules.
- (c) Transmission electron micrograph of keratinocytes at the boundary of the granular layer and stratum corneum, from a normal individual, showing prominent keratohyalin granules (arrowheads). N = nucleus; K = keratinized material in stratum corneum. Original magnification = ~5,600x.
- (d) Transmission electron micrograph of granular layer cells from the proband in Family 4, who is homozygous for nonsense mutation R501X in the *FLG* gene. There is a complete absence of keratohyalin granules (*). The stratum corneum is not fully cornified, as compared with the control (K), indicative of an epidermal barrier defect. N = nucleus. Original magnification = ~5,600x.

- (e) Immunohistochemical staining of formaldehyde-fixed paraffin-embedded tissue using anti-filaggrin repeat monoclonal antibody 15C10 (Novocastra), visualized by the immunoperoxidase method. In skin biopsy material from a normal control, keratohyalin granules are strongly stained in the upper suprabasal layers of the epidermis (arrows).
- (f) Immunoperoxidase staining of skin biopsy material from the proband in Family 4, shows complete absence of staining in the upper suprabasal layers (arrows) with anti-filaggrin repeat monoclonal antibody 15C10 (Novocastra). This demonstrates that no filaggrin peptides are produced in patients homozygous for R501X, consistent with a nonsense mutation within the first filaggrin repeat.
- (g) Immunoperoxidase staining of skin biopsy material from a normal control individual with polyclonal antibody B1, raised against an epitope within the N-terminal domain of profilaggrin, showing prominent staining of keratohyalin granules (arrows).
- (h) Immunoperoxidase staining of skin biopsy material from the proband in Family 4, with profilaggrin N-terminal antibody B1. No granular staining is seen but unlike the filaggrin repeat epitope (f), there is a diffuse pattern of residual staining. This is more pronounced in the upper suprabasal cells where profilaggrin is normally expressed (arrows) but in addition there is some patchy diffuse cytoplasmic staining throughout the epidermis (arrowheads). The epitope of this antibody is upstream of the mutation and so this shows that a truncated fragment of profilaggrin is synthesized in R501X homozygotes.

Figure 4 shows complete sequence of the filaggrin repeats and identifies the positions of the mutations identified by the inventors and positions of where the specific primers identified herein bind. These specific priming sites were identified

by analysis of alignments of the individual filaggrin repeats, including the novel additional repeats identified by the inventors.

Figure 5 shows the pedigrees of a family with IV and corresponding atopy transmission;

Figure 6 is a graph showing that filaggrin variants are associated with increased atopy;

Figure 7 is a graph showing increased number of positive allergens in carriers of filaggrin mutations;

Figure 8 is a graph showing filaggrin variants are stronger risk factors for eczema in the older asthmatics;

Figure 9 shows a) immunostaining of skin biopsy material from a normal control and an IV patient with the R510X/R2447X genotype. b) immunoblotting of skin biopsy protein extracts from a normal control and IV patients with the genotypes R501X/R2447X and R501X/R501X;

Figure 10 is a schematic diagram of profilaggrin proteins encoded by size variant alleles of *FLG*;

Figure 11 shows the DNA sequence of *FLG* size variant allele *FLG*^{δ+};

Figure 12 shows the DNA sequence of *FLG* size variant allele *FLG*¹⁰⁺; and

Figure 13 shows the sequence of a fragment from *FLG* size variant allele *FLG*^{δ+10+}, together with annotations as follows:

Annotated Sequence – repeats in alternate plan and bold text

* = unique base pair specific to this filaggrin repeat sequence

N = base pair shared with only one other filaggrin repeat sequence, number N

N* = base pair essentially specific due to nearby differences in repeat N.

METHODS

Affected individuals and phenotypes

Blood samples were obtained from 15 families with IV and normal ethnically matched controls with informed consent that complies with all principles of the Helsinki Accord.

Long-range PCR for *FLG* exon 3

Primers FilLR2F (+ strand) 5' GTC ACT TAC CCC ATC AAA TC 3' and FilLR1R (- strand) 5' CCA CCA AAC TAA TGA AAT AC 3' were used to amplify approximately 12 kb of the filaggrin gene (including all of exon 3 and therefore all the repeat domains) from genomic DNA using the Expand Long Template PCR System (Roche Diagnostics, East Sussex, UK). A "hot start" was performed with 1U Expand Long Template enzyme mix (Roche). Reactions were amplified using the following extended PCR program: (92°C 5 min x1); (92°C 10 sec, 49°C 30 sec, 68°C 6 min) x10; (92°C 10 sec, 49°C 30 sec, 68°C 6 min plus 10 sec increment/cycle) x28; and (68°C 10 min) x1.

R501X mutation analysis

A shorter PCR fragment was designed to amplify approximately 1.5 kb for mutation analysis of R501X. Primers FilF3 (+ strand) 5' GCT GAT AAT GTG ATT CTG TCT G 3' and RPT1P6 (- strand) 5' ACC TGA GTG TCC AGA CCT ATT 3' were used in High Fidelity PCR buffer (Roche) containing 1.5 mM MgCl₂, 4% DMSO and 1U High Fidelity thermostable DNA polymerase mix (Roche). Reactions were amplified under the following conditions: (94°C 5 min x1); (94°C 30 sec, 57°C 1 min, 72°C 2 min) x30; and (72°C 5 min) x1. Mutation R501X creates a new *Nla* III

restriction enzyme site; this was used to confirm the mutation and screen control samples. Primers FilH1F3 (+ strand) 5' CAC GGA AAG GCT GGG CTG A 3' and RPT1P6 (above) were used to amplify 312 bp of genomic DNA using PCR buffer (Promega) containing 1.5 mM MgCl₂, 4% DMSO and 1U *Taq* polymerase mix (Promega). Reactions were amplified as follows: (94°C 5 min x1); (94°C 30 sec, 58°C 45 sec, 72°C 1 min) x30; and (72°C 5 min) x1. PCR products were digested with 5U *Nla* III for 4 hr at 37°C. Digests were resolved on 3% agarose gels.

2282del4 mutation analysis

A PCR fragment amplifying 811 bp of genomic DNA was amplified with primers RPT1P7 (+ strand) 5' AAT AGG TCT GGA CAC TCA GGT 3' and RPT2P1 (- strand) 5' GGG AGG ACT CAG ACT GTT T 3' using PCR buffer (Applied Biosystems) containing 1.5 mM MgCl₂, 4% DMSO and 1U *Taq* polymerase mix (Promega). PCR amplification conditions were: (94°C 5 min x1); (94°C 30 sec, 57°C 45 sec, 72°C 1 min 30 sec) x35; and (72°C 5 min) x1. Mutation 2282del4 creates a new *Dra* III restriction enzyme site which was used to screen samples for this mutation. PCR products were digested with 5U *Dra* III for 4 hr at 37°C. Digests were resolved on 2% agarose gels. A PCR fragment from a heterozygous individual was cloned into vector pCR2.1 (Invitrogen). Clones were screened by *Dra* III digestion and sequenced to confirm the 4 bp deletion.

Histology and electron microscopy

Routine hematoxylin and eosin (H&E) staining was performed to evaluate morphologic features of each specimen. Immunoperoxidase staining of frozen and paraffin-embedded sections utilized the Envision system (DakoCytomation,

Denmark). Antibodies used were mouse monoclonal 15C10 against an epitope in the C-terminal portion of the human filaggrin repeat unit (Novocastra, Newcastle upon Tyne, UK) and rabbit polyclonal antiserum B1 raised against the N-terminus of profilaggrin²³. For transmission electron microscopy, skin samples from patients were fixed in half-strength Karnovsky's fixative (containing 2.5% glutaraldehyde and 2% formaldehyde) then in 1.3% osmium tetroxide and processed using standard methods, largely as described previously²⁴.

Lod score calculations

Lod scores were calculated with MLINK algorithm of LINKAGE version 5.1, using a semidominant model of the disease where heterozygotes were assigned a mild phenotype with 90% penetrance and homozygotes or compound heterozygotes were assigned as a severe phenotype with 100% penetrance. The combined mutant allele frequency was assumed to be 0.037 (Table 1). Recalculation with 50% penetrance in heterozygotes still yielded a highly significant maximum combined lod score of 7.08 at $\theta=0$.

FLG consists of three exons^{25,26}. Exon 1 (15 bp) consists only of 5'UTR sequences and exon 2 (159 bp) contains the initiation codon. Exon 3 is unusually large (12,753 bp) and codes for most of the N-terminal domain and all filaggrin repeats (Figure 2a). The number of filaggrin repeats varies from 10-12 in the population⁶. The homology between the repeats at the DNA level is almost 100%, making conventional PCR-based sequencing for the internal regions of this exon almost impossible. No sequence changes were found in exons 1 or 2 in five IV families. The present inventors developed long-range PCR conditions to amplify a 12 kb genomic fragment covering exon 3 and therefore all the repeat domains (Figure

2b). Full sequencing of this fragment is on-going, but initial sequencing has revealed a homozygous nonsense mutation R501X near the start of repeat 1 in three affected individuals from Family 1 (Figure 2c - e). Using a smaller PCR fragment, segregation of R501X was confirmed in Family 1 and in addition, this mutation was identified in the other 14 IV kindreds studied. The mutation creates a new *Nla* III restriction enzyme site; this was used to confirm the mutation and screen populations (Figure 2f). By this means, the mutation was found to be present at relatively high allele frequencies in Irish, Scottish and North American Caucasian populations (combined frequency, 0.027; see Table 1).

In 3 families, IV patients with a very pronounced phenotype were homozygous for R501X (Figure 1). In other families and isolated cases, individuals with the marked IV phenotype were found to be heterozygous for R501X. Further sequencing in these cases revealed a second mutation, 2282del4, in exon 3 (Figure 2g - i). This leads to a premature termination codon 107 bp downstream and, like R501X, stops protein translation within the first filaggrin repeat (Figure 2a). Mutation 2282del4 creates a *Dra* III restriction enzyme site which was used to screen IV families and control samples (Figure 2f; Table 1). This mutation segregated in 10 of the IV families studied (Figure 1). Of the 8 "sporadic" cases of clinically significant IV where family history was not available, 4 were homozygous for R501X and the remaining 4 were R501X/2282del4 compound heterozygotes. Interestingly, part of the US family previously reported to show significant linkage to the *FLG* locus²⁷, was studied using freshly obtained high-quality DNA required for analysis of exon 3. The severely affected individuals in Family 7 were compound heterozygous for R501X/2282del4 (Figure 1), consistent with the linkage data previously reported²⁷. The semidominant mode of inheritance is best exemplified in Family 1

where there are multiple examples of IV patients with the very mild presentation as well as examples of R501X homozygotes and R501X/2282del4 compound heterozygotes with the full IV phenotype. In the studied series of families there were only two individuals who were heterozygous for a null-mutation (both R501X) and have no obvious phenotype (Families 5 & 7; Figure 1). On the basis of these small numbers, the penetrance in heterozygotes appears to be about 90%, however, this may be an overestimate due to ascertainment bias. The allele frequency for 2282del4 in US, Irish and Scottish Caucasians was found to be ~0.01 (Table 1). Using the determined allele frequencies and assuming mildly affected heterozygotes and severely affected homozygotes, the maximum combined 2-point lod score for families 1-7 (Figure 1), was 8.11 at $\theta=0$.

Skin biopsy material from an R501X homozygote (proband, Family 4) was subjected to histological and ultrastructural analysis. The granular layer was found to be absent by conventional histology (Figure 3a & b) and electron microscopy showed complete absence of keratohyalin (Figure 3c & d). Immunohistochemistry showed that an epitope conserved in all filaggrin repeat peptides was completely absent in the R501X homozygote (Figure 3e & f). In contrast, an epitope in the N-terminal domain of profilaggrin, encoded by sequences upstream of filaggrin repeat 1, was still present, albeit in an abnormal, diffuse distribution (Figure 3g & h). Immunohistochemical analysis of an R501X/2282del4 compound heterozygote gave identical results (not shown). This confirms that either R501X or 2282del4 result in complete loss of filaggrin peptide production and so functionally, these are null-alleles.

Since profilaggrin is the major component of keratohyalin granules, this explains the absent granular layer associated with the more severe cases of IV²⁷ (Figure 3). The presence of a truncated profilaggrin peptide in IV epidermis (Figure

3b) is consistent with previous studies demonstrating that a peptide containing the unique N-terminal domain and a small amount of filaggrin sequence is stable *in vitro*²³. In normal epidermis, the N-terminal Ca^{2+} -binding domain is cleaved from profilaggrin by a proprotein convertase, and subsequently localizes to different cell compartments including the nucleus^{28,29}. Similar processing of the truncated peptide may occur in IV epidermis.

Here the inventors have shown that in three Caucasian populations, IV appears to be predominantly caused by two frequent null-mutations in *FLG*, leading to loss of filaggrin production and impaired epidermal barrier formation. In the IV families studied, most R501X mutations are in linkage disequilibrium with the same 156 bp allele of a microsatellite in intron 2 of *FLG* (data not shown), suggesting that, in human evolutionary terms, these are ancient mutations. Further analysis of polymorphisms near *FLG* will determine the approximate age of the mutations. Genetic drift may explain why these mutations have become so prevalent. Alternatively, a heterozygote advantage might explain the high frequencies of these alleles. One obvious hypothesis is that impaired barrier function leads to elevated exposure to bacterial or other antigens, leading to greater innate immunity. This “natural cutaneous vaccination” might allow heterozygotes to better survive when challenged by pandemic plagues or other pathogens. This should be testable using *fl* mice¹² or engineered filaggrin null-mice.

Regarding the inheritance pattern and incidence of IV; the very subtle heterozygote phenotype probably does often not come to clinical attention unless specifically sought, as was the case here. Assuming a combined null-allele frequency of ~0.037 (Table 1), and a pronounced heterozygote phenotype, then 1 in 14 people would have IV, which is clearly not the case. With this allele frequency, 1 in 730

should be homozygous or compound heterozygous and have marked IV. The subtlety of the heterozygote phenotype, combined with incomplete penetrance and seasonal variation², probably explains the reported incidence of 1 in 250¹. With these high mutant allele frequencies, IV families will also frequently appear to have dominant or pseudo-dominant inheritance with reduced penetrance (Figure 1). By Southern analysis, polymorphism in the number of filaggrin repeats has been shown in humans (10-12 repeats)⁶ and mice (12-20 repeats)³⁰. The inventors also observed this size variation using long-range PCR and determined the sequences of the longer variant alleles (described below). It is possible that a heterozygote for a null-mutation might carry an expanded exon 3 on their other allele, lessening the overall effect of the mutation. This might explain the phenotypically normal heterozygotes seen in Families 5 and 7 (Figure 1). Due to their relatively high population frequencies, filaggrin null-mutations may themselves be modifying factors in other ichthyotic skin conditions, including congenital ichthyoses, Netherton syndrome or disorders due to defects in suprabasal keratins, where intra- and interfamilial phenotypic variation is well documented³¹⁻³⁴. The association of IV with the atopic diathesis is well established; 37-50% of people with IV have atopic diseases^{1,36} and conversely around 8% of atopic dermatitis patients have classical features of IV^{1,35}. Thus, filaggrin may be a factor in very common skin disorders known to have a major genetic component.

In the IV families studied, many filaggrin-null or heterozygous individuals also had atopic dermatitis (AD; "eczema") and/or asthma. An example is shown in Figure 5, where 3/6 filaggrin-null heterozygotes and 5/5 homozygotes had atopic disease. The inventors therefore sought to examine the role of these variants in common atopy associated with asthma. The two filaggrin variants were genotyped in a cohort of 800 schoolchildren with unknown disease status (population cohort) and in

550 school children and adolescents with physician-diagnosed asthma from the Dundee BREATHE study. The frequency of carriers of R501X was 5.2% and the 2282del4 variant was present in 3.6% of the schoolchildren, giving a combined carrier frequency of 8.8%. Both filaggrin variants were over-represented in the asthmatic cohort, with carriers of either allele demonstrating a dominant risk (Table 2; combined genotype OR= 1.94 95%CI= 1.35-2.80, $p=0.0005$). Homozygotes for both variants were observed in the asthma cohort, as were two compound heterozygotes. AD is known to be co-associated with asthma^{1,36} and since filaggrin is a major epidermal structural protein, one would expect a stronger association with AD/asthma with filaggrin defects. Consistent with this, 75% of all the children in the asthma cohort carrying a filaggrin null-allele had AD, in contrast to only 46.7% of those without these filaggrin variants (Table 3; OR= 2.81 95%CI= 1.64-4.81, $p=0.0001$). This observation appears to be related to allergen exposure, as the risk was largely seen in individuals routinely exposed to animals (OR 5.2 95%CI= 2.36-11.50, $p=0.000006$).

These data suggested that a barrier function defect may lead to greater risk of allergy and this hypothesis was supported by the observation that a significantly greater number of the children with asthma had been referred to an allergy clinic for allergy testing if they carried a filaggrin null variant (OR= 1.78 95%CI=1.08-2.95, $p=0.034$). Even more significantly, every individual tested that carried the null variants ($n=20$) was positive for at least one allergen, whereas 26 out of the 56 non-carrier individuals tested negative for allergens ($p=0.00006$). This striking atopic phenotype resulted in a systematic increase of the carrier frequency of the null variants as we increased the definition of the degree of atopy of the cohort (Figure 6), with 46.7% of all the individuals that had asthma, AD and immunologically-verified allergy having

the filaggrin null variants (n=75). In this group, the variant was still further associated with an increased number of positive allergens, with the mean number of allergens for a null variant carrier being substantially greater than that for the wild type individuals (Figure 7). This demonstrates that a substantial fraction of common, complex atopic disease can be accounted for by a single pair of variants in the filaggrin gene. Given the population carrier frequency of both of these variants (~9%), these observations will have a huge impact in the understanding of atopy and may lead to the development of novel treatments for asthma and allergy. Asthma and allergy can wane during adolescence and the temporal features of childhood atopy are known as the "atopic march". Here the inventors show that individuals haploinsufficient for filaggrin represent a population of persistent atopy, where the observed risk of eczema increases consistently through age in the asthmatic cohort, consistent with the atopic march (Figure 8).

Nut and food allergy

The asthma cohort was analysed for people with a recorded allergy to peanuts and/or other nuts. 23 individuals had a proven nut allergy and of these, 8 carried a filaggrin-null mutation (either 2282del4 or R501X), i.e. 35% were carriers. In a population control cohort, 60 out of 621 individuals carried a filaggrin-null mutation, i.e. 9.7%. Thus, the filaggrin mutation carrier frequency is greatly increased in people with asthma and nut allergy. Fisher's exact test gave a two-sided P value of 0.0008, which is considered extremely significant (odds ratio = 5.520 95%CI 2.248-13.554). Thus, filaggrin mutations are a highly significant risk factor for nut allergy and asthma. In addition, atopy is strongly associated with food allergy especially cow's milk, hen's egg, banana, kiwi, white fish, wheat, prawns/shrimp and strawberries³⁷⁻³⁹.

Since nut allergy is regarded as the most reliable marker for food allergy, this strongly infers that filaggrin mutations are associated with food allergies in general.

A comprehensive mutation detection strategy for FLG.

Using primers ending on bases that had been determined by detailed sequence alignments to be absolutely specific for a given filaggrin repeat, or in a few cases, ending on bases that are shared by only two filaggrin repeats, a series of overlapping PCR fragments was generated that span exon 3 of the *FLG* gene in its entirety. These fragments were fully sequenced using the amplification primers and/or internal primers that again ended on unique bases. In some individuals, the identification of single nucleotide polymorphisms was able to show that the overlapping PCR fragments were amplifying both alleles, thus demonstrating the specificity and utility of this sequencing strategy. Using this method, individuals with a severe IV phenotype predictive of homozygous or compound heterozygous mutations were sequenced. These patients were from European populations, predominantly Irish and Scottish with some Dutch and Austrian individuals. A number of novel loss-of-function mutations were identified, all of which lead to premature termination codons, either as nonsense mutations or frameshift mutations. In many cases, these were inherited in *trans* with the more common mutations R501X or 2282del4. Specifically, these further mutations were 3702delG (repeat 3), R2447X (repeat 7), S3247X (repeat 9), R1474X (repeat 4), Q1745X (repeat 4), Q3683X (repeat 10), 11029delCA (repeat 10) in Irish and Scottish patients; E2422X (repeat 6), 5360delG (repeat 5), 7267delCA (repeat 7) and 11033del4 (repeat 10) in Dutch patients; and 6867delAG (repeat 6) in an Austrian patient. The IV phenotype of the patients carrying these more 3' mutations were essentially indistinguishable to patients carrying R501X or 2282del4

mutations in repeat 1. Thus, premature termination codon mutations essentially anywhere in the profilaggrin molecule appear to have similar or equivalent pathogenicity. The following mutations were recurrent and/or prevalent in the European population R501X, 2282del4, 3702delG, R2447X and S3247X. The Dutch and Austrian mutations were not detected in 188 Irish AD patients and may be population-specific or very rare. The remaining variants were not tested for prevalence.

Mutations in the 3' half of FLG exon 3 are essentially functional null alleles

To determine the biochemical consequences of the more 3' mutations, biopsy material was obtained from two patients with the compound heterozygote genotype R501X/R2447X. Immunostaining of skin sections with Novocastra 15C10 antibody against the filaggrin repeat domain showed that this patient has an identifiable but very restricted granular cell layer in the upper epidermis (**Figure 9A**). The more quantitative technique of immunoblotting, using protein extracts from this biopsy, revealed that only a very small quantity of a truncated profilaggrin molecule is expressed and importantly, this is not processed into mature filaggrin (**Figure 9B**). Essentially identical results were obtained for an R501X/11033del4 compound heterozygote (not shown). Thus, more 3' *FLG* mutations lead to greatly reduced expression of truncated profilaggrin and complete loss of mature filaggrin and therefore, are essentially filaggrin functional null alleles.

Mutations in more 3' repeats and repeat 1 of the FLG gene predispose to AD

A cohort of 188 Irish paediatric cases of moderate-severe AD were genotyped for 5 mutations found to be prevalent and/or recurrent in this population, R501X,

2282del4, 3702delG, R2447X and S3247X. Comparison of allele frequencies was made to an unselected Irish control population of 736 individuals genotyped for the same 5 *FLG* variants. Pearson chi-square analysis revealed that all 5 mutations are independently associated with the AD phenotype, giving individual statistically significant *P* values of <0.05 (**Table 4**). Combining the data for all 5 genotypes gave an extremely significant *P* value of 2.12×10^{-51} . About 48% of the patients in the AD cohort carried one or more of the 5 filaggrin variants. Thus, a wide range of *FLG* mutations contribute to genetic predisposition to atopy and this is a major gene in early-onset moderate-to-severe AD.

A different spectrum of *FLG* mutations predispose to atopy in non-European populations

The European-specific mutations R501X and 2282del4 were found to be absent from 253 Japanese individuals. We therefore sequenced the *FLG* gene in four Japanese families with IV and identified two novel mutations, 3321delA and S2554X.

We screened 143 Japanese AD patients for these null *FLG* mutations and identified them in 8 AD patients (5.6%), including S2554X in 6 patients (4.2%) and 3321delA in 2 patients (1.4%). Both null variants were absent from 156 Japanese non-atopic and non-ichthyotic controls, giving a statistically significant association between the *FLG* mutations and AD (Chi-square *P* value 0.0015).

Thus, in non-European populations, in this case Japan, there appears to be a distinct set of prevalent/recurrent *FLG* mutations that contribute to genetic predisposition to atopy. It is likely that other human populations will have their own spectrum of *FLG* mutations.

Size variants of the filaggrin gene (*FLG*)

It has been reported previously that exon 3 of the *FLG* gene is variable in size in the human population and these variant alleles were predicted, on the basis of their size, to consist of 10, 11 or 12 full filaggrin repeats in addition to the two partial repeats (Gan et al., 1990)⁴⁰. However, the positions of these insertions within *FLG* exon 3 and the precise DNA sequences encoding these additional filaggrin repeats remained unknown.

Using specific PCR primers located in repeat 7 and repeat 11, DNA fragments were generated from unrelated individuals that, from the public sequence of the *FLG* gene (Human Genome, March 2006 Assembly, hg18), would be predicted to be ~4.2 kb in size. For convenience, this allele is designated as *FLG^N*. In some individuals, additional bands of ~5.2 and/or ~6.2 kb were observed. These larger alleles were cloned into plasmid vector pCR3.1 to allow full sequencing of these variant alleles. This revealed that some individual alleles contain a duplication of repeat 8, designated as *FLG⁸⁺*. Another allele consisted of what was essentially a duplication of repeat 10, which was designated as *FLG¹⁰⁺*. Both copies of the repeat 10 sequences on this allele showed some sequence divergence from the published genome sequence. Similarly, there were a smaller number of sequence differences between the two repeat 8 copies on the *FLG⁸⁺* allele. In some individuals, a larger allele was present consisting of the duplicated repeat 8 and the duplicated repeat 10, which was designated as *FLG⁸⁺¹⁰⁺*. The size variants are shown diagrammatically in **Figure 10**, compared to the hg18 genome database sequence, labelled *FLG^N*. The raw sequences of the duplicated regions of these alleles are shown in **Figures 11-13**. A fully annotated sequence of the *FLG⁸⁺¹⁰⁺*, representing all the novel sequence data

generated here, with the positions of the previously known and novel filaggrin repeat sequences, is shown in **Figure 13**.

By alignment of these additional repeat sequences with all the existing filaggrin repeats, a number of priming sites were identified that would allow specific amplification, sequencing and mutation detection within these novel alleles. Forward and reverse primers ending on these specific bases are listed in the sequence listing as SEQ ID Nos. **494 - 539**. It is recognised that the length of these primers may be varied and still allow specific PCR amplification, sequencing, or mutation analysis, provided the 3' end of the primer ends on these specific bases or very close to them. The specific bases within the duplicated repeat regions are also annotated on **Figure 13**.

It is recognised that some individuals with ichthyosis vulgaris and/or atopic disease may carry loss-of-function mutations within the newly identified sequences that constitute these new size variant alleles. It is also recognised that size variation may modulate the phenotype of heterozygous carriers of a loss-of-function or other mutation in the *FLG* gene, i.e. a heterozygous carrier of the R501X mutation may carry a second wild-type allele encoding either 10, 11 or 12 filaggrin repeats. It is recognised that the size of the heterozygous wild-type allele may influence the phenotype observed, for example, a carrier of the 12-repeat (FLG^{8+10+}) allele will express 20% more filaggrin than a R501X carrier carrying a 10-repeat wild-type allele in *trans*. Thus, detection of these size variants may be of prognostic value in ichthyosis vulgaris and atopic disease.

REFERENCES

1. Wells, R.S. and Kerr CB, *Br Med J*, 1:947-949 (1966).
2. Judge, M.R., McLean, W.H.I. & Munro, C.S. Disorders of keratinization. in *Rook's Textbook of Dermatology*, Vol. 2 (eds. Burns, T., Breathnach, S., Cox, C. & Griffiths, C.) 34.54-34.56 (Blackwell Scientific Publishing, Oxford, 2004).
3. Steinert, P.M., Cantieri, J.S., Teller, D.C., Lonsdale-Eccles, J.D. & Dale, B.A. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. *Proc Natl Acad Sci* **78**, 4097-4101 (1981).
4. Dale, B.A., Resing, K.A. & Lonsdale-Eccles, J.D. Filaggrin : a keratin filament associated protein. *Ann. NY Acad. Sci.* **455**, 330-342 (1985).
5. Listwan, P. & Rothnagel, J.A. Keratin bundling proteins. *Methods Cell Biol* **78**, 817-27 (2004).
6. Gan, S.Q., McBride, O.W., Idler, W.W., Markova, N. & Steinert, P.M. Organization, structure, and polymorphisms of the human profilaggrin gene. *Biochemistry* **29**, 9432-40 (1990).
7. Candi, E., Schmidt, R. & Melino, G. The cornified envelope: a model of cell death in the skin. *Nat Rev Mol Cell Biol* **6**, 328-40 (2005).
8. Fleckman, P., Holbrook, K.A., Dale, B.A. & Sybert, V.P. Keratinocytes cultured from subjects with ichthyosis vulgaris are phenotypically abnormal. *J Invest Dermatol* **88**, 640-5 (1987).
9. Pena Penabad, C. et al. Differential patterns of filaggrin expression in lamellar ichthyosis. *Br J Dermatol* **139**, 958-64 (1998).
10. Sybert, V.P., Dale, B.A. & Holbrook, K.A. Ichthyosis vulgaris: identification of a defect in synthesis of filaggrin correlated with an absence of keratohyaline granules. *J Invest Dermatol* **84**, 191-4 (1985).
11. Nirunsuksiri, W., Zhang, S.H. & Fleckman, P. Reduced stability and bi-allelic, coequal expression of profilaggrin mRNA in keratinocytes cultured from subjects with ichthyosis vulgaris. *J Invest Dermatol* **110**, 854-61 (1998).
12. Presland, R.B. et al. Loss of normal profilaggrin and filaggrin in flaky tail (ft/ft) mice: an animal model for the filaggrin-deficient skin disease ichthyosis vulgaris. *J Invest Dermatol* **115**, 1072-81 (2000).
13. Lane, P.W. Two new mutations in linkage group XVI of the house mouse. Flaky tail and varitint-waddler-J. *J Hered* **63**, 135-40 (1972).

14. Rothnagel, J.A. et al. Characterization of the mouse loricrin gene: linkage with profilaggrin and the flaky tail and soft coat mutant loci on chromosome 3. *Genomics* **23**, 450-6 (1994).
15. Sambrook & Russel; "Molecular Cloning - A Laboratory Manual", (2000); Cold Spring Harbor Laboratory Press.
16. Dale BA, Holbrook KA, Kimball JR, Hoff M, Sun TT., Expression of epidermal keratins and filaggrin during human fetal skin development., *J Cell Biol.* 1985 Oct; 101(4):1257-60.
17. Gene Therapy (2004) 11, S57 – 63.
18. Lee DS, Quan G, Choi JY, Kim SY, Lee SC. Chronic ultraviolet radiation modulates epidermal differentiation as it up-regulates transglutaminase 1 and its substrates. *Photodermatol Photoimmunol Photomed.* 2005 Feb;21(1):45-52.
19. Wall, et al. (1992) *J. Cell Biochem.* 49(2): 113-20.
20. McCreath, et al. (2000) *Nature* 405: 1066-1069.
21. Lai, et al. (2002) *Science* 295: 1089-92.
22. Hogan, et al. (1986) In: *Manipulating the mouse embryo. A Laboratory Manual.* Cold Spring Harbour Laboratory Press, Cold Spring Harbor, N.Y.
23. Pearton, D.J., Dale, B.A. & Presland, R.B. Functional analysis of the profilaggrin N-terminal peptide: identification of domains that regulate nuclear and cytoplasmic distribution. *J Invest Dermatol* **119**, 661-9 (2002).
24. Eady, R.A.J. Transmission electron microscopy. in *Methods in Skin Research* (eds. Skerrow, D. & Skerrow, C.J.) 1-36 (John Wiley & Sons, Chichester, 1985).
25. Presland, R.B., Haydock, P.V., Fleckman, P., Nirunsuksiri, W. & Dale, B.A. Characterization of the human epidermal profilaggrin gene. Genomic organization and identification of an S-100-like calcium binding domain at the amino terminus. *J Biol Chem* **267**, 23772-81 (1992).
26. Markova, N.G. et al. Profilaggrin is a major epidermal calcium-binding protein. *Mol Cell Biol* **13**, 613-25 (1993).
27. Compton, J.G., DiGiovanna, J.J., Johnston, K.A., Fleckman, P. & Bale, S.J. Mapping of the associated phenotype of an absent granular layer in ichthyosis vulgaris to the epidermal differentiation complex on chromosome 1. *Exp Dermatol* **11**, 518-26 (2002).
28. Presland, R.B. et al. Evidence for specific proteolytic cleavage of the N-terminal domain of human profilaggrin during epidermal differentiation. *J Invest Dermatol* **108**, 170-8 (1997).

29. Ishida-Yamamoto, A., Takahashi, H., Presland, R.B., Dale, B.A. & Iizuka, H. Translocation of profilaggrin N-terminal domain into keratinocyte nuclei with fragmented DNA in normal human skin and loricrin keratoderma. *Lab Invest* **78**, 1245-53 (1998).
30. Rothnagel, J.A. & Steinert, P.M. The structure of the gene for mouse filaggrin and a comparison of the repeating units. *J. Biol. Chem.* **265**, 1862-1865 (1990).
31. Bale, S.J., Compton, J.G., Russell, L.J. & DiGiovanna, J.J. Genetic heterogeneity in lamellar ichthyosis. *J Invest Dermatol* **107**, 140-1 (1996).
32. Bitoun, E. et al. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. *J Invest Dermatol* **118**, 352-61 (2002).
33. Smith, F.J.D. et al. Genomic organization and fine mapping of the keratin 2e gene (*KRT2E*): K2e V1 domain polymorphism and novel mutations in ichthyosis bullosa of Siemens. *J. Invest. Dermatol.* **111**, 817-821 (1998).
34. McLean, W.H.I. et al. Mutations in the rod 1A domain of keratins 1 and 10 in bullous congenital ichthyosiform erythroderma (BCIE). *J. Invest. Dermatol.* **102**, 24-30 (1994).
35. Tay, Y.K., Khoo, B.P. & Goh, C.L. The epidemiology of atopic dermatitis at a tertiary referral skin center in Singapore. *Asian Pac J Allergy Immunol* **17**, 137-41 (1999).
36. Koukkanen K., Ichthyosis vulgaris. A clinical and histopathological study of patients and their close relatives in the autosomal dominant and sex-linked forms of the disease. *Acta Derm Venereol Suppl* (Stockh). 1969;62:1-72.
37. Werfel T, Breuer K., *Curr Opin Allergy Clin Immunol.* 2004 Oct; 4(5): 379-85. Role of food allergy in atopic dermatitis.
38. Sicherer S.H., Sampson H.A., *J. Allergy Clin Immunol.* 1999 Sep; 104 (3 Pt 2): S114-22. Food hypersensitivity and atopic dermatitis: pathophysiology, epidemiology, diagnosis and management.
39. Ellman L.K., Chatchatee P., Sicherer S.H. & Sampson H.A. *Pediatr Allergy Immunol.* 2002 Aug; 13(4): 205-8. Food hypersensitivity in two groups of children and young adults with atopic dermatitis evaluated a decade apart.
40. Gan S.Q., McBride O.W., Idler W.W., Markova N., Steinert P.M. Organization, structure, and polymorphisms of the human profilaggrin gene. *Biochemistry* 1990; 29: 9432-40.

Table 1Allele frequencies of *FLG* mutations R501X and 2282del4

Population	Allele Frequency R501X	Allele Frequency 2282del4
Irish Caucasian	0.041 (n = 97)	0.005 (n = 91)
Scottish Caucasian	0.021 (n = 145)	0.012 (n = 166)
US Caucasian	0.024 (n = 124)	0.011 (n = 133)
Combined	0.027 (n = 366)	0.01 (n = 390)

Table 2: Both R501X and 2282del4 are overrepresented in a childhood asthma cohort.

R501X		2282del4		Combined	
Population	Asthma	Population	Asthma	Population	Asthma
720	484	714	494	585	390
38	46	27	35	52	69
5	2	0	2	6	6
763	532	741	531	643	465
	p=0.04		p=0.0038		p=0.00045

Table 3 Characteristics of asthmatic children with and without filaggrin variants

	WT n=390	NULLcarriers n=75	p
SEX (%Male)	59.2	59.0	0.522
Age	10.2(2.7-21.2)	10.3(4.1-22)	
BMI	19.1	18.8	
PEFR%	92.8	90.6	
FEV1%	98.1	96.8	
FVC%	97.1	97.0	
Eczema	46.7	73.3	0.0001
Perennial Rhinitis	29	26.7	0.784
Seasonal Rhinitis	14.8	13.3	0.861
Cold air trigger	41.0	44.4	0.596
Exercise trigger	36.1	44.4	0.213
Viral trigger	44.9	46.8	0.787
Tested for allergy	16.6	30.1	0.035

Table 4: Case control association study for 5 FLG mutations (188 Irish AD patients versus 736 Irish population controls)

Genotype	R501X		2282del4		R2447X	
	Population	AD	Population	AD	Population	AD
AA	717	137	717	152	734	18
Aa	19	51	19	35	2	
aa	0	0	0	1	0	
Totals	736	188	736	188	736	18
		$p=7.8 \times 10^{-30}$		$p=7.8 \times 10^{-17}$		$p=1.7 \times 10^{-5}$

Genotype	S3247X		3702delG		Combined	
	Population	Asthma	Population	AD	Population	AD
AA	720	177	735	186	680	10
Aa	16	11	1	2	55	6
aa	0	0	0	0	1	2
	736	188	736	188	736	18
		$p=0.008$		$p=0.046$		$p=2.12 \times 10^{-5}$

CLAIMS

1. A genetic test for ichthyosis vulgaris (IV) comprising the step of:
detecting *in vitro* whether or not a mutation, which would lead to a loss of function or partial loss of function of the filaggrin (FLG) protein encoded by the filaggrin (*FLG*) gene, is present in the *FLG* gene of a sample of nucleic acid from a subject.
2. The test according to claim 1 wherein the test is used to diagnose IV and/or to test if a subject is predisposed to developing IV.
3. The test according to claims 1 or 2 wherein the test is used to also detect whether or not a subject is likely to be predisposed or suffering from atopic dermatitis (eczema), asthma, psoriasis or allergies, such as of a contact type allergy and food allergies (for example, peanut allergy).
4. The test according to claim 1 wherein the test is used to identify mild and/or sub-clinical forms of IV.
5. A genetic test for atopic dermatitis (eczema), asthma, psoriasis and/or allergies comprising the step of:
detecting *in vitro* whether or not a mutation, which would lead to a loss of function or partial loss of function of the FLG protein encoded by the *FLG* gene, is present in the *FLG* gene of a sample of nucleic acid from a subject.

6. The test according to any preceding claim wherein the nucleic acid is a sample of genomic DNA or mRNA.
7. The test according to any preceding claim wherein the subject to be tested is a newborn or a foetus.
8. The test according to any preceding claim wherein the test is carried out in order to test a subject's suitability for a particular job, where he/she may come into contact with agents which are known to lead in some cases to the development of eczema and/or allergy.
9. The test according to any one of claims 1 to 7 wherein the test is carried out in order to categorise a subject and predict an "at risk" status for disease development.
10. The test according to any preceding claim wherein the mutation effects 1 – 10 nucleotides.
11. The test according to any preceding claim wherein the mutation or mutation leads to 1 – 5, 7 – 13 or 15 – 20 reduction in functional filaggrin peptides.
12. The test according to any preceding claim wherein the mutation(s) is/are found in exon 3.
13. The test according to claim 12 wherein the mutation(s) is/are found within the unique, partial repeat, or first filaggrin repeat portion of exon 3.

14. The test according to any of claims 1 to 10 wherein the mutation(s) is selected from the group consisting of R501X, 2282del4, 3702delG, R2447X (repeat 7), S3247X (repeat 9), R1474X (repeat 4), Q3683X (repeat 10), 11029delCA (repeat 10), E2422X (repeat 6), 5360delG (repeat 5), 7267delCA (repeat 7), 11033del4 (repeat 10), 6867delAG (repeat 6), 3321delA (repeat 2) and S2554X (repeat 7).

15. The test according to any one of claims 1 to 10 wherein the mutation(s) is selected from the group consisting of R501X, 2282del4, 3702delG, R2447X and S3247X.

16. The test according to any one of claims 1 to 10 wherein the subject is of Asian origin, especially Japanese and the mutation(s) is/are 3323delA and/or S2554X.

17. The test according to any preceding claim wherein the mutation(s) is/are detected by quantitative or semi-quantitative PCR, including real-time PCR, nucleic acid sequencing, hybridisation studies and/or restriction fragment length polymorphism (RFLP) analysis techniques.

18. The test according to any preceding claim, further comprising the step of identifying the number of filaggrin repeats in the *FLG* gene from said sample.

19. Use of an oligonucleotide identified as SEQ ID. Nos. 1 - 545 in a test according to any preceding claim.

20. Use of an oligonucleotide which having at its 3' position the 3' base identified from any one of SEQ ID. Nos. 1 – 545 and which is approximately 12 – 50 nucleotides in length, in a test according to any of claims 1 – 18.
21. The use according to either of claims 19 or 20 wherein the primer further comprises a label.
22. An isolated oligonucleotide identified as SEQ ID Nos. 1 – 545 or a fragment of at least 12 nucleotides or larger oligonucleotide of up to 50 nucleotides, which fragment or larger oligonucleotide share the same 3' nucleotide as a oligonucleotide identified as SEQ ID Nos. 1 – 545, for use in detecting a mutation in a filaggrin gene of a subject.
23. The oligonucleotide according to claim 22, wherein the mutation is associated with the subject having or being pre-disposed to developing IV, atopic dermatitis, asthma, psoriasis and/or allergies.
24. The use or oligonucleotide according to any one of claims 19 – 23 wherein the oligonucleotide or oligonucleotides is selected from the SEQ ID No. 1 – 8, 9 – 12, 13 – 15, etc, or a fragment or larger oligonucleotide comprising the same 3' base as said SEQ ID No.
25. A kit comprising one or more oligonucleotides according to claims 22 – 24.

26. A method of detecting a mutant peptide expressed from a mutant of the *FLG* gene, comprising the steps of:
detecting *in vitro* whether or not a mutant peptide expressed from a mutant *FLG* gene is present in a sample, by using a binding agent which is specifically reactive to said mutant peptide.
27. The method according to claim 26 wherein the binding agent is an antibody.
28. An binding agent or antibody which is capable of specifically binding to a mutant peptide generated as a result of a mutation occurring in a filaggrin sequence.
29. The binding agent or antibody according to claim 28 which is capable of specifically binding to the peptide generated as a result of the 2282del4 mutation in the filaggrin gene.
30. Use of an *FLG* gene sequence or fragment thereof, capable of encoding one or more copies of the *FLG* protein, in the manufacture of a medicament.
31. An *FLG* gene sequence or fragment thereof, which gene sequence or fragment thereof, is capable of expressing one or more copies of the FLG protein, for use in therapy or prophylaxis.
32. A method of treating prophylactically or therapeutically IV, atopic dermatitis, asthma, psoriasis and/or allergies, by administering to a patient suffering or predisposed to developing any of said aforementioned diseases/conditions, a DNA

construct comprising an *FLG* gene sequence or fragment thereof, which gene sequence or fragment thereof is capable of expressing one or more copies of the *FLG* protein, whereby expression of said one or more copies of the *FLG* protein treats or ameliorates said disease(s)/condition(s).

33. A recombinant molecule comprising an *FLG* sequence or fragment thereof for use in therapy.

34. The present invention also provides a method of treating, preventing and/or ameliorating IV and/or any of the aforementioned diseases, comprising the steps of:


a) determining if expression of one or more copies of the *FLG* polypeptide would occur even if a subject's *FLG* gene comprises one or more mutations; and

b) providing a subject carries *FLG* alleles capable of expressing at least one or more copies of the *FLG* polypeptide, treating the subject using UV light in order to seek to increase *FLG* expression.

35. A transgenic non-human animal which possesses one or more mutations in one or both copies of the *FLG* gene which would lead to a loss or partial loss of function of the *FLG* protein encoded by the *FLG* gene.

36. An *in vivo* assay for identifying an agent which is useful for treating or preventing IV, atopic dermatitis, asthma, psoriasis and/or allergies associated with mutant *FLG* expression comprising the steps of administering a test agent to a *FLG* mutant transgenic animal; and measuring or determining whether the agent decreases

or inhibits at least one sign or symptom of said disease/condition which is indicative that the test agent is capable of treating or preventing said disease/condition.

Figure 1Pedigrees and *FLG* genotypes of of IV families studied

2/62


Figure 2***FLG* mutation detection and confirmation**


Figure 3**Histological and ultrastructural features of ichthyosis vulgaris**

Figure 4**Profilaggrin CDS and translation**

S-100 domain

10 20 30 40 50
ATGTCTACTCTCCTGGAAAACATCTTTGCCATAATTAATCTTTTCAAGCA
TACAGATGAGAGGACCTTTTGTAGAAACGGTATTAATTAGAAAAGTTCGT
M S T L L E N I F A I I N L F K Q

60 70 80 90 100
ATATTCAAAAAAGATAAAAAACACTGACACATTGAGTAAAAAGAGCTGA
TATAAGTTTTTTTCTATTTTGTGACTGTGTAACCTATTTTTCTCGACT
Y S K K D K N T D T L S K K E L

110 120 130 140 150
AGGAACTTCTGGAAAAGGAATTTTCGGCAAATCCTGAAGAATCCAGATGAC
TCCTTGAAGACCTTTTCCTTAAAGCCGTTTAGGACTTCTTAGGTCTACTG
K E L L E K E F R Q I L K N P D D

160 170 180 190 200
CCAGATATGGTTGATGTCTTCATGGATCACTTGGATATAGACCACAACAA
GGTCTATAACCACTACAGAAGTACCTAGTGAACCTATATCTGGTGTGTGTT
P D M V D V F M D H L D I D H N K

210 220 230 240 250
GAAAATTGACTTCACTGAGTTTCTTCTGATGGTATTCAAGTTGGCTCAAG
CTTTTAACTGAAGTGAAGTCAAAGAAGACTACCATAAGTTCAACCGAGTTT
K I D F T E F L L M V F K L A Q

260 270 280 290 300
CATATTATGAGTCTACCAGAAAAGAGAATTTACCGATATCAGGACACAAG
GTATAATACTCAGATGGTCTTTTCTCTTAAATGGCTATAGTCCTGTGTTT
A Y Y E S T R K E N L P I S G H K

310 320 330 340 350
CACAGAAAGCACAGTCATCATGATAAACATGAAGATAATAAACAGGAAGA
GTGTCTTTTCGTGTCAGTAGTACTATTTGTACTTCTATTATTTGTCCTTCT
H R K H S H H D K H E D N K Q E E

360 370 380 390 400
AAACAAAGAAAACAGAAAAAGACCCTCAAGTCTGGAAAGAAGAAACAATA
TTTGTTTCTTTTGTCTTTTCTGGGAGTTCAGACCTTTCTTCTTTGTTAT
N K E N R K R P S S L E R R N N

410 420 430 440 450
GAAAAGGGAATAAGGGAAGATCCAAGAGCCCCAAGAGAAACAGGGGGGAAA
CTTTTCCCTTATTCCCTTCTAGGTTCTCGGGTCTCTTTGTCCCCCTTT
R K G N K G R S K S P R E T G G K

460 470 480 490 500
AGGCATGAATCTAGTTCTGAAAAAAGAAAGAAAAGGATATTCACCTAC
TCCGTACTTAGATCAAGACTTTTTTTTCTTTCTTTTCTTATAGTGGATG

RPT0
low

homology R H E S S S E K K E R K G Y S P T

510 520 530 540 550
TCATAGAGAAGAAGAATATGGAAAAAACCATCATAACTCAAGTAAAAAAG
AGTATCTCTTCTTCTTATACCTTTTTTGGTAGTATTGAGTTCATTTTTTC
H R E E E Y G K N H H N S S K K

560 570 580 590 600
AGAAAAACAAGACTGAAAATACTAGATTAGGAGACAATAGGAAGAGGCTA
TCTTTTTGTTCTGACTTTTATGATCTAATCCTCTGTTATCCTTCTCCGAT
E K N K T E N T R L G D N R K R L

610 620 630 640 650
AGTGAAGACTTGAAGAGAAAGAAGACAATGAAGAAGGAGTATATGATTA
TCACTTTCTGAACCTCTCTTTCTTCTGTTACTTCTTCCTCATATACTAAT
S E R L E E K E D N E E G V Y D Y

660 670 680 690 700
TGAAAATACAGGAAGAATGACTCAAAAATGGATACAATCAGGCCATATTG
ACTTTTATGTCCTTCTTACTGAGTTTTTACCTATGTTAGTCCGGTATAAC
E N T G R M T Q K W I Q S G H I

710 720 730 740 750
CCACATATTACACAATCCAGGATGAAGCCTATGACACCACTGATAGTCTA
GGTGTATAATGTGTTAGGTCCTACTTCGGATACTGTGGTGACTATCAGAT
A T Y Y T I Q D E A Y D T T D S L

760 770 780 790 800
TTAGAAGAAAAACAAAATATATGAAAGATCAAGGTCATCTGATGGCAAATC
AATCTTCTTTTGTTTTATATACTTTCTAGTTCCAGTAGACTACCGTTTAG
L E E N K I Y E R S R S S D G K S

810 820 830 840 850
ATCATCTCAAGTGAACAGGTCAAGACATGAAAATACAAGCCAGGTACCAT
TAGTAGAGTTCACTTGTCCAGTTCTGTACTTTTATGTTCCGGTCCATGGTA
S S Q V N R S R H E N T S Q V P

RPT0
start
high
homology 860 870 880 890 900
TGCAGGAGTCCAGGACAAGAAAGCGTAGGGGATCCAGAGTTAGCCAGGAC
ACGTCCTCAGGTCCTGTTCTTTTCGCATCCCCTAGGTCTCAATCGGTCCTG
L Q E S R T R K R R G S R V S Q D

910 920 930 940 950
AGGGACAGTGAGGGACACTCAGAAGACTCTGAGAGGCACTCTGGGTTCGGC
TCCCTGTCACTCCCTGTGAGTCTTCTGAGACTCTCCGTGAGACCCAGCCG
R D S E G H S E D S E R H S G S A

960 970 980 990 1000
TTCCAGAAACCATCATGGATCTGCGTGGGAGCAGTCAAGAGATGGCTCCA
AAGGTCTTTGGTAGTACCTAGACGCACCCTCGTCAGTTCTCTACCGAGGT
S R N H H G S A W E Q S R D G S

6/62

1010 1020 1030 1040 1050
GACACCCCAGGTCCCATGATGAAGACAGAGCCAGTCATGGGCACTCTGCA
CTGTGGGGTCCAGGGTACTACTTCTGTCTCGGTCACTACCCGTGAGACGT
R H P R S H D E D R A S H G H S A

1060 1070 1080 1090 1100
GACAGCTCCAGACAATCAGGCACTCGTCACGCAGAGACTTCCTCTCGTGG
CTGTGCGAGGTCTGTTAGTCCGTGAGCAGTGCGTCTCTGAAGGAGAGCACC
D S S R Q S G T R H A E T S S R G

1110 1120 1130 1140 1150
ACAGACTGCATCATCCCATGAACAGGCAAGATCAAGTCCAGGAGAAAGAC
TGTCTGACGTAGTAGGGTACTTGTCCGTTCTAGTTCAGGTCCTCTTTCTG
Q T A S S H E Q A R S S P G E R

1160 1170 1180 1190 1200
ATGGATCCGGCCACCAGCAGTCAGCAGACAGCTCCAGACACTCAGCCACT
TACCTAGGCCGGTGGTCGTCACTCGTCTGTGAGGTCTGTGAGTCGGTGA
H G S G H Q Q S A D S S R H S A T

1210 1220 1230 1240 1250
GGGCGCGGGCAAGCTTCATCTGCAGTCAGCGATCGTGGACACCGGGGGTC
CCCGCGCCCGTTTGAAGTAGACGTCACTCGCTAGCACCTGTGGCCCCCAG
G R G Q A S S A V S D R G H R G S

1260 1270 1280 1290 1300
TAGCGGTAGTCAGGCCAGTGACAGTGAGGGACATTCAGAACTCAGACA
ATCGCCATCAGTCCGGTCACTGTCACTCCCTGTAAGTCTTTGAGTCTGT
S G S Q A S D S E G H S E N S D

1310 1320 1330 1340 1350
CACATCAGTGTCAAGCCACGGAAAGGCTGGCTGTCAGCAGAGCCAC
GTGTAGTCACAGTCCGGTGCCTTTCCGACCGACTCTGTCTCGGTG
T Q S V S G H G K A G L R Q Q S H

1360 1370 1380 1390 1400
CAAGAGTCCACGTGGCCGGTCAGGGGAAAGGTCTGGACGTTCAAGGTC
GTTCTCAGG GTGCACCGGCCAGTCCCCTTCCAGACCTGCAAGTCCAG
Q E S T R G R S G E R S G R S G S

End RPT0

1410 1420 1430 1440 1450
TTCTCTACCAGGTGAGCACTCATGAACAGCTGATCTGCCCCATGGAC
AAGGAGATGGTCCACTCGTGAGTACTTGTGCGACTGAGACGGGTACCTG
S L Y Q V S T H E Q P D S A H G

RPT1

1460 1470 1480 1490 1500
GGACCGGGACCAGCACTGGAGGAAGACAAGGATCCACACGACAGGCA
CCTGGCCCTGGTCGTGACCTCCTTCTGTTCTAGGTGGTGCTGTCCGT
R T G T S T G G R Q G S H H E Q A

7/62

1510 1520 1530 1540 1550
GAGACAGCTCCAGGCAATCAGCGTCCCAAGAGGGTCAGGACACCATTG
CTCTGTCGAGGTCCGTAGTCGCAGGGTTCTCCAGTCCTGTGGTAAGC
R D S S R H S A S Q E G Q D T I R

1560 1570 1580 1590 1600
TGGAACCCGGGGTCAAGCAGAGGAGGAAGGCAGGGATCCCACCACGAGC
ACCTTGGGCCCCAGTTCGTCTCCTCCTTCCGTCCCTAGGGTGGTGCTCG
G H P G S S R G G R Q G S H H E

1610 1620 1630 1640 1650
AATCGGTAATAGGTCTGGACACTCAGGTCCCATCACAGCCACACCACA
TTAGCCATATCCAGACCTGTGAGTCCAGGGTAGTGTGGTGTGGTGT
Q S V N R S G H S G S H H S H T T

1660 1670 1680 1690 1700
TCCCAGGGAAGGTCTGATGCCTCCCATGGGCAGTCAGGATCCAGAAGTGC
AGGGTCCCTTCCAGACTACGAGGGGTACCCGTCAGTCCTAGGTCTTCACG
S Q G R S D A S H G Q S G S R S A

4
1710 1720 1730 1740 1750
AAGCAGACAAACACGAAATGAGGAACAATCAGGAGACGGCCACAGGCACT
TTCGTCTGTTTGTGCTTACTCCTTGTTAGTCCTCTGCCGCGGTCCGTGA
S R Q T R N E E Q S G D G T R H

6
1760 1770 1780 1790 1800
CAGGGTCACGTCAATCATGAAGCTTCCTCTCAGGCTGACAGCTCTAGACAC
GTCCCAGTGCACTAGTACTTGAAGGAGAGTCCGACTGTGAGATCTGTG
S G S R H H E A S S Q A D S S R H

1810 1820 1830 1840 1850
TCACAGGTGGGCCAGGGACAATCATCGGGGCCAGGACAAGAGGAACCA
AGTGTCCACCCGGTCCCTGTTAGTAGCCCCGGGTCTGTTCTCCTTGGT
S Q V G Q G Q S S G P R T S R N Q

1860 1870 1880 1890 1900
GGGATCCAGTGTAGCCAGGACAGTGACAGTCAGGGACACTCAGAAGACT
CCCTAGGTCACAATCGGTCTGTCACTGTGAGTCCCTGTGAGTCTTCTGA
G S S V S Q D S D S Q G H S E D

1910 1920 1930 1940 1950
CTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACCATCATGGATCTGCTCAG
GACTCTCCACCAGACCCAGACGAAGGTCTTTGGTAGTACCTAGACGAGTC
S E R W S G S A S R N H H G S A Q

1960 1970 1980 1990 2000
GAGCAGTCAAGAGATGGCTCCAGACACCCAGGTCCCATCACGAAGACAG
CTCGTCAGTTCTCTACCGAGGTCTGTGGGGTCCAGGGTAGTGCTTCTGTC
E Q S R D G S R H P R S H H E D R

2010 2020 2030 2040 2050
AGCTGGTCATGGGCACTCTGCAGACAGCTCCAGAAATCAGGCACTCGTC
TCGACCAGTACCCGTGAGACGTCTGTGCGAGGTCTTTAGTCCGTGAGCAG
A G H G H S A D S S R K S G T R

2060 2070 2080 2090 2100
ACACACAGAATTCCTCTAGTGGACAGGCTGCGTCATCCCATGAACAGGCA
TGTGTGTCTTAAGGAGATCACCTGTCCGACGCAGTAGGGTACTTGTCCGT
H T Q N S S S G Q A A S S H E Q A

2110 2120 2130 2140 2150
AGATCAAGTGCAGGAGAAAGACATGGATCCCGCCACCAGCTCCAGTCAGC
TCTAGTTCACGTCTCTTTCTGTACCTAGGGCGGTGGTCGAGGTTCAGTCG
R S S A G E R H G S R H Q L Q S A

2160 2170 2180 2190 2200
AGACAGCTCCAGACACTCAGGCACTGGGCACGGACAAGCTTCATCTGCAG
TCTGTGCGAGGTCTGTGAGTCCGTGACCCGTGCCTGTTCTGAAGTAGACGTC
D S S R H S G T G H G Q A S S A

2210 2220 2230 2240 2250
TCAGAGACAGTGGACACCGAGGGTCCAGTGGTAGTCAGGCCACTGACAGT
AGTCTCTGTACCTGTGGCTCCCAGGTCACCATCAGTCCGGTGACTGTCA
V R D S G H R G S S G S Q A T D S

2260 2270 2280 2290 2300
GAGGGACATTGAGAAGACTCAGACACACAGTGTGTCAGGCCATGGACA
CTCCCTGTAAGTCTTCTGAGTCTGTGTGTCACTCAGTCCGGTACCTGT
E G H S E D S D T Q S V S G H G Q

2310 2320 2330 2340 2350
GGCTGGTCCATCAGCAGAGCCACCAAGAGTCCGCACGTGACCGGTGAG
CCGACCGGTAGTCGTCTCGGTGGTTCTCAGGCGTGCACTGGCCAGTC
A G H H Q Q S H Q E S A R D R S

2360 2370 2380 2390 2400
GGGAAAGGTCTGACGTTGAGGGTCTTTCTCTACCGGTGAGCACTCAT
CCCTTTCCAGACTGCAAGTCCCAGAAAGGAGATGGTCCACTCGTGAGTA
G E R S R R S G S F L Y Q V S T H

2410 2420 2430 2440 2450
End RPT1 AACAGTCTGAGTCCTCCCATGGATGGACAGGGCCAGCACTGGACAAAG
TTGTCAGACTCAGGAGGGTACCTACCTGTCCCGGGTCGTGACCTCATTTC
K Q S E S S H G W T G P S T G V R

2460 2470 2480 2490 2500
RPT2 ACAAGGATCCCACCATGAGCAGGCACGAGACACTCCAGGCACTCAGCAT
TGTTCTAGGGTGGTACTCGTCCGTGCTCTGTGAGGTCCGTGAGTCGTA
Q G S H H E Q A R D N S R H S A

9/62

2510 2520 2530 2540 2550
CCCAAGA GGCAGGACACCATTTCGTGGACACCCGGGGTCAAGCAGAAGA
GGGTTCT CCAGTCCTGTGGTAAGCACCTGTGGGCCCCAGTTCTGTCTTCT
S Q D G Q D T I R G H P G S S R R

2560 2570 2580 2590 2600
GGAAGGCAGGGGTCCCACCACGAGCAATCGGTAGATAGGTCTGGACACTC
CCTTCCGTCCCCAGGGTGGTGCTCGTTAGCCATCTATCCAGACCTGTGAG
G R Q G S H H E Q S V D R S G H S

2610 2620 2630 2640 2650
AGGGTCCCATCACAGCCACACCACATCCCAGGGAAGGTCTGATGCCTCCC
TCCCAGGGTAGTGTCCGGTGTGGTGTAGGGTCCCTTCCAGACTACGGAGGG
G S H H S H T T S Q G R S D A S

2660 2670 2680 2690 2700
GTGGGCAGTCAGGATCCAGAAGTGCAAGCAGAACAACACGTAATGAGGAA
CACCCGTCAGTCCTAGGTCTTCACGTTCTGTCTTGTGTGCATTACTCCTT
R G Q S G S R S A S R T T R N E E

2710 2720 2730 2740 2750
CAATCA GAGACGGCTCCAGGCACTCAGGGTCACGTCACCATGAAGCTTC
GTTAGT CTCTGCCGAGGTCCGTGAGTCCCAGTGCAGTGGTACTTCAAG
Q S R D G S R H S G S R H H E A S

2760 2770 2780 2790 2800
CTCTCATGCCGACATCTCTAGACACTCACAGGCAGGCCAGGGACAATCAG
GAGAGTACGGCTGTAGAGATCTGTGAGTGTCCGTCCGGTCCCTGTTAGTC
S H A D I S R H S Q A G Q G Q S

2810 2820 2830 2840 2850
AGGGGTCCAGGACAAGCAGGCGCCAGGGATCCAGTGTAGCCAGGACAGT
TCCCCAGGTCTGTTCGTCCGCGGTCCCTAGGTACAATCGGTCTCTGTCA
E G S R T S R R Q G S S V S Q D S

2860 2870 2880 2890 2900
GACAGTGAGGGACATTCAAGACTCTGAGAGGTGGTCTGGGTCTGCTTC
CTGTCACTCCCTGTAAGTCTTCTGAGACTCTCCACCAGACCCAGACGAAG
D S E G H S E D S E R W S G S A S

2910 2920 2930 2940 2950
CAGAAACCATCGTGGATCTGCTCAGGAGCAGTCAAGACATGGCTCCAGAC
GTCTTTGGTAGCACCTAGACGAGTCCCTCGTCAGTTCTGTACCGAGGTCTG
R N H R G S A Q E Q S R H G S R

2960 2970 2980 2990 3000
ACCCAGGTCCCATCACGAAGACAGAGCCGGTCAAGGGCACTCTGCAGAC
TGGGGTCCAGGGTAGTGCTTCTGTCTCGGCCAGTGCCCGTGAGACGTCTG

3460 3470 3480 3490 3500
GACAGCTCCAGGCACTCAGCGTCCCAAGAGGGTCAGGACACCATTTCGTG
CTGTCGAGGTCCGTGAGTCGCAGGGTTCTCCAGTCCTGTGGTAAGCAC
D S S R H S A S Q E G Q D T I R A

11 5
3510 3520 3530 3540 3550
ACACCCGGGGTCAAGGAGAGGAGGAAGGCAGGGATCCCACCATGAGCAAT
TGTGGGCCCCAGTTCCTCTCCTCCTTCCGTCCTAGGGTGGTACTCGTTA
H P G S R R G G R Q G S H H E Q

7
3560 3570 3580 3590 3600
CGGTAGATAGATCTGGACACTCAGGGTCCCATCACAGCCACACCACATCC
GCCATCTATCTAGACCTGTGAGTCCCAGGGTAGTGTCGGTGTGGTGTAGG
S V D R S G H S G S H H S H T T S

3610 3620 3630 3640 3650
CAGGGAAGGTCTGATGCCTCCCATGGGCAGTCAGGATCCAGAAGTGCAAG
GTCCCTTCCAGACTACGGAGGGTACCCGTCAGTCCTAGGTCTTCACGTTC
Q G R S D A S H G Q S G S R S A S

105
3660 3670 3680 3690 3700
CAGACAACTCGTAA GACAAACAATCAGGAGACGGCTCCAGGCACTCAG
GTCTGTTTGAGCATT CTGTTTGTAGTCTCTGCCGAGGTCCGTGAGTC
R Q T R K D K Q S G D G S R H S

6
3710 3720 3730 3740 3750
G TCACGTCAACCATGAAGCT CCTCTTGGGCTGACAGCTCTAGACACTCA
C AGTGCAGTGGTACTTCGA GGAGAACCCGACTGTCGAGATCTGTGAGT
G S R H H E A A S W A D S S R H S

3760 3770 3780 3790 3800
CAGGTGGG CAGG ACAATCATCGGGGTCCAGGACAAGCAGGCACCAGGG
GTCCACCC GTCC TGTAGTAGCCCCAGGTCTGTTCTGTCCTGTTGTTCC
Q V G Q E Q S S G S R T S R H Q G

3810 3820 3830 3840 3850
ATCCAGTGTTAGCCAGGACAGTGACAGTGAG GACACTCAGAG GACTC G
TAGGTACAATCGGTCCTGTCACTGTCACTC CTGTGAGTCTCTGAG C
S S V S Q D S D S E R H S D D S

3860 3870 3880 3890 3900
AGAGGT GTCTGGGTCTGCTTCCAGAAACCATCATGGATCT CTCGGGAG
TCTCCA CAGACCCAGACGAAGGTCTTTGGTAGTACCTAGA GAGCCCTC
E R L S G S A S R N H H G S S R E

55
3910 3920 3930 3940 3950
CAGTCAAGAGATGGCTCCAGACACCCTGGGT CCATCAAGAAGACAGAGC
GTCAGTTCTCTACCGAGGTCTGTGGGACCCA GGTAGTTCTTCTGTCTCG
Q S R D G S R H P G F H Q E D R A

3960 3970 3980 3990 4000
CAGTCACGGGCACTCTGCAGACAGCTCCAGACAATCAGGCACTCATCACA
GTCAGTGCCCGTGAGACGTCTGTGAGGTCTGTTAGTCCGTGAGTAGTGT

S H G H S A D S S R Q S G T H H

5
4010 4020 4030 4040 4050
CAGAGTCTTCTCTCTGGACAGGCTGTGTCATCCCATGAACAGGCAAGA
GTCTCAGAAGGAGAGTACCTGTCCGACACAGTAGGGTACTTGTCCGTTCT
T E S S S H G Q A V S S H E Q A R

4060 4070 4080 4090 4100
TCAAGTCCAGGAGAAAGACATGGATCCCGCCACCAGCAGTCAGCAGACAG
AGTTCAGGTCTCTTTCTGTACCTAGGGCGGTGGTCGTCAGTCGTCTGTCTC
S S P G E R H G S R H Q Q S A D S

4110 4120 4130 4140 4150
CTCCAGACACTCAGGCATTGGGCACAGACAAGCTTCATCTGCAGTCAGAG
GAGGTCTGTGAGTCCGTAACCCGTGTCTGTTTGAAGTAGACGTCAGTCTC
S R H S G I G H R Q A S S A V R

4160 4170 4180 4190 4200
ACAGTGGACACCGAGGGTCCAGTGGTAGTCAGGCACTACAGTGAGGGGA
TGTCACCTGTGGCTCCAGGTCACCATCAGTCCGTGATGTCACTCCCT
D S G H R G S S G S Q V T N S E G

4210 4220 4230 4240 4250
CATTTCAGAAGACTCAGACACACAGTCAGTGTCTAGCCACGGACAAAGCTGG
GTAAGTCTTCTGAGTCTGTGTGTCTAGTCACAGTCGGGTGCCTGTTTCGACC
H S E D S D T Q S V S A H G Q A G

4260 4270 4280 4290 4300
GCCCCATCAGCAGAGCCACAAAGAGTCCGCACGTGGCCAGTCAGGGGAAAG
CGGGGTAGTCTGTCTCGGTGTTTCTCAGGCGTGCACCGGTCTAGTCCCTTT
P H Q Q S H K E S A R G Q S G E

5
End RPT3 4310 4320 4330 4340 4350
GCTCTGGACGTTCAAGGTCTTTCTCTACCAGGTGAGCTCATGAACAG
CGAGACCTGCAAGTCCAGAAAGGAGATGGTCCACTCGAGTACTTGTCTC
S S G R S R S F L Y Q V S S H E Q

6 6 6 6
RPT4 4360 4370 4380 4390 4400
TCTGAGTCCACCAAGGACAGACTGCACCCAGCACTGGAGGAAGACAAGG
AGACTCAGGTGTCTCTGTCTGACGGGGTCTGACCTCCTTCTGTCTCC
S E S T H G Q T A P S T G G R Q G

4410 4420 4430 4440 4450
ATCCCCGCATGAGCAGGCACGAACAGCTCAGGCACTCAGCATCCCAAG
TAGGGCGGTACTCGTCCGTGCTGTGTCGAGTCCGTGAGTCGTAGGGTTC
S R H E Q A R N S S R H S A S Q

4460 4470 4480 4490 4500
ACGGTCAGGACACCATTCTGTGGACACCCGGGGTCAAGCAGAGGAGGAAGG
TGCCAGTCTGTGGTAAGCACCTGTGGGCCCCAGTTCTGTCTCCTCCTTCC

13/62

D G Q D T I R G H P G S S R G G R

11

4510 4520 4530 4540 4550
CAGGGATCCTACCACGAGCAATC GTAGATAGGTCTGGACACTCAGGGT
GTCCCTAGGATGGTGCTCGTTAG CATCTATCCAGACCTGTGAGTCCCA
Q G S Y H E Q S V D R S G H S G Y

4560 4570 4580 4590 4600
CCATCACAGCCACACCACA CCCAGGGAAGGTCTGATGCCTCCCATGGGC
GGTAGTGTGGTGTGGTGT GGGTCCCTTCCAGACTACGGAGGGTACCCG
H H S H T T P Q G R S D A S H G

1

4610 4620 4630 4640 4650
AGTCAGGA CCAGAAGTGCAAGCAG CAAACA GAAATGAGGAACAATCA
TCAGTCCT GGTCTTCACGTTCTGTC GTTTGT CTTTACTCCTTGTTAGT
Q S G P R S A S R Q T R N E E Q S

4660 4670 4680 4690 4700
GGAGACGGCTCCAGGCACTCAGGGTCACGTCACCATGAA CTTCCACTCG
CCTCTGCCGAGGTCCGTGAGTCCCAGTGCAGTGGTACTT GAAGGTGAGC
G D G S R H S G S R H H E P S T R

11

4710 4720 4730 4740 4750
GGCCG CAGCTCTAGACACTCACAGGTGGGCCAGGGAGAATCAGCGGGGT
CCGGC GTCGAGATCTGTGAGTGTCCACCCGGTCCCTCTTAGTCGCCCA
A G S S R H S Q V G Q G E S A G

0

4760 4770 4780 4790 4800
CCA GACAAGCAGGCGCCAGGGATCCAGTGTTAG CAGGACAGGGACAGT
GGT CTGTTCGTCCGCGGTCCCTAGGTCACAATC GTCCTGTCCCTGTCA
S K T S R R Q G S S V S Q D R D S

11 0

4810 4820 4830 4840 4850
GAGGGACACTCAGAAGACTCTGAGAGGCGGTCTGAGTCGGCTTCCAGAAA
CTCCCTGTGAGTCTTCTGAGACTCTCCGCCAGACTCAGCCGAAGGTCTTT
E G H S E D S E R R S E S A S R N

4860 4870 4880 4890 4900
CCAT ATGGATCTGCTCGGGAGCAGTCAAGACATGGCTCCAG ACCCCA
GGTA TACCTAGACGAGCCCTCGTCAGTTCTGTACCGAGGTCT TGGGGT
H Y G S A R E Q S R H G S R N P

11

4910 4920 4930 4940 4950
GGTCCCATCAAGAAGATAGAGCCAGTCATGGGCACTCTGCAGAGAGCTCC
CCAGGGTAGTTCTTCTATCTCGGTCAGTACCCGTGAGACGTCTCTCGAGG
R S H Q E D R A S H G H S A E S S

4960 4970 4980 4990 5000
AGACAATCAGGCACTCGTCATGCAGAGACTTCCTCTGGTGGACAGGCTGC
TCTGTTAGTCCGTGAGCAGTACGTCTCTGAAGGAGACCACCTGTCCGACG

R Q S G T R H A E T S S G G Q A A

5010 5020 5030 5040 5050
ATCATCCCA GAACAGGCAAG TCAAGTCCAGGAGAAAGACATGGATCCC
TAGTAGGGT CTTGTCCGTT AGTTCAGGTCCTCTTTCTGTACCTAGGG
S S Q E Q A R S S P G E R H G S

5060 5070 5080 5090 5100
GCCACCAGCAGTCAGCAGACAGCTCCA AACTCAGGCACTGGGCGCAGA
CGGTGGTTCGTCAGTCGTCTGTCGAGGT TGTGAGTCCGTGACCCGCGTCT
R H Q Q S A D S S T D S G T G R R

5110 5120 5130 5140 5150
CAAG TTCATCTG AGTC GAGACAGTGGAA ACCGAGGGTCCAGTGGTAG
GTTT AAGTAGAC TCAG CTCTGTCACCT TGGCTCCAGGTCACCATC
Q D S S V V G D S G N R G S S G S

5160 5170 5180 5190 5200
CAGGCCAGTGACAG GAGGGACA TCAGAAGAGTCAGACACACAGTCAG
GTCCGGTCACTGTC CTCCCTGT AGTCTTCTCAGTCTGTGTGTCAGTC
Q A S D S E G H S E E S D T Q S

5210 5220 5230 5240 5250
TGTCAGCCACGGACAGGCTGGGCCCCATCAGCAGAGCCACCAAGAGTCC
ACAGTCGGGTGCCTGTCCGACCCGGGGTAGTCGTCTCGGTGGTTCTCAGG
V S A H G Q A G P H Q Q S H Q E S

5260 5270 5280 5290 5300
ACACGTGGCCAGTCAGGGGAAAGGTCTGGACGTT CAGGGTCTTTCTCTTA
TGTGCACCGGTCACTCCCTTTCCAGACCTGCAAGTCCCAGAAAGGAGAT
T R G Q S G E R S G R S G S F L Y

End RPT4 5310 5320 5330 5340 5350
CCAGGTGAGCACTCATGAACAGTCTGAGTCCGCCCATGGACG AC GGGC
GGTCCACTCGTGAGTACTTGTGCACTCAGGCGGGTACCTGC TG CCCG
Q V S T H E Q S E S A H G R T G

RPT5 5360 5370 5380 5390 5400
CCAGCACTGGAGGAAGACAA GATCCCGCCACGAGCAGGCACGAGACAGC
GGTCGTGACCTCCTTCTGTT CTAGGGCGGTGCTCGTCCGTGCTCTGTGCG
P S T G G R Q R S R H E Q A R D S

5410 5420 5430 5440 5450
TCCAGGCACTCAGCGTCCCAAGAGGGTCAGGACACCATTCTGTGGACACCC
AGGTCCGTGAGTCGACGGGTTCTCCAGTCCTGTGGTAAGCACCTGTGGG
S R H S A S Q E G Q D T I R G H P

5460 5470 5480 5490 5500
GGGTCAAGCAGAGGAGGAAGGCAGGGATCCCACTATGAGCAATCGGTAG
CCCAGTTCGTCTCCTCCTCCGTCCCTAGGGTGATACTCGTTAGCCATC

15/62

G S S R G G R Q G S H Y E Q S V

(0)

5510 5520 5530 5540 5550
ATAGTCTGGACACTCAGGGTCTCATCACAGCCACACCACCTCCCAGGAA
TATCAAGACCTGTGAGTCCCAGAGTAGTGTCGGTGTGGTGAGGGTCCCT
D S S G H S G S H H S H T T S Q E

5560 5570 5580 5590 5600
AGGTCTGATGCTCCCGTGGGCAGTCAGGATCCAGAAGTGCTAGCAGACA
TCCAGACTACGAGGGCACCCGTCAGTCCTAGGTCTTCACCTCGTCTGT
R S D V S R G Q S G S R S V S R Q

3(+0)

5610 5620 5630 5640 5650
AACACGTAATGAGAAACAATCAGGAGACGGCTCCAGGCACCTCAGGGTCGC
TTGTGCATTACTCTTTGTTAGTCCTCTGCCGAGGTCCGTGAGTCCCAGCG
T R N E K Q S G D G S R H S G S

7

5660 5670 5680 5690 5700
GTCACCATGAAGCTTCTCTCGGGCCGACAGCTCTAGACACTCGCAGGTG
CAGTGGTACTTTCGAAGGAGAGCCCGGCTGTCGAGATCTGTGAGCGTCCAC
R H H E A S S R A D S S R H S Q V

6

5710 5720 5730 5740 5750
GGCCAGGGACAATCATCAGGGCCAGGACAAGCAGGAACCAGGGATCCAG
CCGGTCCCTGTAGTAGTCCCGGGTCTGTTCTGTCCTTGGTCCCTAGGTG
G Q G Q S S G P R T S R N Q G S S

5760 5770 5780 5790 5800
TGTTAGCCAGGACAGTGACAGTCAGGGACACTCAGAAGACTCTGAGAGGT
ACAATCGGTCTGTCACTGTCACTCCCTGTGAGTCTTCTGAGACTCTCCA
V S Q D S D S Q G H S E D S E R

0

5810 5820 5830 5840 5850
GGTCTGGGTCTGCTTCCAGAAACCATCTGGATCTGCTTGGGAGCAGTCA
CCAGACCCAGACGAAGGTCTTTGGTAGAACCTAGACGAACCCTCGTCAGT
W S G S A S R N H L G S A W E Q S

33

5860 5870 5880 5890 5900
AGAGATGGCTCCAGACACCCTGGGTCCCATCACGAAGACAGAGCCGGTCA
TCTCTACCGAGGTCTGTGGGACCCAGGGTAGTGCTTCTGTCTCGGCCAGT
R D G S R H P G S H H E D R A G H

3

5910 5920 5930 5940 5950
CGGGCACTCTGCAGACAGCTCCAGACAATCAGGCACTCGTCACACAGAGT
GCCCGTGAGACGTCTGTGAGGTCTGTTAGTCCGTGAGCAGTGTGTCTCA
G H S A D S S R Q S G T R H T E

5960 5970 5980 5990 6000
CTTCCTCTCGTGGACAGGCTGCGTCATCCCATGAACAGGCAAGATCAAGT
GAAGGAGAGCACCTGTCCGACGCAGTAGGGTACTTGTCGGTTCTAGTTCA

S S S R G Q A A S S H E Q A R S S

111

6010 6020 6030 6040 6050
GCAGGAGAAAGACATGGATCCCACCACCAGCTCCAGTCAGCAGACAGCTC
CGTCCTCTTTCTGTACCTAGGGTGGTGGTCGAGGTCAGTCGTCTGTGAG
A G E R H G S H H Q L Q S A D S S

9

6060 6070 6080 6090 6100
CAGACACTCAGGCATTGGGCAATGGACAAGCTTCATCTGCAGTCAGAGACA
GTCTGTGAGTCCGTAACCCGTACCTGTTTGAAGTAGACGTCAGTCCTCTGT
R H S G I G H G Q A S S A V R D

6110 6120 6130 6140 6150
GTGGACACCGAGGGTACAGTGGTAGTCAGGCCAGTGACAGTGAGGGACAT
CACCTGTGGCTCCCATGTCACCATCAGTCCGGTCACTGTCACTCCCTGTA
S G H R G Y S G S Q A S D S E G H

3

6160 6170 6180 6190 6200
TCAGAAGACTCAGACACACAGTCAGTGTGAGCAGGAAAGCTGGGCC
AGTCTTCTGAGTCTGTGTGTCAGTCACAGTCGCTCCTTTTCGACCCGG
S E D S D T Q S V S A Q G K A G P

3

3

6210 6220 6230 6240 6250
CCATCAGCAGAGCCACAAAGAGTCCGCACGTGGCCAGTCAGGGGAAAGCT
GGTAGTCGTCTCGGTGTTTCTCAGGCGTGACCCGGTCAGTCCCCCTTTCGA
H Q Q S H K E S A R G Q S G E S

End RPT5

6260 6270 6280 6290 6300
CTGGACGTTTCAAGGTCTTTCTCTACCAGGTGAGCACTCATGAACAGTCT
GACCTGCAAGTCCCAGAAAGGAGATGGTCCACTCGTGAGTACTTGTGAGA
S G R S G S F L Y Q V S T H E Q S

RPT6

4 4 4 4
6310 6320 6330 6340 6350
GAGTCCACCCATGGACAGCTGCGCCAGCACTGGAGGAAGACAAGGATC
CTCAGGTGGGTACCTGTGACGCGGGTCGTGACCTCCTTCTGTTCTTAG
E S T H G Q S A P S T G G R Q G S

6360 6370 6380 6390 6400
CCATATGATCAGGCACAAGACAGCTCCAGGCACTCAGCATCCCAAGAGG
GGTACTGTCCGTGTTCTGTGAGGTCCGTGAGTCGTAGGGTTCTCC
H Y D Q A Q D S S R H S A S Q E

11

6410 6420 6430 6440 6450
GTCAGGACACCATTCGTGGACACCCGGGGCAAGCAGAGGAGGAAGACAG
CAGTCCTGTGGTAAGCACCTGTGGGCCCCGTTTCGTCTCCTCCTTCTGTG
G Q D T I R G H P G P S R G G R Q

6460 6470 6480 6490 6500
GGGTCCCACCAAGAGCAATCGGTAGATAGGTCTGGACACTCAGGGTCTCA
CCCAGGGTGGTCTCGTTAGCCATCTATCCAGACCTGTGAGTCCCAGAGT

G S H Q E Q S V D R S G H S G S H

6510 6520 6530 6540 6550
TCACAGCCACACCACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGT
AGTGTGCGGTGTGGTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCA
H S H T T S Q G R S D A S R G Q

6560 6570 6580 6590 6600
CAGGATCCAGAAGTGCAAGCAGAAAAACATACAGGAACAATCAGGA
GTCCTAGGTCTTCACGTTCGTCTTTTGTATGTCCTTGTAGTCCT
S G S R S A S R K T Y D K E Q S G

10 10 1 3
6610 6620 6630 6640 6650
GATGGCTCAGGCACTCAGGGTCGCATCATGAAGCTTCCTCTGGGC
CTACCGAGATCCGTGAGTCCCAGCGTAGTAGTACTTCGAAGGAGAACCCG
D G S R H S G S H H H E A S S W A

5
6660 6670 6680 6690 6700
CGACAGCTCTAGACACTCACGGTGGGCCAGGGACAATCATCAGGGCCCA
GCTGTGAGATCTGTGAGTGCCACCCGGTCCCTGTTAGTAGTCCCGGGT
D S S R H S L V G Q G Q S S G P

7
6710 6720 6730 6740 6750
GGACAAGCAGGCGCGGGGATCCAGTGTAGCCAGGACAGTGACAGTGAG
CCTGTTTCGTCCGGGCCCTAGGTCACAATCGGTCTGTCACTGTCACTC
R T S R P R G S S V S Q D S D S E

6760 6770 6780 6790 6800
GGACACTCAGAAGATTCTGAGAGGCGGTCTGGGTCTGCTCCAGAAACCA
CCTGTGAGTCTTCTAAGACTCTCCGCCAGACCCAGACGAGGTCTTTGGT
G H S E D S E R R S G S A S R N H

6810 6820 6830 6840 6850
TCATGGATCTGCTCAGGAGCAGTCAAGAGATGGCTCCAGACACCCAGGT
AGTACCTAGACGAGTCCCTCGTCAGTTCTCTACCGAGGTCTGTGGGGTCCA
H G S A Q E Q S R D G S R H P R

6860 6870 6880 6890 6900
CCCATCACGAAGACAGAGCCGGTCATGGGCACTCTGCAGAGAGCTCCAGA
GGGTAGTGCTTCTGTCTCGGCCAGTACCCGTGAGACGTCTCTCGAGGTCT
S H H E D R A G H G H S A E S S R

6910 6920 6930 6940 6950
CAATCAGGCACTCATCATGCAGAGAATTCTCTGGTGGACAGGCTGCATC
GTTAGTCCGTGAGTAGTACGTCTCTTAAGGAGACCACCTGTCCGACGTAG
Q S G T H H A E N S S G G Q A A S

6960 6970 6980 6990 7000
ATCCCATGAACAGGCAAGATCAAGTGCAGGAGAGAGACACGGATCCCACC
TAGGGTACTTGTCCGTTCTAGTTCACGTCTCTCTGTGCCTAGGGTGG

S H E Q A R S S A G E R H G S H

7010 7020 7030 7040 7050
ACCAGCAGTCAGCAGACAGCTCCAGACACTCAGGCATTGGGCACGGACAA
TGGTCGTCAGTCGTCTGTGCGAGGTCTGTGAGTCCGTAACCCGTGCCTGTT
H Q Q S A D S S R H S G I G H G Q

7060 7070 7080 7090 7100
GCTTCATCTGCAGTCAGAGACAGTGGACACCGAGGGTCCAGTGGTAGTCA
CGAAGTAGACGTCAGTCTCTGTACCTGTGGCTCCCAGGTCACCATCAGT
A S S A V R D S G H R G S S G S Q

7110 7120 7130 7140 7150
GGCCAGTGACAGTGAGGGACATTCAGAAGACTCAGACACACAGTCAGTGT
CCGGTCACTGTCACTCCCTGTAAGTCTTCTGAGTCTGTGTGTCAGTCACA
A S D S E G H S E D S D T Q S V

7160 7170 7180 7190 7200
CAGCCCACGGACAGGCTGGGCCCCATCAGCAGAGCCACCAAGAGTCCACA
GTCGGGTGCCTGTCCGACCCGGGTAGTCGTCTCGGTGGTTCTCAGGTGT
S A H G Q A G P H Q Q S H Q E S T

10
7210 7220 7230 7240 7250
CGTGGCCGGTCAGCAGGAAGGTCTGGACGTTTCTCCTCTACCA
GCACCGGCCAGTCGTCCTTCCAGACCTGCAAGTCCCAGAAAGGAGATGGT
R G R S A G R S G R S G S F L Y Q

End RPT6
7260 7270 7280 7290 7300
GGTGAGCACTCATGAACAGTCTGAGTCCGCCCATGGACGGACCGGGACCA
CCACTCGTGAGTACTTGTGCACTCAGGCGGGTACCTGCCTGGCCCTGGT
V S T H E Q S E S A H G R T G T

RPT7
7310 7320 7330 7340 7350
GCACTGGAGGAAGACAAGGATCCCACCACAGCAGGCACGAGACAGCTCC
CGTGACCTCCTTCTGTTCTAGGGTGGTGTCGTCCGTGCTCTGTGAGG
S T G G R Q G S H H K Q A R D S S

7360 7370 7380 7390 7400
AGGCACTCAAGTCCCAAGAGGGTCAGGACACCATTCAGGACACCCGGG
TCCGTGAGTGCAGGGTTCTCCAGTCCTGTGGTAAGACCTGTGGGCCC
R H S T S Q E G Q D T I H G H P G

7410 7420 7430 7440 7450
GTCAAGCAGGGAGGAAGGCAGGGATCCCCTACGAGCAATGGTAGATA
CAGTTCGTCCCTCCTCCGTCCCTAGGGTGATGCTCGTTACCATCTAT
S S S G G R Q G S H Y E Q L V D

3
7460 7470 7480 7490 7500
GATCTGGACACTCAGGGTCTCATCACAGCCACACCACATCCCAGGGAAGG
CTAGACCTGTGAGTCCCAGAGTAGTGTGCGGTGTGGTGTAGGGTCCCTTCC

R S G H S G S H H S H T T S Q G R

7510 7520 7530 7540 7550
TCTGATGCCTCCCATGGGCACTCAGGATCCAGAAGTGCAAGCAGACAAAC
AGACTACGGAGGGTACCCGTAGTCCTAGGTCTTCACGTTCTGTGTTTG
S D A S H G H S G S R S A S R Q T

6
7560 7570 7580 7590 7600
TCGTAAACGAGAACCAATCAGGAGACGGCTCCAGGCACTCAGGGTCGCGTC
AGCATTGCTACTTGTTAGTCTCTGCCGAGGTCCGTGAGTCCCAGCGCAG
R N D E Q S G D G S R H S G S R

5
7610 7620 7630 7640 7650
ACCATGAAGCTTCTCTCGGGCCGACAGCTCTGACACTCGCAGGTGGGC
TGGTACTTCGAAGGAGAGCCCGCTGTGAGACTGTGAGCGTCCACCCG
H H E A S S R A D S S G H S Q V G

6
7660 7670 7680 7690 7700
CAGGGACAATCAGAGGGGGCCAGGACAAGCAGGAACGGGGATCCAGTT
GTCCCTGTAGTCTCCCCGGGTCTGTTTCGTCTTGTCCCTAGGTCATA
Q G Q S E G P R T S R N W G S S F

7710 7720 7730 7740 7750
TAGCCAGGACAGTGACAGTCAGGGGACACTCAGAAGACTCTGAGAGGTGGT
ATCGGTCTGTCACTGTCAGTCCCTGTGAGTCTTCTGAGACTCTCCACCA
S Q D S D S Q G H S E D S E R W

88
7760 7770 7780 7790 7800
CTGGGTCTGCTTCCAGAAAACCATCATGGATCTGCTCAGGAGCAGCTAAGA
GACCCAGACGAAGGTCTTTGGTAGTACCTAGACGAGTCTCGTCGATTCT
S G S A S R N H H G S A Q E Q L R

7810 7820 7830 7840 7850
GATGGCTCCAGACACCCAGGTCCCATCAAGAAGACAGAGCTGGTCATGG
CTACCGAGGTCTGTGGGGTCCAGGGTAGTTCTTCTGTCTCGACCAGTACC
D G S R H P R S H Q E D R A G H G

7860 7870 7880 7890 7900
GCACTCTGCAGACAGCTCCAGACAATCAGGCACTCGTCCACACAGACTT
CGTGAGACGTCTGTGAGGTCTGTTAGTCCGTGAGCAGTGTGTGTCTGAA
H S A D S S R Q S G T R H T Q T

7910 7920 7930 7940 7950
CCTCTGGTGGACAGGCTGCATCATCCCATGAACAGGCAAGATCAAGTGCA
GGAGACCACCTGTCCGACGTAGTAGGGTACTTGTCCGTTCTAGTTCACGT
S S G G Q A A S S H E Q A R S S A

7960 7970 7980 7990 8000
GGAGAAAGACATGGATCCCACCACCAGCAGTCAGCAGACAGCTCCAGACA
CCTCTTTCTGTACCTAGGGTGGTGGTCGTGAGTCGTCTGTGAGGTCTGT

G E R H G S H H Q Q S A D S S R H

8010 8020 8030 8040 8050
CTCAGGCATTGGGCACGGACAAGCTTCATCTGCAGTCAGAGACAGTGGAC
GAGTCCGTAACCCGTGCCTGTTTGAAGTAGACGTCAGTCTCTGTACCTG
S G I G H G Q A S S A V R D S G

8
8060 8070 8080 8090 8100
ACCGAGGGTACAGTGGTAGTCAGGCCAGTGACAATGAGGGACATTTCAGAA
TGGCTCCCATGTACCATCAGTCCGGTCACTGTTACTCCCTGTAAGTCTT
H R G Y S G S Q A S D N E G H S E

8
8110 8120 8130 8140 8150
GACTCAGACACACAGTCAGTGTCTAGCCCCACGGACAGGCTGGGTCCCATCA
CTGAGTCTGTGTGTCTAGTCACAGTCGGGTGCCTGTCCGACCCAGGGTAGT
D S D T Q S V S A H G Q A G S H Q

8
8160 8170 8180 8190 8200
GCAGAGCCACCAAGAGTCCGCACGTGGCCGGTCAAGGGGAAACGTCTGGAC
CGTCTCGGTGGTTCTCAGGCGTGCACCGGCCAGTCCCCTTTCAGACCTG
Q S H Q E S A R G R S G E T S G

8 8
End RPT7 8210 8220 8230 8240 8250
ATTCAGGATCTTTCTCTACCAGGTGAGCACTCATGAACAGTCTGAGTCC
TAAGTCTTAGAAAGGAGATGGTCCACTCGTGAGTACTTGTCTAGACTCAGG
H S G S F L Y Q V S T H E Q S E S

9 9
RPT8 8260 8270 8280 8290 8300
TCCCATGGATGGACGGGGCCAGCACTAGAGGAAGACAAGGATCCCGCCA
AGGGTACCTACCTGCCCCGGGTCTGTATCTCCTTCTGTTCTAGGGCGGT
S H G W T G P S T R G R Q G S R H

8310 8320 8330 8340 8350
TGAGCAGGCACAAGACAGCTCCAGGCACTCAGCATCCCAAGACGGTCAGG
ACTCGTCCGTGTTCTGTCTGAGGTCCGTGAGTCGTAGGGTTCTGCCAGTCC
E Q A Q D S S R H S A S Q D G Q

9
8360 8370 8380 8390 8400
ACACCATTCGTGGACACCCGGGGTCAAGCAGAGGAGGAAGGCAGGGGTAC
TGTGGTAAGCACCTGTGGGCCCCAGTTCGTCTCCTCCTTCCGTCCCCATG
D T I R G H P G S S R G G R Q G Y

9 9
8410 8420 8430 8440 8450
CACCACGAGCATTCGGTAGATAGCTCTGGACACTCAGGGTCCCATCACAG
GTGGTGCTCGTAAGCCATCTATCGAGACCTGTGAGTCCCAGGGTAGTGTC
H H E H S V D S S G H S G S H H S

8460 8470 8480 8490 8500
CCACACCACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGTCAGGAT
GGTGTGGTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCAGTCCTA

H T T S Q G R S D A S R G Q S G

8510 8520 8530 8540 8550
CCAGAAGTGCAAGCAGAACAACACGTAATGAGGAACAATCAGGAGACGGC
GGTCTTCACGTTCTGTTGTGCATTACTCCTTGTTAGTCCTCTGCCG
S R S A S R T T R N E E Q S G D G

8560 8570 8580 8590 8600
TCCAGGCACTCAGGGTCGCGTCACCATGAAGCTTCCACTCATGCCGACAT
AGGTCCGTGAGTCCCAGCGCAGTGGTACTTCGAAGGTGAGTACGGCTGTA
S R H S G S R H H E A S T H A D I

9 9
8610 8620 8630 8640 8650
CTCTAGACACTCACAGGCAGTCCAGGGACAATCAGAGGGGTCCAGGAGAA
GAGATCTGTGAGTGTCCGTCAGGTCCCTGTTAGTCTCCCAGGTCTCTT
S R H S Q A V Q G Q S E G S R R

9
8660 8670 8680 8690 8700
GCAGGCGCCAGGGATCCAGTGTGAGCCAGGACAGTGACAGTGAGGGACAT
CGTCCGCGGTCCCTAGGTACACTCGGTCCTGTCACTGTCACTCCCTGTA
S R R Q G S S V S Q D S D S E G H

8710 8720 8730 8740 8750
TCAGAAGACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACCATCATGG
AGTCTTCTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGGTAGTACC
S E D S E R W S G S A S R N H H G

77
8760 8770 8780 8790 8800
ATCTGCTCAGGAGCAGCTAAGAGATGGCTCCAGACACCCCAGGTCCCATC
TAGACGAGTCCTCGTCGATTCTCTACCGAGGTCTGTGGGGTCCAGGGTAG
S A Q E Q L R D G S R H P R S H

8810 8820 8830 8840 8850
AAGAAGACAGAGCTGGTCATGGGCACTCTGCAGACAGCTCCAGACAATCA
TTCTTCTGTCTCGACCAGTACCCGTGAGACGTCTGTGAGGTCTGTTAGT
Q E D R A G H G H S A D S S R Q S

8860 8870 8880 8890 8900
GGCACTCGTCACACACAGACTTCCTCTGGTGGACAGGCTGCATCATCCCCA
CCGTGAGCAGTGTGTGTCTGAAGGAGACCACCTGTCCGACGTAGTAGGGT
G T R H T Q T S S G G Q A A S S H

8910 8920 8930 8940 8950
TGAACAGGCAAGATCAAGTGCAGGAGAAAGACATGGATCCCACCACCAGC
ACTTGTCCGTTCTAGTTCACGTCCTCTTTCTGTACCTAGGGTGGTGGTGC
E Q A R S S A G E R H G S H H Q

8960 8970 8980 8990 9000
AGTCAGCAGACAGCTCCAGACACTCAGGCATTGGGCACGGACAAGCTTCA
TCAGTCGTCTGTGAGGTCTGTGAGTCCGTAACCCGTGCCTGTTTCAAGT

Q S A D S S R H S G I G H G Q A S

9010 9020 9030 9040 9050
TCTGCAGTCAGAGACAGTGGACACCGAGGGTACAGTGGTAGTCAGGCCAG
AGACGTCAGTCTCTGTACCTGTGGCTCCCATGTCACCATCAGTCCGGTC
S A V R D S G H R G Y S G S Q A S

9
9060 9070 9080 9090 9100
TGACAATGAGGGACATTTCAGAAGACTCAGACACACAGTCAGTGTCTAGCCC
ACTGTTACTCCCTGTAAGTCTTCTGAGTCTGTGTGTCTCAGTCACAGTCGGG
D N E G H S E D S D T Q S V S A

9
9110 9120 9130 9140 9150
ACGGACAGGCTGGGTCCCATCAGCAGAGCCACCAAGAGTCCGCACGTGGC
TGCTGTCCGACCCAGGGTAGTCGTCTCGGTGGTTCTCAGGCGTGCACCG
H G Q A G S H Q Q S H Q E S A R G

7 7 7
9160 9170 9180 9190 9200
CGGTCAGGGGAAACGTCTGGACATTCAGGATCTTTCTCTACCAGGTGAG
GCCAGTCCCCTTTGCAGACCTGTAAGTCTAGAAAGGAGATGGTCCACTC
R S G E T S G H S G S F L Y Q V S

8 8
9210 9220 9230 9240 9250
End RPT8 CACTCATGAACAGTCTGAGTCCCTCCCATGGATGGACGGGGCCCAGCACTA
GTGAGTACTTGTCTCAGACTCAGGAGGGTACCTACCTGCCCCGGGTCTGTAT
T H E Q S E S S H G W T G P S T

8
9260 9270 9280 9290 9300
RPT9 GAGGAAGACAAGGATCCCGCCATGAGCAGGCACAAGACAGCTCCAGGCAC
CTCCTTCTGTTCTAGGGCGGTACTCGTCCGTGTTCTGTCTGAGGTCCGTG
R G R Q G S R H E Q A Q D S S R H

9310 9320 9330 9340 9350
TCAGCATCCCAAACGGTCAGGACACCATTCGTGGACACCCGGGGTCAAG
AGTCGTAGGGTTTGCCAGTCTGTGGTAAGCACCTGTGGGCCCCAGTTC
S A S Q Y G Q D T I R G H P G S S

8 8 8
9360 9370 9380 9390 9400
CAGAGGAGGAAGGCAGGGGTACCACCACGAGCATTCGGTAGATAGCTCTG
GTCTCCTCCTTCCGTCCCCATGGTGGTGCTCGTAAGCCATCTATCGAGAC
R G G R Q G Y H H E H S V D S S

9410 9420 9430 9440 9450
GACACTCAGGGTCCCATCACAGCCACACCACATCCCAGGGAAGGTCTGAT
CTGTGAGTCCCAGGGTAGTGTCTGGTGTGGTGTAGGGTCCCTTCCAGACTA
G H S G S H H S H T T S Q G R S D

9460 9470 9480 9490 9500
GCCTCCCGTGGGCAGTCAGGATCCAGAAGTGCAAGCAGAACAACACGTAA
CGGAGGGCACCCGTCTAGTCTTACGTTCTGTTGTGTCATT

A S R G Q S G S R S A S R T T R N

9510 9520 9530 9540 9550
TGAGGAACAATCAGGAGACGCTCCAGGCACTCAGGTCACGTCACCATG
ACTCCTTGTTAGTCCTCTGCGAGGTCCGTGAGTCAGTGCAGTGGTAC
E E Q S G D S S R H S V S R H H

8 8
9560 9570 9580 9590 9600
AAGCTTCCACTCATGCCGACATCTCTAGACACTCACAGGCAGTCCAGGGA
TTCGAAGGTGAGTACGGCTGTAGAGATCTGTGAGTGTCCGTCCAGTCCCT
E A S T H A D I S R H S Q A V Q G

8
9610 9620 9630 9640 9650
CAATCAGAGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTGTGAGCCA
GTTAGTCTCCCCAGGTCTCTTCGTCCGCGGTCCCTAGGTCACACTCGGT
Q S E G S R R S R R Q G S S V S Q

9660 9670 9680 9690 9700
GGACAGTGACAGTGAGGGACATTGAGAAGACTCTGAGAGGTGGTCTGGGT
CCTGTCACTGTCACTCCCTGTAAGTCTTCTGAGACTCTCCACCAGACCCA
D S D S E G H S E D S E R W S G

9710 9720 9730 9740 9750
CTGCTTCCAGAAACCATCGTGGATCTGTCAGGAGCAGTCAAGGCACGGC
GACGAAGGTCTTTGGTAGCACCTAGACAGTCCCTCGTCAGTTCGGTGCCG
S A S R N H R G S V Q E Q S R H G

9760 9770 9780 9790 9800
TCCAGACACCCCAGGTCCCATCACGAAGACAGAGCCGGTCACGGGCACTC
AGGTCTGTGGGGTCCAGGGTAGTGCTTCTGTCTCGGCCAGTGCCCGTGAG
S R H P R S H H E D R A G H G H S

9810 9820 9830 9840 9850
TGCAGACGCTCCAGACAATCAGGCACTCGTCACGCAGAGACTTCCTCTG
ACGTCTGCGAGGTCTGTTAGTCCGTGAGCAGTGCGTCTCTGAAGGAGAC
A D R S R Q S G T R H A E T S S

9860 9870 9880 9890 9900
GTGGACAGGCTGCATCATCCCATGAACAGGCAAGATCAAGTCCAGGAGAG
CACCTGTCCGACGTAGTAGGGTACTTGTCCGTTCTAGTTCAGGTCCCTCTC
G G Q A A S S H E Q A R S S P G E

9910 9920 9930 9940 9950
AGACACGGATCCCGCCACCAGCAGTCAGCAGACAGCTCCAGACACTCAGG
TCTGTGCCTAGGGCGGTGGTCGTGAGTCGTCTGTGAGGTCTGTGAGTCC
R H G S R H Q Q S A D S S R H S G

22 5 2
9960 9970 9980 9990 10000
CATTCCGCGTGGACAAGCTTCATCTGCAGTCAGAGACAGTGACACTGGG
GTAAGGCGCACCTGTTTGAAGTAGACGTGAGTCTCTGTCACTGTGACCC

24/62

I P R G Q A S S A V R D S R H W

2

10010 10020 10030 10040 10050
GGTCCAGTGGTAGTCAGGCCAGTGATAGTGAGGGACATTCAGAAGAGTCA
CCAGGTCACCATCAGTCCGGTCACTATCACTCCCTGTAAGTCTTCTCAGT
G S S G S Q A S D S E G H S E E S

10060 10070 10080 10090 10100
GACACACAGTCAGTGTGACGGCCATGGACAGGCTGGGCCCCATCAGCAGAG
CTGTGTGTGTCAGTCACAGTCCGGTACCTGTCCGACCCGGGGTAGTCGTCTC
D T Q S V S G H G Q A G P H Q Q S

10110 10120 10130 10140 10150
CCACCAAGAGTCCGCACGTGACCGGTGAGGGGGAAGGTCTGGACGTTTCAG
GGTGGTTCTCAGGCGTGCACTGGCCAGTCCCCCTTCCAGACCTGCAAGTC
H Q E S A R D R S G G R S G R S

End RPT9

10160 10170 10180 10190 10200
GGTCTTTTCTCTACCAGGTGAGCACTCATGAACAGTCTGAGTCTGCCCAT
CCAGAAAGGAGATGGTCCACTCGTGAGTACTTGTGCACTCAGACGGGTA
G S F L Y Q V S T H E Q S E S A H

RPT10

3 3 3
10210 10220 10230 10240 10250
GGGCGGACCAAGGACCAGCACTGGACGAAGACAAGGATCCCACCACGAGCA
CCCGCCTGGTCTTGGTTCGTGACCTGCTTCTGTTCTAGGGTGGTGCTCGT
G R T R T S T G R R Q G S H H E Q

10260 10270 10280 10290 10300
GGCAGCAGACAGCTCCAGGCACTCAGCGTCCCAAGAGGGTCAGGACACCA
CCGTGCTCTGTGAGGTCCGTGAGTCGCAGGGTTCTCCAGTCCTGTGGT
A R D S S R H S A S Q E G Q D T

2

10310 10320 10330 10340 10350
TTCGTGGACACCCGGGGTCAAGCAGAAGAGGAAGGCAGGGATCCCCTAC
AAGCACCTGTGGGCCCCAGTTCGTCTTCTCCTTCCGTCCCTAGGGTGATG
I R G H P G S S R R G R Q G S H Y

10360 10370 10380 10390 10400
GAGCAATCGGTAGATAGGTCTGGACACTCAGGGTCCCATCACAGCCACAC
CTCGTTAGCCATCTATCCAGACCTGTGAGTCCCAGGGTAGTGTGCGGTGTG
E Q S V D R S G H S G S H H S H T

10410 10420 10430 10440 10450
CACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGTCAGGATCCAGAA
GTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCAGTCCTAGGTCTT
T S Q G R S D A S R G Q S G S R

5

3

6

10460 10470 10480 10490 10500
GTGCCAGCAGACAACTCGTAATGACGAACAATCAGGAGATGGCTCCAGG
CACGGTTCGTCTGTTTGAGCATTACTGCTTGTTAGTCCTCTACCGAGGTCC

S A S R Q T R N D E Q S G D G S R

6

(0)

10510 10520 10530 10540 10550
CACTCA GGTTCGATCACCATGAAGCTTCCACTCAGGCGGACAGCTCTAG
GTGAGT CCAGCGTAGTGGTACTTCGAAGGTGAGTCCGCCTGTTCGAGATC
H S W S H H H E A S T Q A D S S R

11

10560 10570 10580 10590 10600
ACACTCACAGTCCGGCCAGGGACAATCAGCGGGGCCCAGGACAAGCAGGA
TGTGAGTGTTCAGGCCGGTCCCTGTTAGTCGCCCCGGGTCTGTTTCGTCTT
H S Q S G Q G Q S A G P R T S R

10610 10620 10630 10640 10650
ACCAGGGATCCAGTGTTAGCCAGGACAGTGACAGTCAGGGACACTCAGAA
TGGTCCCTAGGTCCAAATCGGTCTGTCTACTGTCTAGTCCCTGTGAGTCTT
N Q G S S V S Q D S D S Q G H S E

10660 10670 10680 10690 10700
GACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACCATCGTGGATCTGC
CTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGGTAGCACCTAGACG
D S E R W S G S A S R N H R G S A

10710 10720 10730 10740 10750
TCAGGAGCAGTCAAGAGATGGCTCCAGACACCCCA GTCCCATCACGAAG
AGTCTCGTCAGTTCTCTACCGAGGTCTGTGGGGT CAGGGTAGTGCTTC
Q E Q S R D G S R H P T S H H E

10760 10770 10780 10790 10800
ACAGAGCCGGTCACGGGCACTCTGCAGAGAGCTCCAGACAATCAGGCAC
TGTCTCGGCCAGTGCCCGTGAGACGTCTCTCGAGGTCTGTTAGTCCGTGA
D R A G H G H S A E S S R Q S G T

10810 10820 10830 10840 10850
CATCATGCAGAGAATTCTCTGCTGGACAGGCTGCATCATCCCATGAACA
GTAGTACGTCTCTTAAGGAGACCACCTGTCCGACGTAGTAGGGTACTTGT
H H A E N S S G G Q A A S S H E Q

10860 10870 10880 10890 10900
GGCAAGATCAAGTGCAGGAGAGACATGGATCCCACCACCAGCAGTCAG
CCGTTCTAGTTCACGTCCTCTCTGTACCTAGGGTGGTGGTTCGTCAGTC
A R S S A G E R H G S H H Q Q S

10910 10920 10930 10940 10950
CAGACAGCTCCAGACACTCAGGCATTGGGCACGGACAAGCTTCATCTGCA
GTCTGTTCGAGGTCTGTGAGTCCGTAACCCGTGCCTGTTTGAAGTAGACGT
A D S S R H S G I G H G Q A S S A

10960 10970 10980 10990 11000
GTCAGAGACAGTGGACACCGAGGGTCCAGTGGTAGTCAGGCCAGTGACAG
CAGTCTCTGTACCTGTGGCTCCAGGTACCATCAGTCCGGTCACTGTC

V R D S G H R G S S G S Q A S D S

11010 11020 11030 11040 11050
TGAGGGACATTTCAGAAGACTCAGACACACAGTCAGTGTTCAGCCCACGGAC
ACTCCCTGTAAGTCTTCTGAGTCTGTGTGTTCAGTCACAGTCGGGTGCCTG
E G H S E D S D T Q S V S A H G

11060 11070 11080 11090 11100
AGGCTGGGCCCCATCAGCAGAGCCACCAAGAGTCCACACGTGGCCGGTCA
TCCGACCCGGGGTAGTCGTCTCGGTGGTTCCTCAGGTGTGCACCGGCCAGT
Q A G P H Q Q S H Q E S T R G R S

6
11110 11120 11130 11140 11150
GCAGGAAGGTCTGGACGTTTCAGGGTCTTTCCTCTACCAGGTGAGCACTCA
CGTCCTTCCAGACCTGCAAGTCCCAGAAAGGAGATGGTCCACTCGTGAGT
A G R S G R S G S F L Y Q V S T H

End RPT10 11160 11170 11180 11190 11200
TGAACAGTCTGAGTCTGCCCATGGACGGGCTGGGCCCAGTACTGGAGGAA
ACTTGTTCAGACTCAGACGGGTACCTGCCCCGACCCGGGTCTTGACCTCCTT
E Q S E S A H G R A G P S T G G

RPT11 11210 11220 11230 11240 11250
high GACAAGGATCCCGCCACGAGCAGGCACGAGACAGCTCCAGGCACTCAGCG
homology CTGTTCTTAGGGCGGTGCTCGTCCGTGCTCTGTTCGAGGTCCGTGAGTCGG
R Q G S R H E Q A R D S S R H S A

11260 11270 11280 11290 11300
TCCCAAGAGGGTCAGGACACCATTCGTGGACACCCGGGGTCAAGGAGAGG
AGGGTTCTCCAGTCCTGTGGTAAGCACCTGTGGGCCCCAGTTCCTCTCC
S Q E G Q D T I R G H P G S R R G

11310 11320 11330 11340 11350
AGGAAGACAGGGATCCTACCACGAGCAATCGGTAGATAGGTCTGGACACT
TCCTTCTGTCCCTAGGATGGTGTCTCGTTAGCCATCTATCCAGACCTGTGA
G R Q G S Y H E Q S V D R S G H

11360 11370 11380 11390 11400
CAGGGTCCCATCACAGCCACACCACATCCCAGGGAAGGTCTGATGCCTCC
GTCCCAGGGTAGTGTCTGGTGTGGTGTAGGGTCCCTTCCAGACTACGGAGG
S G S H H S H T T S Q G R S D A S

11410 11420 11430 11440 11450
CATGGGCAGTCAGGATCCAGAAGTGCAAGCAGAGAAACACGTAATGAGGA
GTACCCGTCAGTCCTAGGTCTTCACGTTCTGTCTCTTTGTGCATTACTCT
H G Q S G S R S A S R E T R N E E

11460 11470 11480 11490 11500
ACAGTCAGGAGACGGCTCCAGGCACTCAGGGTCGCGTCACCATGAAGCTT
TGTCAGTCCTCTGCCGAGGTCCGTGAGTCCCAGCGCAGTGGTACTTCGAA

Q S G D G S R H S G S R H H E A

11510 11520 11530 11540 11550
CCACTCAGGCTGACAGCTCTAGACACTCACAGTCCGGCCAGGGTGAATCA
GGTGAGTCCGACTGTCGAGATCTGTGAGTGTGAGGCCGGTCCCACTTAGT
S T Q A D S S R H S Q S G Q G E S

11560 11570 11580 11590 11600
GCGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTGTTAGCCAGGACAG
CGCCCCAGGTCCTCTTCGTCCGCGGTCCCTAGGTCACAATCGGTCTCTGTC
A G S R R S R R Q G S S V S Q D S

11610 11620 11630 11640 11650
TGACAGTGAGGCATACCCAGAGGACTCTGAGAGGCGATCTGAGTCTGCCTT
ACTGTCACTCCGTATGGGTCTCCTGAGACTCTCCGCTAGACTCAGACGAA
D S E A Y P E D S E R R S E S A

11660 11670 11680 11690 11700
CCAGAAACCATCATGGATCTTCTCGGGAGCAGTCAAGAGATGGCTCCAGA
GGTCTTTGGTAGTACCTAGAAGAGCCCTCGTCAGTTCTCTACCGAGGTCT
S R N H H G S S R E Q S R D G S R

RPT11
end
high
homology

11710 11720 11730 11740 11750
CACCCCGGATCCTCTCACCGCGATACAGCCAGTCAATGTACAGTCTTCACC
GTGGGGCCTAGGAGAGTGGCGCTATGTCGGTCAGTACATGTCAGAAGTGG
H P G S S H R D T A S H V Q S S P

11760 11770 11780 11790 11800
TGTACAGTCAGACTCTAGTACCGCTAAGGAACATGGTCACTTTAGTAGTC
ACATGTCAGTCTGAGATCATGGCGATTCTTGTACCAGTGAATCATCAG
V Q S D S S T A K E H G H F S S

11810 11820 11830 11840 11850
TTTCACAAGATTCTGCGTATCACTCAGGAATACAGTCACGTGGCAGTCCCT
AAAGTGTTCTAAGACGCATAGTGAGTCCTTATGTCAGTGCACCGTCAGGA
L S Q D S A Y H S G I Q S R G S P

11860 11870 11880 11890 11900
CACAGTTCTAGTTCTTATCATTATCAATCTGAGGGCACTGAAAGGCAAAA
GTGTCAAGATCAAGAATAGTAATAGTTAGACTCCCGTGACTTTCGGTTTT
H S S S S Y H Y Q S E G T E R Q K

11910 11920 11930 11940 11950
AGGTCAATCAGGTTTGTAGTTTGGAGACATGGCAGCTATGGTAGTGCAGATT
TCCAGTTAGTCCAAATCAAACCTCTGTACCGTCGATACCATCACGTCTAA
G Q S G L V W R H G S Y G S A D

11960 11970 11980 11990 12000
ATGATTATGGTGAATCCGGGTTTAGACACTCTCAGCACGGAAGTGTTAGT
TACTAATACCACTTAGGCCCAAATCTGTGAGAGTCGTGCCTTACAATCA

28/62

Y D Y G E S G F R H S Q H G S V S

12010 12020 12030 12040 12050
TACAATTCCAATCCTGTTGTTTCAAGGAAAGATCTGATATCTGTAAAGC
ATGTTAAGGTTAGGACAACAAAAGTTCCTTTCTAGACTATAGACATTTTCG
Y N S N P V V F K E R S D I C K A

12060 12070 12080 12090 12100
AAGTGCGTTTGGTAAAGATCATCCAAGGTATTATGCAACGTATATTAATA
TTCACGCAAACCATTCTAGTAGGTTCCATAATACGTTGCATATAATTAT
S A F G K D H P R Y Y A T Y I N

End RPT11
low
homology

12110 12120 12130 12140 12150
AGGACCCAGGTTTATGTGGCCATTCTAGTGATATATCGAAACAACCTGGGA
TCCTGGGTCCAAATACACCGGTAAGATCACTATATAGCTTTGTTGACCCT
K D P G L C G H S S D I S K Q L G

Tail

12160 12170 12180
TTTAGTCAGTCACAGAGATACTATTACTATGAGTAA
AAATCAGTCAGTGTCTCTATGATAATGATACTCATT
F S Q S Q R Y Y Y Y E *

Figure 5.
Atopy transmitted as a dominant trait with reduced penetrance in an IV family.




Figure 6. Filaggrin variants are associated with increased atopy





Figure 7**Increased number of positive allergens in carriers of filaggrin mutations.**

Figure 8

**Filaggrin variants are stronger risk factors for eczema
in the older asthmatics**






Figure 9

Biochemical consequences of more 3' *FLG* mutations

(A) Immunohistochemistry



(B) Immunoblotting

**Figure 10**

Schematic diagram of profilaggrin proteins encoded by size variant alleles of FLG.

Profilaggrin protein encoded by Human Genome Sequence



Population size variants encoded by larger alleles



Figure 11
DNA sequence of *FLG* size variant allele *FLG*^{δ+}

Both strands shown with amino acid translation.
Sequence Range: 1 to 5251

```

      10      20      30      40      50
AGGACAAGCAGGAACCGGGGATCCAGTTTATAGCCAGGACAGTGACAGTCA
TCCTGTTTCGTCCTTGGCCCCCTAGGTCAAAATCGGTCTGTCACTGTCAAGT
  R  T  S  R  N  R  G  S  S  F  S  Q  D  S  D  S  Q

      60      70      80      90     100
GGGACACTCAGAAGACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACC
CCCTGTGAGTCTTCTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGG
  G  H  S  E  D  S  E  R  W  S  G  S  A  S  R  N

     110     120     130     140     150
ATCATGGATCTGCTCAGGAGCAGCTAAGAGATGGCTCCAGACACCCCAGG
TAGTACCTAGACGAGTCCTCGTCGATTCTCTACCGAGGTCTGTGGGGTCC
  H  H  G  S  A  Q  E  Q  L  R  D  G  S  R  H  P  R

     160     170     180     190     200
TCCCATCAAGAAGACAGAGCTGGTCATGGGCACTCTGCAGACAGCTCCAG
AGGGTAGTTCTTCTGTCTCGACCAGTACCCGTGAGACGTCTGTCTGAGGTC
  S  H  Q  E  D  R  A  G  H  G  H  S  A  D  S  S  R

     210     220     230     240     250
ACAATCAGGCACTCGTCACACACAGACTTCTCTGGTGGACAGGCTGCAT
TGTTAGTCCGTGAGCAGTGTGTGTCTGAAGGAGACCACCTGTCCGACGTA
  Q  S  G  T  R  H  T  Q  T  S  S  G  G  Q  A  A

     260     270     280     290     300
CATCCCATGAACAGGCAAGATCAAGTGCAGGAGAAAGACATGGATCCAC
GTAGGGTACTTGTCCGTTCTAGTTCACGTCCTCTTTCTGTACCTAGGGTG
  S  S  H  E  Q  A  R  S  S  A  G  E  R  H  G  S  H

     310     320     330     340     350
CACCAGAGTCAGCAGACAGCTCCAGACACTCAGGCATTGGGCACGGACA
GTGGTCGTCACTCGTCTGTCTGAGGTCTGTGAGTCCGTAAACCCGTGCCTGT
  H  Q  Q  S  A  D  S  S  R  H  S  G  I  G  H  G  Q

     360     370     380     390     400
AGCTTCATCTGCAGTCAGAGACAGTGGACACCGAGGGTACAGTGGTAGTC
TCGAAGTAGACGTCACTCTGTCTGACCTGTGGCTCCCATGTCAACATCAG
  A  S  S  A  V  R  D  S  G  H  R  G  Y  S  G  S

     410     420     430     440     450
AGGCCAGTGACAATGAGGGACATTGAGAAGACTCAGACACACAGTCAGTG
TCCGGTCACTGTTACTCCCTGTAAGTCTTCTGAGTCTGTGTGTCACTCAC
  Q  A  S  D  N  E  G  H  S  E  D  S  D  T  Q  S  V

     460     470     480     490     500
TCAGCCCACGGACAGGCTGGGTCCCATCAGCAGAGCCACCAAGAGTCCGC
AGTCGGGTGCCTGTCCGACCCAGGGTAGTCGTCTCGGTGGTTCTCAGGCG
  S  A  H  G  Q  A  G  S  H  Q  Q  S  H  Q  E  S  A

     510     520     530     540     550
ACGTGGCCCGGTGAGGGGAAACGTCTGGACATTGAGGGTCTTTCCTCTACC
TGCACCGGCCAGTCCCCTTTGACAGACCTGTAAGTCCCAGAAAGGAGATGG
  R  G  R  S  G  E  T  S  G  H  S  G  S  F  L  Y
```

560 570 580 590 600
AGGTGAGCACTCATGAACAGTCTGAGTCTCCCATGGATGGACGGGGCCC
TCCACTCGTGAGTACTTGTGAGACTCAGGAGGGTACCTACCTGCCCCGGG
Q V S T H E Q S E S S H G W T G P

610 620 630 640 650
AGCACTAGAGGAAGACAAGGATCCCGCCATGAGCAGGCACAAGACAGCTC
TCGTGATCTCCTTCTGTTCTAGGGCGGTACTCGTCCGTGTTCTGTGCGAG
S T R G R Q G S R H E Q A Q D S S

660 670 680 690 700
CAGGCACTCAGCATCCCAAGACGGTCAGGACACCATTCGTGGACACCCGG
GTCCGTGAGTCGTAGGGTCTGCCAGTCTGTGGTAAGCACCTGTGGGCC
R H S A S Q D G Q D T I R G H P

710 720 730 740 750
GGTCAAGCAGAGGAGGAAGGCAGGGGTACCACCACGAGCATTCGGTAGAT
CCAGTTCGTCTCCTCCTTCCGTCCCATGGTGGTGCTCGTAAGCCATCTA
G S S R G G R Q G Y H H E H S V D

760 770 780 790 800
AGCTCTGGACACTCAGGGTCCCATCACAGCCACACCACATCCCAGGGAAG
TCGAGACCTGTGAGTCCCAGGGTAGTGTGGTGTGGTGTAGGGTCCCTTC
S S G H S G S H H S H T T S Q G R

810 820 830 840 850
GTCTGATGCCTCCCGTGGGCAGTCAGGATCCAGACGTGCAAGCAGAACAA
CAGACTACGGAGGGCACCCGTGAGTCTAGGTCTGCACGTTTCGTCTTGTT
S D A S R G Q S G S R R A S R T

860 870 880 890 900
CACGTAATGAGGAACAATCAGGAGACGGCTCCAGGCACTCAGGGTCGCGT
GTGCATTACTCCTTGTTAGTCCTCTGCCGAGGTCCGTGAGTCCCAGCGCA
T R N E E Q S G D G S R H S G S R

910 920 930 940 950
CACCATGAAGCTTCCACTCATGCCGACATCTCTAGACACTCACAGGCAGT
GTGGTACTTCGAAGGTGAGTACGGCTGTAGAGATCTGTGAGTGTCCGTCA
H H E A S T H A D I S R H S Q A V

960 970 980 990 1000
CCAGGGACAATCAGAGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTG
GGTCCCTGTTAGTCTCCCCAGGTCTTTCGTCCGCGGTCCCTAGGTCAC
Q G Q S E G S R R S R R Q G S S

1010 1020 1030 1040 1050
TTAGCCAGGACAGTGACAGTGAGGGACATTCAGAAGACTCTGAGAGGTGG
AATCGGTCCTGTCACTGTCACTCCCTGTAAGTCTTCTGAGACTCTCCACC
V S Q D S D S E G H S E D S E R W

1060 1070 1080 1090 1100
TCTGGGTCTGCTTCCAGAAACCATCATGGATCTGCTCAGGAGCAGCTAAG
AGACCCAGACGAAGGTCTTTGGTAGTACCTAGACGAGTCCTCGTCGATTC
S G S A S R N H H G S A Q E Q L R

1110 1120 1130 1140 1150
AGATGGCTCCAGACACCCCAGGTCCCATCAAGAAGGCAGAGCTGGTCATG
TCTACCGAGGTCTGTGGGGTCCAGGGTAGTTCTTCCGTCTCGACCAGTAC
D G S R H P R S H Q E G R A G H

1160 1170 1180 1190 1200
GGCACTCTGCAGACAGCTCCAGACAATCAGGCACTCGTCACACACAGACT
CCGTGAGACGTCTGTGCGAGGTCTGTTAGTCCGTGAGCAGTGTGTGTCTGA
G H S A D S S R Q S G T R H T Q T

1210 1220 1230 1240 1250
TCCTCTGGTGGACAGGCTGCATCATCYCATGAACAGGCAAGATCAAGTGC
AGGAGACCACCTGTCCGACGTAGTAGRGTACTTGTCCGTTCTAGTTCACG
S S G G Q A A S S H E Q A R S S A

1260 1270 1280 1290 1300
AGGAGAAAGACATGGATCCCACCACCAGCAGTCAGCAGACAGCTCCAGAC
TCCTCTTTCTGTACCTAGGGTGGTGGTCGTCTGTCTGTCGAGGTCTG
G E R H G S H H Q Q S A D S S R

1310 1320 1330 1340 1350
ACTCAGGCATTGGGCACGGACAAGCTTCATCTGCAGTCAGAGACAGTGGG
TGAGTCCGTAACCCGTGCCTGTTCTGAAGTAGACGTCAGTCTCTGTACCT
H S G I G H G Q A S S A V R D S G

1360 1370 1380 1390 1400
CACCGAGGGTACAGTGGTAGTCAGGCCAGTGACAATGAGGGACATTGAGA
GTGGCTCCCATGTACCATCAGTCCGGTCACTGTTACTCCCTGTAAGTCT
H R G Y S G S Q A S D N E G H S E

1410 1420 1430 1440 1450
AGACTCAGACACACAGTCAGTGTGAGCCACGGACAGGCTGGGTCCCATC
TCTGAGTCTGTGTGTGTCAGTCACAGTCGGGTGCCTGTCCGACCCAGGGTAG
D S D T Q S V S A H G Q A G S H

1460 1470 1480 1490 1500
AGCAGAGCCACCAAGAGTCCGCACGTGGCCGGTCAGGGGAAACGTCTGGA
TCGTCTCGGTGGTTCTCAGGCGTGCACCGGCCAGTCCCCTTTGCAGACCT
Q Q S H Q E S A R G R S G E T S G

1510 1520 1530 1540 1550
CATTGAGATCTTTCTCTACAGGTGAGCACTCATGAACAGTCTGAGTC
GTAAGTCCTAGAAAGGAGATGGTCCACTCGTGAGTACTTGTGAGACTCAG
H S G S F L Y Q V S T H E Q S E S

1560 1570 1580 1590 1600
CTCCCATGGATGGACGGGGCCAGCACTAGAGGAAGACAAGGATCCCGCC
GAGGGTACCTACCTGCCCCGGGTGATCTCCTTCTGTTCTAGGGCGG
S H G W T G P S T R G R Q G S R

1610 1620 1630 1640 1650
ATGAGCAGGCACAAGACAGCTCCAGGCACTCAGCATCCCAAGATGGTCAG
TACTCGTCCGTGTTCTGTGCGAGGTCCGTGAGTCGTAGGGTTCTACAGTC
H E Q A Q D S S R H S A S Q D G Q

1660 1670 1680 1690 1700
GACACCATTCGTGGACACCCGGGGTCAAGCAGAGGAGGAAGGCAGGGGTA
CTGTGGTAAGCACCTGTGGGCCCCAGTTCGTCTCCTCCTTCCGTCCCCAT
D T I R G H P G S S R G G R Q G Y

1710 1720 1730 1740 1750
CCACCACGAGCATTCGGTAGATAGCTCTGGACACTCAGGGTCCCATCACA
GGTGGTGCTCGTAAGCCATCTATCGAGACCTGTGAGTCCCAGGGTAGTGT
H H E H S V D S S G H S G S H H

1760 1770 1780 1790 1800
GCCACACCACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGTCAGGA
CGGTGTGGTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCAGTCCT
S H T T S Q G R S D A S R G Q S G

1810 1820 1830 1840 1850
TCCAGAAGTGCAAGCAGAACAACACGTAATGAGGAACAATCAGGAGACGG
AGGTCTTCACGTTTCGTCTTGTGTGCATTACTCCTTGTTAGTCCTCTGCC
S R S A S R T T R N E E Q S G D G

1860 1870 1880 1890 1900
CTCCAGGCACTCAGGGTCGCGTCACCATGAAGCTTCCACTCATGCCGACA
GAGGTCCGTGAGTCCCAGCGCAGTGGTACTTCGAAGGTGAGTACGGCTGT
S R H S G S R H H E A S T H A D

1910 1920 1930 1940 1950
TCTCTAGACACTCACAGGCAGTCCAGGGACAATCAGAGGGGTCCAGGAGA
AGAGATCTGTGAGTGTCCGTACAGTCCCTGTTAGTCTCCCAGGTCCTCT
I S R H S Q A V Q G Q S E G S R R

1960 1970 1980 1990 2000
AGCAGGCGCCAGGGATCCAGTGTTAGCCAGGACAGTGACAGTGAGGGACA
TCGTCCGCGGTCCCTAGGTCACAATCGGTCCTGTCACTGTCACTCCCTGT
S R R Q G S S V S Q D S D S E G H

2010 2020 2030 2040 2050
TTCAGAAGACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACCATCATG
AAGTCTTCTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGGTAGTAC
S E D S E R W S G S A S R N H H

2060 2070 2080 2090 2100
GATCTGCTCAGGAGCAGCTAAGAGATGGCTCCAGACACCCCAGGTCCCAT
CTAGACGAGTCCCTCGTCGATTCTCTACCGAGGTCTGTGGGGTCCAGGGTA
G S A Q E Q L R D G S R H P R S H

2110 2120 2130 2140 2150
CAAGAAGACAGAGCTGGTCATGGGCACTCTGCAGACAGCTCCAGACAATC
GTTCTTCTGTCTCGACCAGTACCCGTGAGACGTCTGTGAGGTCTGTTAG
Q E D R A G H G H S A D S S R Q S

2160 2170 2180 2190 2200
AGGCACTCGTCACACACAGGCTTCCTCTGGTGGACAGGCTGCATCATCCC
TCCGTGAGCAGTGTGTGTCCGAAGGAGACCACCTGTCCGACGTAGTAGGG
G T R H T Q A S S G G Q A A S S

2210 2220 2230 2240 2250
ATGAACAGGCAAGATCAAGTGCAGGAGAAAGACATGGATCCCACCACCAG
TACTTGTCCGTTCTAGTTCACGTCCTCTTTCTGTACCTAGGGTGGTGGTC
H E Q A R S S A G E R H G S H H Q

2260 2270 2280 2290 2300
CAGTCAGCAGACAGCTCCAGACACTCAGGCATTGGGCACGGACAAGCTTC
GTCAGTCCGTCTGTGAGGTCTGTGAGTCCGTAACCCGTGCCTGTTGGAAG
Q S A D S S R H S G I G H G Q A S

2310 2320 2330 2340 2350
ATCTGCAGTCAGAGACAGTGGACACCGAGGGTACAGTGGTAGTCAGGCCA
TAGACGTCAGTCTCTGTACCTGTGGCTCCCATGTACCATCAGTCCGGT
S A V R D S G H R G Y S G S Q A

2360 2370 2380 2390 2400
GTGACAATGAGGGACATTCAGAAGACTCAGACACACAGTCAGTGTGTCAGCC
CACTGTTACTCCCTGTAACTCTTCTGAGTCTGTGTGTCAGTCACAGTCGG
S D N E G H S E D S D T Q S V S A

2410 2420 2430 2440 2450
CACGGACAGGCTGGGTCCCATCAGCAGAGCCACCAAGAGTCCGCACGTGG
GTGCTGTCCGACCCAGGGTAGTCGTCTCGGTGGTTCTCAGGCGTGCACC
H G Q A G S H Q Q S H Q E S A R G

2460 2470 2480 2490 2500
CCGGTCAGGGGAAACGTCTGGACATTCAGGATCTTTCCTCTACCAGGTGA
GGCCAGTCCCCTTTGCAGACCTGTAAGTCCTAGAAAGGAGATGGTCCACT
R S G E T S G H S G S F L Y Q V

2510 2520 2530 2540 2550
GCACTCATGAACAGTCTGAGTCTCCCATGGATGGACGGGGCCAGCACT
CGTGAGTACTTGTGAGTCTCAGGAGGGTACCTACCTGCCCCGGGTCTGA
S T H E Q S E S S H G W T G P S T

2560 2570 2580 2590 2600
AGAGGAAGACAAGGATCCCGCCATGAGCAGGCACAAGACAGCTCCAGGCA
TCTCCTTCTGTTTCTAGGGCGGTACTCGTCCGTGTTCTGTGAGGTCCGT
R G R Q G S R H E Q A Q D S S R H

2610 2620 2630 2640 2650
CTCAGCATCCCAAGACGGTCAGGACACCATTCGTGGACACCCGGGGTCAA
GAGTCGTAGGGTTCTGCCAGTCTGTGGTAAGCACCTGTGGGCCCCAGTT
S A S Q D G Q D T I R G H P G S

2660 2670 2680 2690 2700
GCAGAGGAGGAAGGCAGGGGTACCACCACGAGCATTCGGTAGATAGCTCT
CGTCTCCTCCTTCCGTCCCCATGGTGGTGCTCGTAAGCCATCTATCGAGA
S R G G R Q G Y H H E H S V D S S

2710 2720 2730 2740 2750
GGACACTCAGGGTCCCATCACAGCCACACCACATCCCAGGGGAAGGTCTGA
CCTGTGAGTCCCAGGGTAGTGTGCGGTGTGGTGTAGGGTCCCTTCCAGACT
G H S G S H H S H T T S Q G R S D

2760 2770 2780 2790 2800
TGCCTCCCGTGGGCAGTCAGGATCCAGAAGTGCAAGCAGAACACACGTA
ACGGAGGGCACCCTCAGTCCTAGGTCTTCACGTTCTGTTGTGTCAT
A S R G Q S G S R S A S R T T R

2810 2820 2830 2840 2850
ATGAGGAACAATCAGGAGACAGCTCCAGGCACTCAGGGTCGCGTCACCAT
TACTCCTTGTTAGTCCTCTGTGAGGTCCGTGAGTCCCAGCGCAGTGGTA
N E E Q S G D S S R H S G S R H H

2860 2870 2880 2890 2900
GAAGCTTCCACTCATGCCGACATCTCTAGACACTCACAGGCAGTCCAGGG
CTTCGAAGGTGAGTACGGCTGTAGAGATCTGTGAGTGTCCGTCAGGTCCC
E A S T H A D I S R H S Q A V Q G

2910 2920 2930 2940 2950
ACAATCAGAGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTGTTAGCC
TGTTAGTCTCCCCAGGTCTTCTCGTCCGCGGTCCCTAGGTCACAATCGG
Q S E G S R R S R R Q G S S V S

2960 2970 2980 2990 3000
AGGACAGTGACAGTGAGGGACATTGAGAAGACTCTGAGAGGTGGTCTGGG
TCCTGTCACTGTCACTCCCTGTAAGTCTTCTGAGACTCTCCACCAGACCC
Q D S D S E G H S E D S E R W S G

3010 3020 3030 3040 3050
TCTGCTTCCAGAAACCATCGTGGATCTGTTTCAGGAGCAGTCAAGGCACGG
AGACGAAGGTCTTTGGTAGCACCTAGACAAGTCCTCGTCAGTTCGGTGCC
S A S R N H R G S V Q E Q S R H G

3060 3070 3080 3090 3100
CTCCAGACACCCCAGGTCCCATCACGAAGACAGAGCCGGTCACGGGCACT
GAGGTCTGTGGGGTCCAGGGTAGTGCTTCTGTCTCGGCCAGTGCCCGTGA
S R H P R S H H E D R A G H G H

3110 3120 3130 3140 3150
CTGCAGACCGCTCCAGACAATCAGGCACCTCGTCACGCAGAGACTTCTCT
GACGTCTGGCGAGGTCTGTTAGTCCGTGAGCAGTGCGTCTCTGAAGGAGA
S A D R S R Q S G T R H A E T S S

3160 3170 3180 3190 3200
GGTGGACAGGCTGCATCATCCCATGAACAGGCAAGATCAAGTCCAGGAGA
CCACCTGTCCGACGTAGTAGGGTACTTGTCCGTTCTAGTTCAGGTCTCT
G G Q A A S S H E Q A R S S P G E

3210 3220 3230 3240 3250
GAGACACGGATCCCGCCACCAGCAGTCAGCAGACAGCTCCAGACACTCAG
CTCTGTGCCTAGGGCGGTGGTTCGTTCAGTCGTCTGTGAGGTCTGTGAGTC
R H G S R H Q Q S A D S S R H S

3260 3270 3280 3290 3300
GCATTCCGCGTGGACAGGCTTCATCTGCAGTCAGAGACAGTAGACACTGG
CGTAAGGCGCACCTGTCCGAAGTAGACGTCACTCTCTGTCATCTGTGACC
G I P R G Q A S S A V R D S R H W

3310 3320 3330 3340 3350
GGGTCCAGTGGTAGTCAAGCCAGTGATAGTGAGGGACATTGAGAAGAGTC
CCCAGGTCACCATCAGTTCGGTCACTATCACTCCCTGTAAGTCTTCTCAG
G S S G S Q A S D S E G H S E E S

3360 3370 3380 3390 3400
AGACACACAGTCAGTGTGAGGCCATGGACAGGCTGGGCCCCATCAGCAGA
TCTGTGTGTGTCAGTCACAGTCCGGTACCTGTCCGACCCGGGGTAGTCGTCT
D T Q S V S G H G Q A G P H Q Q

3410 3420 3430 3440 3450
GCCACCAAGAGTCCGCACGTGACCGGTGAGGGGAAGGTCTGGACGTTCA
CGGTGGTTCTCAGGCGTGCAGTGGCCAGTCCCCCTTCCAGACCTGCAAGT
S H Q E S A R D R S G G R S G R S

3460 3470 3480 3490 3500
GGGTCTTCTCTACCAGGTGAGCACTCATGAACAGTCTGAGTCCGCCCCA
CCCAGAAAGGAGATGGTCCACTCGTGAGTACTTGTGAGACTCAGGCGGGT
G S F L Y Q V S T H E Q S E S A H

3510 3520 3530 3540 3550
TGGGCGGACCAGGACCAGCACTGGACGAAGACAAGGATCCCACCACGAGC
ACCGCCTGGTCTGTCGTGACCTGCTTCTGTTCTAGGGTGGTGCTCG
G R T R T S T G R R Q G S H H E

3560 3570 3580 3590 3600
AGGCACGAGACAGCTCCAGGCACTCAGCGTCCCAAGAGGGTCAGGACACC
TCCGTGCTCTGTGCGAGGTCCGTGAGTCGCAGGGTTCTCCAGTCTGTGG
Q A R D S S R H S A S Q E G Q D T

3610 3620 3630 3640 3650
ATTCGTGCACACCCGGGGTCAAGCAGAAGAGGAAGGCAGGGATCCCCTA
TAAGCACGTGTGGGCCCCAGTTCGTCTTCTCCTTCCGTCCCTAGGGTGAT
I R A H P G S S R R G R Q G S H Y

3660 3670 3680 3690 3700
CGAGCAATCGGTAGATAGGTCTGGACACTCAGGGTCCCATCACAGCCACA
GCTCGTTAGCCATCTATCCAGACCTGTGAGTCCCAGGGTAGTGTGCGGTGT
E Q S V D R S G H S G S H H S H

3710 3720 3730 3740 3750
CCACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGTCAGGATCCAGA
GGTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCAGTCCTAGGTCT
T T S Q G R S D A S R G Q S G S R

3760 3770 3780 3790 3800
AGTGCCAGCAGACAACTCGTAACGACGAACAATCAGGAGACGGCTCCAG
TCACGGTCGTCTGTTTGTGAGCATTGCTGCTTGTAGTCTCTGCCGAGGTC
S A S R Q T R N D E Q S G D G S R

3810 3820 3830 3840 3850
GCACTCATGGTCGCATCACCATGAAGCTTCCACTCAGGCGGACAGCTCTA
CGTGAGTACCAGCGTAGTGGTACTTCTGAAGGTGAGTCCGCTGTGAGAT
H S W S H H H E A S T Q A D S S

3860 3870 3880 3890 3900
GACACTCACAGTCCGGCCAGGGACAATCAGCGGGGCCCAGTACAAGCAGG
CTGTGAGTGTGAGGCCGGTCCCTGTTAGTCGCCCCGGGTGATGTTGCTCC
R H S Q S G Q G Q S A G P S T S R

3910 3920 3930 3940 3950
AACCAGGGATCCAGTGTTAGCCAGGACAGTGACAGTCAGGGACACTCAGA
TTGGTCCCTAGGTACAATCGGTCCTGTCACTGTGAGTCCCTGTGAGTCT
N Q G S S V S Q D S D S Q G H S E

3960 3970 3980 3990 4000
AGACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACCATCATGGATCTG
TCTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGGTAGTACCTAGAC
D S E R W S G S A S R N H H G S

4010 4020 4030 4040 4050
CTGGGGAGCAGTCAAGAGATGGCTCCAGACACCCTGGGTCCCATCAAGAA
GACCCCTCGTCAGTTCTCTACCGAGGTCTGTGGGACCCAGGGTAGTTCTT
A G E Q S R D G S R H P G S H Q E

4060 4070 4080 4090 4100
GACAGAGCCGGTCACGGGCACTCTGCAGACAGCCCCAGACAATCAGGCAC
CTGTCTCGGCCAGTGCCCGTGAGACGTCTGTGCGGGTCTGTTAGTCCGTG
D R A G H G H S A D S P R Q S G T

4110 4120 4130 4140 4150
TCGTACACAGAGTCTTCTCTCGTGGACAGGCTGCGTCATCCCATGAAC
AGCAGTGTGTCTCAGAAGGAGAGCACCTGTCCGACGCAGTAGGGTACTTG
R H T E S S S R G Q A A S S H E

4160 4170 4180 4190 4200
AGGCAAGATCAAGTGCAGGAGAAAGACATGGATCCCACCACCAGCTCCAG
TCCGTTCTAGTTCACGTCTTCTGTACCTAGGGTGGTGGTCGAGGTC
Q A R S S A G E R H G S H H Q L Q

4210 4220 4230 4240 4250
TCAGCAGACAGCTCCAGACACGCAGGCATTGGGCACGGACAAGCTTCATC
AGTCGTCTGTGAGGTCTGTGCGTCCGTAACCCGTGCCTGTTTCAAGTAG
S A D S S R H A G I G H G Q A S S

4260 4270 4280 4290 4300
TGCAGTCAGAGACAGTGGACACCGAGGGTACAGTGGTAGTCAGGCCACTG
ACGTCAGTCTCTGTACCTGTGGCTCCCATGTACCATCAGTCCGGTGAC
A V R D S G H R G Y S G S Q A T

4310 4320 4330 4340 4350
ACAGTGAGGGACATTGAGAAGACTCAGACACACAGTCAGTGTGAGCACAG
TGTCACCTCCCTGTAAGTCTTCTGAGTCTGTGTGTCAGTCACAGTCGTGTC
D S E G H S E D S D T Q S V S A Q

4360 4370 4380 4390 4400
GGAAAAGCTGGGCCCCATCAGCAGAGCCACAAAGAGTCCGCACGTGGCCA
CCTTTTCGACCCGGGGTAGTCGTCTCGGTGTTTCTCAGGCGTGCACCGGT
G K A G P H Q Q S H K E S A R G Q

4410 4420 4430 4440 4450
GTCAGGGGAAAGCTCTAGACGTTTCAAGGTCTTCTCTACCAGGTGAGCA
CAGTCCCCTTTTCGAGATCTGCAAGTCCCAGAAAGGAGATGGTCCACTCGT
S G E S S R R S G S F L Y Q V S

4460 4470 4480 4490 4500
CTCATGAACAGTCTGAGTCTGCCCATGGACGGGCTGGGCCCAGTACTGGA
GAGTACTTGTGAGACTCAGACGGGTACCTGCCCCACCCGGGTCATGACCT
T H E Q S E S A H G R A G P S T G

4510 4520 4530 4540 4550
GGAAGACAAGGATCCCACCACGAGCAGGCACGAGACAGCTCCAGGCACCTC
CCTTCTGTTCTTAGGGTGGTGCTCGTCCGTGCTCTGTGCGAGGTCCGTGAG
G R Q G S H H E Q A R D S S R H S

4560 4570 4580 4590 4600
AGCGTCCCAAGAGGGTCAAGACACCATTCGTGGACACCCGGGGTCAAGGA
TCGCAGGGTTTCTCCAGTCTGTGGTAAGCACCTGTGGGCCCCAGTTCCT
A S Q E G Q D T I R G H P G S R

4610 4620 4630 4640 4650
GAGGAGGAAGACAGGGATCCTACCACGAGCAATCGGTAGATAGGTCTGGA
CTCCTCCTTCTGTCCCTAGGATGGTGCTCGTTAGCCATCTATCCAGACCT
R G G R Q G S Y H E Q S V D R S G

4660 4670 4680 4690 4700
CACTCAGGGTCCCATCACAGCCACACCACATCCCAGGGAAGGTCTGATGC
GTGAGTCCCAGGGTAGTGTGCGTGTGGTGTAGGGTCCCTTCCAGACTACG
H S G S H H S H T T S Q G R S D A

4710 4720 4730 4740 4750
CTCCCATGGGCAGTCAGGATCCAGAAGTGCAAGCAGAGAAACACGTAATG
GAGGGTACCCGTGAGTCTTAGGTCTTACGTTTCTCTTTGTGCATTAC
S H G Q S G S R S A S R E T R N

4760 4770 4780 4790 4800
AGGAACAGTCAGGAGACGGCTCCAGGCACTCAGGGTCGCGTCACCATGAA
TCCTTGTCAGTCCTCTGCCGAGGTCCGTGAGTCCCAGCGCAGTGGTACTT
E E Q S G D G S R H S G S R H H E

4810 4820 4830 4840 4850
GCTTCCACTCAGGCTGACAGCTCTAGACACTCACAGTCCGGCCAGGGTGA
CGAAGGTGAGTCCGACTGTCGAGATCTGTGAGTGTGAGGCCGGTCCCACT
A S T Q A D S S R H S Q S G Q G E

4860 4870 4880 4890 4900
ATCAGCGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTGTTAGCCAGG
TAGTCGCCCCAGGTCTCTTCGTCCGCGGTCCCTAGGTACAATCGGTCC
S A G S R R S R R Q G S S V S Q

4910 4920 4930 4940 4950
ACAGTGACAGTGAGGCATACCCAGAGGACTCTGAGAGGCGATCTGAGTCT
TGTCACTGTCACTCCGTATGGGTCTCTGAGACTCTCCGCTAGACTCAGA
D S D S E A Y P E D S E R R S E S

4960 4970 4980 4990 5000
GCTTCCAGAAACCATCATGGATCTTCTCGGGAGCAGTCAAGAGATGGCTC
CGAAGGTCTTTGGTAGTACCTAGAAGAGCCCTCGTCAGTTCTCTACCGAG
A S R N H H G S S R E Q S R D G S

5010 5020 5030 5040 5050
CAGACACCCCGGATCCTCTCACCGCGATACAGCCAGTCATGTACAGTCTT
GTCTGTGGGGCCTAGGAGAGTGGCGCTATGTCGGTCAGTACATGTCAGAA
R H P G S S H R D T A S H V Q S

5060 5070 5080 5090 5100
CACCTGTACAGTCAGACTCTAGTACCGCTAAGGAACATGGTCACTTTAGT
GTGGACATGTCAGTCTGAGATCATGGCGATTCTTGTACCAGTGAATCA
S P V Q S D S S T A K E H G H F S

5110 5120 5130 5140 5150
AGTCTTTTACAAGATTCTGCGTATCACTCAGGAATACAGTCACGTGGCAG
TCAGAAAGTGTTCTAAGACGCATAGTGAGTCCTTATGTCAGTGCACCGTC
S L S Q D S A Y H S G I Q S R G S

5160 5170 5180 5190 5200
TCCTCACAGTTCTAGTTCTTATCATTATCAATCTGAGGGCACTGAAAGGC
AGGAGTGTCAAGATCAAGAATAGTAATAGTTAGACTCCCGTGACTTTCCG
P H S S S S Y H Y Q S E G T E R

5210 5220 5230 5240 5250
AAAAAGGTCAATCAGGTTTGTAGTTGGAGACATGGCAGCTATGGTAGTGCA G
TTTTTCCAGTTAGTCCAAATCAAACCTCTGTACCGTCGATACCATCACGT C
Q K G Q S G L V W R H G S Y G S A

Figure 12**DNA sequence of *FLG* size variant allele *FLG*^{L10+}**

Both strands shown with amino acid translation.
Sequence Range: 1 to 5251

```

      10      20      30      40      50
AGGACAAGCAGGAACCGGGGATCCAGTTTTAGCCAGGACAGTGACAGTCA
TCCTGTTTCGTCCTTGGCCCCCTAGGTCAAAATCGGTCTGTCAGTGTCA
  R  T  S  R  N  R  G  S  S  F  S  Q  D  S  D  S  Q

      60      70      80      90     100
GGGACACTCAGAAGACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACC
CCCTGTGAGTCTTCTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGG
  G  H  S  E  D  S  E  R  W  S  G  S  A  S  R  N

     110     120     130     140     150
ATCATGGATCTGCTCAGGAGCAGCTAAGAGATGGCTCCAGACACCCCAGG
TAGTACCTAGACGAGTCCTCGTCGATTCTCTACCGAGGTCTGTGGGGTCC
  H  H  G  S  A  Q  E  Q  L  R  D  G  S  R  H  P  R

     160     170     180     190     200
TCCCATCAAGAAGACAGAGCTGGTCATGGGCACTCTGCAGACAGCTCCAG
AGGGTAGTTCTTCTGTCTCGACCAGTACCCGTGAGACGTCTGTGCGAGGTC
  S  H  Q  E  D  R  A  G  H  G  H  S  A  D  S  S  R

     210     220     230     240     250
ACAATCAGGCACTCGTCACACACAGACTTCCTCTGGTGGACAGGCTGCAT
TGTTAGTCCGTGAGCAGTGTGTGTCTGAAGGAGACCACCTGTCCGACGTA
  Q  S  G  T  R  H  T  Q  T  S  S  G  G  Q  A  A

     260     270     280     290     300
CATCCCATGAACAGGCAAGATCAAGTGCAGGAGAAAGACATGGATCCAC
GTAGGGTACTTGTCCGTTCTAGTTCACGTCCTCTTTCTGTACCTAGGGTG
  S  S  H  E  Q  A  R  S  S  A  G  E  R  H  G  S  H

     310     320     330     340     350
CACCAGCAGTCAGCAGACAGCTCCAGACACTCAGGCATTGGGCACGGACA
GTGGTTCGTCAGTCTGTCTGTGAGGTCTGTGAGTCCGTAACCCGTGCCTGT
  H  Q  Q  S  A  D  S  S  R  H  S  G  I  G  H  G  Q

     360     370     380     390     400
AGCTTCATCTGCAGTCAGAGACAGTGGACACCGAGGGTACAGTGGTAGTC
TCGAAGTAGACGTCAGTCTCTGTACCTGTGGCTCCCATGTACCATCAG
  A  S  S  A  V  R  D  S  G  H  R  G  Y  S  G  S

     410     420     430     440     450
AGGCCAGTGACAATGAGGGACATTCAGAAGACTCAGACACACAGTCAGTG
TCCGGTCACTGTACTCCCTGTAAGTCTTCTGAGTCTGTGTGTCAGTCAC
  Q  A  S  D  N  E  G  H  S  E  D  S  D  T  Q  S  V

     460     470     480     490     500
TCAGCCACGGACAGGCTGGGTCCCATCAGCAGAGCCACCAAGAGTCCGC
AGTCGGGTGCCTGTCCGACCCAGGGTAGTCGTCTCGGTGGTTCTCAGGCG
  S  A  H  G  Q  A  G  S  H  Q  Q  S  H  Q  E  S  A

     510     520     530     540     550
ACGTGGCCGGTCAGGGGAAACGTCTGGACATTCAGGGTCTTTCCTCTACC
TGCACCGGCCAGTCCCCTTTGCAGACCTGTAAGTCCCAGAAAGGAGATGG
  R  G  R  S  G  E  T  S  G  H  S  G  S  F  L  Y
```

560 570 580 590 600
AGGTGAGCACTCATGAACAGTCTGAGTCCCTCCCATGGATGGACGGGGCCC
TCCACTCGTGAGTACTTGTCTCAGACTCAGGAGGGTACCTACCTGCCCCGGG
Q V S T H E Q S E S S H G W T G P

610 620 630 640 650
AGCACTAGAGGAAGACAAGGATCCCCGCCATGAGCAGGCACAAGACAGCTC
TCGTGATCTCCTTCTGTTCCCTAGGGCGGTACTCGTCCGTGTTCTGTCGAG
S T R G R Q G S R H E Q A Q D S S

660 670 680 690 700
CAGGCACTCAGCATCCCCAAGACGGTCAGGACACCATTCTGTTGACACCCGG
GTCCGTGAGTCGTAGGGTCTGCCAGTCTGTGGTAAGCACCTGTGGGCC
R H S A S Q D G Q D T I R G H P

710 720 730 740 750
GGTCAAGCAGAGGAGGAAGGCAGGGGTACCACCACGAGCATTCTGGTAGAT
CCAGTTCGTCTCCTCCTTCCGTCCCCATGGTGGTGCTCGTAAGCCATCTA
G S S R G G R Q G Y H H E H S V D

760 770 780 790 800
AGCTCTGGACACTCAGGGTCCCATCACAGCCACACCACATCCCAGGGAAG
TCGAGACCTGTGAGTCCCAGGGTAGTGTCGGTGTTGGTGTAGGGTCCCTTC
S S G H S G S H H S H T T S Q G R

810 820 830 840 850
GTCTGATGCCTCCCGTGGGCAGTCAGGATCCAGACGTGCAAGCAGAACAA
CAGACTACGGAGGGCACCCGTCAGTCCTAGGTCTGCACGTTCTGTTGTT
S D A S R G Q S G S R R A S R T

860 870 880 890 900
CACGTAATGAGGAACAATCAGGAGACGGCTCCAGGCACTCAGGGTTCGCGT
GTGCATTACTCCTTGTAGTCCTCTGCCGAGGTCCGTGAGTCCCAGCGCA
T R N E E Q S G D G S R H S G S R

910 920 930 940 950
CACCATGAAGCTTCCACTCATGCCGACATCTCTAGACACTCACAGGCAGT
GTGGTACTTCAAGGTGAGTACGGCTGTAGAGATCTGTGAGTGTCCGTCA
H H E A S T H A D I S R H S Q A V

960 970 980 990 1000
CCAGGGACAATCAGAGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTG
GGTCCCTGTTAGTCTCCCCAGGTCTCTTCGTCCGCGGTCCCTAGGTCAC
Q G Q S E G S R R S R R Q G S S

1010 1020 1030 1040 1050
TTAGCCAGGACAGTGACAGTGAGGGACATTCTCAGAAGACTCTGAGAGGTGG
AATCGTCCCTGTCACTGTCACTCCCTGTAAGTCTTCTGAGACTCTCCACC
V S Q D S D S E G H S E D S E R W

1060 1070 1080 1090 1100
TCTGGGTCTGCTTCCAGAAACCATCATGGATCTGCTCAGGAGCAGCTAAG
AGACCCAGACGAAGGTCTTTGGTAGTACCTAGACGAGTCCTCGTCGATTCT
S G S A S R N H H G S A Q E Q L R

1110 1120 1130 1140 1150
AGATGGCTCCAGACACCCCAGGTCCCATCAAGAAGGCAGAGCTGGTCATG
TCTACCGAGGTCTGTGGGGTCCAGGGTAGTTCTTCCGTCTCGACCAGTAC
D G S R H P R S H Q E G R A G H

1160 1170 1180 1190 1200
GGCACTCTGCAGACAGCTCCAGACAATCAGGCACTCGTCACACACAGACT
CCGTGAGACGTCTGTCTGAGGTCTGTTAGTCCGTGAGCAGTGTGTGTCTGA
G H S A D S S R Q S G T R H T Q T

1210 1220 1230 1240 1250
TCCTCTGGTGGACAGGCTGCATCATCYCATGAACAGGCAAGATCAAGTGC
AGGAGACCACCTGTCCGACGTAGTAGRGTACTTGTCCGTTCTAGTTCACG
S S G G Q A A S S H E Q A R S S A

1260 1270 1280 1290 1300
AGGAGAAAGACATGGATCCCACCACCAGCAGTCAGCAGACAGCTCCAGAC
TCCTCTTTCTGTACCTAGGGTGGTGGTCCGTGAGTCGTCTGTCTGAGGTCTG
G E R H G S H H Q Q S A D S S R

1310 1320 1330 1340 1350
ACTCAGGCATTGGGCACGGACAAGCTTCATCTGCAGTCAGAGACAGTGGGA
TGAGTCCGTAACCCGTGCCTGTTCTGAAGTAGACGTGAGTCTCTGTACCT
H S G I G H G Q A S S A V R D S G

1360 1370 1380 1390 1400
CACCGAGGGTACAGTGGTAGTCAGGCCAGTGACAATGAGGGACATTGAGA
GTGGCTCCCATGTACCATCAGTCCGGTCACTGTTACTCCCTGTAAGTCT
H R G Y S G S Q A S D N E G H S E

1410 1420 1430 1440 1450
AGACTCAGACACACAGTCAGTGTGAGCCACGGACAGGCTGGGTCCCATC
TCTGAGTCTGTGTGTGAGTCACAGTCGGGTGCCTGTCCGACCCAGGGTAG
D S D T Q S V S A H G Q A G S H

1460 1470 1480 1490 1500
AGCAGAGCCACCAAGAGTCCGCACGTGGCCGGTCAGGGGAAACGTCTGGA
TCGTCTCGGTGGTTCTCAGGCGTGCACCGGCCAGTCCCCTTTGAGACCT
Q Q S H Q E S A R G R S G E T S G

1510 1520 1530 1540 1550
CATTGAGGATCTTTCTCTACCAGGTGAGCACTCATGAACAGTCTGAGTC
GTAAGTCTTAGAAAGGAGATGGTCCACTCGTGAGTACTTGTGAGACTCAG
H S G S F L Y Q V S T H E Q S E S

1560 1570 1580 1590 1600
CTCCCATGGATGGACGGGGCCAGCACTAGAGGAAGACAAGGATCCCGCC
GAGGTACCTACCTGCCCCGGGTGATCTCCTTCTGTTCTAGGGCGG
S H G W T G P S T R G R Q G S R

1610 1620 1630 1640 1650
ATGAGCAGGCACAAGACAGCTCCAGGCACTCAGCATCCCAAGACGGTCAG
TACTCGTCCGTGTTCTGTCTGAGGTCCGTGAGTCGTAGGGTCTGCCAGTC
H E Q A Q D S S R H S A S Q D G Q

1660 1670 1680 1690 1700
GACACCATTCGTGGACACCCGGGGTCAAGCAGAGGAGGAAGGCAGGGGTA
CTGTGGTAAGCACCTGTGGGCCCCAGTTCGTCTCCTCCTTCCGTCCCAT
D T I R G H P G S S R G G R Q G Y

1710 1720 1730 1740 1750
CCACCACGAGCATTCGGTAGATAGCTCTGGCACTCAGGGTCCCATCACA
GGTGGTGCTCGTAAGCCATCTATCGAGACCTGTGAGTCCCAGGGTAGTGT
H H E H S V D S S G H S G S H H

1760 1770 1780 1790 1800
GCCACACCACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGTCAGGA
CGGTGTGGTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCACTCCT
S H T T S Q G R S D A S R G Q S G

1810 1820 1830 1840 1850
TCCAGAAGTGCAAGCAGAACACGTAATGAGGAACAATCAGGAGACAG
AGGTCTTCACGTTTCGTCTTGTGTGCATTACTCCTTGTAGTCTCTGTC
S R S A S R T T R N E E Q S G D S

1860 1870 1880 1890 1900
CTCCAGGCACTCAGGGTCGCGTCACCATGAAGCTTCCACTCATGCCGACA
GAGGTCCGTGAGTCCAGCGCAGTGGTACTTCGAAGGTGAGTACGGCTGT
S R H S G S R H H E A S T H A D

1910 1920 1930 1940 1950
TCTCTAGACACTCACAGGCAGTCCAGGGACAATCAGAGGGGTCCAGGAGA
AGAGATCTGTGAGTGTCCGTCCAGTCCCTGTTAGTCTCCCAGGTCTCT
I S R H S Q A V Q G Q S E G S R R

1960 1970 1980 1990 2000
AGCAGGCGCCAGGGATCCAGTGTAGCCAGGACAGTGACAGTGAGGGACA
TCGTCCGCGGTCCCTAGGTACAATCGGTCTGTACTGTACTCCCTGT
S R R Q G S S V S Q D S D S E G H

2010 2020 2030 2040 2050
TTCAGAAGACTCTGAGAGGTGGTCTGGGTCTGCTTCCAGAAACCATCGTG
AAGTCTTCTGAGACTCTCCACCAGACCCAGACGAAGGTCTTTGGTAGCAC
S E D S E R W S G S A S R N H R

2060 2070 2080 2090 2100
GATCTGTTCAAGGAGCAGTCAAGGCACGGCTCCAGACACCCAGGTCCCAT
CTAGACAAGTCCCTCGTCAGTTCGGTCCGAGGTCTGTGGGGTCCAGGGTA
G S V Q E Q S R H G S R H P R S H

2110 2120 2130 2140 2150
CACGAAGACAGAGCCGGTCACGGGCACTCTGCAGACCGCTCCAGACAATC
GTGCTTCTGTCTCGGCCAGTGCCCGTGAGACGTCTGGCGAGGTCTGTTAG
H E D R A G H G H S A D R S R Q S

2160 2170 2180 2190 2200
AGGCACTCGTCACGCAGAGACTTCCTCTGGTGGACAGGCTGCATCATCCC
TCCGTGAGCAGTGCGTCTCTGAAGGAGACCACCTGTCCGACGTAGTAGGG
G T R H A E T S S G G Q A A S S

2210 2220 2230 2240 2250
ATGAACAGGCAAGATCAAGTCCAGGAGAGAGACACGGATCCCGCCACCAG
TACTTGTCCGTTCTAGTTCAGGTCCCTCTCTCTGTGCCTAGGGCGGTGGTC
H E Q A R S S P G E R H G S R H Q

2260 2270 2280 2290 2300
CAGTCAGCAGACAGCTCCAGACACTCAGGCATTCCGCGTGACAGGCTTC
GTCAGTCGTCTGTGAGGTCTGTGAGTCCGTAAGGCGCACCTGTCCGAAG
Q S A D S S R H S G I P R G Q A S

2310 2320 2330 2340 2350
ATCTGCAGTCAGAGACAGTAGACACTGGGGGTCCAGTGGTAGTCAAGCCA
TAGACGTCACTCTGTGATCTGTGACCCCCAGGTACCATCAGTTCGGT
S A V R D S R H W G S S G S Q A

2360 2370 2380 2390 2400
GTGATAGTGAGGGACATTTCAGAAGAGTCAGACACACAGTCAGTGTTCAGGC
CACTATCACTCCCTGTAAGTCTTCTCAGTCTGTGTGTTCAGTCACAGTCCG
S D S E G H S E E S D T Q S V S G

2410 2420 2430 2440 2450
CATGGACAGGCTGGGCCCCATCAGCAGAGCCACCAAGAGTCCGCACGTGA
GTACCTGTCCGACCCGGGTAGTTCGTCTCGGTGGTTCTCAGGCGTGCCT
H G Q A G P H Q Q S H Q E S A R D

2460 2470 2480 2490 2500
CCGGTCAGGGGGAAGGTCTGGACGTTTCAGGGTCTTTCCTCTACCAGGTGA
GGCCAGTCCCCCTTCCAGACCTGCAAGTCCCAGAAAGGAGATGGTCCACT
R S G G R S G R S G S F L Y Q V

2510 2520 2530 2540 2550
GCACTCATGAACAGTCTGAGTCCGCCCATGGGCGGACCAGGACCAGCACT
CGTGAGTACTTGTTCAGACTCAGGCGGGTACCCGCCTGGTCTGTCTGTCTGA
S T H E Q S E S A H G R T R T S T

2560 2570 2580 2590 2600
GGACGAAGACAAGGATCCCACCACGAGCAGGCACGAGACAGCTCCAGGCA
CCTGCTTCTGTTCTAGGGTGGTGTCTCGTCCGTGCTCTGTCTGAGGTCCGT
G R R Q G S H H E Q A R D S S R H

2610 2620 2630 2640 2650
CTCAGCGTCCCAAGAGGGTCAGGACACCATTTCGTGCACACCCGGGGTCAA
GAGTCGCAGGGTCTTCCCAGTCTGTGGTAAGCACGTGTGGGCCCCAGTT
S A S Q E G Q D T I R A H P G S

2660 2670 2680 2690 2700
GCAGAAGAGGAAGGCAGGGATCCCCTACGAGCAATCGGTAGATAGGTCT
CGTCTTCTCCTTCCGTCCCTAGGGTGATGCTCGTTAGCCATCTATCCAGA
S R R G R Q G S H Y E Q S V D R S

2710 2720 2730 2740 2750
GGACACTCAGGGTCCCCTACAGCCACACCACATCCCAGGGAAGGTCTGA
CCTGTGAGTCCCAGGGTAGTGTCTCGGTGTGGTGTAGGGTCCCTTCCAGACT
G H S G S H H S H T T S Q G R S D

2760 2770 2780 2790 2800
TGCCTCCCGTGGGCAGTCAGGATCCAGAAGTGCCAGCAGACAACTCGTA
ACGGAGGGCACCCGTTCAGTCTAGGTCTTACGGTCTGTCTGTTTGTAGCAT
A S R G Q S G S R S A S R Q T R

2810 2820 2830 2840 2850
ACGACGAACAATCAGGAGACGGCTCCAGGCACTCATGGTTCGCATCACCAT
TGCTGCTTGTAGTCTCTGCCGAGGTCCGTGAGTACCAGCGTAGTGGTA
N D E Q S G D G S R H S W S H H H

2860 2870 2880 2890 2900
GAAGCTTCCACTCAGGCGGACAGCTCTAGACACTCACAGTCCGGCCAGGG
CTTCTGAAGGTGAGTCCGCCTGTCTGAGATCTGTGAGTGTCTCAGGCCGTCCC
E A S T Q A D S S R H S Q S G Q G

2910 2920 2930 2940 2950
ACAATCAGCGGGGCCAGTACAAGCAGGAACCAGGGATCCAGTGTCTAGCC
TGTTAGTCTGCCCCGGGTCTGTTCTGCTCCTTGGTCCCTAGGTACCAATCGG
Q S A G P S T S R N Q G S S V S

2960 2970 2980 2990 3000
AGGACAGTGACAGTCAGGGACACTCAGAAGACTCTGAGAGGTGGTCTGGG
TCCTGTCACTGTGAGTCCCTGTGAGTCTTCTGAGACTCTCCACCAGACCC
Q D S D S Q G H S E D S E R W S G

3010 3020 3030 3040 3050
TCTGCTTCCAGAAACCATCATGGATCTGCTGGGGAGCAGTCAAGAGATGG
AGACGAAGGTCTTTGGTAGTACCTAGACGACCCCTCGTCAGTTCTCTACC
S A S R N H H G S A G E Q S R D G

3060 3070 3080 3090 3100
CTCCAGACACCCTGGGTCCCATCAAGAAGACAGAGCCGGTCACGGGCACT
GAGGTCTGTGGGACCCAGGGTAGTTCTTCTGTCTCGGCCAGTGCCCGTGA
S R H P G S H Q E D R A G H G H

3110 3120 3130 3140 3150
CTGCAGACAGCCCCAGACAATCAGGCACTCGTCACACAGAGTCTTCTCT
GACGTCTGTGCGGGTCTGTTAGTCCGTGAGCAGTGTGTCTCAGAAGGAGA
S A D S P R Q S G T R H T E S S S

3160 3170 3180 3190 3200
CGTGGACAGGCTGCGTCATCCCATGAACAGGCAAGATCAAGTGCAGGAGA
GCACCTGTCCGACGCAGTAGGGTACTTGTCCGTTCTAGTTCACGTCTCT
R G Q A A S S H E Q A R S S A G E

3210 3220 3230 3240 3250
AAGACATGGATCCCACCACCAGCTCCAGTCAGCAGACAGCTCCAGACACG
TTCTGTACCTAGGGTGGTGGTTCGAGGTGAGTCGTCTGTCTGAGGTCTGTGC
R H G S H H Q L Q S A D S S R H

3260 3270 3280 3290 3300
CAGGCATTGGGCACGGACAAGCTTCATCTGCAGTCAGAGACAGTGGACAC
GTCCGTAACCCGTGCCTGTTTGAAGTAGACGTGAGTCTCTGTACCTGTG
A G I G H G Q A S S A V R D S G H

3310 3320 3330 3340 3350
CGAGGGTACAGTGGTAGTCAGGCCACTGACAGTGAGGGACATTGAGAAGA
GCTCCCATGTCAACATCAGTCCGGTGACTGTCACTCCCTGTAAGTCTTCT
R G Y S G S Q A T D S E G H S E D

3360 3370 3380 3390 3400
CTCAGACACACAGTCAGTGTGAGCACAGGGAAAAGCTGGGCCCCATCAGC
GAGTCTGTGTGTGAGTCACAGTCGTGTCCCTTTTCGACCCGGGGTAGTCG
S D T Q S V S A Q G K A G P H Q

3410 3420 3430 3440 3450
AGAGCCACAAAGAGTCCGCACGTGGCCAGTCAGGGGAAAGCTCTAGACGT
TCTCGGTGTTTCTCAGGCGTGCACCGGTGAGTCCCTTTTCGAGATCTGCA
Q S H K E S A R G Q S G E S S R R

3460 3470 3480 3490 3500
TCAGGGTCTTTCTCTACAGGTGAGCACTCATGAACAGTCTGAGTCCAC
AGTCCCAGAAAGGAGATGGTCCACTCGTGAGTACTTGTGAGTCTCAGGTG
S G S F L Y Q V S T H E Q S E S T

3510 3520 3530 3540 3550
CCATGGACAGTCTGTGCCAGCACTGGAGGAAGACAAGGATCCCACCATG
GGTACCTGTGAGACACGGGTGACCTCCTTCTGTTTCTAGGGTGGTAC
H G Q S V P S T G G R Q G S H H

49/62

3560 3570 3580 3590 3600
ATCAGGCACAAGACAGCTCCAGGCACTCAGCATCCCAAGAGGGTCAGGAC
TAGTCCGTGTTCTGTGCGAGGTCCGTGAGTCGTAGGGTTCTCCAGTCCTG
D Q A Q D S S R H S A S Q E G Q D

3610 3620 3630 3640 3650
ACCATTCTGTGGACACCCGGGGCCAAGCAGAGGAGGAAGACAGGGGTCCCA
TGGTAAGCACCTGTGGGCCCCGGTTCGTCTCCTCCTTCTGTCCCCAGGGT
T I R G H P G P S R G G R Q G S H

3660 3670 3680 3690 3700
CCACGAGCAATCGGTAGATAGGTCTGGACACTCAGGGTCCCATCACAGCC
GGTGCTCGTTAGCCATCTATCCAGACCTGTGAGTCCCAGGGTAGTGTCTGG
H E Q S V D R S G H S G S H H S

3710 3720 3730 3740 3750
ACACCACATCCCAGGGAAGGTCTGATGCCTCCCGTGGGCAGTCAGGACCC
TGTGGTGTAGGGTCCCTTCCAGACTACGGAGGGCACCCGTCAGTCCTGGG
H T T S Q G R S D A S R G Q S G P

3760 3770 3780 3790 3800
AGAAGTGCAAGCAGACAAACACATGACAAGGAACAATCAGGAGACGGCTC
TCTTCACGTTTCGTCTGTTTGTGTACTGTTCTTGTAGTCTCTGCCGAG
R S A S R Q T H D K E Q S G D G S

3810 3820 3830 3840 3850
TAGGCACTCAGGGTCGCGTCATCATGAAGCTTCCTCTTGGGCCGACAGCT
ATCCGTGAGTCCCAGCGCAGTAGTACTTGAAGGAGAACCCGGCTGTCTGA
R H S G S R H H E A S S W A D S

3860 3870 3880 3890 3900
CTAGACACTCACAGGCAGTCCAGGGACAATCAGAGGGGTCCAGGAGAAGC
GATCTGTGAGTGTCCGTCAGGTCCCTGTAGTCTCCCCAGGTCTCTTCG
S R H S Q A V Q G Q S E G S R R S

3910 3920 3930 3940 3950
AGGCGCCAGGGATCCAGTGTAGCCAGGACAGTGACAGTCAGGGACACTC
TCCGCGGTCCCTAGGTACAAATCGGTCCTGTCACTGTGAGTCCCTGTGAG
R R Q G S S V S Q D S D S Q G H S

3960 3970 3980 3990 4000
AGAAGACTCTGAGAGGCGGTCTGGGTCTGCTTCCAGAAACCATCGTGGAT
TCTTCTGAGACTCTCCGCCAGACCCAGACGAAGGTCTTTGGTAGCACCTA
E D S E R R S G S A S R N H R G

4010 4020 4030 4040 4050
CTGCTCAGGAGCAGTCAAGAGATGGCTCCAGACACCCAGGTCCCATCAC
GACGAGTCTCTGTCAGTTCTCTACCGAGGTCTGTGGGGTCCAGGGTAGTG
S A Q E Q S R D G S R H P R S H H

4060 4070 4080 4090 4100
GAAGACAGAGCCGGTCATGGGCACTCTGCAGACAGCTCCAGACAATCAGG
CTTCTGTCTCGGCCAGTACCCGTGAGACGTCTGTGAGGTCTGTTAGTCC
E D R A G H G H S A D S S R Q S G

4110 4120 4130 4140 4150
CACTCATCATGCAGAGAATTCTCTGGTGGACAGCCTGCATCATCCCATG
GTGAGTAGTACGTCTCTTAAGGAGACCACCTGTGCGACGTAGTAGGGTAC
T H H A E N S S G G Q P A S S H

4160 4170 4180 4190 4200
AACAGGCAAGATCAAGTGCAGGAGAGACATGGATCCCACCACCAGCAG
TTGTCCGTTCTAGTTCACGTCCCTCTCTCTGTACCTAGGGTGGTGGTCGTC
E Q A R S S A G E R H G S H H Q Q

4210 4220 4230 4240 4250
TCAGCAGACAGCTCCAGACACTCAGGCATTGGGGCACGGACAAGCTTCATC
AGTCGTCTGTGAGGTCTGTGAGTCCGTAAACCCGTGCCTGTTTCAAGTAG
S A D S S R H S G I G H G Q A S S

4260 4270 4280 4290 4300
TGCAGTCAGAGACAGTGGACACCGAGGGTCCAGTGGTAGTCAGGCCAGTG
ACGTCAGTCTCTGTACCTGTGGCTCCCAGGTACCATCAGTCCGGTCAC
A V R D S G H R G S S G S Q A S

4310 4320 4330 4340 4350
ACAGTGAGGGACATTCAGAAGACTCAGACACACAGTCAGTGTTCAGCCCAC
TGTCAGTCCCTGTAAGTCTTCTGAGTCTGTGTGTCAGTCACAGTCGGGTG
D S E G H S E D S D T Q S V S A H

4360 4370 4380 4390 4400
GGACAGGCTGGGCCCCATCAGCAGAGCCACCAAGAGTCCACACGTGGCCG
CCTGTCCGACCCGGGGTAGTCGTCTCGGTGGTTCTCAGGTGTGCACCGGC
G Q A G P H Q Q S H Q E S T R G R

4410 4420 4430 4440 4450
GTCAGCAGGAAGGTCTGGACGTTTCAAGGTCTTTCTCTACCAGGTGAGCA
CAGTCGTCTTCCAGACCTGCAAGTCCAGAAAGGAGATGGTCCACTCGT
S A G R S G R S G S F L Y Q V S

4460 4470 4480 4490 4500
CTCATGAACAGTCTGAGTCTGCCCATGGACGGGCTGGGCCCCAGTACTGGA
GAGTACTTGTGAGTCTGAGACGGGTACCTGCCCCGACCCGGGTCATGACCT
T H E Q S E S A H G R A G P S T G

4510 4520 4530 4540 4550
GGAAGACAAGGATCCCACCACGAGCAGGCACGAGACAGCTCCAGGCACTC
CCTTCTGTTCTAGGGTGGTGCTCGTCCGTGCTCTGTGAGGTCCGTGAG
G R Q G S H H E Q A R D S S R H S

4560 4570 4580 4590 4600
AGCGTCCCAAGAGGGTCAAGACACCATTCGTGGACACCCGGGGTCAAGGA
TCGACAGGGTCTCCAGTCTGTGGTAAGCACCTGTGGGCCCCAGTTCCT
A S Q E G Q D T I R G H P G S R

4610 4620 4630 4640 4650
GAGGAGGAAGACAGGGATCCTACCACGAGCAATCGGTAGATAGGTCTGGA
CTCCTCCTTCTGTCCCTAGGATGGTGCTCGTTAGCCATCTATCCAGACCT
R G G R Q G S Y H E Q S V D R S G

4660 4670 4680 4690 4700
CACTCAGGGTCCCATCACAGCCACACCACATCCCAGGGAAGGTCTGATGC
GTGAGTCCCAGGGTAGTGTGCGGTGTGGTGTAGGGTCCCTTCCAGACTACG
H S G S H H S H T T S Q G R S D A

4710 4720 4730 4740 4750
CTCCCATGGGCAGTCAGGATCCAGAAGTGCAAGCAGAGAAACACGTAATG
GAGGGTACCCGTGAGTCTAGGTCTTACGTTCTGTTTGTGATTAC
S H G Q S G S R S A S R E T R N

4760 4770 4780 4790 4800
AGGAACAGTCAGGAGACGGCTCCAGGCACTCAGGGTCGCGTCACCATGAA
TCCTTGTCACTCCTCTGCCGAGGTCCGTGAGTCCCAGCGCAGTGGTACTT
E E Q S G D G S R H S G S R H H E

4810 4820 4830 4840 4850
GCTTCCACTCAGGCTGACAGCTCTAGACACTCACAGTCCGGCCAGGGTGA
CGAAGGTGAGTCCGACTGTGAGATCTGTGAGTGTGAGGCCGGTCCCACT
A S T Q A D S S R H S Q S G Q G E

4860 4870 4880 4890 4900
ATCAGCGGGGTCCAGGAGAAGCAGGCGCCAGGGATCCAGTGTAGCCAGG
TAGTCGCCCCAGGTCTCTTCGTCCGCGGTCCCTAGGTCACAATCGGTCC
S A G S R R S R R Q G S S V S Q

4910 4920 4930 4940 4950
ACAGTGACAGTGAGGCATACCCAGAGGACTCTGAGAGGCGATCTGAGTCT
TGTCAGTGTCACTCCGTATGGGTCTCCTGAGACTCTCCGCTAGACTCAGA
D S D S E A Y P E D S E R R S E S

4960 4970 4980 4990 5000
GCTTCCAGAAACCATCATGGATCTTCTCGGGAGCAGTCAAGAGATGGCTC
CGAAGGTCTTTGGTAGTACCTAGAAGAGCCCTCGTCAGTTCTCTACCGAG
A S R N H H G S S R E Q S R D G S

5010 5020 5030 5040 5050
CAGACACCCCGGATCCTCTCACCGCGATACAGCCAGTCATGTACAGTCTT
GTCTGTGGGGCCTAGGAGAGTGGCGCTATGTCGGTCAGTACATGTCAGAA
R H P G S S H R D T A S H V Q S

5060 5070 5080 5090 5100
CACCTGTACAGTCAGACTCTAGTACCGCTAAGGAACATGGTCACTTTAGT
GTGGACATGTGAGTCTGAGATCATGGCGATTCTTGTACCAGTGAAATCA
S P V Q S D S S T A K E H G H F S

5110 5120 5130 5140 5150
AGTCTTTTACAAGATTCTGCGTATCACTCAGGAATACAGTCACGTGGCAG
TCAGAAAGTGTTCTAAGACGCATAGTGAGTCCTTATGTCAGTGCACCGTC
S L S Q D S A Y H S G I Q S R G S

5160 5170 5180 5190 5200
TCCTCACAGTTCTAGTTCTTATCATTATCAATCTGAGGGCACTGAAAGGC
AGGAGTGTCAAGATCAAGAATAGTAATAGTTAGACTCCCGTGACTTTCCG
P H S S S S Y H Y Q S E G T E R

5210 5220 5230 5240 5250
AAAAAGGTCAATCAGGTTTAGTTTGGAGACATGGCAGCTATGGTAGTGCA G
TTTTTCCAGTTAGTCCAAATCAAACCTCTGTACCGTCGATACCATCACGT C
Q K G Q S G L V W R H G S Y G S A

Figure 13**Specific fragment from *FLG* size variant allele "*FLG*⁸⁺¹⁰⁺"****Sequence Range: 1 to 6223**

Repeat 7 (partial)

```

AGGACAAGCA GGAACCGGGG ATCCAGTTTT AGCCAGGACA GTGACAGTCA      50
TCCTGTTCGT CCTTGGCCCC TAGGTCAAAA TCGGTCCTGT CACTGTCAGT
R T S R N R G S S F S Q D S D S Q

GGGACACTCA GAAGACTCTG AGAGGTGGTC TGGGTCTGCT TCCAGAAACC      100
CCCTGTGAGT CTTCTGAGAC TCTCCACCAG ACCCAGACGA AGGTCTTTGG
G H S E D S E R W S G S A S R N

ATCATGGATC TGCTCAGGAG CAGCTAAGAG ATGGCTCCAG ACACCCAGG      150
TAGTACCTAG ACGAGTCCTC GTCGATTCTC TACCGAGGTC TGTGGGGTCC
H H G S A Q E Q L R D G S R H P R

TCCCATCAAG AAGACAGAGC TGGTCATGGG CACTCTGCAG ACAGCTCCAG      200
AGGGTAGTTC TTCTGTCTCG ACCAGTACCC GTGAGACGTC TGTGAGGTC
S H Q E D R A G H G H S A D S S R

ACAATCAGGC ACTCGTCACA CACAGACTTC CTCTGGTGGA CAGGCTGCAT      250
TGTTAGTCCG TGAGCAGTGT GTGTCTGAAG GAGACCACCT GTCCGACGTA
Q S G T R H T Q T S S G G Q A A

CATCCCATGA ACAGGCAAGA TCAAGTGCAG GAGAAAGACA TGGATCCCAC      300
GTAGGGTACT TGTCCGTTCT AGTTCACGTC CTCTTTCTGT ACCTAGGGTG
S S H E Q A R S S A G E R H G S H

CACCAGCAGT CAGCAGACAG CTCCAGACAC TCAGGCATTG GGCACGGACA      350
GTGGTCGTCA GTCGTCTGTC GAGGTCTGTG AGTCCGTAAAC CCGTGCCTGT
H Q Q S A D S S R H S G I G H G Q

AGCTTCATCT GCAGTCAGAG ACAGTGGACA CCGAGGGTAC AGTGGTAGTC      400
TCGAAGTAGA CGTCAGTCTC TGTCACCTGT GGCTCCCATG TCACCATCAG
A S S A V R D S G H R G Y S G S

AGGCCAGTGA CAATGAGGGA CATTGAGAAG ACTCAGACAC ACAGTCAGTG      450
TCCGGTCACT GTTACTCCCT GTAAGTCTTC TGAGTCTGTG TGTCAGTCAC
Q A S D N E G H S E D S D T Q S V

TCAGCCCACG GACAGGCTGG GTCCCATCAG CAGAGCCACC AAGAGTCCGC      500
AGTCGGGTGC CTGTCCGACC CAGGGTAGTC GTCTCGGTGG TTCTCAGGCG
S A H G Q A G S H Q Q S H Q E S A

```


ACGTGGCCGG TCAGGGGAAA CGTCTGGACA TTCAGGGTCT TTCCTCTACC 550
 TGCACCGGCC AGTCCCCTTT GCAGACCTGT AAGTCCCAGA AAGGAGATGG
 R G R S G E T S G H S G S F L Y

Repeat 8.1 600
 AGGTGAGCAC TCATGAACAG TCTGAGTCCT CCCATGGATG GACGGGGCCC
 TCCACTCGTG AGTACTTGTC AGACTCAGGA GGGTACCTAC CTGCCCCGGG
 Q V S T H E Q S E S S H G W T G P

Repeat 8.1 650
 AGCACTAGAG GAAGACAAGG ATCCCGCCAT GAGCAGGCAC AAGACAGCTC
 TCGTGATCTC CTTCTGTTCC TAGGGCGGTA CTCGTCCGTG TTCTGTCCGAG
 S T R G R Q G S R H E Q A Q D S S

700
 CAGGCACTCA GCATCCCAAG ACGGTCAGGA CACCATTTCGT GGACACCCGG
 GTCCGTGAGT CGTAGGGTTC TGCCAGTCCT GTGGTAAGCA CCTGTGGGCG
 R H S A S Q D G Q D T I R G H P

750
 GGTCAAGCAG AGGAGGAAGG CAGGGGTACC ACCACGAGCA TTCGGTAGAT
 CCAGTTCGTC TCCTCCTTCC GTCCCATGG TGGTGCTCGT AAGCCATCTA
 G S S R G G R Q G Y H H E H S V D

800
 AGCTCTGGAC ACTCAGGGTC CCATCACAGC CACACCACAT CCCAGGGAAG
 TCGAGACCTG TGAGTCCCAG GGTAGTGTCTG GTGTGGTGTA GGGTCCCTTC
 S S G H S G S H H S H T T S Q G R

850
 GTCTGATGCC TCCCGTGGGC AGTCAGGATC CAGACGTGCA AGCAGAACAA
 CAGACTACGG AGGGCACCCG TCAGTCCTAG GTCTGCACGT TCGTCTTGTT
 S D A S R G Q S G S R R A S R T

900
 CACGTAATGA GGAACAATCA GGAGACGGCT CCAGGCACTC AGGGTCGCGT
 GTGCATTACT CCTTGTTAGT CCTCTGCCGA GGTCCGTGAG TCCAGCGCA
 T R N E E Q S G D G S R H S G S R

950
 CACCATGAAG CTTCCACTCA TGCCGACATC TCTAGACACT CACAGGCAGT
 GTGGTACTTC GAAGGTGAGT ACGGCTGTAG AGATCTGTGA GTGTCCGTCA
 H H E A S T H A D I S R H S Q A V

1000
 CCAGGGACAA TCAGAGGGGT CCAGGAGAAG CAGGCGCCAG GGATCCAGTG
 GGTCCCTGTT AGTCTCCCCA GGTCTCTTTC GTCCGCGGTC CCTAGGTCAC
 Q G Q S E G S R R S R R Q G S S

1050
 TTAGCCAGGA CAGTGACAGT GAGGGACATT CAGAAGACTC TGAGAGGTGG
 AATCGGTCCT GTCAGTGTCA CTCCCTGTAA GTCTTCTGAG ACTCTCCACC
 V S Q D S D S E G H S E D S E R W

1100
 TCTGGGTCTG CTTCCAGAAA CCATCATGGA TCTGCTCAGG AGCAGCTAAG
 AGACCCAGAC GAAGGTCTTT GGTAGTACCT AGACGAGTCC TCGTCGATTC
 S G S A S R N H H G S A Q E Q L R

AGATGGCTCC AGACACCCCA GGTCCCATCA AGAAGGCAGA GCTGGTCATG 1150
 TCTACCGAGG TCTGTGGGGT CCAGGGTAGT TCTTCCGTCT CGACCAGTAC
 D G S R H P R S H Q E G R A G H

GGCACTCTGC AGACAGCTCC AGACAATCAG GCACTCGTCA CACACAGACT 1200
 CCGTGAGACG TCTGTGAGG TCTGTTAGTC CGTGAGCAGT GTGTGTCTGA
 G H S A D S S R Q S G T R H T Q T

TCCTCTGGTG GACAGGCTGC ATCATCCCAT GAACAGGCAA GATCAAGTGC 1250
 AGGAGACCAC CTGTCCGACG TAGTAGRGT CTTGTCCGTT CTAGTTCACG
 S S G G Q A A S S H E Q A R S S A

AGGAGAAAGA CATGGATCCC ACCACCAGCA GTCAGCAGAC AGCTCCAGAC 1300
 TCCTCTTTCT GTACCTAGGG TGGTGGTCGT CAGTCGTCTG TCGAGGTCTG
 G E R H G S H H Q Q S A D S S R

ACTCAGGCAT TGGGCACGGA CAAGCTTCAT CTGCAGTCAG AGACAGTGGA 1350
 TGAGTCCGTA ACCCGTGCCT GTTCGAAGTA GACGTCAGTC TCTGTCACCT
 H S G I G H G Q A S S A V R D S G

CACCGAGGGT ACAGTGGTAG TCAGGCCAGT GACAATGAGG GACATTCAGA 1400
 GTGGCTCCCA TGTCACCATC AGTCCGGTCA CTGTTACTCC CTGTAAGTCT
 H R G Y S G S Q A S D N E G H S E

AGACTCAGAC ACACAGTCAG TGTCAGCCCA CGGACAGGCT GGGTCCCATC 1450
 TCTGAGTCTG TGTGTCAGTC ACAGTCGGGT GCCTGTCCGA CCCAGGGTAG
 D S D T Q S V S A H G Q A G S H

AGCAGAGCCA CCAAGAGTCC GCACGTGGCC GGTGAGGGGA AACGTCTGGA 1500
 TCGTCTCGGT GGTTCCTCAGG CGTGCACCGG CCAGTCCCCT TTGCAGACCT
 Q Q S H Q E S A R G R S G E T S G

CATTGAGGAT CTTTCCTCTA CCAGGTGAGC ACTCATGAAC AGTCTGAGTC Repeat 8.2 1550
 GTAAGTCCTA GAAAGGAGAT GGTCCACTCG TGAGTACTTG TCAGACTCAG
 H S G S F L Y Q V S T H E Q S E S

Repeat 8.2

CTCCCATGGA TGGACGGGGC CCAGCACTAG AGGAAGACAA GGATCCCGCC 1600
 GAGGGTACCT ACCTGCCCCG GGTCTGTGATC TCCTTCTGTT CCTAGGGCGG
 S H G W T G P S T R G R Q G S R

ATGAGCAGGC ACAAGACAGC TCCAGGCACT CAGCATCCCA AGATGGTCAG 1650
 TACTCGTCCG TGTTCTGTG AGGTCCGTGA GTCGTAGGGT TCTACCACTC
 H E Q A Q D S S R H S A S Q D G Q

GACACCATTC GTGGACACCC GGGGTCAAGC AGAGGAGGAA GGCAGGGGTA 1700
 CTGTGGTAAG CACCTGTGGG CCCCAGTTCG TCTCCTCCTT CCGTCCCCAT
 D T I R G H P G S S R G G R Q G Y

1750
 CCACCACGAG CATTCGGTAG ATAGCTCTGG AACTCAGGG TCCCATCACA
 GGTGGTGCTC GTAAGCCATC TATCGAGACC TGTGAGTCCC AGGGTAGTGT
 H H E H S V D S S G H S G S H H

1800
 GCCACACCAC ATCCCAGGGA AGGTCTGATG CCTCCCGTGG GCAGTCAGGA
 CGGTGTGGTG TAGGGTCCCT TCCAGACTAC GGAGGGCACC CGTCAGTCCT
 S H T T S Q G R S D A S R G Q S G

1850
 TCCAGAAGTG CAAGCAGAAC AACACGTAAT GAGGAACAAT CAGGAGACGG
 AGGTCTTCAC GTTCGTCTTG TTGTGCATTA CTCCTTGTTA GTCCTCTGCC
 S R S A S R T T R N E E Q S G D G

1900
 CTCCAGGCAC TCAGGGTCGC GTCACCATGA AGCTTCCACT CATGCCGACA
 GAGGTCCGTG AGTCCCAGCG CAGTGGTACT TCGAAGGTGA GTACGGCTGT
 S R H S G S R H H E A S T H A D

1950
 TCTCTAGACA CTCACAGGCA GTCCAGGGAC AATCAGAGGG GTCCAGGAGA
 AGAGATCTGT GAGTGTCCGT CAGGTCCCTG TTAGTCTCCC CAGGTCTCT
 I S R H S Q A V Q G Q S E G S R R

2000
 AGCAGGCGCC AGGGATCCAG TGTTAGCCAG GACAGTGACA GTGAGGGACA
 TCGTCCGCGG TCCCTAGGTC ACAATCGGTC CTGTCACTGT CACTCCCTGT
 S R R Q G S S V S Q D S D S E G H

2050
 TTCAGAAGAC TCTGAGAGGT GGTCTGGGTC TGCTTCCAGA AACCATCATG
 AAGTCTTCTG AGACTCTCCA CCAGACCCAG ACGAAGGTCT TTGGTAGTAC
 S E D S E R W S G S A S R N H H

2100
 GATCTGCTCA GGAGCAGCTA AGAGATGGCT CCAGACACCC CAGGTCCCAT
 CTAGACGAGT CCTCGTCGAT TCTCTACCGA GGTCTGTGGG GTCCAGGGTA
 G S A Q E Q L R D G S R H P R S H

2150
 CAAGAAGACA GAGCTGGTCA TGGGCACTCT GCAGACAGCT CCAGACAATC
 GTTCTTCTGT CTCGACCAGT ACCCGTGAGA CGTCTGTGCA GGTCTGTTAG
 Q E D R A G H G H S A D S S R Q S

2200
 AGGCACTCGT CACACACAGG CTTCTCTGCG TGGACAGGCT GCATCATCCC
 TCCGTGAGCA GTGTGTGTCC GAAGGAGACC ACCTGTCCGA CGTAGTAGGG
 G T R H T Q A S S G G Q A A S S

2250
 ATGAACAGGC AAGATCAAGT GCAGGAGAAA GACATGGATC CCACCACCAG
 TACTTGTCG TTCTAGTTCA CGTCCTCTTT CTGTACCTAG GGTGGTGGTC
 H E Q A R S S A G E R H G S H H Q

2300
 CAGTCAGCAG ACAGCTCCAG AACTCAGGC ATTGGGCACG GACAAGCTTC
 GTCAGTCGTC TGTCGAGGTC TGTGAGTCCG TAACCCGTGC CTGTTCAAG
 Q S A D S S R H S G I G H G Q A S

2350
 ATCTGCAGTC AGAGACAGTG GACACCGAGG GTACAGTGGT AGTCAGGCCA
 TAGACGTCAG TCTCTGTCAC CTGTGGCTCC CATGTCACCA TCAGTCCGGT
 S A V R D S G H R G Y S G S Q A

2400
 GTGACAATGA GGGACATTCA GAAGACTCAG ACACACAGTC AGTGTACAGCC
 CACTGTTACT CCCTGTAAGT CTTCTGAGTC TGTGTGTCAG TCACAGTCGG
 S D N E G H S E D S D T Q S V S A

2450
 CACGGACAGG CTGGGTCCCA TCAGCAGAGC CACCAAGAGT CCGCACGTGG
 GTGCCTGTCC GACCCAGGGT AGTCGTCTCG GTGGTTCTCA GCGGTGCACC
 H G Q A G S H Q Q S H Q E S A R G

2500
 CCGGTCAGGG GAAACGTCTG GACATTCAGG ATCTTTCCTC TACCAGGTGA
 GGCCAGTCCC CTTTGCAGAC CTGTAAGTCC TAGAAAGGAG ATGGTCCACT
 R S G E T S G H S G S F L Y Q V

Repeat 9 2550
 GCACATCATGA ACAGTCTGAG TCCTCCCATG GATGGACGGG GCCCAGCACT
 CGTGAGTACT TGTCAGACTC AGGAGGGTAC CTACCTGCCC CGGGTCTGTA
 S T H E Q S E S S H G W T G P S T

Repeat 9

2600
 AGAGGAAGAC AAGGATCCCG CCATGAGCAG GCACAAGACA GCTCCAGGCA
 TCTCCTTCTG TTCCTAGGGC GGTACTCGTC CGTGTCTCTGT CGAGGTCCGT
 R G R Q G S R H E Q A Q D S S R H

2650
 CTCAGCATCC CAAGACGGTC AGGACACCAT TCGTGGACAC CCGGGGTCAA
 GAGTCGTAGG GTTCTGCCAG TCCTGTGGTA AGCACCTGTG GGCCCCAGTT
 S A S Q D G Q D T I R G H P G S

2700
 GCAGAGGAGG AAGGCAGGGG TACCACCACG AGCATTCCGGT AGATAGCTCT
 CGTCTCCTCC TTCCGTCCCC ATGGTGGTGC TCGTAAGCCA TCTATCGAGA
 S R G G R Q G Y H H E H S V D S S

2750
 GGACACTCAG GGTCCCATCA CAGCCACACC ACATCCCAGG GAAGGTCTGA
 CCTGTGAGTC CCAGGGTAGT GTCGGTGTGG TGTAGGGTCC CTTCCAGACT
 G H S G S H H S H T T S Q G R S D

2800
 TGCCTCCCGT GGGCAGTCAG GATCCAGAAG TGCAAGCAGA ACAACACGTA
 ACGGAGGGCA CCCGTCAGTC CTAGGTCTTC ACGTTCGTCT TGTTGTGCAT
 A S R G Q S G S R S A S R T T R

2850
 ATGAGGAACA ATCAGGAGAC AGCTCCAGGC ACTCAGGGTC GCGTCACCAT
 TACTCCTTGT TAGTCCTCTG TCGAGGTCCG TGAGTCCCAG CGCAGTGGTA
 N E E Q S G D S S R H S G S R H H

2900
 GAAGCTTCCA CTCATGCCGA CATCTCTAGA CACTCACAGG CAGTCCAGGG
 CTTTGAAGGT GAGTACGGCT GTAGAGATCT GTGAGTGTCC GTCAGGTCCC
 E A S T H A D I S R H S Q A V Q G

2950
 ACAATCAGAG GGGTCCAGGA GAAGCAGGCG CCAGGGATCC AGTGTTAGCC
 TGTTAGTCTC CCCAGGTCCT CTTTCGTCCGC GGTCCCTAGG TCACAATCGG
 Q S E G S R R S R R Q G S S V S

3000
 AGGACAGTGA CAGTGAGGGA CATTGAGAAG ACTCTGAGAG GTGGTCTGGG
 TCCTGTCACT GTCACCTCCCT GTAAGTCTTC TGAGACTCTC CACCAGACCC
 Q D S D S E G H S E D S E R W S G

3050
 TCTGCTTCCA GAAACCATCG TGGATCTGTT CAGGAGCAGT CAAGGCACGG
 AGACGAAGGT CTTTGGTAGC ACCTAGACAA GTCCTCGTCA GTTCCGTGCC
 S A S R N H R G S V Q E Q S R H G

3100
 CTCCAGACAC CCCAGGTCCC ATCAGCAAGA CAGAGCCGGT CACGGGCACT
 GAGGTCTGTG GGGTCCAGGG TAGTGCTTCT GTCTCGGCCA GTGCCCGTGA
 S R H P R S H H E D R A G H G H

3150
 CTGCAGACCG CTCCAGACAA TCAGGCACTC GTCACGCAGA GACTTCCTCT
 GACGTCTGGC GAGGTCTGTT AGTCCGTGAG CAGTGCGTCT CTGAAGGAGA
 S A D R S R Q S G T R H A E T S S

3200
 GGTGGACAGG CTGCATCATC CCATGAACAG GCAAGATCAA GTCCAGGAGA
 CCACCTGTCC GACGTAGTAG GGTACTTGTC CGTTCTAGTT CAGGTCCTCT
 G G Q A A S S H E Q A R S S P G E

3250
 GAGACACGGA TCCCGCCACC AGCAGTCAGC AGACAGCTCC AGACACTCAG
 CTCTGTGCCT AGGGCGGTGG TCGTCAGTCG TCTGTCGAGG TCTGTGAGTC
 R H G S R H Q Q S A D S S R H S

3300
 GCATTCCGCG TGGACAGGCT TCATCTGCAG TCAGAGACAG TAGACACTGG
 CGTAAGGCGC ACCTGTCCGA AGTAGACGTC AGTCTCTGTC ATCTGTGACC
 G I P R G Q A S S A V R D S R H W

3350
 GGGTCCAGTG GTAGTCAAGC CAGTGATAGT GAGGGACATT CAGAAGAGTC
 CCCAGGTCAC CATCAGTTTCG GTCACATCA CTCCCTGTAA GTCTTCTCAG
 G S S G S Q A S D S E G H S E E S

3400
 AGACACACAG TCAGTGTGAG GCCATGGACA GGCTGGGCCC CATCAGCAGA
 TCTGTGTGTC AGTCACAGTC CCGTACCTGT CCGACCCGGG GTAGTCGTCT
 D T Q S V S G H G Q A G P H Q Q

3450
 GCCACCAAGA GTCCGCACGT GACCGGTCAG GGGGAAGGTC TGGACGTTCA
 CGGTGGTTCT CAGGCGTGCA CTGGCCAGTC CCCCTTCCAG ACCTGCAAGT
 S H Q E S A R D R S G G R S G R S

3500
 GGGTCTTTCC TCTACCAGGT GAGCACTCAT GAACAGTCTG AGTCCGCCCA
 CCCAGAAAGG AGATGGTCCA CTCGTGAGTA CTTGTGAGAC TCAGGCGGGT
 G S F L Y Q V S T H E Q S E S A H

Repeat 10.1

3550
 TGGGCGGACC AGGACCAGCA CTGGACGAAG ACAAGGATCC CACCACGAGC
 ACCCGCCTGG TCCTGGTCGT GACCTGCTTC TGTTCTTAGG GTGGTGCTCG
 G R T R T S T G R R Q G S H H E

3600
 AGGCACGAGA CAGCTCCAGG CACTCAGCGT CCCAAGAGGG TCAGGACACC
 TCCGTGCTCT GTCGAGGTCC GTGAGTCGCA GGGTTCTCCC AGTCCTGTGG
 Q A R D S S R H S A S Q E G Q D T

3650
 ATTCTGTCAC ACCCGGGGTC AAGCAGAAGA GGAAGGCAGG GATCCCCTA
 TAAGCACGTG TGGGCCCCAG TTCGTCTTCT CCTTCCGTCC CTAGGGTGAT
 I R A H P G S S R R G R Q G S H Y

3700
 CGAGCAATCG GTAGATAGGT CTGGACACTC AGGGTCCCAT CACAGCCACA
 GTCGTGTTAG CATCTATCCA GACCTGTGAG TCCCAGGGTA GTGTGCGGTG
 E Q S V D R S G H S G S H H S H

3750
 CCACATCCCA GGAAGGTCT GATGCCTCCC GTGGGCAGTC AGGATCCAGA
 GGTGTAGGGT CCCTTCCAGA CTACGGAGGG CACCCGTCAG TCCTAGGTCT
 T T S Q G R S D A S R G Q S G S R

3800
 AGTGCCAGCA GACAACTCG TAACGACGAA CAATCAGGAG ACGGCTCCAG
 TCACGGTCGT CTGTTTGAGC ATTGCTGCTT GTTAGTCCTC TGCCGAGGTC
 S A S R Q T R N D E Q S G D G S R

3850
 GCACTCATGG TCGCATCACC ATGAAGCTTC CACTCAGGCG GACAGCTCTA
 CGTGAGTACC AGCGTAGTGG TACTTCGAAG GTGAGTCCGC CTGTGAGAT
 H S W S H H H E A S T Q A D S S

3900
 GACACTCACA GTCCGGCCAG GGACAATCAG CGGGGCCCAG TACAAGCAGG
 CTGTGAGTGT CAGGCCGGTC CCTGTTAGTC GCCCCGGGTC ATGTTCTGTC
 R H S Q S G Q G Q S A G P S T S R

3950
 AACCAGGGAT CCAGTGTTAG CCAGGACAGT GACAGTCAGG GACACTCAGA
 TTGGTCCCTA GGTCACAATC GGTCCTGTCA CTGTCAGTCC CTGTGAGTCT
 N Q G S S V S Q D S D S Q G H S E

4000
 AGACTCTGAG AGGTGGTCTG GGTCTGCTTC CAGAAACCAT CATGGATCTG
 TCTGAGACTC TCCACCAGAC CCAGACGAAG GTCTTTGGTA GTACCTAGAC
 D S E R W S G S A S R N H H G S

4050
 CTGGGGAGCA GTCAAGAGAT GGCTCCAGAC ACCCTGGGTC CCATCAAGAA
 GACCCCTCGT CAGTTCTCTA CCGAGGTCTG TGGGACCCAG GGTAGTTCTT
 A G E Q S R D G S R H P G S H Q E

4100
 GACAGAGCCG GTCACGGGCA CTCTGCAGAC AGCCCCAGAC AATCAGGCAC
 CTGTCTCGGC CAGTGCCCGT GAGACGTCTG TCGGGGTCTG TTAGTCCGTG
 D R A G H G H S A D S P R Q S G T

TCGTCACACA GAGTCTTCCT CTCGTGGACA GGCTGCGTCA TCCCATGAAC 4150
 AGCAGTGTGT CTCAGAAGGA GAGCACCTGT CCGACGCAGT AGGGTACTTG
 R H T E S S S R G Q A A S S H E

AGGCAAGATC AAGTGCAGGA GAAAGACATG GATCCCACCA CCAGCTCCAG 4200
 TCCGTTCCTAG TTCACGTCCT CTTTCTGTAC CTAGGGTGGT GGTCGAGGTC
 Q A R S S A G E R H G S H H Q L Q

TCAGCAGACA GCTCCAGACA CGCAGGCATT GGGCACGGAC AAGCTTCATC 4250
 AGTCGTCTGT CGAGGTCTGT GCGTCCGTAA CCCGTGCCTG TTCGAAGTAG
 S A D S S R H A G I G H G Q A S S

TGCAGTCAGA GACAGTGGAC ACCGAGGGTA CAGTGGTAGT CAGGCCACTG 4300
 ACGTCAGTCT CTGTCACCTG TGGCTCCCAT GTCACCATCA GTCCGGTGAC
 A V R D S G H R G Y S G S Q A T

ACAGTGAGGG ACATTCAGAA GACTCAGACA CACAGTCAGT GTCAGCACAG 4350
 TGTCACCTCC TGTAAGTCTT CTGAGTCTGT GTGTCAGTCA CAGTCGTGTC
 D S E G H S E D S D T Q S V S A Q

GGAAAAGCTG GGCCCCATCA GCAGAGCCAC AAAGAGTCCG CACGTGGCCA 4400
 CCTTTTCGAC CCGGGGTAGT CGTCTCGGTG TTTCTCAGGC GTGCACCGGT
 G K A G P H Q Q S H K E S A R G Q

GTCAGGGGAA AGCTCTAGAC GTTCAGGGTC TTTCTCTAC CAGGTGAGCA 4450
 CAGTCCCCTT TCGAGATCTG CAAGTCCCAG AAAGGAGATG GTCCACTCGT
 S G E S S R R S G S F L Y Q V S

Repeat 10.2 6 4500
 CTCATGAACA GTCTGAGTCC ACCCATGGAC AGTCTGTGCC CAGCACTGGA
 GAGTACTTGT CAGACTCAGG TGGGTACCTG TCAGACACGG GTCGTGACCT
 T H E Q S E S T H G Q S V P S T G

Repeat 10.2

GGAAGACAAG GATCCCACCA TGATCAGGCA CAAGACAGCT CCAGGCACCTC 4550
 CCTTCTGTTC CTAGGGTGGT ACTAGTCCGT GTTCTGTCTGA GGTCCGTGAG
 G R Q G S H H D Q A Q D S S R H S

AGCATCCCAA GAGGGTCAGG ACACCATTCTG TGGACACCCG GGGCCAAGCA 4600
 TCGTAGGGTT CTCCCAGTCC TGTGGTAAGC ACCTGTGGGC CCCGTTCTGT
 A S Q E G Q D T I R G H P G P S

GAGGAGGAAG ACAGGGGTCC CACCACGAGC AATCGGTAGA TAGGTCTGGA 4650
 CTCCTCCTTC TGTCCCAGG GTGGTGCTCG TTAGCCATCT ATCCAGACCT
 R G G R Q G S H H E Q S V D R S G

CACTCAGGGT CCCATCACAG CCACACCACA TCCCAGGGAA GGTCTGATGC 4700
 GTGAGTCCCA GGGTAGTGTC GGTGTGGTGT AGGGTCCCTT CCAGACTACG
 H S G S H H S H T T S Q G R S D A

CTCCCGTGGG CAGTCAGGAC CCAGAAGTGC AAGCAGACAA ACACATGACA 4750
 GAGGGCACCC GTCAGTCCTG GGTCTTCACG TTCGTCTGTT TGTGTACTGT
 S R G Q S G P R S A S R Q T H D

AGGAACAATC AGGAGACGGC TCTAGGCACT CAGGGTCGCG TCATCATGAA 4800
 TCCTTGTTAG TCCTCTGCCG AGATCCGTGA GTCCCAGCGC AGTAGTACTT
 K E Q S G D G S R H S G S R H H E

GCTTCCTCTT GGGCCGACAG CTCTAGACAC TCACAGGCAG TCCAGGGACA 4850
 CGAAGGAGAA CCCGGCTGTC GAGATCTGTG AGTGTCCGTC AGGTCCCTGT
 A S S W A D S S R H S Q A V Q G Q

ATCAGAGGGG TCCAGGAGAA GCAGGCGCCA GGGATCCAGT GTTAGCCAGG 4900
 TAGTCTCCCC AGGTCTCTT CGTCCGCGGT CCCTAGGTCA CAATCGGTCC
 S E G S R R S R R Q G S S V S Q

ACAGTGACAG TCAGGGACAC TCAGAAGACT CTGAGAGGCG GTCTGGGTCT 4950
 TGTCACTGTC AGTCCCTGTG AGTCTTCTGA GACTCTCCGC CAGACCCAGA
 D S D S Q G H S E D S E R R S G S

GCTTCCAGAA ACCATCGTGG ATCTGCTCAG GAGCAGTCAA GAGATGGCTC 5000
 CGAAGGTCTT TGGTAGCACC TAGACGAGTC CTCGTCAGTT CTCTACCGAG
 A S R N H R G S A Q E Q S R D G S

CAGACACCCC AGGTCCCATC ACGAAGACAG AGCCGGTCAT GGGCACTCTG 5050
 GTCTGTGGGG TCCAGGGTAG TGCTTCTGTC TCGGCCAGTA CCCGTGAGAC
 R H P R S H H E D R A G H G H S

CAGACAGCTC CAGACAATCA GGCATCATC ATGCAGAGAA TTCCTCTGGT 5100
 GTCTGTGCGAG GTCTGTTAGT CCGTGAGTAG TACGTCTCTT AAGGAGACCA
 A D S S R Q S G T H H A E N S S G

GGACAGCCTG CATCATCCCA TGAACAGGCA AGATCAAGTG CAGGAGAGAG 5150
 CCTGTCCGAC GTAGTAGGGT ACTTGTCCGT TCTAGTTCAC GTCCTCTCTC
 G Q P A S S H E Q A R S S A G E R

ACATGGATCC CACCACCAGC AGTCAGCAGA CAGCTCCAGA CACTCAGGCA 5200
 TGTACCTAGG GTGGTGGTCC TCAGTCGTCT GTCGAGGTCT GTGAGTCCGT
 H G S H H Q Q S A D S S R H S G

TTGGGCACGG ACAAGCTTCA TCTGCAGTCA GAGACAGTGG ACACCGAGGG 5250
 AACCCGTGCC TGTTCCAAGT AGACGTCAGT CTCTGTCACC TGTGGCTCCC
 I G H G Q A S S A V R D S G H R G

TCCAGTGGTA GTCAGGCCAG TGACAGTGAG GGACATTGAG AAGACTCAGA 5300
 AGGTCACCAT CAGTCCGGTC ACTGTCACTC CCTGTAAGTC TTCTGAGTCT
 S S G S Q A S D S E G H S E D S D

5350
CACACAGTCA GTGTCAGCCC ACGGACAGGC TGGGCCCCAT CAGCAGAGCC
GTGTGTCAGT CACAGTCGGG TGCCTGTCCG ACCCGGGGTA GTCGTCTCGG
T Q S V S A H G Q A G P H Q Q S

5400
ACCAAGAGTC CACACGTGGC CGGTCAGCAG GAAGGTCTGG ACGTTCAGGG
TGGTTCTCAG GTGTGCACCG GCCAGTCGTC CTTCCAGACC TGAAGTCCC
H Q E S T R G R S A G R S G R S G

Repeat 11 5450
TCTTTCCTCT ACCAGGTGAG CACTCATGAA CAGTCTGAGT CTGCCCATGG
AGAAAGGAGA TGGTCCACTC GTGAGTACTT GTCAGACTCA GACGGGTACC
S F L Y Q V S T H E Q S E S A H G

Repeat 11 (partial)

5500
ACGGGCTGGG CCCAGTACTG GAGGAAGACA AGGATCCCAC CACGAGCAGG
TGCCCCAGCC GGGTCATGAC CTCCTTCTGT TCCTAGGGTG GTGCTCGTCC
R A G P S T G G R Q G S H H E Q

5550
CACGAGACAG CTCCAGGCAC TCAGCGTCCC AAGAGGGTCA GGACACCATT
GTGCTCTGTC GAGGTCCGTG AGTCGCAGGG TTCTCCAGT CCTGTGGTAA
A R D S S R H S A S Q E G Q D T I

5600
CGTGGACACC CGGGGTCAAG GAGAGGAGGA AGACAGGGAT CCTACCACGA
GCACCTGTGG GCCCCAGTTC CTCTCCTCCT TCTGTCCCTA GGATGGTGCT
R G H P G S R R G G R Q G S Y H E

5650
GCAATCGGTA GATAGGTCTG GACACTCAGG GTCCCATCAC AGCCACACCA
CGTTAGCCAT CTATCCAGAC CTGTGAGTCC CAGGGTAGTG TCGGTGTGGT
Q S V D R S G H S G S H H S H T

5700
CATCCCAGGG AAGGTCTGAT GCCTCCCATG GGCAGTCAGG ATCCAGAAGT
GTAGGGTCCC TTCCAGACTA CGGAGGGTAC CCGTCAGTCC TAGGTCTTCA
T S Q G R S D A S H G Q S G S R S

5750
GCAAGCAGAG AAACACGTAA TGAGGAACAG TCAGGAGACG GCTCCAGGCA
CGTTCGTCTC TTTGTGCATT ACTCCTTGTC AGTCCTCTGC CGAGGTCCGT
A S R E T R N E E Q S G D G S R H

5800
CTCAGGGTCG CGTCACCATG AAGCTTCCAC TCAGGCTGAC AGCTCTAGAC
GAGTCCCAGC GCAGTGGTAC TTCGAAGGTG AGTCCGACTG TCGAGATCTG
S G S R H H E A S T Q A D S S R

5850
ACTCACAGTC CGGCCAGGGT GAATCAGCGG GGTCCAGGAG AAGCAGGCGC
TGAGTGTCAG GCCGGTCCCA CTTAGTCGCC CCAGGTCTCT TCGTCCGCG
H S Q S G Q G E S A G S R R S R R

5900
CAGGGATCCA GTGTTAGCCA GGACAGTGAC AGTGAGGCAT ACCCAGAGGA
GTCCCTAGGT CACAATCGGT CCTGTCACTG TCACTCCGTA TGGGTCTCCT
Q G S S V S Q D S D S E A Y P E D

5950

CTCTGAGAGG CGATCTGAGT CTGCTTCCAG AAACCATCAT GGATCTTCTC
GAGACTCTCC GCTAGACTCA GACGAAGGTC TTTGGTAGTA CCTAGAAGAG
S E R R S E S A S R N H H G S S

6000

GGGAGCAGTC AAGAGATGGC TCCAGACACC CCGGATCCTC TCACCGCGAT
CCCTCGTCAG TTCTCTACCG AGGTCTGTGG GGCCTAGGAG AGTGGCGCTA
R E Q S R D G S R H P G S S H R D

6050

ACAGCCAGTC ATGTACAGTC TTCACCTGTA CAGTCAGACT CTAGTACCGC
TGTCGGTCAG TACATGTCAG AAGTGGACAT GTCAGTCTGA GATCATGGCG
T A S H V Q S S P V Q S D S S T A

6100

TAAGGAACAT GGTCACITTA GTAGTCTTTC ACAAGATTCT GCGTATCACT
ATTCCTTGTA CCAGTGAAAT CATCAGAAAG TGTTCCTAAGA CGCATAGTGA
K E H G H F S S L S Q D S A Y H

6150

CAGGAATACA GTCACGTGGC AGTCCTCACA GTTCTAGTTC TTATCATTAT
GTCCTTATGT CAGTGCACCG TCAGGAGTGT CAAGATCAAG AATAGTAATA
S G I Q S R G S P H S S S S Y H Y

6200

CAATCTGAGG GCACTGAAAG GCAAAAAGGT CAATCAGGTT TAGTTTGGAG
GTTAGACTCC CGTGACTTTC CGTTTTTCCA GTTAGTCCAA ATCAAACCTC
Q S E G T E R Q K G Q S G L V W R

6223

ACATGGCAGC TATGGTAGTG CAG
TGTACCGTCG ATACCATCAC GTC
H G S Y G S A

filaggrin Sequence listing.ST25
SEQUENCE LISTING

<110> The University Court Of The University Of Dundee
McLean , Irwin
smith, Frances J D

<120> Filaggrin

<130> P14417GB

<160> 558

<170> PatentIn version 3.1

<210> 1

<211> 22

<212> DNA

<213> Artificial Sequence FILF3

<400> 1
gctgataatg tgattctgtc tg 22

<210> 2

<211> 22

<212> DNA

<213> Artificial Sequence H1F2

<400> 2
gccacatatt acacaatcca gg 22

<210> 3

<211> 19

<212> DNA

<213> Artificial Sequence H1F3

<400> 3
cacggaaagg ctgggctga 19

filaggrin Sequence listing.ST25

<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence H1F4

<400> 4
ggtgagcact catgaacagc 20

<210> 5
<211> 20
<212> DNA
<213> Artificial Sequence H1F5

<400> 5
ggtgagcact catgaacagt 20

<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence LR3F

<400> 6
cctctgtgac ttccctctgt a 21

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence LR2F

<400> 7
gtcacttacc ccatcaaadc 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence LR1R

filaggrin Sequence listing.ST25

<400> 8
ccaccaaact aatgaaatac 20

<210> 9
<211> 21
<212> DNA
<213> Artificial Sequence 501.F1

<400> 9
actggaggaa gacaaggatc g 21

<210> 10
<211> 18
<212> DNA
<213> Artificial Sequence 501.R1

<400> 10
ccctcttggg acgctgaa 18

<210> 11
<211> 19
<212> DNA
<213> Artificial Sequence 501.F2

<400> 11
tggaggaaga caaggatcg 19

<210> 12
<211> 17
<212> DNA
<213> Artificial Sequence 501.R2

<400> 12
cctcttggga cgctgaa 17

<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence DEL4.R1

filaggrin Sequence listing.ST25

<400> 13
gtggctctgc tgatggtga 19

<210> 14
<211> 22
<212> DNA
<213> Artificial Sequence DEL4.F1

<400> 14
cgtcacacac agaattcctc ta 22

<210> 15
<211> 16
<212> DNA
<213> Artificial Sequence DEL4.F2

<400> 15
tcccgccacc agctcc 16

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence DELG.F1

<400> 16
gcaagcagac aaactcgtaa g 21

<210> 17
<211> 28
<212> DNA
<213> Artificial Sequence DELG.R1

<400> 17
gtttcttctc ggagtcgtct gagtgtct 28

<210> 18
<211> 27
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence DELG.R2

<400> 18

gtttcttcag acaacctctc ggagtcg

27

<210> 19

<211> 21

<212> DNA

<213> Artificial Sequence FILr0.F1

<400> 19

gggaaaaggc atgaatctag t

21

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P1F

<400> 20

cagtgaggga cattcagaaa

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P2F

<400> 21

cagaaaactc agacacacaa

20

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P3F

<400> 22

ggccacggaa aggctgggct

20

<210> 23

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT0 P4F

<400> 23

gccacggaaa ggctgggctg

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P5F

<400> 24

ccacggaaag gctgggctga

20

<210> 25

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P6F

<400> 25

cacggaaagg ctgggctgag

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P7F

<400> 26

acggaaaggc tgggctgaga

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P8F

<400> 27

ggccacggaa aggctaggct

20

<210> 28

filaggrin Sequence listing.ST25

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P9F

<400> 28

gccacggaaa ggctaggctg

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P10F

<400> 29

ccacggaaag gctaggctga

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P11F

<400> 30

cacggaaagg ctaggctgag

20

<210> 31

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P12F

<400> 31

acggaaaggc taggctgaga

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P13F

<220>

<221> misc_feature

filaggrin Sequence listing.ST25

<222> (1)..(20)

<223> x = Inosine

<400> 32

ggccacggaa aggctnggct

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P14F

<220>

<221> misc_feature

<222> (1)..(20)

<223> n = Inosine

<400> 33

gccacggaaa ggctnggctg

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P15F

<220>

<221> misc_feature

<222> (1)..(20)

<223> n= Inosine

<400> 34

ccacggaaag gctnggctga

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P16F

filaggrin Sequence listing.ST25

<220>

<221> misc_feature

<222> (1)..(20)

<223> n = Inosine

<400> 35

cacggaagg ctnggctgag

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P17F

<220>

<221> misc_feature

<222> (1)..(20)

<223> n = Inosine

<400> 36

acggaaggc tnggctgaga

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P18F

<400> 37

acgtggccgg tcagggaac

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P19F

<400> 38

tctggacgtt cagggtcttc

20

<210> 39

filaggrin Sequence listing.ST25

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P20F

<400> 39

ggtgagcact catgaacagc

20

<210> 40

<211> 20

<212> DNA

<213> Artificial Sequence RPT0 P21F

<400> 40

ggtgagcact catgaacagt

20

<210> 41

<211> 22

<212> DNA

<213> Artificial Sequence FILr1.F1

<400> 41

caggccatgg acaggctggt ca

22

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence RPT1 P1R

<400> 42

cgtccatggg cagagtcagg.

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence RPT1 P2R

<400> 43

cgtccatggg cagagtcaga

20

filaggrin Sequence listing.ST25

<210> 44
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT1 P3F

<400> 44
 gcactcatga acagcctgac 20

<210> 45
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT1 P4F

<400> 45
 ctggaggaag acaaggatcg 20

<210> 46
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT1 P5R

<400> 46
 ctcgtgcctg ctcgtggtgc 20

<210> 47
 <211> 21
 <212> DNA
 <213> Artificial Sequence RPT1 P6F

<400> 47
 gcacgagaca gctccaggca t 21

<210> 48
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT1 P7R

<400> 48
 gaccctcttg ggacgctgaa 20

filaggrin Sequence listing.ST25

<210> 49
<211> 21
<212> DNA
<213> Artificial Sequence RPT1 P8F

<400> 49
cccaccacga gcaatcggt a 21

<210> 50
<211> 21
<212> DNA
<213> Artificial Sequence RPT1 P9R

<400> 50
acctgagtgt ccagacctat t 21

<210> 51
<211> 21
<212> DNA
<213> Artificial Sequence RPT1P10F

<400> 51
aataggtctg gacactcagg t 21

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence RPT1P11R

<400> 52
tggtgtggct gtgatgggaa 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence RPT1P12F

filaggrin Sequence listing.ST25

<400> 53
ggaacaatca ggagacggca 20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence RPT1P13R

<400> 54
cgtgaccctg agtgcctggt 20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence RPT1P14F

<400> 55
catcggggcc caggacaagt 20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence RPT1P15R

<400> 56
cactggatcc ctggttccta 20

<210> 57

<211> 18

<212> DNA

<213> Artificial Sequence HR1B

<400> 57
ctgcagacag ctccagaa 18

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence RPT1P16R

filaggrin Sequence listing.ST25

<400> 58
gtgtgacgag tgcctgattt 20

<210> 59
<211> 18
<212> DNA
<213> Artificial Sequence HR1A

<400> 59
acacacagaa ttcctcta 18

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence RPT1P17R

<400> 60
gatgacgcag cctgtccact 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence RPT1 P18F

<400> 61
caggccatgg acaggctggt 20

<210> 62
<211> 21
<212> DNA
<213> Artificial Sequence RPT1 P19F

<400> 62
aggccatgga caggctggtc a 21

<210> 63
<211> 24
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT1P20R

<400> 63

actcttggtg gctctgctga tggg

24

<210> 64

<211> 24

<212> DNA

<213> Artificial Sequence RPT1P21R

<400> 64

tcttggtggc tctgctgatg gtga

24

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence RPT1 P22F

<400> 65

ccggtcaggg gaaaggtctc

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence RPT1 P23R

<400> 66

aggaaagacc ctgaacgtcg

20

<210> 67

<211> 20

<212> DNA

<213> Artificial Sequence RPT1 P24F

<400> 67

ctaccaggtg agcactcata

20

<210> 68

<211> 19

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT2P20F

<400> 68

ccagacaatc aggaactcc

19

<210> 69

<211> 21

<212> DNA

<213> Artificial Sequence RPT2P20F

<400> 69

gaagtctctg cgtgaggagt t

21

<210> 70

<211> 21

<212> DNA

<213> Artificial Sequence DelA.F1

<400> 70

agtgaggac attcagagga g

21

<210> 71

<211> 28

<212> DNA

<213> Artificial Sequence GS-DelA.F1

<400> 71

gtttcttagt gagggacatt cagaggag

28

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence DelA.F2

<400> 72

gtgtcaggcc atggacagga

20

<210> 73

filaggrin sequence listing.ST25

<211> 27

<212> DNA

<213> Artificial Sequence GS-De1A.F2

<400> 73

gtttcttggtg tcaggccatg gacagga

27

<210> 74

<211> 21

<212> DNA

<213> Artificial Sequence FAMde1A.R

<220>

<221> misc_feature

<222> (1)..(21)

<223> Carboxyfluorescein labelled adenine

<400> 74

ntgagtgtc acctggtaga t

21

<210> 75

<211> 19

<212> DNA

<213> Artificial Sequence RPT2 P1R

<400> 75

gggaggactc agactgttt

19

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence RPT2 P2F

<400> 76

catgagcagg cacgagacaa

20

<210> 77

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT2 P3R

<400> 77

ggatgctgag tgcctggagt

20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence RPT2 P4F

<400> 78

ggcactcagc atccaagat

20

<210> 79

<211> 20

<212> DNA

<213> Artificial Sequence RPT2 P5R

<400> 79

cacgaatggg gtcctgacca

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence RPT2 P6F

<400> 80

acgtaatgag gaacaatcaa

20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence RPT2 P7R

<400> 81

gagtgctgg agccgtctct

20

<210> 82

filaggrin Sequence listing.ST25

<211> 21
<212> DNA
<213> Artificial Sequence RPT 2 P8F

<400> 82
gacagctcca gacaatcagg a 21

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence RPT2 P9F

<400> 83
tccagacaat caggaactcc 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence RPT2 P10R

<400> 84
aagtctctgc gtgaggagtt 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence RPT2 P11R

<400> 85
agaggaagtc tctgcgtgag 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence RPT2 P12F

<400> 86
atagtgaggg acattcagag 20

filaggrin Sequence listing.ST25

<210> 87
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT2 P13R

 <400> 87
 ctgactgtgt gtctgactcc 20

 <210> 88
 <211> 19
 <212> DNA
 <213> Artificial Sequence RPT2 P14F

 <400> 88
 tgtcaggcca tggacagga 19

 <210> 89
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT2 P15R

 <400> 89
 gctctgctga tggggcccat 20

 <210> 90
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT2 P16F

 <400> 90
 ccaagagtcc gcacgtgact 20

 <210> 91
 <211> 21
 <212> DNA
 <213> Artificial Sequence RPT2 P17R

 <400> 91
 tccagacctt ccccctgacc a 21

filaggrin sequence listing.ST25

<210> 92
<211> 21
<212> DNA
<213> Artificial Sequence RPT2 P18F

<400> 92
ctggacgttc agggctctttc a 21

<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence RPT 2 P19R

<400> 93
tgagtgtca cctggtagat 20

<210> 94
<211> 21
<212> DNA
<213> Artificial Sequence FILr3.F1

<400> 94
gggtcaggac accattcgtg c 21

<210> 95
<211> 21
<212> DNA
<213> Artificial Sequence FILr3.F2

<400> 95
gcaagcagac aaactcgtaa g 21

<210> 96
<211> 21
<212> DNA
<213> Artificial Sequence FAMDe1G.F1

filaggrin Sequence listing.ST25

<220>

<221> misc_feature

<222> (1)..(21)

<223> Carboxyfluorescein labelled guanine

<400> 96

ncaagcagac aaactcgtaa g

21

<210> 97

<211> 22

<212> DNA

<213> Artificial Sequence FILD R

<400> 97

gaatgtccct cactgttagt ga

22

<210> 98

<211> 21

<212> DNA

<213> Artificial Sequence R1474X.F

<400> 98

ctttcctcta ccaggtgagc t

21

<210> 99

<211> 20

<212> DNA

<213> Artificial sequence RPT3 P1F

<400> 99

ggtcaggaca ccattcgtgc

20

<210> 100

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P2R

<400> 100

tctccttgac cccgggtgtg

20

filaggrin Sequence listing.ST25

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P3F

<400> 101

gtgcacaccc ggggtcaagg

20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P4R

<400> 102

atccctgcct tcctcctctc

20

<210> 103

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P5F

<400> 103

caagcagaca aactcgtaag

20

<210> 104

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P6R

<400> 104

cgtctcctga ttgtttgtcc

20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P7F

filaggrin Sequence listing.ST25

<400> 105
gtcacgtcac catgaagctg 20

<210> 106

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P8R

<400> 106
gagctgtcag cccaagaggc 20

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P9F

<400> 107
ctagacactc acaggtggga 20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P10R

<400> 108
accccgatga ttgttcctgt 20

<210> 109

<211> 21

<212> DNA

<213> Artificial Sequence RPT3P10Ra

<400> 109
gaccccgatg attgttcctg t 21

<210> 110

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P11F

filaggrin Sequence listing.ST25

<400> 110
cactcacagg tgggacagga 20

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P12R

<400> 111
cctggacccc gatgattggt 20

<210> 112

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P15F

<400> 112
ccaggacagt gacagtgaga 20

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P16R

<400> 113
tcggagtcgt ctgagtgtct 20

<210> 114

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P17F

<400> 114
acagtgagag acactcagac 20

<210> 115

<211> 20

<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT3 P18R

<400> 115
cagacaacct ctcggagtcg 20

<210> 116

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P18R

<400> 116
agagacactc agacgactcc 20

<210> 117

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P20R

<400> 117
cagaccaga caacctctcg 20

<210> 118

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P21F

<400> 118
tcagacgact ccgagaggtt 20

<210> 119

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P22R

<400> 119
tctggaagca gaccagaca 20

<210> 120

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence

<400> 120

cagaaacat catggatctt

20

<210> 121

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P24R

<400> 121

tctcttgact gctcccgaga

20

<210> 122

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P25F

<400> 122

ggctccagac accctgggtt

20

<210> 123

<211> 21

<212> DNA

<213> Artificial Sequence RPT3 P26R

<400> 123

tggctctgtc ttcttgatgg a

21

<210> 124

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P27F

<400> 124

cacacagagt cttcctctca

20

<210> 125

filaggrin Sequence listing.ST25

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P29F

<400> 125

ggatgacaca gcctgtccat

20

<210> 126

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 126

tcctctcatg gacaggctgt

20

<210> 127

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P30R

<400> 127

tgcctgttca tgggatgaca

20

<210> 128

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P31F

<400> 128

gggtccagtg gtagtcaggt

20

<210> 129

<211> 20

<212> DNA

<213> Artificial Sequence RPT3 P32R

<400> 129

atgtccctca ctgttagtga

20

filaggrin Sequence listing.ST25

<210> 130
<211> 20
<212> DNA
<213> Artificial Sequence

<400> 130
cagtggtagt caggtcacta 20

<210> 131
<211> 20
<212> DNA
<213> Artificial Sequence RPT3 P34R

<400> 131
tctgaatgtc cctcactgtt 20

<210> 132
<211> 20
<212> DNA
<213> Artificial Sequence RPT3 P35F

<400> 132
ggaaagctct ggacgttcaa 20

<210> 133
<211> 20
<212> DNA
<213> Artificial Sequence RPT3 P36R

<400> 133
acctggtaga ggaaagacct 20

<210> 134
<211> 20
<212> DNA
<213> Artificial Sequence RPT3 P37F

<400> 134
tttcctctac caggtgagct 20

filaggrin Sequence listing.ST25

<210> 135
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT3 P38R

<400> 135
 gactcagact gttcatgaga 20

<210> 136
 <211> 21
 <212> DNA
 <213> Artificial Sequence R1474X.R

<400> 136
 gagtgtccag acctatctac t 21

<210> 137
 <211> 21
 <212> DNA
 <213> Artificial Sequence RPT4.F1

<400> 137
 gacaagattc atctgtagtc g 21

<210> 138
 <211> 28
 <212> DNA
 <213> Artificial GS-RPT4.F1

<400> 138
 gtttcttgac aagattcatc t gtagtcg 28

<210> 139
 <211> 19
 <212> DNA
 <213> Artificial Sequence RPT4.F2

filaggrin Sequence listing.ST25

<400> 139 gtagtcggag acagtggaa	19
<210> 140	
<211> 20	
<212> DNA	
<213> Artificial Sequence RPT4 P1F	
<400> 140 atgaacagtc tgagtccaca	20
<210> 141	
<211> 20	
<212> DNA	
<213> Artificial Sequence RPT4 P2R	
<400> 141 tgggtgcagt ctgtccgtgt	20
<210> 142	
<211> 20	
<212> DNA	
<213> Artificial Sequence RPT4 P3F	
<400> 142 aacagtctga gtccacacac	20
<210> 143	
<211> 20	
<212> DNA	
<213> Artificial Sequence RPT4 P4R	
<400> 143 tgctgggtgc agtctgtccg	20
<210> 144	
<211> 20	
<212> DNA	
<213> Artificial Sequence RPT4 P5F	

filaggrin Sequence listing.ST25

<400> 144
ccacacacgg acagactgca 20

<210> 145
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P6R

<400> 145
gtcttcctcc agtgctgggt 20

<210> 146
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P7F

<400> 146
ccgccatgag caggcacgaa 20

<210> 147
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P8R

<400> 147
gctgagtgcc tagagctggt 20

<210> 148
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P9F

<400> 148
agcaggcacg aaacagctct 20

<210> 149
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT4 P10R

<400> 149
cttgggatgc tgagtccta 20

<210> 150

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P11F

<400> 150
aggaggaagg caggatcct 20

<210> 151

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P12R

<400> 151
tctactgatt gctcgtggta 20

<210> 152

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P13F

<400> 152
gatcctacca cgagcaatca 20

<210> 153

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P14R

<400> 153
agtgtccaga cctatctact 20

<210> 154

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT4 P15F

<400> 154
aggtctggac actcagggtg 20

<210> 155

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P16R

<400> 155
tgtggtgtgg ctgtgatggt 20

<210> 156

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P17F

<400> 156
ccatcacagc cacaccacac 20

<210> 157

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P18R

<400> 157
gcatcagacc ttccctgggg 20

<210> 158

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P19F

<400> 158
ctcccatggg cagtcaggac 20

<210> 159

filaggrin Sequence listing.ST25

<211> 21

<212> DNA

<213> Artificial Sequence RPT4 P20R

<400> 159

ttgcctgctt gcacttctgg g

21

<210> 160

<211> 21

<212> DNA

<213> Artificial Sequence RPT4 P21F

<400> 160

ggaccagaa gtgcaagcag g

21

<210> 161

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P22R

<400> 161

gttcctcatt tcttgtttgc

20

<210> 162

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P23F

<400> 162

aagtgaagc aggcaaaca

20

<210> 163

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P24R

<400> 163

cctgattgtt cctcatttct

20

filaggrin Sequence listing.ST25

<210> 164

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P25F

<400> 164

agggtcacgt caccatgaac

20

<210> 165

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P26R

<400> 165

ctgccggccc gagtggaagg

20

<210> 166

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P27F

<400> 166

gaaccttcca ctcgggccgg

20

<210> 167

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P28R

<400> 167

ctgtgagtgt ctagagctgc

20

<210> 168

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P29F

<400> 168

ctcacaggtg ggccagggag

20

filaggrin Sequence listing.ST25

<210> 169
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P30R

<400> 169
gtcttgacc ccgctgattc 20

<210> 170
<211> 21
<212> DNA
<213> Artificial Sequence RPT4 P31F

<400> 170
gggagaatca gcggggtcca a 21

<210> 171
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P32R

<400> 171
tccctggcgc ctgcttgtct 20

<210> 172
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P33F

<400> 172
gccaggatc cagtgttagt 20

<210> 173
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P34R

filaggrin Sequence listing.ST25

<400> 173
cctcactgtc cctgtcctga 20

<210> 174

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P35F

<400> 174
gtcggcttcc agaaaccatt 20

<210> 175

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P36R

<400> 175
tgctcccgag cagatccata 20

<210> 176

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P37F

<400> 176
agtcaagaca tggctccagg 20

<210> 177

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P38R

<400> 177
gaaccccagg tcccatcaag 20

<210> 178

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P39F

filaggrin Sequence listing.ST25

<400> 178
gtcaagacat ggctccagga 20

<210> 179
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P40R

<400> 179
gacaggctgc atcatcccag 20

<210> 180
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P41F

<400> 180
gacaggctgc atcatcccag 20

<210> 181
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P42R

<400> 181
gacttgacct tgcctgttcc 20

<210> 182
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P43F

<400> 182
catcccagga acaggcaagg 20

<210> 183
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT4 P44R

<400> 183
gtctttctcc tggacttgac 20

<210> 184

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P45F

<400> 184
cagtcagcag acagctccac 20

<210> 185

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P46R

<400> 185
gcgcccagtg cctgagtctg 20

<210> 186

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P47F

<400> 186
gtcagcagac agctccacag 20

<210> 187

<211> 19

<212> DNA

<213> Artificial Sequence RPT4 P48R

<400> 187
tgcgcccagt gcctgagtc 19

<210> 188

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT4 P49F

<400> 188

ggcactgggc gcagacaaga

20

<210> 189

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P50R

<400> 189

gtctccgact acagatgaat

20

<210> 190

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P51F

<400> 190

cgcagacaag attcatctgt

20

<210> 191

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P52R

<400> 191

gtttccactg tctccgacta

20

<210> 192

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P53F

<400> 192

acaagattca tctgtagtcg

20

<210> 193

filaggrin sequence listing.ST25

<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P54R

<400> 193
cctcggtttc cactgtctcc 20

<210> 194
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P55F

<400> 194
tgtagtcgga gacagtggaa 20

<210> 195
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P56R

<400> 195
ctaccactgg accctcggtt 20

<210> 196
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P57F

<400> 196
accgagggtc cagtggtagc 20

<210> 197
<211> 20
<212> DNA
<213> Artificial Sequence RPT4 P58R

<400> 197
cctcgctgtc actggcctgg 20

filaggrin Sequence listing.ST25

<210> 198

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P59F

<400> 198

gtagccaggc cagtgacagc

20

<210> 199

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P60R

<400> 199

actcttctga gtgtccctcg

20

<210> 200

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P61F

<400> 200

ccagtgacag cgagggacac

20

<210> 201

<211> 20

<212> DNA

<213> Artificial Sequence RPT4 P62R

<400> 201

gtgtgtctga ctcttctgag

20

<210> 202

<211> 19

<212> DNA

<213> Artificial Sequence RPT5.R2

<400> 202

cctgctcgtg gcgggatct

19

filaggrin Sequence listing.ST25

<210> 203
 <211> 19
 <212> DNA
 <213> Artificial Sequence FAMRPT5.R2

 <220>
 <221> misc_feature
 <222> (1)..(19)
 <223> Carboxyfluorescein labelled cytosine

 <400> 203
 nctgctcgtg gcgggatct 19

 <210> 204
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILEF

 <400> 204
 gtcccaggaa aggtctgatg t 21

 <210> 205
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILER

 <400> 205
 acatcagacc tttcctggga c 21

 <210> 206
 <211> 22
 <212> DNA
 <213> Artificial Sequence FILr5.F1

 <400> 206
 catggatccc accaccagct cc 22

filaggrin Sequence listing.ST25

<210> 207

<211> 22

<212> DNA

<213> Artificial Sequence RPT5.F2

<400> 207

agacacacag tcagtgtcag ca

22

<210> 208

<211> 22

<212> DNA

<213> Artificial Sequence RPT5.F3

<400> 208

cacacagtca gtgtcagcac ag

22

<210> 209

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P1F

<400> 209

ctgagtccgc ccatggacgc

20

<210> 210

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P2R

<400> 210

ctccagtgtg gggccctgtg

20

<210> 211

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P3F

<400> 211

agtccgccca tggacgcaca

20

filaggrin Sequence listing.ST25

<210> 212
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P4R

<400> 212
ttcctccagt gctgggccct 20

<210> 213
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P5F

<400> 213
cagcactgga ggaagacaaa 20

<210> 214
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P6R

<400> 214
gcctgctcgt ggcgggatct 20

<210> 215
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P7F

<400> 215
acaccattcg tggacaccca 20

<210> 216
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P8R

filaggrin Sequence listing.ST25

<400> 216
ttcctcctct gcttgaccct 20

<210> 217
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P9F

<400> 217
gaaggcagg atcccactat 20

<210> 218
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P10R

<400> 218
atctatctac cgattgctca 20

<210> 219
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P11F

<400> 219
atgagcaatc ggtagatagt 20

<210> 220
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P12R

<400> 220
gagaccctga gtgtccagaa 20

<210> 221
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P13F

filaggrin Sequence listing.ST25

<400> 221
ctcatcacag ccacaccacg 20

<210> 222
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P14R

<400> 222
catcagacct ttcctgggac 20

<210> 223
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P15F

<400> 223
agccacacca cgtcccagga 20

<210> 224
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P16R

<400> 224
acgggagaca tcagaccttt 20

<210> 225
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P17F

<400> 225
tcccaggaaa ggtctgatgt 20

<210> 226
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT5.P18R

<400> 226
tcctgactgc ccacgggaga 20

<210> 227

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P19F

<400> 227
cagtcaggat ccagaagtgt 20

<210> 228

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P20R

<400> 228
tgtctggagc tgtctgctga 20

<210> 229

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P21F

<400> 229
agtcaggatc cagaagtgtc 20

<210> 230

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P22R

<400> 230
gtgtctggag ctgtctgctg 20

<210> 231

<211> 20

filaggrin Sequence listing.ST25

<212> DNA
 <213> Artificial Sequence RPT5.P23F

 <400> 231
 cagacaaaca cgtaatgaga 20

 <210> 232
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <400> 232
 gagccgtctc ctgattgttt 20

 <210> 233
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P25F

 <400> 233
 ccgacagctc tagacactcg 20

 <210> 234
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P26R

 <400> 234
 attgtccctg gcccacctgc 20

 <210> 235
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P27F

 <400> 235
 tgggccaggg acaatcatca 20

 <210> 236

filaggrin Sequence listing.ST25

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P28R

<400> 236

tcctgcttgt cctgggccct

20

<210> 237

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P29F

<400> 237

tctgcttcca gaaaccatct

20

<210> 238

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P30R

<400> 238

ctgctcccaa gcagatccaa

20

<210> 239

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P31F

<400> 239

aaaccatctt ggatctgctt

20

<210> 240

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P32R

<400> 240

tgtcttcgtg atgggaccca

20

filaggrin Sequence listing.ST25

<210> 241

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P33F

<400> 241

gagatggctc cagacaccct

20

<210> 242

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P34R

<400> 242

tgtcttcgtg atgggaccca

20

<210> 243

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P35F

<400> 243

agatggctcc agacaccctg

20

<210> 244

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P36R

<400> 244

ctgtcttcgt gatgggaccc

20

<210> 245

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P37F

<400> 245

aggcactcgt cacacagagt

20

filaggrin Sequence listing.ST25

<210> 246
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P38R

<400> 246
 gcctgtccac gagaggaaga 20

<210> 247
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P39F

<400> 247
 catgatccc accaccagct 20

<210> 248
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P40R

<400> 248
 ggagctgtct gctgactgga 20

<210> 249
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P41F

<400> 249
 atggatccca ccaccagctc 20

<210> 250
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT5.P42R

filaggrin Sequence listing.ST25

<400> 250
tggagctgtc tgctgactgg 20

<210> 251

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P43F

<400> 251
tggatccac caccagctcc 20

<210> 252

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P44R

<400> 252
ctggagctgt ctgctgactg 20

<210> 253

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P45F

<400> 253
gacactcagg cattgggcat 20

<210> 254

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P46R

<400> 254
ctgcagatga agcttgtcca 20

<210> 255

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P47F

filaggrin Sequence listing.ST25

<400> 255
acacacagtc agtgtcagca 20

<210> 256
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P48R

<400> 256
ggggcccagc tttccctgt 20

<210> 257
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P49F

<400> 257
cacagtcagt gtcagcacag 20

<210> 258
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P50R

<400> 258
gatggggccc agcttttccc 20

<210> 259
<211> 20
<212> DNA
<213> Artificial Sequence RPT5.P51F

<400> 259
cagtgtcagc acagggaaaa 20

<210> 260
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT5.P52R

<400> 260
tctgctgatg gggcccagct 20

<210> 261

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 261
gccccatcag cagagccaca 20

<210> 262

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P54R

<400> 262
tggccacgtg cggactcttt 20

<210> 263

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 263
gtggccagtc aggggaaagc 20

<210> 264

<211> 20

<212> DNA

<213> Artificial Sequence RPT5.P56R

<400> 264
aagaccctga acgtccagag 20

<210> 265

<211> 21

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence FILF1F

<400> 265
gaggaagaca aggatcccat t 21

<210> 266

<211> 22

<212> DNA

<213> Artificial Sequence FILFIR

<400> 266
gctgtcttgt gcctgatcat aa 22

<210> 267

<211> 22

<212> DNA

<213> Artificial Sequence FILF2F

<400> 267
gaagtgcaag cagaaaaaca ta 22

<210> 268

<211> 22

<212> DNA

<213> Artificial Sequence FILF2R

<400> 268
ctcctgattg ttccttgtca ta 22

<210> 269

<211> 21

<212> DNA

<213> Artificial Sequence RPT6.F1

<400> 269
gaacaatcag gagatggctc t 21

<210> 270

filaggrin Sequence listing.ST25

<211> 22
 <212> DNA
 <213> Artificial Sequence RPT6.F2

<400> 270
 ccgacagctc tagacactca ct 22

<210> 271
 <211> 27
 <212> DNA
 <213> Artificial Sequence GSFIL6867del.F

<400> 271
 gtttcttaga ggcggtctgg gtctgcg 27

<210> 272
 <211> 22
 <212> DNA
 <213> Artificial Sequence FIL6867delG.R

<400> 272
 ccagaggaat tctctgcatg at 22

<210> 273
 <211> 27
 <212> DNA
 <213> Artificial Sequence GSRPT6P1F

<400> 273
 gtttcttcca cacgtggccg gtcagca 27

<210> 274
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT6.P1F

<400> 274
 tcatgaacag tctgagtcca 20

filaggrin Sequence Listing.ST25

<210> 275
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P2R

<400> 275
ggcgcagact gtccatgggt 20

<210> 276
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P3F

<400> 276
tctgagtcca cccatggaca 20

<210> 277
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P4R

<400> 277
tccagtgctg ggcgcagact 20

<210> 278
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P5F

<400> 278
tgagtccacc catggacagt 20

<210> 279
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P6R

<400> 279
cctccagtgc tgggcgcaga 20

filaggrin Sequence listing.ST25

<210> 280
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P7F

<400> 280
cctccagtgc tgggcgcaga 20

<210> 281
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P8R

<400> 281
ttcctccagt gctgggcgca 20

<210> 282
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P9F

<400> 282
tccacccatg gacagtctgc 20

<210> 283
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P10R

<400> 283
tcttcctcca gtgctgggcg 20

<210> 284
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P11F

filaggrin Sequence listing.ST25

<400> 284
tcagcatccc aagaggccat 20

<210> 285

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P12R

<400> 285
tgtcttgtgc ctgataataa 20

<210> 286

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P13F

<400> 286
cagcatccca agaggccatt 20

<210> 287

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P14R

<400> 287
ctgtcttgtg cctgataata 20

<210> 288

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P15F

<400> 288
gacaaggatc ccattatgat 20

<210> 289

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P16R

filaggrin Sequence listing.ST25

<400> 289
tggagctgtc ttgtgcctga 20

<210> 290
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P17F

<400> 290
cattcgtgga cacccggggc 20

<210> 291
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P18R

<400> 291
tgtcttcctc ctctgcttgg 20

<210> 292
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P19F

<400> 292
ggccaagcag aggaggaaga 20

<210> 293
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P20R

<400> 293
gctcttgggtg ggacccctgt 20

<210> 294
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence

<400> 294
gaagacaggg gtcccaccaa 20

<210> 295

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P22R

<400> 295
acctatctac cgattgctct 20

<210> 296

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P23F

<400> 296
aagtgaagc agaaaaacat 20

<210> 297

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P24R

<400> 297
cctgattgtt ccttgtcata 20

<210> 298

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P25F

<400> 298
agtgaagca gaaaaacata 20

<210> 299

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT6.P26R

<400> 299

tcctgattgt tccttgatcat

20

<210> 300

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P27F

<400> 300

tgcaagcaga aaaacatatg

20

<210> 301

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P28R

<400> 301

tctcctgatt gttccttgct

20

<210> 302

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P29F

<400> 302

caagcagaaa aacatatgac

20

<210> 303

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P30R

<400> 303

catctcctga ttgttccttg

20

<210> 304

filaggrin Sequence listing.ST25

<211> 20
 <212> DNA
 <213> Artificial Sequence RPT6.P31F

<400> 304
 aagcagaaaa acatatgaca 20

<210> 305
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT6.P32R

<400> 305
 ccatctcctg attgttcctt 20

<210> 306
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT6.P33F

<400> 306
 acaaggaaca atcaggagat 20

<210> 307
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT6.P34R

<400> 307
 accctgagtg cctagagcca 20

<210> 308
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT6.P35F

<400> 308
 aacaatcagg agatggctct 20

filaggrin Sequence listing.ST25

<210> 309

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P36R

<400> 309

gatgcgaccc tgagtccta

20

<210> 310

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P37F

<400> 310

tctaggcact cagggtcgca

20

<210> 311

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P38R

<400> 311

agaggaagct tcatgatgat

20

<210> 312

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P39F

<400> 312

ggcactcagg gtcgcatcat

20

<210> 313

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P40R

<400> 313

cccaagagga agcttcatga

20

filaggrin Sequence listing.ST25

<210> 314
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P41F

<400> 314
tcatcatgaa gcttcctctt 20

<210> 315
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P42R

<400> 315
tgtctagagc tgcggccca 20

<210> 316
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P43F

<400> 316
gacagctcta gacactcact 20

<210> 317
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P44R

<400> 317
tgattgtccc tggcccacca 20

<210> 318
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P45F

filaggrin Sequence listing.ST25

<400> 318
tgggccagg acaatcatca 20

<210> 319
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P46R

<400> 319
gcctgcttgt cctgggccct 20

<210> 320
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P47F

<400> 320
gggcccagga caagcaggcc 20

<210> 321
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P48R

<400> 321
gctaactg gatccccggg 20

<210> 322
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P49F

<400> 322
cccaggacaa gcaggccccg 20

<210> 323
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P50R

filaggrin Sequence listing.ST25

<400> 323
ctggctaaca ctggatcccc 20

<210> 324
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P51F

<400> 324
agaggcggtc tgggtctgcg 20

<210> 325
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P52R

<400> 325
atccatgatg gtttctggac 20

<210> 326
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P53F

<400> 326
tccacacgtg gccggtcagc 20

<210> 327
<211> 20
<212> DNA
<213> Artificial Sequence RPT6.P54R

<400> 327
tgaacgtcca gaccttcctg 20

<210> 328
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT6.P55F

<400> 328

ccacacgtgg ccggtcagca

20

<210> 329

<211> 20

<212> DNA

<213> Artificial Sequence RPT6.P56R

<400> 329

ctgaacgtcc agaccttcct

20

<210> 330

<211> 19

<212> DNA

<213> Artificial Sequence RPT7.R1

<400> 330

agctgtctcg tgcctgctt

19

<210> 331

<211> 21

<212> DNA

<213> Artificial Sequence R2447X.R

<400> 331

gtcctgaccc tcttgggacg t

21

<210> 332

<211> 21

<212> DNA

<213> Artificial Sequence HEXR2447X.R

<220>

<221> misc_feature

<222> (1)..(21)

<223> hexachlorofluorescein labelled guanine

filaggrin Sequence listing.ST25

<400> 332
ntcctgaccc tcttgggacg t 21

<210> 333
<211> 19
<212> DNA
<213> Artificial Sequence RPT7.F2

<400> 333
cccaggacaa gcaggaact 19

<210> 334
<211> 21
<212> DNA
<213> Artificial Sequence RPT7P1R

<400> 334
ctggctaaaa ctggatcccc a 21

<210> 335
<211> 19
<212> DNA
<213> Artificial Sequence RPT7.R2

<400> 335
ggctaaaact ggatcccca 19

<210> 336
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P1F

<400> 336
aagacaagga tcccaccaca 20

<210> 337
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT7.P2R

<400> 337
gagctgtctc gtgcctgctt 20

<210> 338

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P3F

<400> 338
agacagctcc aggcactcaa 20

<210> 339

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P4R

<400> 339
tcctgaccct cttgggacgt 20

<210> 340

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P5F

<400> 340
gaagggtcagg acaccattca 20

<210> 341

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P6R

<400> 341
gcttgacccc ggggtgtccat 20

<210> 342

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT7.P7F

<400> 342

gacacccggg gtcaagcagt

20

<210> 343

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P8R

<400> 343

gggatccctg ccttcctcca

20

<210> 344

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P9F

<400> 344

ggatcccact acgagcaatt

20

<210> 345

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P10R

<400> 345

gtgtccagat ctatctacca

20

<210> 346

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P11F

<400> 346

acgagcaatt ggtagataga

20

<210> 347

filaggrin Sequence listing.ST25

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P12R

<400> 347

gagaccctga gtgtccagat

20

<210> 348

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P13F

<400> 348

ctgatgcctc ccatgggcac

20

<210> 349

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P14R

<400> 349

ttgcacttct ggatcctgag

20

<210> 350

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P15F

<400> 350

caagcagaca aactcgtaac

20

<210> 351

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P16R

<400> 351

cgtctcctga ttgttcacgcg

20

filaggrin Sequence listing.ST25

<210> 352

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P17F

<400> 352

gcagacaaac tcgtaacgat

20

<210> 353

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 353

agccgtctcc tgattgttca

20

<210> 354

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P19F

<400> 354

agccgtctcc tgattgttca

20

<210> 355

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P20R

<400> 355

tggcccacct gcgagtgtcc

20

<210> 356

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P21F

<400> 356

ccgacagctc tggacactcg

20

filaggrin Sequence listing.ST25

<210> 357

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P22R

<400> 357

attgtccctg gcccacctgc

20

<210> 358

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P23F

<400> 358

gccccaggaca agcaggaact

20

<210> 359

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P24R

<400> 359

tggctaaaac tggatcccca

20

<210> 360

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P25F

<400> 360

cccaggacaa gcaggaactg

20

<210> 361

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P26R

filaggrin sequence listing.ST25

<400> 361
ctggctaata ctggatcccc 20

<210> 362
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P27F

<400> 362
caggaactgg ggatccagtt 20

<210> 363
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P28R

<400> 363
ctgtcactgt cctggctaata 20

<210> 364
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P29F

<400> 364
tggatctgct caggagcagc 20

<210> 365
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P30R

<400> 365
tgtctggagc catctcttag 20

<210> 366
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P31F

filaggrin Sequence listing.ST25

<400> 366
ggatctgctc aggagcagct 20

<210> 367
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P32R

<400> 367
gtgtctggag ccatctctta 20

<210> 368
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P33F

<400> 368
ggtagtcagg ccagtgacaa 20

<210> 369
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P34R

<400> 369
gtcttctgaa tgtccctcat 20

<210> 370
<211> 20
<212> DNA
<213> Artificial Sequence RPT7.P35F

<400> 370
agccccacgga caggctgggt 20

<210> 371
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT7.P36R

<400> 371
tggtggctct gctgatggga 20

<210> 372

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P37F

<400> 372
cgtggccggt caggggaaac 20

<210> 373

<211> 20

<212> DNA

<213> Artificial Sequence

<400> 373
agatcctgaa tgtccagacg 20

<210> 374

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P39F

<400> 374
tcaggggaaa cgtctggaca 20

<210> 375

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P40R

<400> 375
gtagaggaaa gatcctgaat 20

<210> 376

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT7.P41F

<400> 376

aaacgtctgg acattcagga

20

<210> 377

<211> 20

<212> DNA

<213> Artificial Sequence RPT7.P42R

<400> 377

tcacctggta gaggaagat

20

<210> 378

<211> 21

<212> DNA

<213> Artificial Sequence RPT8.F1

<400> 378

gatggacggg gcccgact a

21

<210> 379

<211> 21

<212> DNA

<213> Artificial Sequence RPT8.R1

<400> 379

cttcctctag tgctgggcc c

21

<210> 380

<211> 21

<212> DNA

<213> Artificial Sequence RPT8P1R

<400> 380

ctaccgaatg ctcgtggtgg t

21

<210> 381

filaggrin sequence listing.ST25

<211> 21

<212> DNA

<213> Artificial Sequence RPT8.F2

<400> 381

cacgagcatt cggtagatag c

21

<210> 382

<211> 21

<212> DNA

<213> Artificial Sequence FILRPT8.F3

<400> 382

aggcgccagg gatccagtgt g

21

<210> 383

<211> 22

<212> DNA

<213> Artificial Sequence RPT8.R4

<400> 383

cttggtggct ctgctgatgg ga

22

<210> 384

<211> 21

<212> DNA

<213> Artificial Sequence FILr8.F1

<400> 384

gaaacgtctg gacattcagg a

21

<210> 385

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P1F

<400> 385

agtcctccca tggatggacg

20

filaggrin Sequence listing.ST25

<210> 386

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P2R

<400> 386

ttcctctagt gctgggcccc

20

<210> 387

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P3F

<400> 387

atggacgggg cccagcacta

20

<210> 388

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P4R

<400> 388

cgggatcctt gtcttcctct

20

<210> 389

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P5F

<400> 389

agaggaggaa ggcaggggta

20

<210> 390

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P6R

<400> 390

taccgaatgc tcgtggtggt

20

filaggrin Sequence listing.ST25

<210> 391
<211> 20
<212> DNA
<213> Artificial Sequence RPT8.P7F

<400> 391
aggggtacca ccacgagcat 20

<210> 392
<211> 20
<212> DNA
<213> Artificial Sequence RPT8.P8R

<400> 392
gtccagagct atctaccgaa 20

<210> 393
<211> 20
<212> DNA
<213> Artificial Sequence RPT8.P9F

<400> 393
acgagcattc ggtagatagc 20

<210> 394
<211> 20
<212> DNA
<213> Artificial Sequence RPT8.P10R

<400> 394
gggaccctga gtgtccagag 20

<210> 395
<211> 20
<212> DNA
<213> Artificial Sequence RPT8.P11F

filaggrin Sequence listing.ST25

<400> 395
tctagacact cacaggcagt 20

<210> 396

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P12R

<400> 396
cccctctgat tgtccctgga 20

<210> 397

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P13F

<400> 397
caatcagagg ggtccaggag 20

<210> 398

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P14R

<400> 398
ggatccctgg cgcctgcttc 20

<210> 399

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P15F

<400> 399
ggcgccaggg atccagtgtg 20

<210> 400

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P16R

filaggrin Sequence listing.ST25

<400> 400
cactgtcact gtcctggctc 20

<210> 401

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P17F

<400> 401
tggatctgct caggagcagc 20

<210> 402

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P18R

<400> 402
tgtctggagc catctcttag 20

<210> 403

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P19F

<400> 403
ggatctgctc aggagcagct 20

<210> 404

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P20R

<400> 404
gtgtctggag ccatctctta 20

<210> 405

<211> 20

<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT8.P21F

<400> 405
 ggtagtcagg ccagtgacaa 20

<210> 406

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P22R

<400> 406
 gtcttctgaa tgtccctcat 20

<210> 407

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P23F

<400> 407
 agccccacgga caggctgggt 20

<210> 408

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P24R

<400> 408
 tggtggctct gctgatggga 20

<210> 409

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P25F

<400> 409
 cgtggccggt caggggaaac 20

<210> 410

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT8.P26R

<400> 410

agatcctgaa tgtccagacg

20

<210> 411

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P27F

<400> 411

tcaggggaaa cgtctggaca

20

<210> 412

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P28R

<400> 412

gtagaggaaa gatcctgaat

20

<210> 413

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P29F

<400> 413

aaacgtctgg acattcagga

20

<210> 414

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.P30R

<400> 414

tcacctggta gaggaagat

20

<210> 415

filaggrin Sequence listing.ST25

<211> 21
 <212> DNA
 <213> Artificial Sequence FILRPT9.F1

<400> 415
 ccaggcactc agcatcccaa t 21

<210> 416
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILr9.R1

<400> 416
 acgaatgggtg tcctgaccgt a 21

<210> 417
 <211> 24
 <212> DNA
 <213> Artificial Sequence S3247X.F

<400> 417
 gtaatgagga acaatcagga gaca 24

<210> 418
 <211> 22
 <212> DNA
 <213> Artificial Sequence RPT9.R1

<400> 418
 gtgacactga gtgcctggag ct 22

<210> 419
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILr9.F1

<400> 419
 cagaaacccat cgtggatctg t 21

filaggrin Sequence listing.ST25

<210> 420
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILr9.R2

<400> 420
 ctgggggtgtc tggagccgtg c 21

<210> 421
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILr9.F2

<400> 421
 gtcacgggca ctctgcagac c 21

<210> 422
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P1F

<400> 422
 agtcctccca tggatggacg 20

<210> 423
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P2R

<400> 423
 ttcctctagt gctgggcccc 20

<210> 424
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P3F

<400> 424
 atggacgggg cccagcacta 20

filaggrin Sequence Listing.ST25

<210> 425
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P4R

<400> 425
 cgggatcctt gtcttcctct 20

<210> 426
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P5F

<400> 426
 tcccgccatg agcaggcaca 20

<210> 427
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P6R

<400> 427
 tgagtgcctg gagctgtctt 20

<210> 428
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P7F

<400> 428
 caggcactca gcatcccaat 20

<210> 429
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT9.P8R

filaggrin Sequence listing.ST25

<400> 429
cgaatggtgt cctgaccgta 20

<210> 430
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P9F

<400> 430
agaggaggaa ggcaggggta 20

<210> 431
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P10R

<400> 431
taccgaatgc tcgtggtggt 20

<210> 432
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P11F

<400> 432
aggggtacca ccacgagcat 20

<210> 433
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P12R

<400> 433
gtccagagct atctaccgaa 20

<210> 434
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P13F

filaggrin Sequence listing.ST25

<400> 434
acgagcattc ggtagatagc 20

<210> 435
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P14R

<400> 435
gggaccctga gtgtccagag 20

<210> 436
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P15F

<400> 436
tgaggaacaa tcaggagaca 20

<210> 437
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P16

<400> 437
gacactgagt gcctggagct 20

<210> 438
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P17F

<400> 438
gacagctcca ggcactcagt 20

<210> 439
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT9.P18R

<400> 439
agcttcatgg tgacgtgaca 20

<210> 440

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P19F

<400> 440
tctctagaca ctcacaggca 20

<210> 441

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P20R

<400> 441
cctctgattg tccctggact 20

<210> 442

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P21F

<400> 442
tctagacact cacaggcagt 20

<210> 443

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P22R

<400> 443
cccctctgat tgtccctgga 20

<210> 444

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT9.P23F

<400> 444

ggcgccaggg atccagtgtg

20

<210> 445

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P24R

<400> 445

cactgtcact gtcctggctc

20

<210> 446

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P25F

<400> 446

agaaaccatc gtggatctgt

20

<210> 447

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P26R

<400> 447

gtgccttgac tgctcctgaa

20

<210> 448

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P27F

<400> 448

tcacgggcac tctgcagacc

20

<210> 449

filaggrin Sequence listing.ST25

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P28R

<400> 449

gtgcctgatt gtctggagcg

20

<210> 450

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P29F

<400> 450

ctccagacac tcaggcattc

20

<210> 451

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P30R

<400> 451

gatgaagctt gtccacgcgg

20

<210> 452

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P31F

<400> 452

tccagacact caggcattcc

20

<210> 453

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P32R

<400> 453

agatgaagct tgtccacgcg

20

filaggrin Sequence listing.ST25

<210> 454

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P33F

<400> 454

gacactcagg cattccgcgt

20

<210> 455

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P34R

<400> 455

ctgcagatga agcttgtcca

20

<210> 456

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P35F

<400> 456

atctgcagtc agagacagta

20

<210> 457

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P36R

<400> 457

ccactggacc cccagtgctt

20

<210> 458

<211> 20

<212> DNA

<213> Artificial Sequence RPT9.P37F

<400> 458

agtcagagac agtagacact

20

filaggrin Sequence listing.ST25

<210> 459
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P38R

<400> 459
tgactaccac tggaccccca 20

<210> 460
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P39F

<400> 460
gtggtagtca ggccagtgat 20

<210> 461
<211> 20
<212> DNA
<213> Artificial Sequence RPT9.P40R

<400> 461
cttctgaatg tccctcacta 20

<210> 462
<211> 19
<212> DNA
<213> Artificial Sequence FILr10.F1

<400> 462
gcccattgggc ggaccagga 19

<210> 463
<211> 19
<212> DNA
<213> Artificial Sequence FILJF

filaggrin Sequence listing.ST25

<400> 463 gatggctcca ggcactcat	19
<210> 464	
<211> 20	
<212> DNA	
<213> Artificial Sequence FILr10.F2	
<400> 464 gggcccagga caagcaggaa	20
<210> 465	
<211> 21	
<212> DNA	
<213> Artificial Sequence Q3683X.F	
<400> 465 gtcagagaca gtggacaccg a	21
<210> 466	
<211> 28	
<212> DNA	
<213> Artificial Sequence 11033del4.F	
<400> 466 gtttcttgtc agagacagtg gacaccga	28
<210> 467	
<211> 21	
<212> DNA	
<213> Artificial Sequence FILr10.R1	
<400> 467 ctgaacgtcc agaccttcct g	21
<210> 468	
<211> 20	
<212> DNA	
<213> Artificial Sequence RPT10.P1F	

filaggrin Sequence listing.ST25

<400> 468
agtctgagtc tgcccatggg 20

<210> 469
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P2R

<400> 469
cagtgctggc cctgggtccgc 20

<210> 470
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P3F

<400> 470
gtctgcccac gggcggacca 20

<210> 471
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P4R

<400> 471
cttcgtccag tgctggtcct 20

<210> 472
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P5F

<400> 472
gaccaggacc agcactggac 20

<210> 473
<211> 20
<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT10.P6R

<400> 473
tggtgggatc cttgtcttcg 20

<210> 474

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P7F

<400> 474
acaccggggg tcaagcagaa 20

<210> 475

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P8R

<400> 475
tgggatccct gccttcctct 20

<210> 476

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P9F

<400> 476
agtcaggatc cagaagtgcc 20

<210> 477

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P10R

<400> 477
cattacgagt ttgtctgctg 20

<210> 478

<211> 20

filaggrin Sequence listing.ST25

<212> DNA

<213> Artificial Sequence RPT10.P11F

<400> 478

gcagacaaac tcgtaatgac

20

<210> 479

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P12R

<400> 479

agccatctcc tgattgttcg

20

<210> 480

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P13F

<400> 480

atgacgaaca atcaggagat

20

<210> 481

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P14R

<400> 481

accatgagtg cctggagcca

20

<210> 482

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P15F

<400> 482

agatggctcc aggactcat

20

<210> 483

filaggrin sequence listing.ST25

<211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.P16R

<400> 483
 gcttcattggt gatgcgacca 20

<210> 484
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.P17F

<400> 484
 tccaggcact catggctcgca 20

<210> 485
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.P18R

<400> 485
 agtgggaagct tcatggtgat 20

<210> 486
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.P19F

<400> 486
 atgaagcttc cactcaggcg 20

<210> 487
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.P20R

<400> 487
 gtgagtgtct agagctgtcc 20

filaggrin Sequence listing.ST25

<210> 488
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P21F

<400> 488
cagctctaga cactcacagt 20

<210> 489
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P22R

<400> 489
gctgattgtc cctggccgga 20

<210> 490
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P23F

<400> 490
gatggctcca gacacccac 20

<210> 491
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P24R

<400> 491
tctgtcttcg tgatgggacg 20

<210> 492
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.P25F .

<400> 492
ccacacgtgg ccggtcagca 20

filaggrin Sequence listing.ST25

<210> 493

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.P26R

<400> 493

ctgaacgtcc agaccttcct

20

<210> 494

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.1.P1F

<400> 494

tgggcagtca ggatccagac

20

<210> 495

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.1.P2R

<400> 495

cgtgttggtc tgcttcacg

20

<210> 496

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.1.P3F

<400> 496

cccaggtccc atcaagaagg

20

<210> 497

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.1.P4R

filaggrin Sequence listing.ST25

<400> 497
gtgcccata ga ccagctctgc 20

<210> 498

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.2.P1F

<400> 498
ggcactcagc atcccaagat 20

<210> 499

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.2.P2R

<400> 499
cacgaatggc gtcctgacca 20

<210> 500

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.2.P3F

<400> 500
aggcactcgt cacacacagg 20

<210> 501

<211> 20

<212> DNA

<213> Artificial Sequence RPT8.2.P4R

<400> 501
gcctgtccac cagaggaagc 20

<210> 502

<211> 22

<212> DNA

<213> Artificial Sequence FILr10/1.F1

filaggrin Sequence listing.ST25

<400> 502
catggatccc accaccagct cc 22

<210> 503

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P1F

<400> 503
agacggctcc aggcactcat 20

<210> 504

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P2R

<400> 504
gcttcatggg gatgcgacca 20

<210> 505

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P3F

<400> 505
atgaagcttc cactcaggcg 20

<210> 506

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P4R

<400> 506
gtgagtgtct agagctgtcc 20

<210> 507

<211> 20

<212> DNA

filaggrin Sequence listing.ST25

<213> Artificial Sequence RPT10.1.P5F

<400> 507
cagctctaga cactcacagt 20

<210> 508

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P6R

<400> 508
gctgattgtc cctggccgga 20

<210> 509

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P7F

<400> 509
gacaatcagc ggggccagc 20

<210> 510

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P8R

<400> 510
atccctgggt cctgcttgta 20

<210> 511

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.1.P9F

<400> 511
cgggcactct gcagacagcc 20

<210> 512

<211> 20

filaggrin Sequence listing.ST25

<212> DNA
<213> Artificial Sequence RPT10.1.P10R

<400> 512
cgagtgcctg attgtctggg 20

<210> 513
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.1.P11F

<400> 513
agcagacagc tccagacacg 20

<210> 514
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.1.P12R

<400> 514
tgtccgtgcc caatgcctgc 20

<210> 515
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.1.P13F

<400> 515
acacacagtc agtgtcagca 20

<210> 516
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.1.P14R

<400> 516
ggggcccagc ttttccctgt 20

<210> 517

filaggrin sequence listing.ST25

<211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.1.P15F

<400> 517
 ccagtcaggg gaaagctcta 20

<210> 518
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.1.P16R

<400> 518
 aggaaagacc ctgaacgtct 20

<210> 519
 <211> 21
 <212> DNA
 <213> Artificial Sequence FILr10/2.F1

<400> 519
 gtccacccat ggacagtctg t 21

<210> 520
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.2.P1F

<400> 520
 tgagtcacc catggacagt 20

<210> 521
 <211> 20
 <212> DNA
 <213> Artificial Sequence RPT10.2.P2R

<400> 521
 cctccagtgc tgggcacaga 20

filaggrin Sequence listing.ST25

<210> 522

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P3F

<400> 522

gacaaggatc ccaccatgat

20

<210> 523

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P4R

<400> 523

tggagctgtc ttgtgcctga

20

<210> 524

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P5F

<400> 524

cattcgtgga caccgggggc

20

<210> 525

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P6R

<400> 525

tgtcttcctc ctctgcttgg

20

<210> 526

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P7F

<400> 526

ctcccgtggg cagtcaggac

20

filaggrin Sequence listing.ST25

<210> 527
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.2.P8R

<400> 527
cccagaagtg caagcagaca 20

<210> 528
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.2.P9F

<400> 528
agtgaagca gacaaacaca 20

<210> 529
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.2.P10R

<400> 529
tcctgattgt tccttgcat 20

<210> 530
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.2.P11F

<400> 530
tgcaagcaga caaacacatg 20

<210> 531
<211> 20
<212> DNA
<213> Artificial Sequence RPT10.2.P12R

filaggrin Sequence listing.ST25

<400> 531
tctcctgatt gttccttgtc 20

<210> 532

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P13F

<400> 532
agcagacaaa cacatgacaa 20

<210> 533

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P14R

<400> 533
gccgtctcct gattgttcct 20

<210> 534

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P15F

<400> 534
aacaatcagg agacggctct 20

<210> 535

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P16R

<400> 535
gacgcgaccc tgagtgcccta 20

<210> 536

<211> 20

<212> DNA

<213> Artificial Sequence RPT10.2.P17F

filaggrin Sequence listing.ST25

<400> 536		
gaattcctct ggtggacagc		20
<210> 537		
<211> 20		
<212> DNA		
<213> Artificial Sequence RPT10.2.P18R		
<400> 537		
tgttcatggg atgatgcagg		20
<210> 538		
<211> 20		
<212> DNA		
<213> Artificial Sequence RPT10.2.P19F		
<400> 538		
ccacacgtgg ccggtcagca		20
<210> 539		
<211> 20		
<212> DNA		
<213> Artificial Sequence RPT10.2.P20R		
<400> 539		
ctgaacgtcc agaccttcct		20
<210> 540		
<211> 21		
<212> DNA		
<213> Artificial Sequence FAM11033del4.R		
<220>		
<221> misc_feature		
<222> (1)..(21)		
<223> Carboxyfluorescein labelled guanine		

filaggrin Sequence listing.ST25

<400> 540
natccttggtc ttcctccagt a 21

<210> 541

<211> 21

<212> DNA

<213> Artificial Sequence Q3683X.R

<400> 541
gatccttggtc ttcctccagt a 21

<210> 542

<211> 22

<212> DNA

<213> Artificial Sequence FLGendF1

<400> 542
ctagtaccgc taaggaacat gg 22

<210> 543

<211> 19

<212> DNA

<213> Artificial Sequence FILKF

<400> 543
ggcagctatg gtagtgcag 19

<210> 544

<211> 19

<212> DNA

<213> Artificial Sequence FILKR

<400> 544
ctgcactacc atagctgcc 19

<210> 545

<211> 21

<212> DNA

<213> Artificial Sequence FLGendR1

filaggrin Sequence listing.ST25

<400> 545
 tggctccttc gatatttctg a 21

<210> 546
 <211> 12186
 <212> DNA
 <213> Human Profilaggrin

<400> 546
 atgtctactc tcctggaaaa catctttgcc ataattaatc ttttcaagca atattcaaaa 60
 aaagataaaa aactgacac attgagtaaa aaagagctga aggaacttct ggaaaaggaa 120
 tttcggcaaa tcctgaagaa tccagatgac ccagatatgg ttgatgtctt catggatcac 180
 ttggatatag accacaacaa gaaaattgac ttcactgagt ttcttctgat ggtattcaag 240
 ttggctcaag catattatga gtctaccaga aaagagaatt taccgatatc aggacacaag 300
 cacagaaagc acagtcatca tgataaacat gaagataata aacaggaaga aaacaaagaa 360
 aacagaaaaa gacctcaag tctggaaaga agaaacaata gaaaaggga taagggaaga 420
 tccaagagcc caagagaaac aggggggaaa aggcattgaat ctagtcttga aaaaaagaa 480
 agaaaaggat attcacctac tcatagagaa gaagaatatg gaaaaaacca tcataactca 540
 agtaaaaaag agaaaaacaa gactgaaaat actagattag gagacaatag gaagaggcta 600
 agtgaaagac ttgaagagaa agaagacaat gaagaaggag tatatgatta tgaaaatata 660
 ggaagaatga ctcaaaaatg gatacaatca ggccatattg ccacatatta cacaatccag 720
 gatgaagcct atgacaccac tgatagtcta ttagaagaaa acaaaatata tgaaagatca 780
 aggtcatctg atggcaaatc atcatctcaa gtgaacagggt caagacatga aaatacaagc 840
 caggtaccat tgcaggagtc caggacaaga aagcgtaggg gatccagagt tagccaggac 900
 agggacagtg agggacactc agaagactct gagaggcact ctgggtcggc ttccagaaac 960
 catcatggat ctgctgaggga gcagtcaaga gatggctcca gacacccag gtcccatgat 1020
 gaagacagag ccagtcattg gcactctgca gacagctcca gacaatcagg cactcgtcac 1080
 gcagagactt cctctctgtg acagactgca tcatcccatg aacaggcaag atcaagtcca 1140
 ggagaaagac atggatccgg ccaccagcag tcagcagaca gctccagaca ctacagccact 1200
 gggcgcgggc aagcttcatc tgcagtcagc gatcgtggac accgggggtc tagcggtagt 1260
 caggccagtg acagtgaggg acattcagaa aactcagaca cacaatcagt gtcaggccac 1320
 ggaaaggctg ggctgagaca gcagagccac caagagtcca cacgtggccg gtcaggggaa 1380
 cggtctggac gttcagggtc ttccctctac cagggtgagca ctcatgaaca gcctgactct 1440
 gcccatggac ggaccgggac cagcactgga ggaagacaag gatcgacca cgagcaggca 1500
 cgagacagct ccaggcattc agcgtcccaa gagggtcagg acaccattcg tggacacccg 1560

filaggrin Sequence listing.ST25

gggtcaagca gaggaggaag gcagggatcc caccacgagc aatcggtaaa taggtctgga	1620
cactcagggtt cccatcacag ccacaccaca tcccagggaa ggtctgatgc ctcccatggg	1680
cagtcaggat ccagaagtgc aagcagacaa acacgaaatg aggaacaatc aggagacggc	1740
accaggcact cagggtcacg tcatcatgaa gcttcctctc aggctgacag ctctagacac	1800
tcacaggtgg gccagggaca atcatcgggg cccaggacaa gtaggaacca gggatccagt	1860
gttagccagg acagtgacag tcagggacac tcagaagact ctgagaggtg gtctgggtct	1920
gcttcagaa accatcatgg atctgctcag gagcagtcaa gagatggctc cagacacccc	1980
agggtcccatc acgaagacag agctgggtcat gggcactctg cagacagctc cagaaaatca	2040
ggcactcgtc acacacagaa ttcctctagt ggacaggctg cgtcatcca tgaacaggca	2100
agatcaagtg caggagaaag acatggatcc cgccaccagc tccagtcagc agacagctcc	2160
agacactcag gcactgggca cggacaagct tcatctgcag tcagagacag tggacaccga	2220
gggtccagtg gtagtcaggc cactgacagt gagggacatt cagaagactc agacacacag	2280
tcagtgtcag gccatggaca ggctgggtcac catcagcaga gccaccaaga gtccgcacgt	2340
gaccgggtcag gggaaaggtc tcgacgttca ggggtctttcc tctaccaggt gagcactcat	2400
aaacagtctg agtcctccca tggatggaca gggcccagca ctggagtaag acaaggatcc	2460
caccatgagc aggcacgaga caactccagg cactcagcat cccaagatgg tcaggacacc	2520
attcgtggac acccggggtc aagcagaaga ggaaggcagg ggtcccacca cgagcaatcg	2580
gtagataggt ctggacactc aggggtcccat cacagccaca ccacatcca gggaaaggtct	2640
gatgcctccc gtgggcagtc aggatccaga agtgcaagca gaacaacacg taatgaggaa	2700
caatcaagag acgggtccag gcactcaggg tcacgtcacc atgaagcttc ctctcatgcc	2760
gacatctcta gacactcaca ggcaggccag ggacaatcag aggggtccag gacaagcagg	2820
cgccagggat ccagtgttag ccaggacagt gacagtgagg gacattcaga agactctgag	2880
agggtggtctg ggtctgcttc cagaaaccat cgtggatctg ctcaggagca gtcaagacat	2940
ggctccagac accccaggtc ccatcacgaa gacagagccg gtcacgggca ctctgcagac	3000
agctccagac aatcaggaac tcctcacgca gagacttcct ctggtggaca ggctgcgtca	3060
tcccatgaac aggcaagatc aagtccagga gaaagacacg gatcccgcca ccagcagtca	3120
gcagacagct ccagacactc aggcattccg cgcagacaag cttcatctgc agtcagagac	3180
agtggacact ggggggtccag tggtagtcag gccagtgata gtgagggaca ttcagaggag	3240
tcagacacac agtcagtgtc aggccatgga caggatgggc cccatcagca gagccaccaa	3300
gagtccgcac gtgactggtc agggggaagg tctggacgtt caggggtctt catctaccag	3360
gtgagcactc atgaacagtc tgagtctgcc catgggcgga ccaggaccag cactggacga	3420
agacaaggat cccaccacga gcaggcacga gacagctcca ggcactcagc gtcccaagag	3480
ggtcaggaca ccattcgtgc acaccgggg tcaaggagag gaggaaggca gggatcccac	3540
catgagcaat cggtagatag atctggacac tcagggtccc atcacagcca caccacatcc	3600

filaggrin Sequence listing.ST25

caggggaaggt	ctgatgcctc	ccatgggacag	tcaggatcca	gaagtgcaag	cagacaaact	3660
cgtaaggaca	aacaatcagg	agacggctcc	aggcactcag	ggtcacgtca	ccatgaagct	3720
gcctcttggg	ctgacagctc	tagacactca	caggtgggac	aggaacaatc	atcgggggtcc	3780
aggacaagca	ggcaccagg	atccagtgtt	agccaggaca	gtgacagtga	gagacactca	3840
gacgactccg	agaggttgct	tgggtctgct	tccagaaacc	atcatggatc	ttctcgggag	3900
cagtcaagag	atggctccag	acaccctggg	ttccatcaag	aagacagagc	cagtcacggg	3960
cactctgcag	acagctccag	acaatcaggc	actcatcaca	cagagtcttc	ctctcatgga	4020
caggctgtgt	catcccatga	acaggcaaga	tcaagtccag	gagaaagaca	tggatcccg	4080
caccagcagt	cagcagacag	ctccagacac	tcaggcattg	ggcacagaca	agcttcatct	4140
gcagtccag	acagtggaca	ccgaggggtcc	agtggtagtc	aggctactaa	cagtggaggga	4200
cattcagaag	actcagacac	acagtccagt	tcagcccacg	gacaagctgg	gccccatcag	4260
cagagccaca	aagagtccgc	acgtggccag	tcaggggaaa	gctctggacg	ttcaaggctt	4320
ttcctctacc	aggtgagctc	tcatgaacag	tctgagtcca	cacacggaca	gactgcaccc	4380
agcactggag	gaagacaagg	atcccgccat	gagcaggcac	gaaacagctc	taggcactca	4440
gcatcccaag	acggtcagga	caccattcgt	ggacacccgg	ggtcaagcag	aggaggaagg	4500
cagggatcct	accacgagca	atcagtagat	aggtctggac	actcagggta	ccatcacagc	4560
cacaccacac	cccaggaag	gtctgatgcc	tcccatgggc	agtcaggacc	cagaagtgca	4620
agcaggcaaa	caagaaatga	ggaacaatca	ggagacggct	ccaggcactc	agggtcacgt	4680
caccatgaac	cttccactcg	ggccggcagc	tctagacact	cacagggtggg	ccaggggagaa	4740
tcagcgggg	ccaagacaag	caggcgccag	ggatccagt	ttagtcagga	caggacagt	4800
gagggacact	cagaagactc	tgagaggcgg	tctgagtcgg	cttccagaaa	ccattatgga	4860
tctgctcggg	agcagtcaag	acatggctcc	aggaacccca	ggtcccatca	agaagataga	4920
gccagtcagt	ggcactctgc	agagagctcc	agacaatcag	gcactcgtca	tgcagagact	4980
tcctctggtg	gacaggctgc	atcatcccag	gaacaggcaa	ggtcaagtcc	aggagaaaga	5040
catggatccc	gccaccagca	gtcagcagac	agctccacag	actcaggcac	tgggcgcaga	5100
caagattcat	ctgtagtcgg	agacagtgg	aaccgaggg	ccagtggtag	ccaggccagt	5160
gacagcgagg	gacactcaga	agagtcagac	acacagtcag	tgtcagccca	cggacaggct	5220
gggccccatc	agcagagcca	ccaagagtcc	acacgtggcc	agtcagggga	aaggctctgga	5280
cgttcaggg	ctttcctcta	ccaggtgagc	actcatgaac	agtctgagtc	cgcccatgga	5340
cgcacaggg	ccagcactgg	aggaagacaa	agatcccgcc	acgagcaggc	acgagacagc	5400
tccaggcact	cagcgtccca	agagggtcag	gacaccattc	gtggacaccc	agggctcaagc	5460
agaggaggaa	ggcagggatc	ccactatgag	caatcggtag	atagttctgg	acactcagg	5520
tctcatcaca	gccacaccac	gtcccaggaa	aggtctgatg	tctcccgtgg	gcagtcagga	5580
tccagaagtg	tcagcagaca	aacacgtaat	gagaaacaat	caggagacgg	ctccaggcac	5640

filaggrin Sequence listing.ST25

tcaggggtcgc gtcacccatga agcttcctct cgggccgaca gctctagaca ctcgcaggtg	5700
ggccaggggac aatcatcagg gccccaggaca agcaggaacc agggatccag tgtagccag	5760
gacagtgcaca gtcaggggaca ctcagaagac tctgagaggt ggtctgggtc tgcttccaga	5820
aaccatcttg gatctgcttg ggagcagtca agagatgggt ccagacaccc tgggtcccat	5880
cacgaagaca gagccggtca cgggcactct gcagacagct ccagacaatc aggcactcgt	5940
cacacagagt cttcctctcg tggacagggt gcgtcatccc atgaacaggc aagatcaagt	6000
gcaggagaaa gacatggatc ccaccaccag ctccagtcag cagacagctc cagacactca	6060
ggcattgggc atggacaagc ttcattctgca gtcagagaca gtggacaccg aggttacagt	6120
ggtagtcagg ccagtgacag tgagggacat tcagaagact cagacacaca gtcagtgtca	6180
gcacagggaa aagctgggcc ccatcagcag agccacaaaag agtccgcacg tggccagtca	6240
ggggaaagct ctggacgttc agggctcttc ctctaccagg tgagcactca tgaacagtct	6300
gagtccaccc atggacagtc tgcgcccagc actggaggaa gacaaggatc ccattatgat	6360
caggcacaag acagctccag gcactcagca tcccaagagg gtcaggacac cattcgtgga	6420
cacccggggc caagcagagg aggaagacag gggctccacc aagagcaatc ggtagatagg	6480
tctggacact cagggctctca tcacagccac accacatccc agggaaaggtc tgatgcctcc	6540
cgtgggcagt caggatccag aagtgcagc agaaaaacat atgacaagga acaatcagga	6600
gatggctcta ggcactcagg gtcgcatcat catgaagctt cctcttgggc cgacagctct	6660
agacactcac tgggtgggcca gggacaatca tcagggccca ggacaagcag gccccgggga	6720
tccagtgtta gccaggacag tgacagtgcg ggacactcag aagattctga gaggcgggtct	6780
gggtctgcgt ccagaaacca tcatggatct gctcaggagc agtcaagaga tggctccaga	6840
caccccaggt cccatcacga agacagagcc ggtcatgggc actctgcaga gagctccaga	6900
caatcaggca ctcatcatgc agagaattcc tctggtggac aggtctgcat atcccatgaa	6960
caggcaagat caagtgcagg agagagacac ggatcccacc accagcagtc agcagacagc	7020
tccagacact caggcattgg gcacggacaa gcttcatctg cagtgcagga cagtggacac	7080
cgaggggtcca gtggtagtca ggccagtgc agtgagggac attcagaaga ctcagacaca	7140
cagtcagtgt cagcccacgg acaggctggg ccccatcagc agagccacca agagtccaca	7200
cgtggccggt cagcaggaag gtctggacgt tcaggggtctt tcctctacca ggtgagcact	7260
catgaacagt ctgagtccgc ccatggacgg accgggacca gcactggagg aagacaagga	7320
tcccaccaca agcaggcacg agacagctcc aggcactcaa cgtcccaaga gggtcaggac	7380
accattcatg gacacccggg gtcaagcagt ggaggaaggc agggatccca ctacagcaa	7440
ttggtagata gatctggaca ctcaggggtct catcacagcc acaccacatc ccagggaagg	7500
tctgatgcct cccatgggca ctcaggatcc agaagtgcaa gcagacaaac tcgtaacgat	7560
gaacaatcag gagacggctc caggcactca gggtcgcgtc accatgaagc ttcctctcgg	7620
gccgacagct ctggacactc gcagggtgggc caggggacaat cagagggggc caggacaagc	7680

filaggrin Sequence Listing.ST25

aggaactggg gatccagttt tagccaggac agtgacagtc agggacactc agaagactct	7740
gagaggtggt ctgggtctgc ttccagaaac catcatggat ctgctcagga gcagctaaga	7800
gatggctcca gacaccccag gtcccatcaa gaagacagag ctgggtcatgg gcactctgca	7860
gacagctcca gacaatcagg cactcgtcac acacagactt cctctgggtgg acaggctgca	7920
tcatcccatg aacaggcaag atcaagtgc ggagaaagac atggatcca ccaccagcag	7980
tcagcagaca gctccagaca ctcaggcatt gggcacggac aagcttcac tgcagtcaga	8040
gacagtggac accgagggtta cagtggtagt caggccagtg acaatgaggg acattcagaa	8100
gactcagaca cacagtcagt gtcagcccac ggacaggctg ggtcccatca gcagagccac	8160
caagagtccg cacgtggccg gtcaggggaa acgtctggac attcaggatc tttcctctac	8220
caggtgagca ctcatgaaca gtctgagtcc tcccatggat ggacggggcc cagcactaga	8280
ggaagacaag gatcccgcca tgagcaggca caagacagct ccaggcactc agcatcccaa	8340
gacggtcagg acaccattcg tggacacccg gggtaagca gaggaggaag gcaggggtac	8400
caccacgagc attcggtaga tagctctgga cactcagggt cccatcacag ccacaccaca	8460
tcccaggga ggtctgatgc ctcccgtggg cagtcaggat ccagaagtgc aagcagaaca	8520
acacgtaatg aggaacaatc aggagacggc tccaggcact cagggtcgcg tcaccatgaa	8580
gcttcactc atgccgacat ctctagacac tcacaggcag tccagggaca atcagagggg	8640
tccaggagaa gcaggcgcca gggatccagt gtgagccagg acagtgacag tgagggacat	8700
tcagaagact ctgagaggtg gtctgggtct gcttcagaa accatcatgg atctgctcag	8760
gagcagctaa gagatggctc cagacacccc aggtcccatc aagaagacag agctggtcac	8820
gggactctg cagacagctc cagacaatca ggcactcgtc acacacagac ttcctctggt	8880
ggacaggctg catcatcca tgaacaggca agatcaagtg caggagaaag acatggatcc	8940
caccaccagc agtcagcaga cagctccaga cactcaggca ttgggcacgg acaagcttca	9000
tctgcagtca gagacagtgg acaccgaggg tacagtggta gtcaggccag tgacaatgag	9060
ggacattcag aagactcaga cacacagtca gtgtcagccc acggacaggc tgggtcccat	9120
cagcagagcc accaagagtc cgcacgtggc cggtcagggg aaacgtctgg acattcagga	9180
tctttcctct accaggtgag cactcatgaa cagtctgagt cctcccatgg atggacgggg	9240
cccagcacta gaggaagaca aggatcccg ccatgagcagg cacaagacag ctccaggcac	9300
tcagcatccc aatacggta ggacaccatt cgtggacacc cggggtcaag cagaggagga	9360
aggcaggggt accaccacga gcattcggta gatagctctg gacactcagg gtcccatcac	9420
agccacacca catcccaggg aaggctctgat gcctcccggtg ggcagtcagg atccagaagt	9480
gcaagcagaa caacacgtaa tgaggaacaa tcaggagaca gctccaggca ctcagtgtca	9540
cgtcaccatg aagcttcac tcatgccgac atctctagac actcacaggc agtccagggg	9600
caatcagagg ggtccaggag aagcaggcgc cagggatcca gtgtgagcca ggacagtgc	9660
agtgaggggac attcagaaga ctctgagagg tggctgggt ctgcttcag aaaccatcgt	9720

filaggrin Sequence listing.ST25

ggatctgttc	aggagcagtc	aaggcacggc	tccagacacc	ccaggtccca	tcacgaagac	9780
agagccggtc	acgggcactc	tgcagaccgc	tccagacaat	caggcactcg	tcacgcagag	9840
acttcctctg	gtggacaggc	tgcattcatcc	catgaacagg	caagatcaag	tccaggagag	9900
agacacggat	cccgccacca	gcagtcagca	gacagctcca	gacactcagg	cattccgcgt	9960
ggacaagctt	catctgcagt	cagagacagt	agacactggg	ggtccagtgg	tagtcaggcc	10020
agtgatagtg	agggacattc	agaagagtca	gacacacagt	cagtgtcagg	ccatggacag	10080
gctgggcccc	atcagcagag	ccaccaagag	tccgcacgtg	accggtcagg	gggaagggtct	10140
ggacgttcag	ggtctttcct	ctaccagggtg	agcactcatg	aacagtctga	gtctgcccac	10200
gggcggaacca	ggaccagcac	tggacgaaga	caaggatccc	accacgagca	ggcacgagac	10260
agctccaggc	actcagcgtc	ccaagagggt	caggacacca	ttcgtggaca	cccgggggtca	10320
agcagaagag	gaaggcaggg	atcccactac	gagcaatcgg	tagatagggtc	tggacactca	10380
gggtcccatc	acagccacac	cacatcccag	ggaagggtctg	atgcctcccg	tgggcagtca	10440
ggatccagaa	gtgccagcag	acaaactcgt	aatgacgaac	aatcaggaga	tgggtccagg	10500
cactcatggt	cgcattacca	tgaagcttcc	actcaggcgg	acagctctag	acactcacag	10560
tccggccagg	gacaatcagc	ggggcccagg	acaagcagga	accagggatc	cagtgttagc	10620
caggacagtg	acagtcaggg	acactcagaa	gactctgaga	ggtggtctgg	gtctgtcttc	10680
agaaaccatc	gtggatctgc	tcaggagcag	tcaagagatg	gctccagaca	ccccacgtcc	10740
catcacgaag	acagagccgg	tcacgggcac	tctgcagaga	gctccagaca	atcaggcact	10800
catcatgcag	agaattcctc	tgggtggacag	gctgcatcat	cccatgaaca	ggcaagatca	10860
agtgaggag	agagacatgg	atcccaccac	cagcagtcag	cagacagctc	cagacactca	10920
ggcattgggc	acggacaagc	ttcatctgca	gtcagagaca	gtggacaccg	aggggtccagt	10980
ggtagttagg	ccagtgcag	tgagggacat	tcagaagact	cagacacaca	gtcagtgtca	11040
gcccacggac	aggctggggc	ccatcagcag	agccaccaag	agtccacacg	tggccgggtca	11100
gcaggaagg	ctggacgttc	aggggtctttc	ctctaccagg	tgagcactca	tgaacagtct	11160
gagtctgccc	atggacgggc	tggggccagg	actggaggaa	gacaaggatc	ccgccacgag	11220
caggcacgag	acagctccag	gcactcagcg	tcccaagagg	gtcaggacac	cattcgtgga	11280
cacccgggg	caaggagagg	aggaagacag	ggatcctacc	acgagcaatc	ggtagatagg	11340
tctggacact	cagggtccca	tcacagccac	accacatccc	aggggaagg	tgatgcctcc	11400
catgggcagt	caggatccag	aagtgaagc	agagaaacac	gtaatgagga	acagtcagga	11460
gacgggtcca	ggcactcagg	gtcgcgtcac	catgaagctt	ccactcaggc	tgacagctct	11520
agacactcac	agtccggcca	gggtgaatca	gcgggggtcca	ggagaagcag	gcgccaggga	11580
tccagtgtta	gccaggacag	tgacagttag	gcatacccag	aggactctga	gaggcgatct	11640
gagtctgctt	ccagaaacca	tcatggatct	tctcgggagc	agtcaagaga	tgggtccaga	11700
caccccgat	cctctcaccg	cgatacagcc	agtcattgtac	agtccttacc	tgtacagtca	11760

filaggrin Sequence listing.ST25

```

gactctagta ccgctaagga acatgggtcac tttagtagtc tttcacaaga ttctgcgtat 11820
cactcaggaa tacagtcacg tggcagtcct cacagttcta gttcttatca ttatcaatct 11880
gagggcactg aaaggcaaaa aggtcaatca ggtttagttt ggagacatgg cagctatggg 11940
agtgcagatt atgattatgg tgaatccggg tttagacact ctcagcacgg aagtgttagt 12000
tacaattcca atcctgttgt tttcaaggaa agatctgata tctgtaaagc aagtgcgttt 12060
ggtaaagatc atccaaggta ttatgcaacg tatattaata aggaccagg tttatgtggc 12120
cattctagtg atatatcgaa acaactggga tttagtcagt cacagagata ctattactat 12180
gagtaa 12186

```

<210> 547

<211> 975

<212> DNA

<213> Human Profilaggrin Repeat 1

```

<400> 547
cctgactctg cccatggacg gaccgggacc agcactggag gaagacaagg atcgccaccac 60
gagcaggcac gagacagctc caggcattca gcgtcccaag agggtcagga caccattcgt 120
ggacaccccg ggtcaagcag aggaggaagg cagggatccc accacgagca atcggtaaat 180
aggtctggac actcaggttc ccatcacagc cacaccacat cccagggaag gtctgatgcc 240
tcccatgggc agtcaggatc cagaagtgc agcagacaaa cacgaaatga ggaacaatca 300
ggagacggca ccaggcactc agggtcacgt catcatgaag cttcctctca ggctgacagc 360
tctagacact cacagggtgg ccagggacaa tcatcggggc ccaggacaag taggaaccag 420
ggatccagtg ttagccagga cagtgcagct cagggacact cagaagactc tgagaggtgg 480
tctgggtctg cttccagaaa ccatcatgga tctgctcagg agcagtcaag agatggctcc 540
agacacccca ggtcccatca cgaagacaga gctgggtcatg ggcaactctgc agacagctcc 600
agaaaatcag gcaactcgta cacacagaat tcctctagtg gacaggctgc gtcattccat 660
gaacaggcaa gatcaagtgc aggagaaaga catggatccc gccaccagct ccagtcagca 720
gacagctcca gacactcagg cactgggcac ggacaagctt catctgcagt cagagacagt 780
ggacaccgag ggtccagtgg tagtcaggcc actgacagtg agggacattc agaagactca 840
gacacacagt cagtgtcagg ccatggacag gctggtcacc atcagcagag ccaccaagag 900
tccgcacgtg accggtcagg ggaaagggtc cgacgttcag ggtctttcct ctaccaggtg 960
agcactcata aacag 975

```

<210> 548

<211> 325

filaggrin Sequence listing.ST25

<212> PRT

<213> Human Profilaggrin Repeat 1

<400> 548

Pro Asp Ser Ala His Gly Arg Thr Gly Thr Ser Thr Gly Gly Arg Gln
 1 5 10 15
 Gly Ser His His Glu Gln Ala Arg Asp Ser Ser Arg His Ser Ala Ser
 20 25 30
 Gln Glu Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser Arg Gly
 35 40 45
 Gly Arg Gln Gly Ser His His Glu Gln Ser Val Asn Arg Ser Gly His
 50 55 60
 Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala
 65 70 75 80
 Ser His Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Gln Thr Arg Asn
 85 90 95
 Glu Glu Gln Ser Gly Asp Gly Thr Arg His Ser Gly Ser Arg His His
 100 105 110
 Glu Ala Ser Ser Gln Ala Asp Ser Ser Arg His Ser Gln Val Gly Gln
 115 120 125
 Gly Gln Ser Ser Gly Pro Arg Thr Ser Arg Asn Gln Gly Ser Ser Val
 130 135 140
 Ser Gln Asp Ser Asp Ser Gln Gly His Ser Glu Asp Ser Glu Arg Trp
 145 150 155 160
 Ser Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu Gln Ser
 165 170 175
 Arg Asp Gly Ser Arg His Pro Arg Ser His His Glu Asp Arg Ala Gly
 180 185 190
 His Gly His Ser Ala Asp Ser Ser Arg Lys Ser Gly Thr Arg His Thr
 195 200 205
 Gln Asn Ser Ser Ser Gly Gln Ala Ala Ser Ser His Glu Gln Ala Arg
 210 215 220
 Ser Ser Ala Gly Glu Arg His Gly Ser Arg His Gln Leu Gln Ser Ala
 225 230 235 240

filaggrin Sequence listing.ST25

Asp Ser Ser Arg His Ser Gly Thr Gly His Gly Gln Ala Ser Ser Ala
 245 250 255

Val Arg Asp Ser Gly His Arg Gly Ser Ser Gly Ser Gln Ala Thr Asp
 260 265 270

Ser Glu Gly His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Gly His
 275 280 285

Gly Gln Ala Gly His His Gln Gln Ser His Gln Glu Ser Ala Arg Asp
 290 295 300

Arg Ser Gly Glu Arg Ser Arg Arg Ser Gly Ser Phe Leu Tyr Gln Val
 305 310 315 320

Ser Thr His Lys Gln
 325

<210> 549

<211> 971

<212> DNA

<213> Human Profilaggrin Repeat 1 - 2282del4

<400> 549

cctgactctg cccatggacg gaccgggacc agcactggag gaagacaagg atcgcaccac	60
gagcaggcac gagacagctc caggcattca gcgtcccaag agggtcagga caccattcgt	120
ggacacccgg ggtcaagcag aggaggaagg cagggatccc accacgagca atcggtaa	180
aggtctggac actcaggttc ccatcacagc cacaccacat cccagggaag gtctgatgcc	240
tcccatgggc agtcaggatc cagaagtgc agcagacaaa cacgaaatga ggaacaatca	300
ggagacggca ccaggcactc agggtcacgt catcatgaag cttcctctca ggctgacagc	360
tctagacact cacaggtggg ccagggacaa tcatcggggc ccaggacaag taggaaccag	420
ggatccagtg ttagccagga cagtgcagct caggacactc cagaagactc tgagaggtag	480
tctgggtctg cttccagaaa ccatcatgga tctgctcagg agcagtcaag agatggctcc	540
agacacccca ggtcccatca cgaagacaga gctgggtcatg ggcaactctgc agacagctcc	600
agaaaatcag gcactcgtca cacacagaat tcctctagtgc gacaggctgc gtcacccat	660
gaacaggcaa gatcaagtgc aggagaaaga catggatccc gccaccagct ccagtcagca	720
gacagctcca gacactcagg cactgggcac ggacaagctt catctgcagt cagagacagt	780
ggacaccgag ggtccagtgg tagtcaggcc actgacagtg agggacattc agaagactca	840
gacacacagt gtcaggccat ggacaggctg gtcaccatca gcagagccac caagagtccg	900
cacgtgaccg gtcaggggaa aggtctcgac gttcagggtc tttcctctac caggtgagca	960
ctcataaaca g	971

filaggrin sequence listing.ST25

<210> 550
 <211> 323
 <212> PRT
 <213> Human Profilaggrin Repeat 1 - 2282del4

<220>
 <221> MISC_FEATURE
 <222> (319)..()
 <223> X = STOP

<220>
 <221> MISC_FEATURE
 <222> (1)..(323)
 <223> X = STOP

<400> 550
 Pro Asp Ser Ala His Gly Arg Thr Gly Thr Ser Thr Gly Gly Arg Gln
 1 5 10 15
 Gly Ser His His Glu Gln Ala Arg Asp Ser Ser Arg His Ser Ala Ser
 20 25 30
 Gln Glu Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser Arg Gly
 35 40 45
 Gly Arg Gln Gly Ser His His Glu Gln Ser Val Asn Arg Ser Gly His
 50 55 60
 Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala
 65 70 75 80
 Ser His Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Gln Thr Arg Asn
 85 90 95
 Glu Glu Gln Ser Gly Asp Gly Thr Arg His Ser Gly Ser Arg His His
 100 105 110
 Glu Ala Ser Ser Gln Ala Asp Ser Ser Arg His Ser Gln Val Gly Gln
 115 120 125
 Gly Gln Ser Ser Gly Pro Arg Thr Ser Arg Asn Gln Gly Ser Ser Val
 130 135 140

filaggrin Sequence listing.ST25

Ser Gln Asp Ser Asp Ser Gln Gly His Ser Glu Asp Ser Glu Arg Trp
 145 150 155 160

Ser Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu Gln Ser
 165 170 175

Arg Asp Gly Ser Arg His Pro Arg Ser His His Glu Asp Arg Ala Gly
 180 185 190

His Gly His Ser Ala Asp Ser Ser Arg Lys Ser Gly Thr Arg His Thr
 195 200 205

Gln Asn Ser Ser Ser Gly Gln Ala Ala Ser Ser His Glu Gln Ala Arg
 210 215 220

Ser Ser Ala Gly Glu Arg His Gly Ser Arg His Gln Leu Gln Ser Ala
 225 230 235 240

Asp Ser Ser Arg His Ser Gly Thr Gly His Gly Gln Ala Ser Ser Ala
 245 250 255

Val Arg Asp Ser Gly His Arg Gly Ser Ser Gly Ser Gln Ala Thr Asp
 260 265 270

Ser Glu Gly His Ser Glu Asp Ser Asp Thr Gln Cys Gln Ala Met Asp
 275 280 285

Arg Leu Val Thr Ile Ser Arg Ala Thr Lys Ser Pro His Val Thr Gly
 290 295 300

Gln Gly Lys Gly Leu Asp Val Gln Gly Leu Ser Ser Thr Arg Xaa Ala
 305 310 315 320

Leu Ile Asn

<210> 551

<211> 975

<212> DNA

<213> Human Profilaggrin repeat 1 - R501X C>T

<400> 551
 cctgactctg cccatggacg gaccgggacc agcactggag gaagacaagg atcgcaccac 60
 gagcaggcat gagacagctc caggcattca gcgtcccaag agggtcagga caccattcgt 120
 ggacacccgg ggtcaagcag aggaggaagg cagggatccc accacgagca atcggtaaata 180
 aggtctggac actcaggttc ccatcacagc cacaccacat cccaggggaag gtctgatgcc 240

filaggrin Sequence listing.ST25

```

tcccatgggc agtcaggatc cagaagtgc agcagacaaa cacgaaatga ggaacaatca    300
ggagacggca ccaggcactc agggtcacgt catcatgaag cttcctctca ggctgacagc    360
tctagacact cacaggtggg ccagggacaa tcatcggggc ccaggacaag taggaaccag    420
ggatccagtg ttagccagga cagtgcagct cagggacact cagaagactc tgagaggtgg    480
tctgggtctg cttccagaaa ccatcatgga tctgctcagg agcagtcaag agatggctcc    540
agacacccca ggtcccatca cgaagacaga gctggtcatg ggcaactctgc agacagctcc    600
agaaaatcag gcaactcgtca cacacagaat tcctctagtg gacaggctgc gtcatcccat    660
gaacaggcaa gatcaagtgc aggagaaaga catggatccc gccaccagct ccagtcagca    720
gacagctcca gacactcagg cactgggcac ggacaagctt catctgcagt cagagacagt    780
ggacaccgag ggtccagtgg tagtcaggcc actgacagtg agggacattc agaagactca    840
gacacacagt cagtgtcagg ccatggacag gctgggtcacc atcagcagag ccaccaagag    900
tccgcacgtg accggtcagg ggaaaggtct cgacgttcag ggtctttcct ctaccaggtg    960
agcactcata aacag                                         975

```

<210> 552

<211> 325

<212> PRT

<213> Human Profilaggrin Repeat 1 R501X C>T

<220>

<221> MISC_FEATURE

<222> (1)..(325)

<223> X = STOP

<400> 552

```

Pro Asp Ser Ala His Gly Arg Thr Gly Thr Ser Thr Gly Gly Arg Gln
1           5           10          15

```

```

Gly Ser His His Glu Gln Ala Xaa Asp Ser Ser Arg His Ser Ala Ser
          20          25          30

```

```

Gln Glu Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser Arg Gly
          35          40          45

```

```

Gly Arg Gln Gly Ser His His Glu Gln Ser Val Asn Arg Ser Gly His
          50          55          60

```

```

Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala
65          70          75          80

```


filaggrin Sequence listing.ST25

Ser His Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Gln Thr Arg Asn
 85 90 95
 Glu Glu Gln Ser Gly Asp Gly Thr Arg His Ser Gly Ser Arg His His
 100 105 110
 Glu Ala Ser Ser Gln Ala Asp Ser Ser Arg His Ser Gln Val Gly Gln
 115 120 125
 Gly Gln Ser Ser Gly Pro Arg Thr Ser Arg Asn Gln Gly Ser Ser Val
 130 135 140
 Ser Gln Asp Ser Asp Ser Gln Gly His Ser Glu Asp Ser Glu Arg Trp
 145 150 155 160
 Ser Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu Gln Ser
 165 170 175
 Arg Asp Gly Ser Arg His Pro Arg Ser His His Glu Asp Arg Ala Gly
 180 185 190
 His Gly His Ser Ala Asp Ser Ser Arg Lys Ser Gly Thr Arg His Thr
 195 200 205
 Gln Asn Ser Ser Ser Gly Gln Ala Ala Ser Ser His Glu Gln Ala Arg
 210 215 220
 Ser Ser Ala Gly Glu Arg His Gly Ser Arg His Gln Leu Gln Ser Ala
 225 230 235 240
 Asp Ser Ser Arg His Ser Gly Thr Gly His Gly Gln Ala Ser Ser Ala
 245 250 255
 Val Arg Asp Ser Gly His Arg Gly Ser Ser Gly Ser Gln Ala Thr Asp
 260 265 270
 Ser Glu Gly His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Gly His
 275 280 285
 Gly Gln Ala Gly His His Gln Gln Ser His Gln Glu Ser Ala Arg Asp
 290 295 300
 Arg Ser Gly Glu Arg Ser Arg Arg Ser Gly Ser Phe Leu Tyr Gln Val
 305 310 315 320
 Ser Thr His Lys Gln
 325

<210> 553

filaggrin Sequence listing.ST25

<211> 5251

<212> DNA

<213> Homo sapiens

<400> 553

```

aggacaagca ggaaccgggg atccagtttt agccaggaca gtgacagtca gggacactca      60
gaagactctg agaggtgggtc tgggtctgct tccagaaacc atcatggatc tgctcaggag    120
cagctaagag atgggtccag acaccccagg tcccatcaag aagacagagc tgggtcatggg    180
cactctgcag acagctccag acaatcaggc actcgtcaca cacagacttc ctctgggtgga    240
caggctgcat catcccatga acaggcaaga tcaagtgcag gagaaagaca tggatcccac    300
caccagcagt cagcagacag ctccagacac tcaggcattg ggcacggaca agcttcatct    360
gcagtcagag acagtggaca ccgaggggtac agtggttagtc aggccagtga caatgagggg    420
cattcagaag actcagacac acagtcagtg tcagcccacg gacaggctgg gtcccatcag    480
cagagccacc aagagtccgc acgtggccgg tcaggggaaa cgtctggaca ttcaggggtct    540
ttcctctacc aggtgagcac tcatgaacag tctgagtcct cccatggatg gacggggccc    600
agcactagag gaagacaagg atcccgccat gagcaggcac aagacagctc caggcactca    660
gcatcccaag acggtcagga caccattcgt ggacacccgg ggtcaagcag aggaggaagg    720
caggggtacc accacgagca ttcggtagat agctctggac actcagggtc ccatcacagc    780
cacaccacat cccagggaag gtctgatgcc tcccgtgggc agtcaggatc cagacgtgca    840
agcagaacaa cacgtaatga ggaacaatca ggagacggct ccaggcactc agggctcgcgt    900
caccatgaag cttccactca tgccgacatc tctagacact cacaggcagt ccagggacaa    960
tcagaggggt ccaggagaag caggcgccag ggatccagtg ttagccagga cagtgcagct   1020
gaggggacatt cagaagactc tgagaggtgg tctgggtctg cttccagaaa ccatcatgga   1080
tctgctcagg agcagctaag agatgggtcc agacacccca ggtcccatca agaaggcaga   1140
gctggtcatg ggcactctgc agacagctcc agacaatcag gcactcgtca cacacagact   1200
tcctctggtg gacaggctgc atcatcycat gaacaggcaa gatcaagtgc aggagaaaga   1260
catggatccc accaccagca gtcagcagac agtccagac actcaggcat tgggcacgga   1320
caagcttcat ctgcagtcag agacagtggg caccgagggg acagtggtag tcaggccagt   1380
gacaatgagg gacattcaga agactcagac acacagtcag tgtcagccca cggacaggct   1440
gggtcccatc agcagagcca ccaagagtcc gcacgtggcc ggtcagggga aacgtctgga   1500
cattcaggat ctttctctta ccagggtgagc actcatgaac agtctgagtc ctcccatgga   1560
tggtacggggc ccagcactag aggaagacaa ggatcccgcc atgagcaggc acaagacagc   1620
tccaggcact cagcatccca agatgggtcag gacaccattc gtggacaccc ggggtcaagc   1680
agaggaggaa ggcaggggta ccaccacgag cattcggtag atagctctgg acactcaggg   1740
tcccatcaca gccacaccac atcccaggga aggtctgatg cctcccgtgg gcagtcagga   1800

```

filaggrin Sequence listing.ST25

tccagaagtg	caagcagaac	aacacgtaat	gaggaacaat	caggagacgg	ctccaggcac	1860
tcagggctgc	gtcaccatga	agcttccact	catgccgaca	tctctagaca	ctcacaggca	1920
gtccagggac	aatcagaggg	gtccaggaga	agcaggcgcc	agggatccag	tgttagccag	1980
gacagtgaca	gtgagggaca	ttcagaagac	tctgagaggt	ggtctgggtc	tgcttccaga	2040
aaccatcatg	gatctgctca	ggagcagcta	agagatggct	ccagacaccc	caggtcccat	2100
caagaagaca	gagctgggtca	tgggcactct	gcagacagct	ccagacaatc	aggcactcgt	2160
cacacacagg	cttcctctgg	tggacaggct	gcatcatccc	atgaacaggc	aagatcaagt	2220
gcaggagaaa	gacatggatc	ccaccaccag	cagtcagcag	acagctccag	acactcaggc	2280
attgggcacg	gacaagcttc	atctgcagtc	agagacagtg	gacaccgagg	gtacagtggg	2340
agtcaggcca	gtgacaatga	gggacattca	gaagactcag	acacacagtc	agtgtcagcc	2400
cacggacagg	ctgggtccca	tcagcagagc	caccaagagt	ccgcacgtgg	ccggtcaggg	2460
gaaacgtctg	gacattcagg	atctttcctc	taccagggtga	gcactcatga	acagtctgag	2520
tcctcccatg	gatggacggg	gcccagcact	agaggaagac	aaggatcccc	ccatgagcag	2580
gcacaagaca	gctccaggca	ctcagcatcc	caagacgggtc	aggacacccat	tcgtggacac	2640
ccgggggtcaa	gcagaggagg	aaggcagggg	taccaccacg	agcattcggg	agatagctct	2700
ggacactcag	gggtcccatca	cagccacacc	acatcccagg	gaagggtctga	tgcctcccgt	2760
gggcagtcag	gatccagaag	tgcaagcaga	acaacacgta	atgaggaaca	atcaggagac	2820
agctccaggc	actcaggggtc	gcgtcaccat	gaagcttcca	ctcatgccga	catctctaga	2880
cactcacagg	cagtcagggtg	acaatcagag	gggtccagga	gaagcaggcg	ccagggatcc	2940
agtgttagcc	aggacagtga	cagtgaggga	cattcagaag	actctgagag	gtgggtctggg	3000
tctgcttcca	gaaaccatcg	tggatctggt	caggagcagt	caaggcacgg	ctccagacac	3060
cccagggtccc	atcacgaaga	cagagccggg	cacgggcact	ctgcagaccg	ctccagacaa	3120
tcaggcactc	gtcacgcaga	gacttcctct	ggtggacagg	ctgcatcatc	ccatgaacag	3180
gcaagatcaa	gtccaggaga	gagacacgga	tcccgccacc	agcagtcagc	agacagctcc	3240
agacactcag	gcattccgcg	tggacagggt	tcatctgcag	tcagagacag	tagacactgg	3300
gggtccagtg	gtagtcaagc	cagtgatagt	gagggacatt	cagaagagtc	agacacacag	3360
tcagtgtcag	gccatggaca	ggctggggccc	catcagcaga	gccaccaaga	gtccgcacgt	3420
gaccgggtcag	ggggaagggtc	tggacgttca	gggtctttcc	tctaccagggt	gagcactcat	3480
gaacagtctg	agtccgcccc	tgggcggacc	aggaccagca	ctggacgaag	acaaggatcc	3540
caccacgagc	aggcacgaga	cagctccagg	cactcagcgt	cccaagaggg	tcaggacacc	3600
attcgtgcac	acccgggggtc	aagcagaaga	ggaaggcagg	gatcccacta	cgagcaatcg	3660
gtagataggt	ctggacactc	aggggtcccat	cacagccaca	ccacatccca	gggaagggtct	3720
gatgcctccc	gtgggcagtc	aggatccaga	agtgccagca	gacaaactcg	taacgacgaa	3780
caatcaggag	acgggtccag	gcactcatgg	tcgcatcacc	atgaagcttc	cactcaggcg	3840

filaggrin Sequence listing.ST25

```

gacagctcta gacactcaca gtccggccag ggacaatcag cggggcccag tacaagcagg 3900
aaccagggat ccagtgttag ccaggacagt gacagtcagg gacactcaga agactctgag 3960
aggtggtctg ggtctgcttc cagaaaccat catggatctg ctggggagca gtcaagagat 4020
ggctccagac accctgggtc ccatcaagaa gacagagccg gtcacgggca ctctgcagac 4080
agccccagac aatcaggcac tcgtcacaca gagtcttctt ctcgtggaca ggctgcgtca 4140
tcccatgaac aggcaagatc aagtgcagga gaaagacatg gatccccacca ccagctccag 4200
tcagcagaca gctccagaca cgcaggcatt gggcacggac aagcttcatc tgcagtcaga 4260
gacagtggac accgagggta cagtggtagt caggccactg acagtgaggg acattcagaa 4320
gactcagaca cacagtcagt gtcagcacag ggaaaagctg ggccccatca gcagagccac 4380
aaagagtccg cacgtggcca gtcaggggaa agctctagac gttcagggtc tttcctctac 4440
caggtgagca ctcatgaaca gtctgagtct gcccatggac gggctgggccc cagtactgga 4500
ggaagacaag gatccccacca cgagcaggca cgagacagct ccaggcactc agcgtcccaa 4560
gagggtcagg acaccattcg tggacacccg gggtaagga gaggaggaag acagggatcc 4620
taccacgagc aatcggtaga taggtctgga cactcagggt cccatcacag ccacaccaca 4680
tcccagggaa ggtctgatgc ctcccatggg cagtcaggat ccagaagtgc aagcagagaa 4740
acacgtaatg aggaacagtc aggagacggc tccaggcact cagggtcgcg tcaccatgaa 4800
gcttccactc aggctgacag ctctagacac tcacagtccg gccaggggtga atcagcgggg 4860
tccaggagaa gcaggcgcca gggatccagt gttagccagg acagtgacag tgaggcatac 4920
ccagaggact ctgagaggcg atctgagtct gcttcagaa accatcatgg atcttctcgg 4980
gagcagtcaa gagatggctc cagacacccc ggatcctctc accgcgatac agccagtcat 5040
gtacagtctt cacctgtaca gtcagactct agtaccgcta aggaacatgg tcacttttagt 5100
agtctttcac aagattctgc gtatcactca ggaatacagt cacgtggcag tcctcacagt 5160
tctagttctt atcattatca atctgagggc actgaaaggc aaaaagggtca atcaggttta 5220
gtttggagac atggcagcta tggtagtgca g 5251

```

<210> 554

<211> 1750

<212> PRT

<213> Homo sapiens

<400> 554

Arg Thr Ser Arg Asn Arg Gly Ser Ser Phe Ser Gln Asp Ser Asp Ser
 1 5 10 15

Gln Gly His Ser Glu Asp Ser Glu Arg Trp Ser Gly Ser Ala Ser Arg
 20 25 30

filaggrin Sequence listing.ST25

Asn His His Gly Ser Ala Gln Glu Gln Leu Arg Asp Gly Ser Arg His
 35 40 45
 Pro Arg Ser His Gln Glu Asp Arg Ala Gly His Gly His Ser Ala Asp
 50 55 60
 Ser Ser Arg Gln Ser Gly Thr Arg His Thr Gln Thr Ser Ser Gly Gly
 65 70 75 80
 Gln Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser Ala Gly Glu Arg
 85 90 95
 His Gly Ser His His Gln Gln Ser Ala Asp Ser Ser Arg His Ser Gly
 100 105 110
 Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp Ser Gly His Arg
 115 120 125
 Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu Gly His Ser Glu Asp
 130 135 140
 Ser Asp Thr Gln Ser Val Ser Ala His Gly Gln Ala Gly Ser His Gln
 145 150 155 160
 Gln Ser His Gln Glu Ser Ala Arg Gly Arg Ser Gly Glu Thr Ser Gly
 165 170 175
 His Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His Glu Gln Ser Glu
 180 185 190
 Ser Ser His Gly Trp Thr Gly Pro Ser Thr Arg Gly Arg Gln Gly Ser
 195 200 205
 Arg His Glu Gln Ala Gln Asp Ser Ser Arg His Ser Ala Ser Gln Asp
 210 215 220
 Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser Arg Gly Gly Arg
 225 230 235 240
 Gln Gly Tyr His His Glu His Ser Val Asp Ser Ser Gly His Ser Gly
 245 250 255
 Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser Arg
 260 265 270
 Gly Gln Ser Gly Ser Arg Arg Ala Ser Arg Thr Thr Arg Asn Glu Glu
 275 280 285
 Gln Ser Gly Asp Gly Ser Arg His Ser Gly Ser Arg His His Glu Ala
 290 295 300

filaggrin Sequence listing.ST25

Ser Thr His Ala Asp Ile Ser Arg His Ser Gln Ala Val Gln Gly Gln
 305 310 315 320
 Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser Ser Val Ser Gln
 325 330 335
 Asp Ser Asp Ser Glu Gly His Ser Glu Asp Ser Glu Arg Trp Ser Gly
 340 345 350
 Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu Gln Leu Arg Asp
 355 360 365
 Gly Ser Arg His Pro Arg Ser His Gln Glu Gly Arg Ala Gly His Gly
 370 375 380
 His Ser Ala Asp Ser Ser Arg Gln Ser Gly Thr Arg His Thr Gln Thr
 385 390 395 400
 Ser Ser Gly Gly Gln Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser
 405 410 415
 Ala Gly Glu Arg His Gly Ser His His Gln Gln Ser Ala Asp Ser Ser
 420 425 430
 Arg His Ser Gly Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp
 435 440 445
 Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu Gly
 450 455 460
 His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala His Gly Gln Ala
 465 470 475 480
 Gly Ser His Gln Gln Ser His Gln Glu Ser Ala Arg Gly Arg Ser Gly
 485 490 495
 Glu Thr Ser Gly His Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His
 500 505 510
 Glu Gln Ser Glu Ser Ser His Gly Trp Thr Gly Pro Ser Thr Arg Gly
 515 520 525
 Arg Gln Gly Ser Arg His Glu Gln Ala Gln Asp Ser Ser Arg His Ser
 530 535 540
 Ala Ser Gln Asp Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser
 545 550 555 560
 Arg Gly Gly Arg Gln Gly Tyr His His Glu His Ser Val Asp Ser Ser
 565 570 575

filaggrin Sequence listing.ST25

Gly His Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser
 580 585 590
 Asp Ala Ser Arg Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Thr Thr
 595 600 605
 Arg Asn Glu Glu Gln Ser Gly Asp Gly Ser Arg His Ser Gly Ser Arg
 610 615 620
 His His Glu Ala Ser Thr His Ala Asp Ile Ser Arg His Ser Gln Ala
 625 630 635 640
 Val Gln Gly Gln Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser
 645 650 655
 Ser Val Ser Gln Asp Ser Asp Ser Glu Gly His Ser Glu Asp Ser Glu
 660 665 670
 Arg Trp Ser Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu
 675 680 685
 Gln Leu Arg Asp Gly Ser Arg His Pro Arg Ser His Gln Glu Asp Arg
 690 695 700
 Ala Gly His Gly His Ser Ala Asp Ser Ser Arg Gln Ser Gly Thr Arg
 705 710 715 720
 His Thr Gln Ala Ser Ser Gly Gly Gln Ala Ala Ser Ser His Glu Gln
 725 730 735
 Ala Arg Ser Ser Ala Gly Glu Arg His Gly Ser His His Gln Gln Ser
 740 745 750
 Ala Asp Ser Ser Arg His Ser Gly Ile Gly His Gly Gln Ala Ser Ser
 755 760 765
 Ala Val Arg Asp Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser
 770 775 780
 Asp Asn Glu Gly His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala
 785 790 795 800
 His Gly Gln Ala Gly Ser His Gln Gln Ser His Gln Glu Ser Ala Arg
 805 810 815
 Gly Arg Ser Gly Glu Thr Ser Gly His Ser Gly Ser Phe Leu Tyr Gln
 820 825 830
 Val Ser Thr His Glu Gln Ser Glu Ser Ser His Gly Trp Thr Gly Pro
 835 840 845

filaggrin Sequence listing.ST25

Ser Thr Arg Gly Arg Gln Gly Ser Arg His Glu Gln Ala Gln Asp Ser
 850 855 860
 Ser Arg His Ser Ala Ser Gln Asp Gly Gln Asp Thr Ile Arg Gly His
 865 870 875 880
 Pro Gly Ser Ser Arg Gly Gly Arg Gln Gly Tyr His His Glu His Ser
 885 890 895
 Val Asp Ser Ser Gly His Ser Gly Ser His His Ser His Thr Thr Ser
 900 905 910
 Gln Gly Arg Ser Asp Ala Ser Arg Gly Gln Ser Gly Ser Arg Ser Ala
 915 920 925
 Ser Arg Thr Thr Arg Asn Glu Glu Gln Ser Gly Asp Ser Ser Arg His
 930 935 940
 Ser Gly Ser Arg His His Glu Ala Ser Thr His Ala Asp Ile Ser Arg
 945 950 955 960
 His Ser Gln Ala Val Gln Gly Gln Ser Glu Gly Ser Arg Arg Ser Arg
 965 970 975
 Arg Gln Gly Ser Ser Val Ser Gln Asp Ser Asp Ser Glu Gly His Ser
 980 985 990
 Glu Asp Ser Glu Arg Trp Ser Gly Ser Ala Ser Arg Asn His Arg Gly
 995 1000 1005
 Ser Val Gln Glu Gln Ser Arg His Gly Ser Arg His Pro Arg Ser
 1010 1015 1020
 His His Glu Asp Arg Ala Gly His Gly His Ser Ala Asp Arg Ser
 1025 1030 1035
 Arg Gln Ser Gly Thr Arg His Ala Glu Thr Ser Ser Gly Gly Gln
 1040 1045 1050
 Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser Pro Gly Glu Arg
 1055 1060 1065
 His Gly Ser Arg His Gln Gln Ser Ala Asp Ser Ser Arg His Ser
 1070 1075 1080
 Gly Ile Pro Arg Gly Gln Ala Ser Ser Ala Val Arg Asp Ser Arg
 1085 1090 1095
 His Trp Gly Ser Ser Gly Ser Gln Ala Ser Asp Ser Glu Gly His
 1100 1105 1110

filaggrin Sequence listing.ST25

Ser Glu Glu Ser Asp Thr Gln Ser Val Ser Gly His Gly Gln Ala
 1115 1120 1125
 Gly Pro His Gln Gln Ser His Gln Glu Ser Ala Arg Asp Arg Ser
 1130 1135 1140
 Gly Gly Arg Ser Gly Arg Ser Gly Ser Phe Leu Tyr Gln Val Ser
 1145 1150 1155
 Thr His Glu Gln Ser Glu Ser Ala His Gly Arg Thr Arg Thr Ser
 1160 1165 1170
 Thr Gly Arg Arg Gln Gly Ser His His Glu Gln Ala Arg Asp Ser
 1175 1180 1185
 Ser Arg His Ser Ala Ser Gln Glu Gly Gln Asp Thr Ile Arg Ala
 1190 1195 1200
 His Pro Gly Ser Ser Arg Arg Gly Arg Gln Gly Ser His Tyr Glu
 1205 1210 1215
 Gln Ser Val Asp Arg Ser Gly His Ser Gly Ser His His Ser His
 1220 1225 1230
 Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser Arg Gly Gln Ser Gly
 1235 1240 1245
 Ser Arg Ser Ala Ser Arg Gln Thr Arg Asn Asp Glu Gln Ser Gly
 1250 1255 1260
 Asp Gly Ser Arg His Ser Trp Ser His His His Glu Ala Ser Thr
 1265 1270 1275
 Gln Ala Asp Ser Ser Arg His Ser Gln Ser Gly Gln Gly Gln Ser
 1280 1285 1290
 Ala Gly Pro Ser Thr Ser Arg Asn Gln Gly Ser Ser Val Ser Gln
 1295 1300 1305
 Asp Ser Asp Ser Gln Gly His Ser Glu Asp Ser Glu Arg Trp Ser
 1310 1315 1320
 Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gly Glu Gln Ser
 1325 1330 1335
 Arg Asp Gly Ser Arg His Pro Gly Ser His Gln Glu Asp Arg Ala
 1340 1345 1350
 Gly His Gly His Ser Ala Asp Ser Pro Arg Gln Ser Gly Thr Arg
 1355 1360 1365

filaggrin Sequence listing.ST25

His Thr Glu Ser Ser Ser Arg Gly Gln Ala Ala Ser Ser His Glu
 1370 1375 1380
 Gln Ala Arg Ser Ser Ala Gly Glu Arg His Gly Ser His His Gln
 1385 1390 1395
 Leu Gln Ser Ala Asp Ser Ser Arg His Ala Gly Ile Gly His Gly
 1400 1405 1410
 Gln Ala Ser Ser Ala Val Arg Asp Ser Gly His Arg Gly Tyr Ser
 1415 1420 1425
 Gly Ser Gln Ala Thr Asp Ser Glu Gly His Ser Glu Asp Ser Asp
 1430 1435 1440
 Thr Gln Ser Val Ser Ala Gln Gly Lys Ala Gly Pro His Gln Gln
 1445 1450 1455
 Ser His Lys Glu Ser Ala Arg Gly Gln Ser Gly Glu Ser Ser Arg
 1460 1465 1470
 Arg Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His Glu Gln Ser
 1475 1480 1485
 Glu Ser Ala His Gly Arg Ala Gly Pro Ser Thr Gly Gly Arg Gln
 1490 1495 1500
 Gly Ser His His Glu Gln Ala Arg Asp Ser Ser Arg His Ser Ala
 1505 1510 1515
 Ser Gln Glu Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Arg
 1520 1525 1530
 Arg Gly Gly Arg Gln Gly Ser Tyr His Glu Gln Ser Val Asp Arg
 1535 1540 1545
 Ser Gly His Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly
 1550 1555 1560
 Arg Ser Asp Ala Ser His Gly Gln Ser Gly Ser Arg Ser Ala Ser
 1565 1570 1575
 Arg Glu Thr Arg Asn Glu Glu Gln Ser Gly Asp Gly Ser Arg His
 1580 1585 1590
 Ser Gly Ser Arg His His Glu Ala Ser Thr Gln Ala Asp Ser Ser
 1595 1600 1605
 Arg His Ser Gln Ser Gly Gln Gly Glu Ser Ala Gly Ser Arg Arg
 1610 1615 1620

filaggrin Sequence listing.ST25

Ser Arg Arg Gln Gly Ser Ser Val Ser Gln Asp Ser Asp Ser Glu
 1625 1630 1635
 Ala Tyr Pro Glu Asp Ser Glu Arg Arg Ser Glu Ser Ala Ser Arg
 1640 1645 1650
 Asn His His Gly Ser Ser Arg Glu Gln Ser Arg Asp Gly Ser Arg
 1655 1660 1665
 His Pro Gly Ser Ser His Arg Asp Thr Ala Ser His Val Gln Ser
 1670 1675 1680
 Ser Pro Val Gln Ser Asp Ser Ser Thr Ala Lys Glu His Gly His
 1685 1690 1695
 Phe Ser Ser Leu Ser Gln Asp Ser Ala Tyr His Ser Gly Ile Gln
 1700 1705 1710
 Ser Arg Gly Ser Pro His Ser Ser Ser Ser Tyr His Tyr Gln Ser
 1715 1720 1725
 Glu Gly Thr Glu Arg Gln Lys Gly Gln Ser Gly Leu Val Trp Arg
 1730 1735 1740
 His Gly Ser Tyr Gly Ser Ala
 1745 1750

<210> 555

<211> 5251

<212> DNA

<213> Homo sapiens

<400> 555

```

aggacaagca ggaaccgggg atccagtttt agccaggaca gtgacagtca gggacactca      60
gaagactctg agaggtggtc tgggtctgct tccagaaacc atcatggatc tgctcaggag      120
cagctaagag atggctccag acaccccagg tcccatcaag aagacagagc tggatcatggg      180
cactctgcag acagctccag acaatcaggc actcgtcaca cacagacttc ctctggtgga      240
caggctgcat catcccatga acaggcaaga tcaagtgcag gagaaagaca tggatcccac      300
caccagcagt cagcagacag ctccagacac tcaggcattg ggcacggaca agcttcatct      360
gcagtcagag acagtggaca ccgaggggtac agtggtagtc aggccagtga caatgagggg      420
cattcagaag actcagacac acagtcagtg tcagcccacg gacaggctgg gtcccatcag      480
cagagccacc aagagtccgc acgtggccgg tcaggggaaa cgtctggaca ttcagggtct      540
ttcctctacc aggtgagcac tcatgaacag tctgagtcct cccatggatg gacggggccc      600

```

filaggrin Sequence listing.ST25

agcactagag	gaagacaagg	atccccccat	gagcaggcac	aagacagctc	caggcactca	660
gcatcccaag	acgggtcagga	caccattcgt	ggacacccgg	ggtcaagcag	aggaggaagg	720
caggggtacc	accacgagca	ttcggtagat	agctctggac	actcagggtc	ccatcacagc	780
cacaccacat	cccaggaag	gtctgatgcc	tcccgtgggc	agtcaggatc	cagacgtgca	840
agcagaacaa	cacgtaatga	ggaacaatca	ggagacggct	ccaggcactc	agggtcgcgt	900
caccatgaag	cttccactca	tgccgacatc	tctagacact	cacaggcagt	ccagggacaa	960
tcagaggggt	ccaggagaag	caggcgccag	ggatccagt	ttagccagga	cagtgcagct	1020
gaggacatt	cagaagactc	tgagaggtgg	tctgggtctg	cttccagaaa	ccatcatgga	1080
tctgctcagg	agcagctaag	agatggctcc	agacacccca	gggtcccatca	agaaggcaga	1140
gctggctcatg	ggcactctgc	agacagctcc	agacaatcag	gcactcgtca	cacacagact	1200
tcctctggtg	gacaggctgc	atcatcycat	gaacaggcaa	gatcaagtgc	aggagaaaga	1260
catggatccc	accaccagca	gtcagcagac	agctccagac	actcaggcat	tgggcacgga	1320
caagcttcat	ctgcagtcag	agacagtggg	caccgagggg	acagtggtag	tcaggccagt	1380
gacaatgagg	gacattcaga	agactcagac	acacagtcag	tgtcagccca	cggacaggct	1440
gggtcccatc	agcagagcca	ccaagagtcc	gcacgtggcc	ggtcagggga	aacgtctgga	1500
cattcaggat	ctttcctcta	ccaggtgagc	actcatgaac	agtctgagtc	ctcccatgga	1560
tggacggggc	ccagcactag	aggaagacaa	ggatcccgc	atgagcaggc	acaagacagc	1620
tccaggcact	cagcatccca	agacggtcag	gacaccattc	gtggacaccc	gggggtcaagc	1680
agaggaggaa	ggcaggggta	ccaccacgag	cattcggtag	atagctctgg	acactcaggg	1740
tcccatcaca	gccacaccac	atcccaggga	aggtctgatg	cctcccgtgg	gcagtcagga	1800
tccagaagtg	caagcagaac	aacacgtaat	gaggaacaat	caggagacag	ctccaggcac	1860
tcagggctgc	gtcaccatga	agcttccact	catgccgaca	tctctagaca	ctcacaggca	1920
gtccagggac	aatcagaggg	gtccaggaga	agcaggcgcc	agggatccag	tgtagccag	1980
gacagtgcga	gtgagggaca	ttcagaagac	tctgagaggt	ggctctgggtc	tgcttccaga	2040
aaccatcgtg	gatctgttca	ggagcagtc	aggcacggct	ccagacaccc	cagggtcccat	2100
cacgaagaca	gagccggtca	cgggcactct	gcagaccgct	ccagacaatc	aggcactcgt	2160
cacgcagaga	cttcctctgg	tggacaggct	gcacatccc	atgaacaggc	aagatcaagt	2220
ccaggagaga	gacacggatc	ccgccaccag	cagtcagcag	acagctccag	acactcaggg	2280
attccgcgtg	gacaggcttc	atctgcagtc	agagacagta	gacactgggg	gtccagtggg	2340
agtcaagcca	gtgatagtga	gggacattca	gaagagtcag	acacacagtc	agtgtcaggc	2400
catggacagg	ctggggccca	tcagcagagc	caccaagagt	ccgcacgtga	ccgggtcaggg	2460
ggaaggtctg	gacgttcagg	gtctttcctc	taccaggtga	gcactcatga	acagtctgag	2520
tccgcccattg	ggcggaccag	gaccagcact	ggacgaagac	aaggatccca	ccacgagcag	2580
gcacgagaca	gctccaggca	ctcagcgtcc	caagaggggtc	aggacaccat	tcgtgcacac	2640

filaggrin Sequence Listing.ST25

ccgggggtcaa	gcagaagagg	aaggcagggg	tcccactacg	agcaatcggg	agataggtct	2700
ggacactcag	gggtcccatca	cagccacacc	acatcccagg	gaagggtctga	tgccctcccg	2760
gggcagtcag	gatccagaag	tgccagcaga	caaactcgta	acgacgaaca	atcaggagac	2820
ggctccaggc	actcatgggtc	gcataccat	gaagcttcca	ctcaggcgga	cagctctaga	2880
cactcacagt	ccggccagg	acaatcagcg	gggccagta	caagcaggaa	ccagggatcc	2940
agtgttagcc	aggacagtga	cagtcagggg	cactcagaag	actctgagag	gtgggtctggg	3000
tctgtctcca	gaaacatca	tggatctgct	ggggagcagt	caagagatgg	ctccagacac	3060
cctgggtccc	atcaagaaga	cagagccggg	cacgggcact	ctgcagacag	ccccagacaa	3120
tcaggcactc	gtcacacaga	gtcttcctct	cgtggacagg	ctgcgtcatc	ccatgaacag	3180
gcaagatcaa	gtgcaggaga	aagacatgga	tcccaccacc	agctccagtc	agcagacagc	3240
tccagacacg	caggcattgg	gcacggacaa	gcttcattctg	cagtcagaga	cagtggacac	3300
cgaggggtaca	gtggtagtca	ggccactgac	agtgagggac	attcagaaga	ctcagacaca	3360
cagtcagtgt	cagcacagg	aaaagctggg	ccccatcagc	agagccacaa	agagtccgca	3420
cgtggccagt	caggggaaag	ctctagacgt	tcagggtctt	tcctctacca	ggtgagcact	3480
catgaacagt	ctgagtccac	ccatggacag	tctgtgcccc	gcactggagg	aagacaagga	3540
tcccaccatg	atcaggcaca	agacagctcc	aggcactcag	catcccaaga	gggtcaggac	3600
accattcgtg	gacacccggg	gccaagcaga	ggaggaagac	aggggtccca	ccacgagcaa	3660
tcggtagata	ggtctggaca	ctcagggtcc	catcacagcc	acaccacatc	ccaggggaagg	3720
tctgatgcct	cccgtgggca	gtcaggaccc	agaagtgcaa	gcagacaaac	acatgacaag	3780
gaacaatcag	gagacgggtc	taggcactca	gggtcgcgtc	atcatgaagc	ttcctcttgg	3840
gccgacagct	ctagacactc	acaggcagtc	cagggacaat	cagaggggtc	caggagaagc	3900
aggcgccagg	gatccagtgt	tagccaggac	agtgacagtc	agggacactc	agaagactct	3960
gagaggcggt	ctgggtctgc	ttccagaaac	catcgtggat	ctgctcagga	gcagtcaaga	4020
gatgggtcca	gacaccccag	gtcccatcac	gaagacagag	ccggtcatgg	gcactctgca	4080
gacagctcca	gacaatcagg	cactcatcat	gcagagaatt	cctctggtgg	acagcctgca	4140
tcattcccatg	aacaggcaag	atcaagtgca	ggagagagac	atggatccca	ccaccagcag	4200
tcagcagaca	gctccagaca	ctcaggcatt	gggcacggac	aagcttcata	tgcaagtcaga	4260
gacagtggac	accgaggggtc	cagtggtagt	caggccagtg	acagtgaggg	acattcagaa	4320
gactcagaca	cacagtcaat	gtcagcccac	ggacaggctg	ggccccatca	gcagagccac	4380
caagagtcca	cacgtggccg	gtcagcagga	aggtctggac	gttcaggggtc	tttctcttac	4440
cagggtgagca	ctcatgaaca	gtctgagtct	gcccatggac	gggctggggc	cagtactgga	4500
ggaagacaag	gatcccacca	cgagcaggca	cgagacagct	ccaggcactc	agcgtcccaa	4560
gaggggtcagg	acaccattcg	tggacacccg	gggtcaagga	gaggaggaag	acagggatcc	4620
taccacgagc	aatcggtaga	taggtctgga	cactcagggt	cccatcacag	ccacaccaca	4680

filaggrin Sequence listing.ST25

```

tcccagggaa ggtctgatgc ctcccatggg cagtcaggat ccagaagtgc aagcagagaa 4740
acacgtaatg aggaacagtc aggagacggc tccaggcact cagggtcgcg tcaccatgaa 4800
gcttccactc aggtctgacag ctctagacac tcacagtccg gccaggggtga atcagcgggg 4860
tccaggagaa gcagggcgcca gggatccagt gttagccagg acagtgcag tgaggcatac 4920
ccagaggact ctgagaggcg atctgagtct gcttccagaa accatcatgg atcttctcgg 4980
gagcagtcaa gagatggctc cagacacccc ggatcctctc accgcgatac agccagtcac 5040
gtacagtctt cacctgtaca gtcagactct agtaccgcta aggaacatgg tcactttagt 5100
agtctttcac aagattctgc gtatcactca ggaatacagt cacgtggcag tcctcacagt 5160
tctagttctt atcattatca atctgagggc actgaaaggc aaaaagggtca atcaggttta 5220
gtttggagac atggcagcta tggtagtgca g 5251

```

<210> 556

<211> 1750

<212> PRT

<213> Homo sapiens

<400> 556

```

Arg Thr Ser Arg Asn Arg Gly Ser Ser Phe Ser Gln Asp Ser Asp Ser
1           5           10           15

```

```

Gln Gly His Ser Glu Asp Ser Glu Arg Trp Ser Gly Ser Ala Ser Arg
20           25           30

```

```

Asn His His Gly Ser Ala Gln Glu Gln Leu Arg Asp Gly Ser Arg His
35           40           45

```

```

Pro Arg Ser His Gln Glu Asp Arg Ala Gly His Gly His Ser Ala Asp
50           55           60

```

```

Ser Ser Arg Gln Ser Gly Thr Arg His Thr Gln Thr Ser Ser Gly Gly
65           70           75           80

```

```

Gln Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser Ala Gly Glu Arg
85           90           95

```

```

His Gly Ser His His Gln Gln Ser Ala Asp Ser Ser Arg His Ser Gly
100          105          110

```

```

Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp Ser Gly His Arg
115          120          125

```

```

Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu Gly His Ser Glu Asp
130          135          140

```

filaggrin sequence listing.ST25

Ser Asp Thr Gln Ser Val Ser Ala His Gly Gln Ala Gly Ser His Gln
 145 150 155 160
 Gln Ser His Gln Glu Ser Ala Arg Gly Arg Ser Gly Glu Thr Ser Gly
 165 170 175
 His Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His Glu Gln Ser Glu
 180 185 190
 Ser Ser His Gly Trp Thr Gly Pro Ser Thr Arg Gly Arg Gln Gly Ser
 195 200 205
 Arg His Glu Gln Ala Gln Asp Ser Ser Arg His Ser Ala Ser Gln Asp
 210 215 220
 Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser Arg Gly Gly Arg
 225 230 235 240
 Gln Gly Tyr His His Glu His Ser Val Asp Ser Ser Gly His Ser Gly
 245 250 255
 Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser Arg
 260 265 270
 Gly Gln Ser Gly Ser Arg Arg Ala Ser Arg Thr Thr Arg Asn Glu Glu
 275 280 285
 Gln Ser Gly Asp Gly Ser Arg His Ser Gly Ser Arg His His Glu Ala
 290 295 300
 Ser Thr His Ala Asp Ile Ser Arg His Ser Gln Ala Val Gln Gly Gln
 305 310 315 320
 Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser Ser Val Ser Gln
 325 330 335
 Asp Ser Asp Ser Glu Gly His Ser Glu Asp Ser Glu Arg Trp Ser Gly
 340 345 350
 Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu Gln Leu Arg Asp
 355 360 365
 Gly Ser Arg His Pro Arg Ser His Gln Glu Gly Arg Ala Gly His Gly
 370 375 380
 His Ser Ala Asp Ser Ser Arg Gln Ser Gly Thr Arg His Thr Gln Thr
 385 390 395 400
 Ser Ser Gly Gly Gln Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser
 405 410 415

filaggrin Sequence listing.ST25

Ala Gly Glu Arg His Gly Ser His His Gln Gln Ser Ala Asp Ser Ser
 420 425 430
 Arg His Ser Gly Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp
 435 440 445
 Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu Gly
 450 455 460
 His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala His Gly Gln Ala
 465 470 475 480
 Gly Ser His Gln Gln Ser His Gln Glu Ser Ala Arg Gly Arg Ser Gly
 485 490 495
 Glu Thr Ser Gly His Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His
 500 505 510
 Glu Gln Ser Glu Ser Ser His Gly Trp Thr Gly Pro Ser Thr Arg Gly
 515 520 525
 Arg Gln Gly Ser Arg His Glu Gln Ala Gln Asp Ser Ser Arg His Ser
 530 535 540
 Ala Ser Gln Asp Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser
 545 550 555 560
 Arg Gly Gly Arg Gln Gly Tyr His His Glu His Ser Val Asp Ser Ser
 565 570 575
 Gly His Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser
 580 585 590
 Asp Ala Ser Arg Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Thr Thr
 595 600 605
 Arg Asn Glu Glu Gln Ser Gly Asp Ser Ser Arg His Ser Gly Ser Arg
 610 615 620
 His His Glu Ala Ser Thr His Ala Asp Ile Ser Arg His Ser Gln Ala
 625 630 635 640
 Val Gln Gly Gln Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser
 645 650 655
 Ser Val Ser Gln Asp Ser Asp Ser Glu Gly His Ser Glu Asp Ser Glu
 660 665 670
 Arg Trp Ser Gly Ser Ala Ser Arg Asn His Arg Gly Ser Val Gln Glu
 675 680 685

filaggrin Sequence listing.ST25

Gln Ser Arg His Gly Ser Arg His Pro Arg Ser His His Glu Asp Arg
 690 695 700
 Ala Gly His Gly His Ser Ala Asp Arg Ser Arg Gln Ser Gly Thr Arg
 705 710 715 720
 His Ala Glu Thr Ser Ser Gly Gly Gln Ala Ala Ser Ser His Glu Gln
 725 730 735
 Ala Arg Ser Ser Pro Gly Glu Arg His Gly Ser Arg His Gln Gln Ser
 740 745 750
 Ala Asp Ser Ser Arg His Ser Gly Ile Pro Arg Gly Gln Ala Ser Ser
 755 760 765
 Ala Val Arg Asp Ser Arg His Trp Gly Ser Ser Gly Ser Gln Ala Ser
 770 775 780
 Asp Ser Glu Gly His Ser Glu Glu Ser Asp Thr Gln Ser Val Ser Gly
 785 790 795 800
 His Gly Gln Ala Gly Pro His Gln Gln Ser His Gln Glu Ser Ala Arg
 805 810 815
 Asp Arg Ser Gly Gly Arg Ser Gly Arg Ser Gly Ser Phe Leu Tyr Gln
 820 825 830
 Val Ser Thr His Glu Gln Ser Glu Ser Ala His Gly Arg Thr Arg Thr
 835 840 845
 Ser Thr Gly Arg Arg Gln Gly Ser His His Glu Gln Ala Arg Asp Ser
 850 855 860
 Ser Arg His Ser Ala Ser Gln Glu Gly Gln Asp Thr Ile Arg Ala His
 865 870 875 880
 Pro Gly Ser Ser Arg Arg Gly Arg Gln Gly Ser His Tyr Glu Gln Ser
 885 890 895
 Val Asp Arg Ser Gly His Ser Gly Ser His His Ser His Thr Thr Ser
 900 905 910
 Gln Gly Arg Ser Asp Ala Ser Arg Gly Gln Ser Gly Ser Arg Ser Ala
 915 920 925
 Ser Arg Gln Thr Arg Asn Asp Glu Gln Ser Gly Asp Gly Ser Arg His
 930 935 940
 Ser Trp Ser His His His Glu Ala Ser Thr Gln Ala Asp Ser Ser Arg
 945 950 955 960

filaggrin Sequence listing.ST25

His Ser Gln Ser Gly Gln Gly Gln Ser Ala Gly Pro Ser Thr Ser Arg
 965 970 975

Asn Gln Gly Ser Ser Val Ser Gln Asp Ser Asp Ser Gln Gly His Ser
 980 985 990

Glu Asp Ser Glu Arg Trp Ser Gly Ser Ala Ser Arg Asn His His Gly
 995 1000 1005

Ser Ala Gly Glu Gln Ser Arg Asp Gly Ser Arg His Pro Gly Ser
 1010 1015 1020

His Gln Glu Asp Arg Ala Gly His Gly His Ser Ala Asp Ser Pro
 1025 1030 1035

Arg Gln Ser Gly Thr Arg His Thr Glu Ser Ser Ser Arg Gly Gln
 1040 1045 1050

Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser Ala Gly Glu Arg
 1055 1060 1065

His Gly Ser His His Gln Leu Gln Ser Ala Asp Ser Ser Arg His
 1070 1075 1080

Ala Gly Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp Ser
 1085 1090 1095

Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Thr Asp Ser Glu Gly
 1100 1105 1110

His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala Gln Gly Lys
 1115 1120 1125

Ala Gly Pro His Gln Gln Ser His Lys Glu Ser Ala Arg Gly Gln
 1130 1135 1140

Ser Gly Glu Ser Ser Arg Arg Ser Gly Ser Phe Leu Tyr Gln Val
 1145 1150 1155

Ser Thr His Glu Gln Ser Glu Ser Thr His Gly Gln Ser Val Pro
 1160 1165 1170

Ser Thr Gly Gly Arg Gln Gly Ser His His Asp Gln Ala Gln Asp
 1175 1180 1185

Ser Ser Arg His Ser Ala Ser Gln Glu Gly Gln Asp Thr Ile Arg
 1190 1195 1200

Gly His Pro Gly Pro Ser Arg Gly Gly Arg Gln Gly Ser His His
 1205 1210 1215

filaggrin Sequence listing.ST25

Glu Gln Ser Val Asp Arg Ser Gly His Ser Gly Ser His His Ser
 1220 1225 1230
 His Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser Arg Gly Gln Ser
 1235 1240 1245
 Gly Pro Arg Ser Ala Ser Arg Gln Thr His Asp Lys Glu Gln Ser
 1250 1255 1260
 Gly Asp Gly Ser Arg His Ser Gly Ser Arg His His Glu Ala Ser
 1265 1270 1275
 Ser Trp Ala Asp Ser Ser Arg His Ser Gln Ala Val Gln Gly Gln
 1280 1285 1290
 Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser Ser Val Ser
 1295 1300 1305
 Gln Asp Ser Asp Ser Gln Gly His Ser Glu Asp Ser Glu Arg Arg
 1310 1315 1320
 Ser Gly Ser Ala Ser Arg Asn His Arg Gly Ser Ala Gln Glu Gln
 1325 1330 1335
 Ser Arg Asp Gly Ser Arg His Pro Arg Ser His His Glu Asp Arg
 1340 1345 1350
 Ala Gly His Gly His Ser Ala Asp Ser Ser Arg Gln Ser Gly Thr
 1355 1360 1365
 His His Ala Glu Asn Ser Ser Gly Gly Gln Pro Ala Ser Ser His
 1370 1375 1380
 Glu Gln Ala Arg Ser Ser Ala Gly Glu Arg His Gly Ser His His
 1385 1390 1395
 Gln Gln Ser Ala Asp Ser Ser Arg His Ser Gly Ile Gly His Gly
 1400 1405 1410
 Gln Ala Ser Ser Ala Val Arg Asp Ser Gly His Arg Gly Ser Ser
 1415 1420 1425
 Gly Ser Gln Ala Ser Asp Ser Glu Gly His Ser Glu Asp Ser Asp
 1430 1435 1440
 Thr Gln Ser Val Ser Ala His Gly Gln Ala Gly Pro His Gln Gln
 1445 1450 1455
 Ser His Gln Glu Ser Thr Arg Gly Arg Ser Ala Gly Arg Ser Gly
 1460 1465 1470

filaggrin Sequence listing.ST25

Arg Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His Glu Gln Ser
 1475 1480 1485
 Glu Ser Ala His Gly Arg Ala Gly Pro Ser Thr Gly Gly Arg Gln
 1490 1495 1500
 Gly Ser His His Glu Gln Ala Arg Asp Ser Ser Arg His Ser Ala
 1505 1510 1515
 Ser Gln Glu Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Arg
 1520 1525 1530
 Arg Gly Gly Arg Gln Gly Ser Tyr His Glu Gln Ser Val Asp Arg
 1535 1540 1545
 Ser Gly His Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly
 1550 1555 1560
 Arg Ser Asp Ala Ser His Gly Gln Ser Gly Ser Arg Ser Ala Ser
 1565 1570 1575
 Arg Glu Thr Arg Asn Glu Glu Gln Ser Gly Asp Gly Ser Arg His
 1580 1585 1590
 Ser Gly Ser Arg His His Glu Ala Ser Thr Gln Ala Asp Ser Ser
 1595 1600 1605
 Arg His Ser Gln Ser Gly Gln Gly Glu Ser Ala Gly Ser Arg Arg
 1610 1615 1620
 Ser Arg Arg Gln Gly Ser Ser Val Ser Gln Asp Ser Asp Ser Glu
 1625 1630 1635
 Ala Tyr Pro Glu Asp Ser Glu Arg Arg Ser Glu Ser Ala Ser Arg
 1640 1645 1650
 Asn His His Gly Ser Ser Arg Glu Gln Ser Arg Asp Gly Ser Arg
 1655 1660 1665
 His Pro Gly Ser Ser His Arg Asp Thr Ala Ser His Val Gln Ser
 1670 1675 1680
 Ser Pro Val Gln Ser Asp Ser Ser Thr Ala Lys Glu His Gly His
 1685 1690 1695
 Phe Ser Ser Leu Ser Gln Asp Ser Ala Tyr His Ser Gly Ile Gln
 1700 1705 1710
 Ser Arg Gly Ser Pro His Ser Ser Ser Ser Tyr His Tyr Gln Ser
 1715 1720 1725

filaggrin Sequence listing.ST25

Glu Gly Thr Glu Arg Gln Lys Gly Gln Ser Gly Leu Val Trp Arg
 1730 1735 1740

His Gly Ser Tyr Gly Ser Ala
 1745 1750

<210> 557

<211> 6173

<212> DNA

<213> Homo sapiens

<400> 557

```

aggacaagca ggaaccgggg atccagtttt agccaggaca gtgacagtca gggacactca      60
gaagactctg agaggtgggtc tgggtctgct tccagaaacc atcatggatc tgctcaggag      120
cagctaagag atgggtccag acaccccgagg tcccatcaag aagacagagc tgggtcatggg      180
cactctgcag acagctccag acaatcaggc actcgtcaca cacagacttc ctctgggtgga      240
caggctgcat catcccatga acaggcaaga tcaagtgcag gagaaagaca tggatcccac      300
caccagcagt cagcagacag ctccagacac tcaggcattg ggcacggaca agcttcatct      360
gcagtcagag acagtggaca ccgaggggtac agtggtagtc aggccagtga caatgagggga      420
cattcagaag actcagacac acagtcaagt tcagcccacg gacaggctgg gtcccatcag      480
cagagccacc aagagtccgc acgtggccgg tcaggggaaa cgtctggaca ttcaggggtct      540
ttcctctacc aggtgagcac tcatgaacag tctgagtcct cccatggatg gacggggccc      600
agcactagag gaagacaagg atcccgccat gagcaggcac aagacagctc caggcactca      660
gcatcccaag acggtcagga caccattcgt ggacacccgg ggtcaagcag aggaggaagg      720
caggggtacc accacgagca ttcggtagat agctctggac actcaggggtc ccatcacagc      780
cacaccacat cccaggggaag gtctgatgcc tcccgtgggc agtcaggatc cagacgtgca      840
agcagaacaa cacgtaatga ggaacaatca ggagacggct ccaggcactc agggtcgcgt      900
caccatgaag cttccactca tgccgacatc tctagacact cacaggcagt ccagggacaa      960
tcagaggggt ccaggagaag caggcgccag ggatccagtg ttagccagga cagtgcagct      1020
gagggacatt cagaagactc tgagaggtgg tctgggtctg cttccagaaa ccatcatgga      1080
tctgctcagg agcagctaag agatggctcc agacacccca ggtcccatca agaaggcaga      1140
gctgggtcatg tcctctggtg gacaggctgc atcatcccat gaacaggcaa gatcaagtgc      1200
aggagaaaga catggatccc accaccagca gtcagcagac agctccagac actcaggcat      1260
tgggcacgga caagcttcat ctgcagtcag agacagtgga caccgagggg acagtggtag      1320
tcaggccagt gacaatgagg gacattcaga agactcagac acacagtcag tgtcagccca      1380
cggacagggt ggggtcccatc agcagagcca ccaagagtcc gcacgtggcc ggtcagggga      1440

```

filaggrin Sequence listing.ST25

aacgtctgga cattcaggat ctttctcta ccaggtgagc actcatgaac agtctgagtc 1500
 ctcccatgga tggacggggc ccagcactag aggaagacaa ggatcccgcc atgagcaggc 1560
 acaagacagc tccaggcact cagcatccca agatgggtcag gacaccattc gtggacaccc 1620
 ggggtcaagc agaggaggaa ggcaggggta ccaccacgag cattcggtag atagctctgg 1680
 aactcaggg tcccatcaca gccacaccac atcccaggga aggtctgatg cttcccgtgg 1740
 gcagtcagga tccagaagtg caagcagaac aacacgtaat gaggaacaat caggagacgg 1800
 ctccaggcac tcagggctgc gtcaccatga agcttccact catgccgaca tctctagaca 1860
 ctacaggca gtccaggga aatcagaggg gtccaggaga agcaggcgcc agggatccag 1920
 tgtagccag gacagtgaca gtgagggaca ttcagaagac tctgagaggt ggtctgggtc 1980
 tgcttcaga aaccatcatg gatctgctca ggagcagcta agagatggct ccagacaccc 2040
 caggtcccat caagaagaca gagctgggtca tgggcactct gcagacagct ccagacaatc 2100
 aggcactcgt cacacacagg cttcctctgg tggacaggct gcatcatccc atgaacaggc 2160
 aagatcaagt gcaggagaaa gacatggatc ccaccaccag cagtcagcag acagctccag 2220
 aactcaggc attgggcacg gacaagcttc atctgcagtc agagacagtg gacaccgagg 2280
 gtacagtgg agtcaggcca gtgacaatga gggacattca gaagactcag acacacagtc 2340
 agtgtcagcc cacggacagg ctgggtccca tcagcagagc caccaagagt ccgcacgtgg 2400
 ccggtcagg gaaacgtctg gacattcagg atctttcctc taccaggtga gcatcatga 2460
 acagtctgag tcctcccatg gatggacggg gccagcact agaggaagac aaggatcccg 2520
 ccatgagcag gcacaagaca gctccaggca ctcagcatcc caagacggtc aggacaccat 2580
 tcgtggacac ccgggggtcaa gcagaggagg aaggcagggg taccaccacg agcattcggg 2640
 agatagctct ggacactcag ggtcccatca cagccacacc acatcccagg gaaggtctga 2700
 tgctcccgt gggcagtcag gatccagaag tgcaagcaga acaacacgta atgaggaaca 2760
 atcaggagac agtccaggc actcagggtc gcgtcaccat gaagcttcca ctcatgccga 2820
 catctctaga cactcacagg cagtccaggg acaatcagag ggggtccagga gaagcaggcg 2880
 ccagggatcc agtggttagcc aggacagtga cagtgaggga cattcagaag actctgagag 2940
 gtgggtctggg tctgcttcca gaaaccatcg tggatctgtt caggagcagt caaggcacgg 3000
 ctccagacac cccagggtccc atcacgaaga cagagccggg cacgggcact ctgcagaccg 3060
 ctccagacaa tcaggcactc gtcacgcaga gacttctct ggtggacagg ctgcatcatc 3120
 ccatgaacag gcaagatcaa gtccaggaga gagacacgga tcccgccacc agcagtcagc 3180
 agacagctcc agacactcag gcattccgag tggacagggt tcatctgcag tcagagacag 3240
 tagacactgg ggggtccagt gtagtcaagc cagtgatagt gaggacatt cagaagagtc 3300
 agacacacag tcagtgtcag gccatggaca ggctggggcc catcagcaga gccaccaaga 3360
 gtccgcacgt gaccggtcag ggggaagggtc tggacgttca gggcttttcc tctaccagg 3420
 gagcactcat gaacagtctg agtccgccc tgggcggacc aggaccagca ctggacgaag 3480

filaggrin Sequence listing.ST25

acaaggatcc caccacgagc aggcacgaga cagctccagg cactcagcgt cccaagaggg	3540
tcaggacacc attcgtgcac acccgggggtc aagcagaaga ggaaggcagg gatcccacta	3600
cgagcaatcg gtagataggt ctggacactc aggggtcccat cacagccaca ccacatccca	3660
gggaagggtct gatgcctccc gtgggcagtc aggatccaga agtgccagca gacaaactcg	3720
taacgacgaa caatcaggag acggctccag gcactcatgg tcgcatcacc atgaagcttc	3780
cactcaggcg gacagctcta gacactcaca gtccggccag ggacaatcag cggggcccg	3840
tacaagcagg aaccagggat ccagtgttag ccaggacagt gacagtcagg gacactcaga	3900
agactctgag aggtggtctg ggtctgcttc cagaaacat catggatctg ctggggagca	3960
gtcaagagat ggctccagac accctgggtc ccatcaagaa gacagagccg gtcacgggca	4020
ctctgcagac agccccagac aatcaggcac tcgtcacaca gagtcttcct ctctgtggaca	4080
ggctgcgtca tcccatgaac aggcaagatc aagtgcagga gaaagacatg gatcccacca	4140
ccagctccag tcagcagaca gctccagaca cgcaggcatt gggcacggac aagcttcac	4200
tgcagtcaga gacagtggac accgagggtc cagtggtagt caggccactg acagtgaggg	4260
acattcagaa gactcagaca cacagtcagt gtcagcacag ggaaaagctg ggccccatca	4320
gcagagccac aaagagtccg cacgtggcca gtcaggggaa agctctagac gttcagggtc	4380
tttctctac cagggtgagca ctcatgaaca gtctgagtc acccatggac agtctgtgcc	4440
cagcactgga ggaagacaag gatcccacca tgatcaggca caagacagct ccaggcactc	4500
agcatcccaa gagggtcagg acaccattcg tggacacccg gggccaagca gaggaggaag	4560
acaggggtcc caccacgagc aatcggtaga taggtctgga cactcagggt cccatcacag	4620
ccacaccaca tcccaggga ggtctgatgc ctcccgtggg cagtcaggac ccagaagtgc	4680
aagcagacaa acacatgaca aggaacaatc aggagacggc tctaggcact cagggtcgcg	4740
tcacatgaa gcttctctt gggccgacag ctctagacac tcacaggcag tccagggaca	4800
atcagagggg tccaggagaa gcaggcgcca gggatccagt gttagccagg acagtgcag	4860
tcagggacac tcagaagact ctgagaggcg gtctgggtct gcttcagaa accatcgtgg	4920
atctgctcag gagcagtcaa gagatggctc cagacacccc aggtcccatc acgaagacag	4980
agccggtcat gggcactctg cagacagctc cagacaatca ggcactcatc atgcagagaa	5040
ttctctggt ggacagcctg catcatccca tgaacaggca agatcaagtg caggagagag	5100
acatggatcc caccaccagc agtcagcaga cagctccaga cactcaggca ttgggcacgg	5160
acaagcttca tctgcagtca gagacagtgg acaccgaggg tccagtggta gtcaggccag	5220
tgacagtgag ggacattcag aagactcaga cacacagtca gtgtcagccc acggacaggc	5280
tgggccccat cagcagagcc accaagagtc cacacgtggc cggtcagcag gaaggctctg	5340
acgttcaggg tctttctct accaggtgag cactcatgaa cagtctgagt ctgcccattg	5400
acgggctggg cccagtactg gaggaagaca aggatccac cagcagcagg cacgagacag	5460
ctccaggcac tcagcgtccc aagagggtca ggacaccatt cgtggacacc cgggggtcaag	5520

filaggrin Sequence listing.ST25

gagaggagga agacagggat cctaccacga gcaatcggta gataggtctg gacactcagg 5580
 gtcccatcac agccacacca catcccaggg aaggtctgat gcctcccatg ggcagtcagg 5640
 atccagaagt gcaagcagag aaacacgtaa tgaggaacag tcaggagacg gctccaggca 5700
 ctcaggggtcg cgtcaccatg aagcttccac tcaggctgac agctctagac actcacagtc 5760
 cggccaggggt gaatcagcgg ggtccaggag aagcaggcgc cagggatcca gtgttagcca 5820
 ggacagtgc agtgaggcat acccagagga ctctgagagg cgatctgagt ctgcttccag 5880
 aaaccatcat ggatcttctc gggagcagtc aagagatggc tccagacacc ccggatcctc 5940
 tcaccgcgat acagccagtc atgtacagtc ttcacctgta cagtcagact ctagtaccgc 6000
 taaggaacat ggtcacttta gtagtctttc acaagattct gcgtatcact caggaataca 6060
 gtcacgtggc agtcctcaca gttctagttc ttatcattat caatctgagg gcactgaaag 6120
 gcaaaaagggt caatcagggt tagtttggag acatggcagc tatggtagtg cag 6173

<210> 558

<211> 2074

<212> PRT

<213> Homo sapiens

<400> 558

Arg Thr Ser Arg Asn Arg Gly Ser Ser Phe Ser Gln Asp Ser Asp Ser
 1 5 10 15

Gln Gly His Ser Glu Asp Ser Gln Arg Trp Ser Gly Ser Ala Ser Arg
 20 25 30

Asn His His Gly Ser Ala Gln Glu Gln Leu Arg Asp Gly Ser Arg His
 35 40 45

Pro Arg Ser His Gln Glu Asp Arg Ala Gly His Gly His Ser Ala Asp
 50 55 60

Ser Ser Arg Gln Ser Gly Thr Arg His Thr Gln Thr Ser Ser Gly Gly
 65 70 75 80

Gln Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser Ala Gly Glu Arg
 85 90 95

His Gly Ser His His Gln Gln Ser Ala Asp Ser Ser Arg His Ser Gly
 100 105 110

Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp Ser Gly His Arg
 115 120 125

filaggrin Sequence listing.ST25

Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu Gly His Ser Glu Asp
 130 135 140
 Ser Asp Thr Gln Ser Val Ser Ala His Gly Gln Ala Gly Ser His Gln
 145 150 155 160
 Gln Ser His Gln Glu Ser Ala Arg Gly Arg Ser Gly Glu Thr Ser Gly
 165 170 175
 His Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His Glu Gln Ser Glu
 180 185 190
 Ser Ser His Gly Trp Thr Gly Pro Ser Thr Arg Gly Arg Gln Gly Ser
 195 200 205
 Arg His Glu Gln Ala Gln Asp Ser Ser Arg His Ser Ala Ser Gln Asp
 210 215 220
 Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser Arg Gly Gly Arg
 225 230 235 240
 Gln Gly Tyr His His Glu His Ser Val Asp Ser Ser Gly His Ser Gly
 245 250 255
 Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser Arg
 260 265 270
 Gly Gln Ser Gly Ser Arg Arg Ala Ser Arg Thr Thr Arg Asn Glu Glu
 275 280 285
 Gln Ser Gly Asp Gly Ser Arg His Ser Gly Ser Arg His His Glu Ala
 290 295 300
 Ser Thr His Ala Asp Ile Ser Arg His Ser Gln Ala Val Gln Gly Gln
 305 310 315 320
 Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser Ser Val Ser Gln
 325 330 335
 Asp Ser Asp Ser Glu Gly His Ser Glu Asp Ser Glu Arg Trp Ser Gly
 340 345 350
 Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu Gln Leu Arg Asp
 355 360 365
 Gly Ser Arg His Pro Arg Ser His Gln Glu Gly Arg Ala Gly His Gly
 370 375 380
 His Ser Ala Asp Ser Ser Arg Gln Ser Gly Thr Arg His Thr Gln Thr
 385 390 395 400

filaggrin Sequence listing.ST25

Ser Ser Gly Gly Gln Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser
 405 410 415
 Ala Gly Glu Arg His Gly Ser His His Gln Gln Ser Ala Asp Ser Ser
 420 425 430
 Arg His Ser Gly Ile Gly His Gly Gln Ala Ser Ser Ala Val Arg Asp
 435 440 445
 Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser Asp Asn Glu Gly
 450 455 460
 His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala His Gly Gln Ala
 465 470 475 480
 Gly Ser His Gln Gln Ser His Gln Glu Ser Ala Arg Gly Arg Ser Gly
 485 490 495
 Glu Thr Ser Gly His Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His
 500 505 510
 Glu Gln Ser Glu Ser Ser His Gly Trp Thr Gly Pro Ser Thr Arg Gly
 515 520 525
 Arg Gln Gly Ser Arg His Glu Gln Ala Gln Asp Ser Ser Arg His Ser
 530 535 540
 Ala Ser Gln Asp Gly Gln Asp Thr Ile Arg Gly His Pro Gly Ser Ser
 545 550 555 560
 Arg Gly Gly Arg Gln Gly Tyr His His Glu His Ser Val Asp Ser Ser
 565 570 575
 Gly His Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly Arg Ser
 580 585 590
 Asp Ala Ser Arg Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Thr Thr
 595 600 605
 Arg Asn Glu Glu Gln Ser Gly Asp Gly Ser Arg His Ser Gly Ser Arg
 610 615 620
 His His Glu Ala Ser Thr His Ala Asp Ile Ser Arg His Ser Gln Ala
 625 630 635 640
 Val Gln Gly Gln Ser Glu Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser
 645 650 655
 Ser Val Ser Gln Asp Ser Asp Ser Glu Gly His Ser Glu Asp Ser Glu
 660 665 670

filaggrin Sequence listing.ST25

Arg Trp Ser Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gln Glu
 675 680 685
 Gln Leu Arg Asp Gly Ser Arg His Pro Arg Ser His Gln Glu Asp Arg
 690 695 700
 Ala Gly His Gly His Ser Ala Asp Ser Ser Arg Gln Ser Gly Thr Arg
 705 710 715 720
 His Thr Gln Ala Ser Ser Gly Gly Gln Ala Ala Ser Ser His Glu Gln
 725 730 735
 Ala Arg Ser Ser Ala Gly Glu Arg His Gly Ser His His Gln Gln Ser
 740 745 750
 Ala Asp Ser Ser Arg His Ser Gly Ile Gly His Gly Gln Ala Ser Ser
 755 760 765
 Ala Val Arg Asp Ser Gly His Arg Gly Tyr Ser Gly Ser Gln Ala Ser
 770 775 780
 Asp Asn Glu Gly His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala
 785 790 795 800
 His Gly Gln Ala Gly Ser His Gln Gln Ser His Gln Glu Ser Ala Arg
 805 810 815
 Gly Arg Ser Gly Glu Thr Ser Gly His Ser Gly Ser Phe Leu Tyr Gln
 820 825 830
 Val Ser Thr His Glu Gln Ser Glu Ser Ser His Gly Trp Thr Gly Pro
 835 840 845
 Ser Thr Arg Gly Arg Gln Gly Ser Arg His Glu Gln Ala Gln Asp Ser
 850 855 860
 Ser Arg His Ser Ala Ser Gln Asp Gly Gln Asp Thr Ile Arg Gly His
 865 870 875 880
 Pro Gly Ser Ser Arg Gly Gly Arg Gln Gly Tyr His His Glu His Ser
 885 890 895
 Val Asp Ser Ser Gly His Ser Gly Ser His His Ser His Thr Thr Ser
 900 905 910
 Gln Gly Arg Ser Asp Ala Ser Arg Gly Gln Ser Gly Ser Arg Ser Ala
 915 920 925
 Ser Arg Thr Thr Arg Asn Glu Glu Gln Ser Gly Asp Ser Ser Arg His
 930 935 940

filaggrin sequence listing.ST25

Ser Gly Ser Arg His His Glu Ala Ser Thr His Ala Asp Ile Ser Arg
 945 950 955 960
 His Ser Gln Ala Val Gln Gly Gln Ser Glu Gly Ser Arg Arg Ser Arg
 965 970 975
 Arg Gln Gly Ser Ser Val Ser Gln Asp Ser Asp Ser Glu Gly His Ser
 980 985 990
 Glu Asp Ser Glu Arg Trp Ser Gly Ser Ala Ser Arg Asn His Arg Gly
 995 1000 1005
 Ser Val Gln Glu Gln Ser Arg His Gly Ser Arg His Pro Arg Ser
 1010 1015 1020
 His His Glu Asp Arg Ala Gly His Gly His Ser Ala Asp Arg Ser
 1025 1030 1035
 Arg Gln Ser Gly Thr Arg His Ala Glu Thr Ser Ser Gly Gly Gln
 1040 1045 1050
 Ala Ala Ser Ser His Glu Gln Ala Arg Ser Ser Pro Gly Glu Arg
 1055 1060 1065
 His Gly Ser Arg His Gln Gln Ser Ala Asp Ser Ser Arg His Ser
 1070 1075 1080
 Gly Ile Pro Arg Gly Gln Ala Ser Ser Ala Val Arg Asp Ser Arg
 1085 1090 1095
 His Trp Gly Ser Ser Gly Ser Gln Ala Ser Asp Ser Glu Gly His
 1100 1105 1110
 Ser Glu Glu Ser Asp Thr Gln Ser Val Ser Gly His Gly Gln Ala
 1115 1120 1125
 Gly Pro His Gln Gln Ser His Gln Glu Ser Ala Arg Asp Arg Ser
 1130 1135 1140
 Gly Gly Arg Ser Gly Arg Ser Gly Ser Phe Leu Tyr Gln Val Ser
 1145 1150 1155
 Thr His Glu Gln Ser Glu Ser Ala His Gly Arg Thr Arg Thr Ser
 1160 1165 1170
 Thr Gly Arg Arg Gln Gly Ser His His Glu Gln Ala Arg Asp Ser
 1175 1180 1185
 Ser Arg His Ser Ala Ser Gln Glu Gly Gln Asp Thr Ile Arg Ala
 1190 1195 1200

filaggrin Sequence listing.ST25

His Pro Gly Ser Ser Arg Arg Gly Arg Gln Gly Ser His Tyr Glu
 1205 1210 1215
 Gln Ser Val Asp Arg Ser Gly His Ser Gly Ser His His Ser His
 1220 1225 1230
 Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser Arg Gly Gln Ser Gly
 1235 1240 1245
 Ser Arg Ser Ala Ser Arg Gln Thr Arg Asn Asp Glu Gln Ser Gly
 1250 1255 1260
 Asp Gly Ser Arg His Ser Trp Ser His His His Glu Ala Ser Thr
 1265 1270 1275
 Gln Ala Asp Ser Ser Arg His Ser Gln Ser Gly Gln Gly Gln Ser
 1280 1285 1290
 Ala Gly Pro Ser Thr Ser Arg Asn Gln Gly Ser Ser Val Ser Gln
 1295 1300 1305
 Asp Ser Asp Ser Gln Gly His Ser Glu Asp Ser Glu Arg Trp Ser
 1310 1315 1320
 Gly Ser Ala Ser Arg Asn His His Gly Ser Ala Gly Glu Gln Ser
 1325 1330 1335
 Arg Asp Gly Ser Arg His Pro Gly Ser His Gln Glu Asp Arg Ala
 1340 1345 1350
 Gly His Gly His Ser Ala Asp Ser Pro Arg Gln Ser Gly Thr Arg
 1355 1360 1365
 His Thr Glu Ser Ser Ser Arg Gly Gln Ala Ala Ser Ser His Glu
 1370 1375 1380
 Gln Ala Arg Ser Ser Ala Gly Glu Arg His Gly Ser His His Gln
 1385 1390 1395
 Leu Gln Ser Ala Asp Ser Ser Arg His Ala Gly Ile Gly His Gly
 1400 1405 1410
 Gln Ala Ser Ser Ala Val Arg Asp Ser Gly His Arg Gly Tyr Ser
 1415 1420 1425
 Gly Ser Gln Ala Thr Asp Ser Glu Gly His Ser Glu Asp Ser Asp
 1430 1435 1440
 Thr Gln Ser Val Ser Ala Gln Gly Lys Ala Gly Pro His Gln Gln
 1445 1450 1455

filaggrin Sequence listing.ST25

Ser His Lys Glu Ser Ala Arg Gly Gln Ser Gly Glu Ser Ser Arg
 1460 1465 1470
 Arg Ser Gly Ser Phe Leu Tyr Gln Val Ser Thr His Glu Gln Ser
 1475 1480 1485
 Glu Ser Thr His Gly Gln Ser Val Pro Ser Thr Gly Gly Arg Gln
 1490 1495 1500
 Gly Ser His His Asp Gln Ala Gln Asp Ser Ser Arg His Ser Ala
 1505 1510 1515
 Ser Gln Glu Gly Gln Asp Thr Ile Arg Gly His Pro Gly Pro Ser
 1520 1525 1530
 Arg Gly Gly Arg Gln Gly Ser His His Glu Gln Ser Val Asp Arg
 1535 1540 1545
 Ser Gly His Ser Gly Ser His His Ser His Thr Thr Ser Gln Gly
 1550 1555 1560
 Arg Ser Asp Ala Ser Arg Gly Gln Ser Gly Pro Arg Ser Ala Ser
 1565 1570 1575
 Arg Gln Thr His Asp Lys Glu Gln Ser Gly Asp Gly Ser Arg His
 1580 1585 1590
 Ser Gly Ser Arg His His Glu Ala Ser Ser Trp Ala Asp Ser Ser
 1595 1600 1605
 Arg His Ser Gln Ala Val Gln Gly Gln Ser Glu Gly Ser Arg Arg
 1610 1615 1620
 Ser Arg Arg Gln Gly Ser Ser Val Ser Gln Asp Ser Asp Ser Gln
 1625 1630 1635
 Gly His Ser Glu Asp Ser Glu Arg Arg Ser Gly Ser Ala Ser Arg
 1640 1645 1650
 Asn His Arg Gly Ser Ala Gln Glu Gln Ser Arg Asp Gly Ser Arg
 1655 1660 1665
 His Pro Arg Ser His His Glu Asp Arg Ala Gly His Gly His Ser
 1670 1675 1680
 Ala Asp Ser Ser Arg Gln Ser Gly Thr His His Ala Glu Asn Ser
 1685 1690 1695
 Ser Gly Gly Gln Pro Ala Ser Ser His Glu Gln Ala Arg Ser Ser
 1700 1705 1710

filaggrin Sequence listing.ST25

Ala Gly Glu Arg His Gly Ser His His Gln Gln Ser Ala Asp Ser
 1715 1720 1725

Ser Arg His Ser Gly Ile Gly His Gly Gln Ala Ser Ser Ala Val
 1730 1735 1740

Arg Asp Ser Gly His Arg Gly Ser Ser Gly Ser Gln Ala Ser Asp
 1745 1750 1755

Ser Glu Gly His Ser Glu Asp Ser Asp Thr Gln Ser Val Ser Ala
 1760 1765 1770

His Gly Gln Ala Gly Pro His Gln Gln Ser His Gln Glu Ser Thr
 1775 1780 1785

Arg Gly Arg Ser Ala Gly Arg Ser Gly Arg Ser Gly Ser Phe Leu
 1790 1795 1800

Tyr Gln Val Ser Thr His Glu Gln Ser Glu Ser Ala His Gly Arg
 1805 1810 1815

Ala Gly Pro Ser Thr Gly Gly Arg Gln Gly Ser His His Glu Gln
 1820 1825 1830

Ala Arg Asp Ser Ser Arg His Ser Ala Ser Gln Glu Gly Gln Asp
 1835 1840 1845

Thr Ile Arg Gly His Pro Gly Ser Arg Arg Gly Gly Arg Gln Gly
 1850 1855 1860

Ser Tyr His Glu Gln Ser Val Asp Arg Ser Gly His Ser Gly Ser
 1865 1870 1875

His His Ser His Thr Thr Ser Gln Gly Arg Ser Asp Ala Ser His
 1880 1885 1890

Gly Gln Ser Gly Ser Arg Ser Ala Ser Arg Glu Thr Arg Asn Glu
 1895 1900 1905

Glu Gln Ser Gly Asp Gly Ser Arg His Ser Gly Ser Arg His His
 1910 1915 1920

Glu Ala Ser Thr Gln Ala Asp Ser Ser Arg His Ser Gln Ser Gly
 1925 1930 1935

Gln Gly Glu Ser Ala Gly Ser Arg Arg Ser Arg Arg Gln Gly Ser
 1940 1945 1950

Ser Val Ser Gln Asp Ser Asp Ser Glu Ala Tyr Pro Glu Asp Ser
 1955 1960 1965

filaggrin Sequence listing.ST25

Glu Arg Arg Ser Glu Ser Ala Ser Arg Asn His His Gly Ser Ser
 1970 1975 1980
 Arg Glu Gln Ser Arg Asp Gly Ser Arg His Pro Gly Ser Ser His
 1985 1990 1995
 Arg Asp Thr Ala Ser His Val Gln Ser Ser Pro Val Gln Ser Asp
 2000 2005 2010
 Ser Ser Thr Ala Lys Glu His Gly His Phe Ser Ser Leu Ser Gln
 2015 2020 2025
 Asp Ser Ala Tyr His Ser Gly Ile Gln Ser Arg Gly Ser Pro His
 2030 2035 2040
 Ser Ser Ser Ser Tyr His Tyr Gln Ser Glu Gly Thr Glu Arg Gln
 2045 2050 2055
 Lys Gly Gln Ser Gly Leu Val Trp Arg His Gly Ser Tyr Gly Ser
 2060 2065 2070

Ala